<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
    <PubmedArticle>
        <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
            <PMID Version="1">35958013</PMID>
            <DateRevised>
                <Year>2022</Year>
                <Month>08</Month>
                <Day>13</Day>
            </DateRevised>
            <Article PubModel="Print">
                <Journal>
                    <ISSN IssnType="Print">2224-4344</ISSN>
                    <JournalIssue CitedMedium="Print">
                        <Volume>11</Volume>
                        <Issue>7</Issue>
                        <PubDate>
                            <Year>2022</Year>
                            <Month>Jul</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>Translational pediatrics</Title>
                    <ISOAbbreviation>Transl Pediatr</ISOAbbreviation>
                </Journal>
                <ArticleTitle>The protective effect of MiR-27a on the neonatal hypoxic-ischemic encephalopathy by targeting FOXO1 in rats.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>1199-1208</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.21037/tp-22-259</ELocationID>
                <Abstract>
                    <AbstractText Label="Background" NlmCategory="UNASSIGNED">Neonatal hypoxic-ischemic encephalopathy (HIE), a kind of hypoxic-ischemic brain damage caused by perinatal asphyxia, is the most crucial cause of neonatal death and long-term neurological dysfunction in children. We aimed to investigate the protective effects of micro (mi)R-27a on HIE in neonatal rats.</AbstractText>
                    <AbstractText Label="Methods" NlmCategory="UNASSIGNED">A rat model of neonatal HIE was constructed by modification of the Rice-Vannucci model. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to test the expressions of miR-27a, FOXO1 messenger RNA (mRNA), interleukin-1β (IL-1β) mRNA, and tumor necrosis factor-α (TNF-α) mRNA, and western blot was applied to test the expression of FOXO1. In order to overexpress miR-27a, an intracerebroventricular injection (i.c.v) of miR-27a mimic was administered. We adopted 2,3,5-triphenytetrazolium chloride (TTC) staining and brain water content measurement to test the effects of miR-27a on the infarcted volume and edema in brain after HIE. Flow cytometry (FCM) analysis was applied to test the effects of miR-27a on the infiltrated peripheral immune cells in the rat brains after HIE.</AbstractText>
                    <AbstractText Label="Results" NlmCategory="UNASSIGNED">We successfully established a rat model of neonatal HIE. It was revealed that the expressions of miR-27a decreased gradually after HIE, however, the expressions of FOXO1 mRNA increased. After injection of the miR-27a mimic, the expression of miR-27a in the rat HIE model brains was significantly upregulated, however, the expression of FOXO1 was robustly downregulated. Both TTC staining and brain water content showed that the infarcted volume and brain edema was markedly increased after HIE. Interestingly, the overexpression of miR-27a reduced the infarcted volume and edema induced by HIE. Additionally, RT-qPCR and FCM analysis showed that HIE lead to increases of IL-1β, TNF-α, and infiltrated immune cells. Overexpression of miR-27a could reduce the expressions of IL-1β mRNA and TNF-α mRNA, and the cell numbers of infiltrated peripheral macrophages and neutrophils in the brain.</AbstractText>
                    <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">MiR-27a plays protective roles by reducing infarct volume and brain edema, and inhibiting inflammatory factors and infiltrated peripheral immune cells by targeting FOXO1 in neonatal HIE rats.</AbstractText>
                    <CopyrightInformation>2022 Translational Pediatrics. All rights reserved.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Cai</LastName>
                        <ForeName>Qun</ForeName>
                        <Initials>Q</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Pediatrics, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Zhang</LastName>
                        <ForeName>Xiaoqun</ForeName>
                        <Initials>X</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Pediatrics, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Shen</LastName>
                        <ForeName>Liyuan</ForeName>
                        <Initials>L</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Pediatrics, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Song</LastName>
                        <ForeName>Honghua</ForeName>
                        <Initials>H</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Pediatrics, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Wang</LastName>
                        <ForeName>Ting</ForeName>
                        <Initials>T</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Emergency, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
            </Article>
            <MedlineJournalInfo>
                <Country>China</Country>
                <MedlineTA>Transl Pediatr</MedlineTA>
                <NlmUniqueID>101649179</NlmUniqueID>
                <ISSNLinking>2224-4336</ISSNLinking>
            </MedlineJournalInfo>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">FOXO1</Keyword>
                <Keyword MajorTopicYN="N">infarcted volume</Keyword>
                <Keyword MajorTopicYN="N">infiltrated peripheral immune cells</Keyword>
                <Keyword MajorTopicYN="N">inflammation</Keyword>
                <Keyword MajorTopicYN="N">miR-27a</Keyword>
            </KeywordList>
            <CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-22-259/coif). The authors have no conflicts of interest to declare.</CoiStatement>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2022</Year>
                    <Month>05</Month>
                    <Day>16</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2022</Year>
                    <Month>07</Month>
                    <Day>04</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>8</Month>
                    <Day>12</Day>
                    <Hour>2</Hour>
                    <Minute>50</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>8</Month>
                    <Day>13</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>8</Month>
                    <Day>13</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35958013</ArticleId>
                <ArticleId IdType="doi">10.21037/tp-22-259</ArticleId>
                <ArticleId IdType="pii">tp-11-07-1199</ArticleId>
                <ArticleId IdType="pmc">PMC9360825</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Neural Regen Res. 2021 Feb;16(2):205-213</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32859765</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Acta Neurol Belg. 2020 Apr;120(2):277-288</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32112349</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Behav. 2021 Aug;11(8):e2293</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34331407</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am J Cancer Res. 2021 Oct 15;11(10):4700-4710</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34765288</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820965576</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33025840</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105553</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33360521</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Synaptic Neurosci. 2021 Aug 24;13:709301</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34504417</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nat Commun. 2019 Sep 4;10(1):3983</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31484925</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Immunobiology. 2022 May;227(3):152178</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">35259691</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cells. 2021 Jun 02;10(6):</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34199498</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Trends Pharmacol Sci. 2021 Jul;42(7):605-616</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33992468</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nature. 2021 Apr;592(7854):444-449</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33762736</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>EMBO Mol Med. 2021 Nov 8;13(11):e13659</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34633146</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neural Regen Res. 2016 Aug;11(8):1285-92</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27651777</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Oncol. 2021 Oct 13;11:759346</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34722314</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Oncol. 2019 Sep 12;9:893</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31572683</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Res. 2021 Oct 1;1768:147588</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34310937</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cells. 2020 Jul 15;9(7):</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32679881</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Blood. 2021 Sep 2;138(9):758-772</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33786575</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neuropsychiatr Dis Treat. 2021 Apr 22;17:1165-1181</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33911865</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nature. 2021 Sep;597(7878):709-714</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34497421</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Curr Pharm Des. 2021;27(5):687-694</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33185158</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neoreviews. 2021 Mar;22(3):e148-e162</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33649088</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neural Regen Res. 2022 Feb;17(2):277-282</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34269188</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neonatal Netw. 2021 Nov 1;40(6):406-413</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34845092</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Dev Neurosci. 2005 Mar-Aug;27(2-4):81-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16046840</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Immunol. 2020 Mar 25;11:421</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32269564</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neuroinflammation. 2020 Aug 31;17(1):256</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32867797</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Science. 2021 Jan 22;371(6527):405-410</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33479154</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Biochem Biophys Res Commun. 2020 Jan 22;521(4):933-938</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31718799</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Exp Neurol. 2022 May;351:113985</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">35063438</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pediatr Res. 2021 Oct 8;:</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34625655</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci Res. 2021 Apr;99(4):991-1008</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33416205</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Life Sci. 2020 Nov 1;260:118098</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32679145</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>JAMA Pediatr. 2020 Jan 1;174(1):48-55</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31710357</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neurosci Lett. 2020 Jan 10;715:134649</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31778769</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Pediatr. 2019 Nov;214:217-221.e1</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31301853</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Theranostics. 2022 Jan 1;12(2):512-529</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34976198</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mol Neurobiol. 2021 Jan;58(1):329-347</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32944919</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Histol Histopathol. 2020 Sep;35(9):929-936</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32167570</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Aging (Albany NY). 2021 Apr 19;13(8):11727-11737</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33875617</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedBookArticle>
        <BookDocument>
            <PMID Version="1">35881737</PMID>
            <ArticleIdList>
                <ArticleId IdType="bookaccession">NBK582132</ArticleId>
            </ArticleIdList>
            <Book>
                <Publisher>
                    <PublisherName>StatPearls Publishing</PublisherName>
                    <PublisherLocation>Treasure Island (FL)</PublisherLocation>
                </Publisher>
                <BookTitle book="statpearls">StatPearls</BookTitle>
                <PubDate>
                    <Year>2022</Year>
                    <Month>01</Month>
                </PubDate>
                <BeginningDate>
                    <Year>2022</Year>
                    <Month>01</Month>
                </BeginningDate>
                <Medium>Internet</Medium>
            </Book>
            <ArticleTitle book="statpearls" part="article-145086">Applanation Tonometry</ArticleTitle>
            <Language>eng</Language>
            <AuthorList Type="authors">
                <Author>
                    <LastName>Zeppieri</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Hospital of Udine, Italy</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Gurnani</LastName>
                    <ForeName>Bharat</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Aravind Eye Care System</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <PublicationType UI="D000072643">Study Guide</PublicationType>
            <Abstract>
                <AbstractText>Tonometry involves diagnostic testing to measure the pressure inside the eye or intraocular pressure (IOP). Glaucoma is a silent disease that causes irreversible functional peripheral visual field loss that can ultimately lead to blindness in the very late stages of the disease if not treated. Tonometry should be performed during routine ophthalmic examinations to screen for glaucoma and other ocular diseases. IOP must be monitored periodically during the management of patients with glaucoma, ocular hypertension (OHT), and subjects at risk of developing glaucoma. Normal IOP measures in the range of 10 to 21 (mmHg), which is based on average IOP levels in populations surveys in normal subjects, and less than 2 % of normal subjects show IOP greater than 21 mmHg.[1]  Possible causes for an IOP under normal rages (hypotonus) include uveitis, ocular traumas, retinal detachment, and post-surgery complications, especially after filtering surgery. Elevated IOP is normally caused by glaucoma. The definition of glaucoma in the past years has evolved from a disease solely defined by IOP&gt;21 mmHg to include the assessments of functional and morphological defects. The concept of determining and re-evaluating a personalized target IOP is currently an important issue in managing patients. These ranges in mmHg are associated with levels of IOP that are thought to cause a minimal likelihood of optic nerve damage or visual field loss, or progression of an existing lesion due to OHT.[2]  Treatment of OHT and glaucoma involves lowering IOP using local drop therapy, laser, and/or surgery. It is thus of utmost importance that instruments used to measure IOP are properly calibrated, accurate and precise, considering that the treatment options are based on IOP levels, together with visual field results, clinical evaluations, and morphological assessments of the optic nerve and retinal nerve fiber layer. The true IOP inside the eyeball can be measured by inserting a probe in the anterior chamber to measure the manometric pressure. However, this invasive technique tends to be strictly used in animal models and can surely not be considered in a routine clinical setting.[3] Numerous instruments and tonometers have been created since the 1800s to measure IOP, which have been designed to provide accurate, reliable, precise, and reproducible measurements of IOP. Each method has advantages, disadvantages, and limits and is more or less influenced by ocular factors, rendering some methods clinically acceptable and practical while others are obsolete. Tonometers are based on different concepts and principles of physics that define how IOP levels are measured and what factors can theoretically influence these readings. The force needed to applanate, indent, and/or rebound the surface of the eye is used to estimate and calculate the IOP provided by the numerous tonometers used to date. It is important to note that IOP readings can be influenced by numerous factors based on each tonometer used.[4] These factors can influence accuracy, precision, repeatability, measurement variability, and specificity. The factors that need to be considered include the amount of fluorescein, excessive tear production, corneal astigmatism, scarring, scleral rigidity, corneal edema, central corneal thickness, and arterial perfusion, central venous pressures, eye position, etc.[4] Goldmann applanation tonometry (GAT) is currently the most widely accepted method used to measure IOP and is considered the gold standard tonometer in clinics.[5] GAT indirectly measures the IOP by assessing the force needed to flatten a predetermined surface area of the cornea. Taken simplistically, if the eyeball is hard, it takes more force to flatten the surface of the cornea, which is directly influenced by the IOP. GAT is based on the principles of applanation tonometry. Other instruments that have been built using the principles of applanation include the Perkins applanation tonometer, non-contact tonometers, and the Ocular Response tonometer (ORA).[6]</AbstractText>
                <CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation>
            </Abstract>
            <Sections>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s1">Continuing Education Activity</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s2">Introduction</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s3">Indications</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s4">Contraindications</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s5">Equipment</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s6">Technique</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s7">Complications</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s8">Clinical Significance</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s9">Enhancing Healthcare Team Outcomes </SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s10">Nursing, Allied Health, and Interprofessional Team Interventions</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s11">Nursing, Allied Health, and Interprofessional Team Monitoring</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s12">Review Questions</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="statpearls" part="article-145086" sec="article-145086.s18">References</SectionTitle>
                </Section>
            </Sections>
            <ContributionDate>
                <Year>2022</Year>
                <Month>6</Month>
                <Day>6</Day>
            </ContributionDate>
        </BookDocument>
        <PubmedBookData>
            <History>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>7</Month>
                    <Day>27</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>7</Month>
                    <Day>27</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>7</Month>
                    <Day>27</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35881737</ArticleId>
            </ArticleIdList>
        </PubmedBookData>
    </PubmedBookArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">35491065</PMID>
            <DateCompleted>
                <Year>2022</Year>
                <Month>05</Month>
                <Day>03</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2022</Year>
                <Month>05</Month>
                <Day>03</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1557-9859</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>106</Volume>
                        <Issue>3</Issue>
                        <PubDate>
                            <Year>2022</Year>
                            <Month>May</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>The Medical clinics of North America</Title>
                    <ISOAbbreviation>Med Clin North Am</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Congestive Heart Failure.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>447-458</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="pii" ValidYN="Y">S0025-7125(21)00176-0</ELocationID>
                <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mcna.2021.12.002</ELocationID>
                <Abstract>
                    <AbstractText>Heart disease is the leading cause of death in the United States with an estimated 6 million adults living with heart failure. In patients with heart failure, the physical examination can provide important prognostic information and is also used to guide both diagnosis and management, including determining the need for inpatient versus outpatient management. Presenting symptoms include dyspnea, peripheral edema, orthopnea, paroxysmal nocturnal dyspnea, and bendopnea. In patients with suspected heart failure, a "head-to-toe" physical examination approach is recommended with the addition of special maneuvers such as the measurement of jugular venous pressure, valsalva maneuver, and hepatojugular reflux as needed.</AbstractText>
                    <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Chen</LastName>
                        <ForeName>Jennifer</ForeName>
                        <Initials>J</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Internal Medicine, University of California, Davis, 4860 Y Street Suite 0100, Sacramento, CA 95817, USA. Electronic address: jecchen@ucdavis.edu.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Aronowitz</LastName>
                        <ForeName>Paul</ForeName>
                        <Initials>P</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Internal Medicine, University of California, Davis, 4150 V Street Suite 3100 PSSB, Sacramento, CA 95817, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D016454">Review</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2022</Year>
                    <Month>04</Month>
                    <Day>04</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>United States</Country>
                <MedlineTA>Med Clin North Am</MedlineTA>
                <NlmUniqueID>2985236R</NlmUniqueID>
                <ISSNLinking>0025-7125</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName>
                    <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                    <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName>
                    <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                    <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                    <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008171" MajorTopicYN="Y">Lung Diseases</DescriptorName>
                    <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D010808" MajorTopicYN="N">Physical Examination</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Congestive heart failure</Keyword>
                <Keyword MajorTopicYN="N">Jugular venous pressure</Keyword>
                <Keyword MajorTopicYN="N">Valsalva</Keyword>
            </KeywordList>
            <CoiStatement>Disclosure The authors have nothing to disclose.</CoiStatement>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>5</Month>
                    <Day>1</Day>
                    <Hour>21</Hour>
                    <Minute>5</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>5</Month>
                    <Day>2</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>5</Month>
                    <Day>4</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35491065</ArticleId>
                <ArticleId IdType="pii">S0025-7125(21)00176-0</ArticleId>
                <ArticleId IdType="doi">10.1016/j.mcna.2021.12.002</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">35269413</PMID>
            <DateCompleted>
                <Year>2022</Year>
                <Month>04</Month>
                <Day>11</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2022</Year>
                <Month>04</Month>
                <Day>11</Day>
            </DateRevised>
            <Article PubModel="Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">2073-4409</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>11</Volume>
                        <Issue>5</Issue>
                        <PubDate>
                            <Year>2022</Year>
                            <Month>02</Month>
                            <Day>24</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Cells</Title>
                    <ISOAbbreviation>Cells</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Experimental Arthritis Inhibits Adult Hippocampal Neurogenesis in Mice.</ArticleTitle>
                <ELocationID EIdType="pii" ValidYN="Y">791</ELocationID>
                <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11050791</ELocationID>
                <Abstract>
                    <AbstractText>
                        <b>Background:</b> Adult-born neurons of the hippocampal dentate gyrus play a role in specific forms of learning, and disturbed neurogenesis seems to contribute to the development of neuropsychiatric disorders, such as major depression. Neuroinflammation inhibits adult neurogenesis, but the effect of peripheral inflammation on this form of neuroplasticity is ambiguous. <b>Objective</b>: Our aim was to investigate the influence of acute and chronic experimental arthritis on adult hippocampal neurogenesis and to elucidate putative regulatory mechanisms. <b>Methods</b>: Arthritis was triggered by subcutaneous injection of complete Freund's adjuvant (CFA) into the hind paws of adult male mice. The animals were killed either seven days (acute inflammation) or 21 days (chronic inflammation) after the CFA injection. Behavioral tests were used to demonstrate arthritis-related hypersensitivity to painful stimuli. We used in vivo bioluminescence imaging to verify local inflammation. The systemic inflammatory response was assessed by complete blood cell counts and by measurement of the cytokine/chemokine concentrations of TNF-α, IL-1α, IL-4, IL-6, IL-10, KC and MIP-2 in the inflamed hind limbs, peripheral blood and hippocampus to characterize the inflammatory responses in the periphery and in the brain. In the hippocampal dentate gyrus, the total number of newborn neurons was determined with quantitative immunohistochemistry visualizing BrdU- and doublecortin-positive cells. Microglial activation in the dentate gyrus was determined by quantifying the density of Iba1- and CD68-positive cells. <b>Results</b>: Both acute and chronic arthritis resulted in paw edema, mechanical and thermal hyperalgesia. We found phagocytic infiltration and increased levels of TNF-α, IL-4, IL-6, KC and MIP-2 in the inflamed hind paws. Circulating neutrophil granulocytes and IL-6 levels increased in the blood solely during the acute phase. In the dentate gyrus, chronic arthritis reduced the number of doublecortin-positive cells, and we found increased density of CD68-positive macrophages/microglia in both the acute and chronic phases. Cytokine levels, however, were not altered in the hippocampus. <b>Conclusions</b>: Our data suggest that acute peripheral inflammation initiates a cascade of molecular and cellular changes that eventually leads to reduced adult hippocampal neurogenesis, which was detectable only in the chronic inflammatory phase.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Rusznák</LastName>
                        <ForeName>Kitti</ForeName>
                        <Initials>K</Initials>
                        <AffiliationInfo>
                            <Affiliation>Structural Neurobiology Research Group, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Laboratory Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Horváth</LastName>
                        <ForeName>Ádám István</ForeName>
                        <Initials>ÁI</Initials>
                        <Identifier Source="ORCID">0000-0002-4724-8201</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Molecular Pharmacology Research Group, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Pohli-Tóth</LastName>
                        <ForeName>Kinga</ForeName>
                        <Initials>K</Initials>
                        <AffiliationInfo>
                            <Affiliation>Structural Neurobiology Research Group, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Futácsi</LastName>
                        <ForeName>Anett</ForeName>
                        <Initials>A</Initials>
                        <AffiliationInfo>
                            <Affiliation>Structural Neurobiology Research Group, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kemény</LastName>
                        <ForeName>Ágnes</ForeName>
                        <Initials>Á</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Medical Biology, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kiss</LastName>
                        <ForeName>Gabriella</ForeName>
                        <Initials>G</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Laboratory Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Helyes</LastName>
                        <ForeName>Zsuzsanna</ForeName>
                        <Initials>Z</Initials>
                        <AffiliationInfo>
                            <Affiliation>Molecular Pharmacology Research Group, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>PharmInVivo Ltd., 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Czéh</LastName>
                        <ForeName>Boldizsár</ForeName>
                        <Initials>B</Initials>
                        <Identifier Source="ORCID">0000-0002-4926-5400</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Structural Neurobiology Research Group, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Laboratory Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Histology and Light Microscopy Core Facility, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <GrantList CompleteYN="Y">
                    <Grant>
                        <GrantID>2017-1.2.1-NKP-2017-00002</GrantID>
                        <Agency>National Research, Development and Innovation Office</Agency>
                        <Country/>
                    </Grant>
                    <Grant>
                        <GrantID>EFOP-3.6.1.-16-2016-00004</GrantID>
                        <Agency>European Social Fund</Agency>
                        <Country/>
                    </Grant>
                </GrantList>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2022</Year>
                    <Month>02</Month>
                    <Day>24</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Switzerland</Country>
                <MedlineTA>Cells</MedlineTA>
                <NlmUniqueID>101600052</NlmUniqueID>
                <ISSNLinking>2073-4409</ISSNLinking>
            </MedlineJournalInfo>
            <ChemicalList>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D000089662">Doublecortin Protein</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>207137-56-2</RegistryNumber>
                    <NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>9007-81-2</RegistryNumber>
                    <NameOfSubstance UI="D005620">Freund's Adjuvant</NameOfSubstance>
                </Chemical>
            </ChemicalList>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001169" MajorTopicYN="Y">Arthritis, Experimental</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
                    <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000089662" MajorTopicYN="N">Doublecortin Protein</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D005620" MajorTopicYN="N">Freund's Adjuvant</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
                    <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName>
                    <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D014409" MajorTopicYN="Y">Tumor Necrosis Factor-alpha</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="Y">animal model</Keyword>
                <Keyword MajorTopicYN="Y">cell proliferation</Keyword>
                <Keyword MajorTopicYN="Y">chemokine</Keyword>
                <Keyword MajorTopicYN="Y">chronic inflammation</Keyword>
                <Keyword MajorTopicYN="Y">chronic pain</Keyword>
                <Keyword MajorTopicYN="Y">cytokine</Keyword>
                <Keyword MajorTopicYN="Y">dentate gyrus</Keyword>
                <Keyword MajorTopicYN="Y">hippocampus</Keyword>
                <Keyword MajorTopicYN="Y">microglia</Keyword>
                <Keyword MajorTopicYN="Y">neuroplasticity</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2022</Year>
                    <Month>02</Month>
                    <Day>03</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="revised">
                    <Year>2022</Year>
                    <Month>02</Month>
                    <Day>16</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2022</Year>
                    <Month>02</Month>
                    <Day>18</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>3</Month>
                    <Day>10</Day>
                    <Hour>15</Hour>
                    <Minute>34</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>3</Month>
                    <Day>11</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>4</Month>
                    <Day>12</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>epublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35269413</ArticleId>
                <ArticleId IdType="pii">cells11050791</ArticleId>
                <ArticleId IdType="doi">10.3390/cells11050791</ArticleId>
                <ArticleId IdType="pmc">PMC8909078</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Cell Tissue Res. 2008 Jan;331(1):243-50</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17938969</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Sci Rep. 2021 Sep 17;11(1):18549</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34535707</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>BMC Med. 2013 Sep 12;11:200</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24228900</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Proc Natl Acad Sci U S A. 1999 May 11;96(10):5768-73</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10318959</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Biol Psychiatry. 2002 Dec 1;52(11):1057-65</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12460689</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Sci Rep. 2014 Dec 19;4:7554</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25523081</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Learn Mem. 2009 Jan 29;16(2):147-54</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19181621</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Evid Based Complement Alternat Med. 2018 Aug 27;2018:4816905</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30224931</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Behav Immun. 2019 Feb;76:165-181</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30465881</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Psychosom Med. 2002 Jan-Feb;64(1):52-60</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11818586</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Behav Immun. 2015 Oct;49:156-70</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26074461</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Shock. 2007 Nov;28(5):576-81</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18084824</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Trends Cogn Sci. 2010 Jul;14(7):325-37</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20471301</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mol Cell Neurosci. 2003 Nov;24(3):623-31</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14664813</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Pharmacol Exp Ther. 2005 Jul;314(1):111-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15831443</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci Res. 2007 Apr;85(5):994-1009</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17265469</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nat Immunol. 2018 Feb;19(2):151-161</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29292385</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mol Psychiatry. 2008 Jul;13(7):717-28</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17700577</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Neurosci. 2014 Apr 21;8:83</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24795557</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Neurosci. 2011 Mar;33(6):1139-51</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21395858</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neuropsychopharmacology. 2006 Dec;31(12):2619-26</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16823390</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18178625</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Behav Brain Res. 2020 Mar 2;381:112458</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31899214</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:277-84</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26111720</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci. 2002 Jan 15;22(2):486-92</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11784794</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Prog Neurobiol. 2014 Apr;115:116-37</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24384539</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci Methods. 2003 Sep 30;128(1-2):45-52</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12948547</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neuroimmunol. 2017 Aug 15;309:12-22</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28601280</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell. 2016 Nov 3;167(4):897-914</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27814520</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7579-84</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10840056</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci. 2012 Apr 25;32(17):5747-56</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22539837</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Arthritis Rheum. 2004 May;50(5):1677-85</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15146439</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Comp Neurol. 2003 Dec 1;467(1):1-10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14574675</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Behav Immun. 2020 Jan;83:172-179</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31604142</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Trends Neurosci. 2015 Mar;38(3):145-57</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25579391</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Arthritis Rheumatol. 2014 Oct;66(10):2739-50</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25048575</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell Stem Cell. 2021 Feb 4;28(2):285-299.e9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33207218</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neuropathol Appl Neurobiol. 2016 Dec;42(7):621-638</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27424496</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell Stem Cell. 2018 Apr 5;22(4):589-599.e5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29625071</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Cell Sci. 2013 Sep 15;126(Pt 18):4208-19</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23843621</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nature. 2011 Aug 03;476(7361):458-61</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21814201</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neural Regen Res. 2019 May;14(5):817-825</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30688267</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Development. 2003 Jan;130(2):391-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12466205</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Cell Neurosci. 2017 Jul 24;11:216</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28790893</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neuroinflammation. 2015 Apr 03;12:65</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25889852</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Acta Neuropathol. 2010 Sep;120(3):277-86</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20644946</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Immun Ageing. 2019 Jul 30;16:18</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31384283</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci. 1996 Mar 15;16(6):2027-33</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8604047</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neurosci Biobehav Rev. 2016 Feb;61:121-31</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26695382</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Cell Dev Biol. 2019 Mar 05;7:24</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30891446</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neuroinflammation. 2014 Dec 31;11:211</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25551794</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci Res. 2005 Jun 15;80(6):789-97</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15884015</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neuropsychopharmacology. 2012 Mar;37(4):939-49</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22071871</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Leukoc Biol. 2004 Mar;75(3):388-97</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14612429</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5263-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10220454</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell. 2013 Jun 6;153(6):1219-1227</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23746839</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neuroscience. 2009 Feb 6;158(3):1021-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18662748</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Stem Cells. 2008 Sep;26(9):2361-71</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18583543</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Proc Natl Acad Sci U S A. 1989 Jan;86(2):612-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">2643119</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci Res. 2008 May 1;86(6):1199-208</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18058947</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rheumatology (Oxford). 2013 Dec;52(12):2136-48</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24003249</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Pharmacol. 2018 Jul 23;9:786</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30083103</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nat Med. 2016 Nov;22(11):1239-1247</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27783068</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neurobiol Dis. 2004 Jun;16(1):133-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15207270</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nat Rev Neurosci. 2008 Jan;9(1):46-56</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18073775</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Chem Biol. 2012 Sep 21;19(9):1199-209</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22999887</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>PLoS One. 2013 Apr 23;8(4):e61684</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23626716</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Arthritis Res Ther. 2016 Jan 08;18:6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26746673</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>FASEB J. 2009 Sep;23(9):3121-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19433626</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Science. 2003 Dec 5;302(5651):1760-5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14615545</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mol Psychiatry. 2021 May 14;:</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33990771</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lab Invest. 2017 Jan;97(1):4-13</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27869795</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mol Psychiatry. 2021 Apr;26(4):1248-1263</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31969694</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nature. 2018 Mar 15;555(7696):377-381</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29513649</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Int J Biol Sci. 2012;8(9):1254-66</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23136554</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell Stem Cell. 2010 Oct 8;7(4):483-95</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20887954</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Res Mol Brain Res. 1998 Jun 1;57(1):1-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">9630473</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Struct Funct. 2019 Sep;224(7):2281-2295</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31278571</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell Rep. 2020 Mar 24;30(12):4082-4095.e6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32209470</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neurobiol Stress. 2021 Jun 18;15:100356</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">34355047</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Biol Psychiatry. 2020 Oct 15;88(8):597-610</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32307038</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Neurosci. 2005 Jan;21(1):1-14</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15654838</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Neurosci. 2021 Jan;53(1):151-171</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32150310</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci. 2017 Apr 12;37(15):4145-4157</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28292830</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neural Plast. 2014;2014:610343</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24772353</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cell Death Dis. 2018 Feb 14;9(2):250</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29445154</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Cell Neurosci. 2013 Nov 22;7:229</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24319411</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Behav Immun. 2013 Mar;29:28-38</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23108061</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Behav Brain Res. 2020 Jul 15;390:112640</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32434062</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brain Behav Immun. 2016 Nov;58:1-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26802985</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mol Cell Neurosci. 2006 Jan;31(1):149-60</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16297637</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12796-801</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11675510</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nature. 2011 Apr 28;472(7344):466-70</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21460835</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci. 2006 Sep 20;26(38):9703-12</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16988041</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neuroinflammation. 2007 Jan 15;4:4</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17224051</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Pain. 2006 Aug;7(8):544-55</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16885011</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Clin Exp Immunol. 1992 Dec;90(3):459-65</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">1458683</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">35249117</PMID>
            <DateRevised>
                <Year>2022</Year>
                <Month>08</Month>
                <Day>03</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1432-5195</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>46</Volume>
                        <Issue>6</Issue>
                        <PubDate>
                            <Year>2022</Year>
                            <Month>06</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>International orthopaedics</Title>
                    <ISOAbbreviation>Int Orthop</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Analysis of peripheral bone reconstruction after the failure of hip osteonecrosis treatment with porous tantalum rod implantation.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>1323-1330</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00264-022-05334-z</ELocationID>
                <Abstract>
                    <AbstractText Label="PURPOSE">Failure of porous tantalum rod (PTR) implantation in treating early osteonecrosis of femoral head (ONFH) has been frequently reported, but the underlying mechanism remains uncertain, which raised the concern of its efficacy. The study aimed to discuss the underlying mechanism from the perspectives of bone reconstruction and pathological changes.</AbstractText>
                    <AbstractText Label="METHODS">Five patients with PTR implantation experienced total hip arthroplasty (THA) due to recurrent pain, whose femoral heads were collected as "tantalum group." Normal (fracture) and necrotic femoral heads were respectively collected (both n = 5) after THA. The bone quality and structure, biomechanical properties, and histopathological features were analyzed by micro-CT scanning, mechanical measurement, and histological examination.</AbstractText>
                    <AbstractText Label="RESULTS">Both the tantalum group and necrotic group had significantly poorer bone quantity and quality than the normal group. Three-dimensional imaging reconstruction showed that the trabeculae of the tantalum group were poorest in quality. Significant differences in terms of bone quality, structure, and biomechanical properties were present between the inside and outside regions around PTR, which revealed abnormal bone reconstruction. Biomechanical analysis revealed inferior properties in the tantalum group and necrosis group. H&amp;E staining demonstrated neutrophil infiltration among the peripheral trabeculae around PTR, and the inflammation cells were significantly more abundant than that in the normal and necrosis groups.</AbstractText>
                    <AbstractText Label="CONCLUSION">Abnormal bone reconstruction around PTR was an important cause for failure of PTR implantation in the treatment of ONFH, which was related to biomechanical stress distribution and chronic inflammation infiltration. Insufficient biomechanical support and inflammatory trabeculae edema might account for the recurrent pain.</AbstractText>
                    <CopyrightInformation>© 2022. The Author(s) under exclusive licence to SICOT aisbl.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Liu</LastName>
                        <ForeName>Weilu</ForeName>
                        <Initials>W</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Hu</LastName>
                        <ForeName>Yong</ForeName>
                        <Initials>Y</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Orthopaedic Surgery, The Fifth Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510000, Guangdong Province, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Huang</LastName>
                        <ForeName>Zhifa</ForeName>
                        <Initials>Z</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Joint Surgery, Liuzhou Worker's Hospital, Liuzhou, 545000, Guangxi Province, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Shi</LastName>
                        <ForeName>Zhanjun</ForeName>
                        <Initials>Z</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Xiao</LastName>
                        <ForeName>Jun</ForeName>
                        <Initials>J</Initials>
                        <Identifier Source="ORCID">0000-0001-5165-1207</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China. orthopaedxj@163.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2022</Year>
                    <Month>03</Month>
                    <Day>06</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Germany</Country>
                <MedlineTA>Int Orthop</MedlineTA>
                <NlmUniqueID>7705431</NlmUniqueID>
                <ISSNLinking>0341-2695</ISSNLinking>
            </MedlineJournalInfo>
            <ChemicalList>
                <Chemical>
                    <RegistryNumber>6424HBN274</RegistryNumber>
                    <NameOfSubstance UI="D013635">Tantalum</NameOfSubstance>
                </Chemical>
            </ChemicalList>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D005271" MajorTopicYN="Y">Femur Head Necrosis</DescriptorName>
                    <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                    <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D013635" MajorTopicYN="Y">Tantalum</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="Y">Bone reconstruction</Keyword>
                <Keyword MajorTopicYN="Y">Femoral head</Keyword>
                <Keyword MajorTopicYN="Y">Osteonecrosis</Keyword>
                <Keyword MajorTopicYN="Y">Porous tantalum rod</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2022</Year>
                    <Month>01</Month>
                    <Day>14</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2022</Year>
                    <Month>01</Month>
                    <Day>30</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>3</Month>
                    <Day>7</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>5</Month>
                    <Day>21</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>3</Month>
                    <Day>6</Day>
                    <Hour>20</Hour>
                    <Minute>37</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35249117</ArticleId>
                <ArticleId IdType="doi">10.1007/s00264-022-05334-z</ArticleId>
                <ArticleId IdType="pii">10.1007/s00264-022-05334-z</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Tsao AK, Roberson JR, Christie MJ, Dore DD, Heck DA, Robertson DD, Poggie RA (2005) Biomechanical and clinical evaluations of a porous tantalum implant for the treatment of early-stage osteonecrosis. The Journal of bone and joint surgery American 87(Suppl 2):22–27. https://doi.org/10.2106/jbjs.e.00490</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.2106/jbjs.e.00490</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Shuler MS, Rooks MD, Roberson JR (2007) Porous tantalum implant in early osteonecrosis of the hip: preliminary report on operative, survival, and outcomes results. J Arthroplasty 22(1):26–31. https://doi.org/10.1016/j.arth.2006.03.007</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.arth.2006.03.007</ArticleId>
                        <ArticleId IdType="pubmed">17197305</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Liu G, Wang J, Yang S, Xu W, Ye S, Xia T (2010) Effect of a porous tantalum rod on early and intermediate stages of necrosis of the femoral head. Biomedical materials (Bristol, England) 5(6):065003. https://doi.org/10.1088/1748-6041/5/6/065003</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1088/1748-6041/5/6/065003</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Zhang Y, Li L, Shi ZJ, Wang J, Li ZH (2013) Porous tantalum rod implant is an effective and safe choice for early-stage femoral head necrosis: a meta-analysis of clinical trials. European journal of orthopaedic surgery &amp; traumatology : orthopedie traumatologie 23(2):211–217. https://doi.org/10.1007/s00590-012-0962-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00590-012-0962-7</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Liu ZH, Guo WS, Li ZR, Cheng LM, Zhang QD, Yue DB, Shi ZC, Wang BL, Sun W, Zhang NF (2014) Porous tantalum rods for treating osteonecrosis of the femoral head. Genetics and molecular research : GMR 13(4):8342–8352. https://doi.org/10.4238/2014.October.20.10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.4238/2014.October.20.10</ArticleId>
                        <ArticleId IdType="pubmed">25366728</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Floerkemeier T, Thorey F, Daentzer D, Lerch M, Klages P, Windhagen H, von Lewinski G (2011) Clinical and radiological outcome of the treatment of osteonecrosis of the femoral head using the osteonecrosis intervention implant. Int Orthop 35(4):489–495. https://doi.org/10.1007/s00264-009-0940-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00264-009-0940-9</ArticleId>
                        <ArticleId IdType="pubmed">20119747</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Aurégan J-C, Villain B, Bégué T (2018) What is the rate of patients undergoing a total hip arthroplasty after core decompression and insertion of a tantalum rod in osteonecrosis of the femoral head: a systematic review. Int Orthop 42(7):1631–1638. https://doi.org/10.1007/s00264-018-3961-4</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00264-018-3961-4</ArticleId>
                        <ArticleId IdType="pubmed">29728733</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ma J, Sun W, Gao F, Guo W, Wang Y, Li Z (2016) Porous Tantalum Implant in Treating Osteonecrosis of the Femoral Head: Still a Viable Option? Sci Rep 6:28227. https://doi.org/10.1038/srep28227</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1038/srep28227</ArticleId>
                        <ArticleId IdType="pubmed">27324659</ArticleId>
                        <ArticleId IdType="pmcid">4915004</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Stronach BM, Duke JN, Rozensweig SD, Stewart RL (2010) Subtrochanteric femur fracture after core decompression and placement of a tantalum strut for osteonecrosis of the femoral head. J Arthroplasty 25(7):1168.e1165–1167. https://doi.org/10.1016/j.arth.2009.08.008</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.arth.2009.08.008</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Tanzer M, Bobyn JD, Krygier JJ, Karabasz D (2008) Histopathologic retrieval analysis of clinically failed porous tantalum osteonecrosis implants. The Journal of bone and joint surgery American 90(6):1282–1289. https://doi.org/10.2106/jbjs.f.00847</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.2106/jbjs.f.00847</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Dickinson A, Taylor A, Browne M (2012) Implant-bone interface healing and adaptation in resurfacing hip replacement. Comput Methods Biomech Biomed Engin 15(9):935–947. https://doi.org/10.1080/10255842.2011.567269</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1080/10255842.2011.567269</ArticleId>
                        <ArticleId IdType="pubmed">21547786</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ohta H, Kobayashi S, Saito N, Nawata M, Horiuchi H, Takaoka K (2003) Sequential changes in periprosthetic bone mineral density following total hip arthroplasty: a 3-year follow-up. J Bone Miner Metab 21(4):229–233. https://doi.org/10.1007/s00774-002-0414-2</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00774-002-0414-2</ArticleId>
                        <ArticleId IdType="pubmed">12811628</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pal B, Gupta S, New AM (2009) A numerical study of failure mechanisms in the cemented resurfaced femur: effects of interface characteristics and bone remodelling. Proc Inst Mech Eng [H] 223(4):471–484. https://doi.org/10.1243/09544119jeim488</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1243/09544119jeim488</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Fernandez-Fairen M, Murcia A, Iglesias R, Sevilla P, Manero JM, Gil FJ (2012) Analysis of tantalum implants used for avascular necrosis of the femoral head: a review of five retrieved specimens. Journal of applied biomaterials &amp; functional materials 10(1):29–36. https://doi.org/10.5301/jabfm.2012.9273</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.5301/jabfm.2012.9273</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Amanatullah DF, Farac R, McDonald TJ, Moehring HD, Di Cesare PE (2013) Subtrochanteric fracture following removal of a porous tantalum implant. Case Rep Orthop 2013:946745. https://doi.org/10.1155/2013/946745</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1155/2013/946745</ArticleId>
                        <ArticleId IdType="pubmed">24367733</ArticleId>
                        <ArticleId IdType="pmcid">3866835</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Oh KJ, Pandher DS (2010) A new mode of clinical failure of porous tantalum rod. Indian journal of orthopaedics 44(4):464–467. https://doi.org/10.4103/0019-5413.69322</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.4103/0019-5413.69322</ArticleId>
                        <ArticleId IdType="pubmed">20924493</ArticleId>
                        <ArticleId IdType="pmcid">2947739</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Zhang X, Wang J, Xiao J, Shi Z (2016) Early failures of porous tantalum osteonecrosis implants: a case series with retrieval analysis. Int Orthop 40(9):1827–1834. https://doi.org/10.1007/s00264-015-3087-x</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00264-015-3087-x</ArticleId>
                        <ArticleId IdType="pubmed">26739599</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ghosh R, Gupta S (2014) Bone remodelling around cementless composite acetabular components: the effects of implant geometry and implant-bone interfacial conditions. J Mech Behav Biomed Mater 32:257–269. https://doi.org/10.1016/j.jmbbm.2014.01.010</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.jmbbm.2014.01.010</ArticleId>
                        <ArticleId IdType="pubmed">24508712</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Waizy H, Behrens BA, Radtke K, Almohallami A, Stukenborg-Colsman C, Bouguecha A (2017) Bone cyst formation after ankle arthroplasty may be caused by stress shielding. A numerical simulation of the strain adaptive bone remodelling. Foot (Edinb) 33:14–19. https://doi.org/10.1016/j.foot.2017.07.001</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.foot.2017.07.001</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Georgeanu V, Atasiei T, Gruionu L (2014) Periprosthetic bone remodelling in total knee arthroplasty. Maedica 9(1):56–61</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25553127</ArticleId>
                        <ArticleId IdType="pmcid">4268292</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Zou X, Li H, Bunger M, Egund N, Lind M, Bunger C (2004) Bone ingrowth characteristics of porous tantalum and carbon fiber interbody devices: an experimental study in pigs. The spine journal : official journal of the North American Spine Society 4(1):99–105</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/S1529-9430(03)00407-8</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Guermazi A, Miaux Y, Zaim S, Peterfy CG, White D, Genant HK (2003) Metallic artefacts in MR imaging: effects of main field orientation and strength. Clin Radiol 58(4):322–328. https://doi.org/10.1016/s0009-9260(02)00540-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/s0009-9260(02)00540-8</ArticleId>
                        <ArticleId IdType="pubmed">12662956</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neumann E, Müller-Ladner U, Frommer KW (2014) Inflammation and bone metabolism. Z Rheumatol 73(4):342–348. https://doi.org/10.1007/s00393-013-1288-5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00393-013-1288-5</ArticleId>
                        <ArticleId IdType="pubmed">24811358</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Haynes DR (2006) Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Inflammopharmacology 14(5–6):193–197. https://doi.org/10.1007/s10787-006-0006-1</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s10787-006-0006-1</ArticleId>
                        <ArticleId IdType="pubmed">17093901</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="Publisher" Owner="NLM">
            <PMID Version="1">35195847</PMID>
            <DateRevised>
                <Year>2022</Year>
                <Month>02</Month>
                <Day>23</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1863-4362</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <PubDate>
                            <Year>2022</Year>
                            <Month>Feb</Month>
                            <Day>23</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Irish journal of medical science</Title>
                    <ISOAbbreviation>Ir J Med Sci</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Early detection and treatment device for diabetic foot neuropathy.</ArticleTitle>
                <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11845-022-02958-3</ELocationID>
                <Abstract>
                    <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diabetic foot neuropathy is one of the complications of diabetes that affects around 50% of diabetic people. Because peripheral neuropathy involves nerve loss around the foot areas, patients with diabetic neuropathy frequently lose sensation in their feet while walking or standing. Furthermore, since sensory nerves are damaged, the area that holds the majority of the foot pressure and temperature is at high risk of injury. If not diagnosed and treated properly, it can cause foot injury and eventually lead to edema, gangrene, ulcers, amputation, and even death. There are now several techniques of detecting diabetic neuropathy, but they are limited in their availability, cost-effectiveness, and complexity.</AbstractText>
                    <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The primary goal of this research was to develop devices for early detection and treatment of diabetic foot neuropathy.</AbstractText>
                    <AbstractText Label="METHODS" NlmCategory="METHODS">The proposed device combines a foot pressure monitoring method and a foot temperature measurement method to diagnose diabetic neuropathy early on, with red light therapy added as a treatment method. For 2 weeks, the device measures the patient's foot pressure and temperature, and light therapy is provided if a change in pressure or temperature at a specific area is observed.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">The device prototype was successfully developed, and numerous tests were carried out in accordance with the design specifications. For pressure measurement and temperature measurement, measurement accuracy of 99.05% and 99.30%, respectively, were attained.</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The early detection and treatment device developed in this study could be used at home by diabetic patients as well as in hospitals to test for and treat diabetic foot neuropathy at an early stage. The device incorporates two different methods of diabetic foot neuropathy detection with high measurement accuracy which makes it suitable for use in resource-limited areas at low cost. The incorporation of red light therapy together with the two methods of diabetic neuropathy detection gives another unique feature for our device.</AbstractText>
                    <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Kumsa</LastName>
                        <ForeName>Hunduma Tolossa</ForeName>
                        <Initials>HT</Initials>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Gida Ayana General Hospital, Gida Ayana, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Abdisa</LastName>
                        <ForeName>Lelisa Getaneh</ForeName>
                        <Initials>LG</Initials>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Teltele Primary Hospital, Teltele, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Tolessa</LastName>
                        <ForeName>Lelisa Tesema</ForeName>
                        <Initials>LT</Initials>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Badessa Primary Hospital, Badessa, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Wubneh</LastName>
                        <ForeName>Sosina Ayele</ForeName>
                        <Initials>SA</Initials>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>ICMC Hospital, Addis Ababa, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kusa</LastName>
                        <ForeName>Wadajo Feyisa</ForeName>
                        <Initials>WF</Initials>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Wise Team PLC, Addis Ababa, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Hordofa</LastName>
                        <ForeName>Shimelis Nigusu</ForeName>
                        <Initials>SN</Initials>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Nemomssa</LastName>
                        <ForeName>Hundessa Daba</ForeName>
                        <Initials>HD</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0002-1020-845X</Identifier>
                        <AffiliationInfo>
                            <Affiliation>School of Biomedical Engineering, Jimma Institute of Technology, Jimma University, Jimma, Oromia, Ethiopia. hundedb@gmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2022</Year>
                    <Month>02</Month>
                    <Day>23</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Ireland</Country>
                <MedlineTA>Ir J Med Sci</MedlineTA>
                <NlmUniqueID>7806864</NlmUniqueID>
                <ISSNLinking>0021-1265</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Diabetes</Keyword>
                <Keyword MajorTopicYN="N">Diabetic foot ulcer</Keyword>
                <Keyword MajorTopicYN="N">Foot pressure</Keyword>
                <Keyword MajorTopicYN="N">Foot temperature</Keyword>
                <Keyword MajorTopicYN="N">Red light therapy</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2022</Year>
                    <Month>01</Month>
                    <Day>12</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2022</Year>
                    <Month>02</Month>
                    <Day>15</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>2</Month>
                    <Day>23</Day>
                    <Hour>12</Hour>
                    <Minute>28</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>2</Month>
                    <Day>24</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>2</Month>
                    <Day>24</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>aheadofprint</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35195847</ArticleId>
                <ArticleId IdType="doi">10.1007/s11845-022-02958-3</ArticleId>
                <ArticleId IdType="pii">10.1007/s11845-022-02958-3</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Lin X et al (2020) Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 2020 101 10(1):1–11. https://doi.org/10.1038/s41598-020-71908-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1038/s41598-020-71908-9</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cho NH et al (2018) IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281. https://doi.org/10.1016/J.DIABRES.2018.02.023</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/J.DIABRES.2018.02.023</ArticleId>
                        <ArticleId IdType="pubmed">29496507</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Iqbal Z et al (2018) Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther 40(6):828–849. https://doi.org/10.1016/J.CLINTHERA.2018.04.001</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/J.CLINTHERA.2018.04.001</ArticleId>
                        <ArticleId IdType="pubmed">29709457</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cardoso CRL, Salles GF (2008) Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients. J Diabetes Complications 22(3):164–170. https://doi.org/10.1016/J.JDIACOMP.2007.02.004</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/J.JDIACOMP.2007.02.004</ArticleId>
                        <ArticleId IdType="pubmed">18413219</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lee CC et al (2015) Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: the PROMISE cohort. Diabetes Care 38(5):793–800. https://doi.org/10.2337/DC14-2585/-/DC1</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.2337/DC14-2585/-/DC1</ArticleId>
                        <ArticleId IdType="pubmed">25665810</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Weledji EP, Fokam P (2014) Treatment of the diabetic foot - to amputate or not?. BMC Surg 14(1):1–6. https://doi.org/10.1186/1471-2482-14-83/FIGURES/1</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1186/1471-2482-14-83/FIGURES/1</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Fu XL, Ding H, Miao WW et al (2019) Global recurrence rates in diabetic foot ulcers: a systematic review and meta-analysis. Diabetes Metab Res Rev 35(2019).  https://doi.org/10.1002/DMRR.3160</Citation>
                </Reference>
                <Reference>
                    <Citation>Sen P, Demirdal T, Emir B (2019) Meta-analysis of risk factors for amputation in diabetic foot infections. Diabetes Metab Res Rev 35(7).  https://doi.org/10.1002/DMRR.3165</Citation>
                </Reference>
                <Reference>
                    <Citation>Petropoulos IN, Ponirakis G, Khan A et al (2018) Diagnosing diabetic neuropathy: something old, something new. Diabetes Metab J 42(4):255. https://doi.org/10.4093/DMJ.2018.0056</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.4093/DMJ.2018.0056</ArticleId>
                        <ArticleId IdType="pubmed">30136449</ArticleId>
                        <ArticleId IdType="pmcid">6107364</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nebuchennykh M, Løseth S, Lindal S, Mellgren SI (2009) The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. J Neurol 256(7):1067–1075. https://doi.org/10.1007/S00415-009-5065-Y</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/S00415-009-5065-Y</ArticleId>
                        <ArticleId IdType="pubmed">19252773</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Jiang MS, Yuan Y, Gu ZX, Zhuang SL (2016) Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. Br J Ophthalmol 100(1):9–14. https://doi.org/10.1136/BJOPHTHALMOL-2014-306038</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1136/BJOPHTHALMOL-2014-306038</ArticleId>
                        <ArticleId IdType="pubmed">25677672</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ahmed A et al (2012) Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. Diabetes Care 35(4):821. https://doi.org/10.2337/DC11-1396</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.2337/DC11-1396</ArticleId>
                        <ArticleId IdType="pubmed">22323412</ArticleId>
                        <ArticleId IdType="pmcid">3308301</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Shiferaw WS, Akalu TY, Work Y, Aynalem YA (2020) Prevalence of diabetic peripheral neuropathy in Africa: a systematic review and meta-analysis. BMC Endocr Disord 20(1):1–9. https://doi.org/10.1186/S12902-020-0534-5/FIGURES/5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1186/S12902-020-0534-5/FIGURES/5</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Yeboah K et al (2018) Arterial stiffness is associated with peripheral sensory neuropathy in diabetes patients in Ghana. J Diabetes Res 2018.  https://doi.org/10.1155/2018/2320737</Citation>
                </Reference>
                <Reference>
                    <Citation>Al Washali AY, Azuhairi AA, Hejar AR, Amani YW (2014) Prevalence and associated risk factors of diabetic peripheral neuropathy among diabetic patients in National Center of Diabetes in Yemen. Int J Public Heal Clin Sci 1(1):141–150</Citation>
                </Reference>
                <Reference>
                    <Citation>Kamei N et al (2005) Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening. J Diabetes Complications 19(1):47–53. https://doi.org/10.1016/J.JDIACOMP.2003.12.006</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/J.JDIACOMP.2003.12.006</ArticleId>
                        <ArticleId IdType="pubmed">15642490</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Tan LS (2010) The clinical use of the 10 g monofilament and its limitations: a review. Diabetes Res Clin Pract 90(1):1–7. https://doi.org/10.1016/J.DIABRES.2010.06.021</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/J.DIABRES.2010.06.021</ArticleId>
                        <ArticleId IdType="pubmed">20655123</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Burgess J et al (2021) Early detection of diabetic peripheral neuropathy: a focus on small nerve fibres. Diagnostics 2021 11(2):165. https://doi.org/10.3390/DIAGNOSTICS11020165</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.3390/DIAGNOSTICS11020165</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nithyaa AN, Premkumar R, Dhivya S, Vennila M (2013) A real time foot pressure measurement for early detection of ulcer formation in diabetics patients using labview. Procedia Eng 64:1302–1309. https://doi.org/10.1016/J.PROENG.2013.09.211</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/J.PROENG.2013.09.211</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Fawzy OA, Arafa AI, El Wakeel MA, Abdul Kareem SH (2014) Plantar pressure as a risk assessment tool for diabetic foot ulceration in Egyptian patients with diabetes. Clin Med Insights Endocrinol Diabetes 7:31.  https://doi.org/10.4137/CMED.S17088</Citation>
                </Reference>
                <Reference>
                    <Citation>Van Netten JJ, Prijs M, Van Baal JG et al (2014) Diagnostic values for skin temperature assessment to detect diabetes-related foot complications. Diabetes Technol Ther 16(11):714–721.  https://doi.org/10.1089/dia.2014.0052 . Epub 2014 Aug 6. PMID: 25098361</Citation>
                </Reference>
                <Reference>
                    <Citation>Kim MS, Cho YI, Kook MS et al (2015) Effect of 660 nm light-emitting diode on the wound healing in fibroblast-like cell lines. Int J Photoenergy 2015(916838):9.  https://doi.org/10.1155/2015/916838</Citation>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">35065447</PMID>
            <DateCompleted>
                <Year>2022</Year>
                <Month>03</Month>
                <Day>28</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2022</Year>
                <Month>04</Month>
                <Day>01</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1878-0180</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>127</Volume>
                        <PubDate>
                            <Year>2022</Year>
                            <Month>03</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>Journal of the mechanical behavior of biomedical materials</Title>
                    <ISOAbbreviation>J Mech Behav Biomed Mater</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Independent changes in bone mineralized and marrow soft tissues following acute knee injury require dual-energy or high-resolution computed tomography for accurate assessment of bone mineral density and stiffness.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>105091</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="pii" ValidYN="Y">S1751-6161(22)00018-2</ELocationID>
                <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmbbm.2022.105091</ELocationID>
                <Abstract>
                    <AbstractText>Musculoskeletal injuries often induce local accumulation of blood and/or fluid within the bone marrow, which is detected on medical imaging as edema-like marrow signal intensities (EMSI). In addition to its biological effects on post-injury recovery, the displacement of low-attenuating, largely adipocytic marrow by EMSI may introduce errors into quantitative computed tomography (QCT) measurements of bone mineral density (vBMD) and resulting bone stiffness estimates from image-based finite element (FE) analysis. We aimed to investigate the impact of post-injury changes in marrow soft tissue composition on CT-based bone measurements by applying CT imaging at multiple spatial resolutions. To do so, dual energy QCT (DECT) material decomposition was used to detect EMSI in the tibiae of nineteen participants with a recent anterior cruciate ligament tear. We then measured bone density and FE-based apparent modulus within the EMSI region and in a matched volume in the uninjured contralateral knee. Three measurement methods were applied: 1.) standard, QCT density calibration and density-based FEM; 2.) a DECT density calibration that provides density measurements adjusted for marrow soft tissues; and 3.) high-resolution peripheral QCT (HR-pQCT) density and microFE analyses. When measured using standard, single-energy QCT, vBMD and apparent modulus were elevated in the EMSI compared to the contralateral. After adjusting for marrow soft tissue composition using DECT, these measurements were no longer different between the two regions. By allowing for high-resolution, localized density analysis, HR-pQCT indicated that trabecular tissue mineral density was 9 mgHA/cm<sup>3</sup> lower, while density of marrow soft tissues was 18 mgHA/cm<sup>3</sup> higher, in the EMSI than the contralateral region, suggesting that EMSI have opposite effects on the measured density of trabecular bone and the underlying soft marrow. Thus, after an acute injury, altered composition of marrow soft tissues may artificially inflate overall measurements of bone density and apparent modulus obtained using standard QCT. This can be corrected by accounting for marrow soft tissue attenuation, either by using DECT-based density calibration or HR-pQCT microFE and measurements of local density of trabeculae.</AbstractText>
                    <CopyrightInformation>Copyright © 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>de Bakker</LastName>
                        <ForeName>Chantal M J</ForeName>
                        <Initials>CMJ</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Cumming School of Medicine, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Knowles</LastName>
                        <ForeName>Nikolas K</ForeName>
                        <Initials>NK</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Cumming School of Medicine, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Walker</LastName>
                        <ForeName>Richard E A</ForeName>
                        <Initials>REA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Cumming School of Medicine, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Manske</LastName>
                        <ForeName>Sarah L</ForeName>
                        <Initials>SL</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Cumming School of Medicine, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Boyd</LastName>
                        <ForeName>Steven K</ForeName>
                        <Initials>SK</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Cumming School of Medicine, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada. Electronic address: skboyd@ucalgary.ca.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <GrantList CompleteYN="Y">
                    <Grant>
                        <GrantID>PJT-162189</GrantID>
                        <Agency>CIHR</Agency>
                        <Country>Canada</Country>
                    </Grant>
                </GrantList>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2022</Year>
                    <Month>01</Month>
                    <Day>15</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Netherlands</Country>
                <MedlineTA>J Mech Behav Biomed Mater</MedlineTA>
                <NlmUniqueID>101322406</NlmUniqueID>
                <ISSNLinking>1878-0180</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D015519" MajorTopicYN="Y">Bone Density</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
                    <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D007718" MajorTopicYN="Y">Knee Injuries</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
                    <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="Y">Acute knee injury</Keyword>
                <Keyword MajorTopicYN="Y">Bone density measurement</Keyword>
                <Keyword MajorTopicYN="Y">Bone marrow edema</Keyword>
                <Keyword MajorTopicYN="Y">Dual-energy computed tomography</Keyword>
                <Keyword MajorTopicYN="Y">Finite element analysis</Keyword>
                <Keyword MajorTopicYN="Y">Material decomposition</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2021</Year>
                    <Month>09</Month>
                    <Day>22</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="revised">
                    <Year>2021</Year>
                    <Month>12</Month>
                    <Day>12</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2022</Year>
                    <Month>01</Month>
                    <Day>12</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2022</Year>
                    <Month>1</Month>
                    <Day>23</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>3</Month>
                    <Day>29</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2022</Year>
                    <Month>1</Month>
                    <Day>22</Day>
                    <Hour>20</Hour>
                    <Minute>13</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">35065447</ArticleId>
                <ArticleId IdType="pii">S1751-6161(22)00018-2</ArticleId>
                <ArticleId IdType="doi">10.1016/j.jmbbm.2022.105091</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">34855654</PMID>
            <DateCompleted>
                <Year>2022</Year>
                <Month>03</Month>
                <Day>07</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2022</Year>
                <Month>03</Month>
                <Day>07</Day>
            </DateRevised>
            <Article PubModel="Print">
                <Journal>
                    <ISSN IssnType="Electronic">1473-5725</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>27</Volume>
                        <Issue>2</Issue>
                        <PubDate>
                            <Year>2022</Year>
                            <Month>Apr</Month>
                            <Day>01</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Blood pressure monitoring</Title>
                    <ISOAbbreviation>Blood Press Monit</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Relationship between noninvasive central blood pressure and brain natriuretic peptide levels in patients with hypertensive pulmonary edema.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>113-120</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1097/MBP.0000000000000574</ELocationID>
                <Abstract>
                    <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Hypertensive pulmonary edema is a fatal condition unless early and properly diagnosed and managed. Central blood pressure (cBP) has been proven to be more associated with adverse cardiovascular events. We aimed to study the correlation between cBP and heart damage in patients with Hypertensive pulmonary edema.</AbstractText>
                    <AbstractText Label="METHODS" NlmCategory="METHODS">We included 50 patients admitted to the emergency department in a university hospital for hypertensive pulmonary edema, 27 women and 23 men aged 50 to 70 years. We excluded patients with suspected acute coronary syndrome, significant valvular heart disease, and pericardial diseases. We measured cBP non-invasively from pulse wave analysis of the brachial artery. Brain natriuretic peptide (BNP) and cBP were repeatedly measured for every patient.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median BNP levels of patients significantly decreased from 284 pg/ml (232-352.5) to 31.5 pg/ml (24-54) on discharge, P &lt; 0.001. We found a significant correlation between admission BNP and central SBP (cSBP), urea, creatinine, arterial blood gases parameters, and left ventricular end-diastolic diameter (LVEDD). Concurrently, BNP at discharge was correlated with age, central DBP (cDBP), urea, creatinine, LVEDD, partial oxygen pressure (pO2), and oxygen saturation (SO2). Delta BNP was correlated with cSBP, peripheral SBP, urea, creatinine, pO2, and SO2. Linear regression analysis revealed that creatinine, and cSBP, were independent predictors of admission BNP, while urea and cDBP were the independent predictors of discharge BNP.</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This simple, noninvasive method of cBP measurement was significantly associated with the extent of myocardial damage in patients presenting with hypertensive pulmonary edema.</AbstractText>
                    <CopyrightInformation>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Algowhary</LastName>
                        <ForeName>Magdy Ibrahim Aldesowky Mohammed</ForeName>
                        <Initials>MIAM</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Razik</LastName>
                        <ForeName>Nady A</ForeName>
                        <Initials>NA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Youssef</LastName>
                        <ForeName>Amr Ahmed Aly</ForeName>
                        <Initials>AAA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Fouad</LastName>
                        <ForeName>Lateef Gerges Lateef</ForeName>
                        <Initials>LGL</Initials>
                        <AffiliationInfo>
                            <Affiliation>Cardiology Department, Al-Eman General Hospital, Assiut, Egypt.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Hassan</LastName>
                        <ForeName>Ayman Khairy M</ForeName>
                        <Initials>AKM</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
            </Article>
            <MedlineJournalInfo>
                <Country>England</Country>
                <MedlineTA>Blood Press Monit</MedlineTA>
                <NlmUniqueID>9606438</NlmUniqueID>
                <ISSNLinking>1359-5237</ISSNLinking>
            </MedlineJournalInfo>
            <ChemicalList>
                <Chemical>
                    <RegistryNumber>114471-18-0</RegistryNumber>
                    <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
                </Chemical>
            </ChemicalList>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName>
                    <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                    <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D011654" MajorTopicYN="Y">Pulmonary Edema</DescriptorName>
                    <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                    <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                </MeshHeading>
            </MeshHeadingList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>12</Month>
                    <Day>3</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2022</Year>
                    <Month>3</Month>
                    <Day>8</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>12</Month>
                    <Day>2</Day>
                    <Hour>17</Hour>
                    <Minute>24</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">34855654</ArticleId>
                <ArticleId IdType="doi">10.1097/MBP.0000000000000574</ArticleId>
                <ArticleId IdType="pii">00126097-900000000-99264</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>López-Rivera F, Cintrón Martínez HR, Castillo LaTorre C, Rivera González A, Rodríguez Vélez JG, Fonseca Ferrer V, et al. Treatment of hypertensive cardiogenic edema with intravenous high-dose nitroglycerin in a patient presenting with signs of respiratory failure: a case report and review of the literature. Am J Case Rep 2019; 20:83–90.</Citation>
                </Reference>
                <Reference>
                    <Citation>Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4(suppl 7):S21–S30.</Citation>
                </Reference>
                <Reference>
                    <Citation>Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008; 51:2432–2439.</Citation>
                </Reference>
                <Reference>
                    <Citation>Johnstone D, Limacher M, Rousseau M, Liang CS, Ekelund L, Herman M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992; 70:894–900.</Citation>
                </Reference>
                <Reference>
                    <Citation>Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43:317–327.</Citation>
                </Reference>
                <Reference>
                    <Citation>Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014; 383:999–1008.</Citation>
                </Reference>
                <Reference>
                    <Citation>Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol 2017; 33:1342–1433.</Citation>
                </Reference>
                <Reference>
                    <Citation>Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 2003; 24:883–896.</Citation>
                </Reference>
                <Reference>
                    <Citation>Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et alBNP Consensus Panel. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10:1–30.</Citation>
                </Reference>
                <Reference>
                    <Citation>Sever PS. The Anglo-Scandinavian Cardiac Outcomes Trial: implications and further outcomes. Hypertension 2012; 60:248–259.</Citation>
                </Reference>
                <Reference>
                    <Citation>Lamarche F, Agharazii M, Madore F, Goupil R. Prediction of cardiovascular events by type I central systolic blood pressure: a prospective study. Hypertension 2021; 77:319–327.</Citation>
                </Reference>
                <Reference>
                    <Citation>Horváth IG, Németh A, Lenkey Z, Alessandri N, Tufano F, Kis P, et al. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J Hypertens 2010; 28:2068–2075.</Citation>
                </Reference>
                <Reference>
                    <Citation>Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197–203.</Citation>
                </Reference>
                <Reference>
                    <Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et alAuthors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18:891–975.</Citation>
                </Reference>
                <Reference>
                    <Citation>Ford LE. Acute hypertensive pulmonary edema: a new paradigm. Can J Physiol Pharmacol 2010; 88:9–13.</Citation>
                </Reference>
                <Reference>
                    <Citation>Daniel ACQG, Machado JP, Veiga EV. Blood pressure documentation in the emergency department. Einstein (Sao Paulo) 2017; 15:29–33.</Citation>
                </Reference>
                <Reference>
                    <Citation>Agabiti-Rosei E, Mancia G, O’Rourke MF, Roman MJ, Safar ME, Smulyan H, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007; 50:154–160.</Citation>
                </Reference>
                <Reference>
                    <Citation>Sánchez R, Pessana F, Lev G, Mirada M, Mendiz O, Ramírez A, Fischer EC. Central blood pressure waves assessment: a validation study of non-invasive aortic pressure measurement in human beings. High Blood Press Cardiovasc Prev 2020; 27:165–174.</Citation>
                </Reference>
                <Reference>
                    <Citation>Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev 2014; 19:453–470.</Citation>
                </Reference>
                <Reference>
                    <Citation>Zhu WH, Chen LY, Dai HL, Chen JH, Chen Y, Fang LZ. Correlation between B type natriuretic peptide and metabolic risk factors. Arch Med Sci 2016; 12:334–340.</Citation>
                </Reference>
                <Reference>
                    <Citation>Luchner A, Behrens G, Stritzke J, Markus M, Stark K, Peters A, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Fail 2013; 15:859–867.</Citation>
                </Reference>
                <Reference>
                    <Citation>Harada M, Hara F, Yamazaki J. Correlation between plasma B-type natriuretic peptide levels and left ventricular diastolic function using color kinetic imaging. J Cardiol 2010; 56:91–96.</Citation>
                </Reference>
                <Reference>
                    <Citation>Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et alGet With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126:65–75.</Citation>
                </Reference>
                <Reference>
                    <Citation>Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655–663.</Citation>
                </Reference>
                <Reference>
                    <Citation>Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59:442–451.</Citation>
                </Reference>
                <Reference>
                    <Citation>McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et alBreathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41:571–579.</Citation>
                </Reference>
                <Reference>
                    <Citation>Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011; 123:2006–13; discussion 2014.</Citation>
                </Reference>
                <Reference>
                    <Citation>Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. Hypertension 2016; 67:183–190.</Citation>
                </Reference>
                <Reference>
                    <Citation>Seki S, Tsurusaki T, Kasai T, Taniguchi I, Mochizuki S, Yoshimura M. Clinical significance of B-type natriuretic Peptide in the assessment of untreated hypertension. Circ J 2008; 72:770–777.</Citation>
                </Reference>
                <Reference>
                    <Citation>Mansour AE, Abdelsamad AA, El Arman MM. Prognostic value of plasma brain natriuretic peptide in patients with stable chronic obstructive pulmonary disease. Egyptian J Chest Dis Tuberculosis 2012; 61:297–300.</Citation>
                </Reference>
                <Reference>
                    <Citation>Park JJ, Choi DJ, Yoon CH, Oh IY, Lee JH, Ahn S, et alKorHF Registry. The prognostic value of arterial blood gas analysis in high-risk acute heart failure patients: an analysis of the Korean Heart Failure (KorHF) registry. Eur J Heart Fail 2015; 17:601–611.</Citation>
                </Reference>
                <Reference>
                    <Citation>Chi SY, Kim EY, Ban HJ, Oh IJ, Kwon YS, Kim KS, et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 2012; 190:271–276.</Citation>
                </Reference>
                <Reference>
                    <Citation>Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133:1088–1094.</Citation>
                </Reference>
                <Reference>
                    <Citation>Chen LJ, Hung CL, Yeh HI, Jeng MJ, Su CH, Wu TY, et al. The utilization and prognostic impact of B-type Natriuretic Peptide in hospitalized acute decompensated heart failure in an Asian population. BMC Cardiovasc Disord 2016; 16:178.</Citation>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
            <PMID Version="1">34190937</PMID>
            <DateCompleted>
                <Year>2021</Year>
                <Month>07</Month>
                <Day>02</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2022</Year>
                <Month>05</Month>
                <Day>31</Day>
            </DateRevised>
            <Article PubModel="Electronic-eCollection">
                <Journal>
                    <ISSN IssnType="Electronic">1518-8345</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>29</Volume>
                        <PubDate>
                            <Year>2021</Year>
                        </PubDate>
                    </JournalIssue>
                    <Title>Revista latino-americana de enfermagem</Title>
                    <ISOAbbreviation>Rev Lat Am Enfermagem</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Elaboration and validation of an algorithm for treating peripheral intravenous infiltration and extravasation in children.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>e3435</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="pii" ValidYN="Y">S0104-11692021000100339</ELocationID>
                <ELocationID EIdType="doi" ValidYN="Y">10.1590/1518-8345.4314.3435</ELocationID>
                <Abstract>
                    <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">to elaborate and validate the content and appearance of an algorithm for treating infiltration and extravasation of non-chemotherapy drugs and solutions administered to children.</AbstractText>
                    <AbstractText Label="METHOD" NlmCategory="METHODS">a methodological study of the technology formulation and validation type. To elaborate the algorithm, a bibliographic review was carried out to list the scientific evidence on the treatment of infiltration and extravasation. Content and appearance validation was in charge of 14 specialists in pediatric nursing, using the Delphi technique, adopting a value equal to or greater than 0.80 as Content Validation Index.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">the algorithm was validated in the third evaluation by the judges, reaching a Global Content Validation Index of 0.99, being composed by the perception of the occurrence of the complication; discontinuation of intravenous therapy infusion; verification of signs and symptoms; measurement of edema; application of an infiltration and extravasation assessment scale and conduits to be used according to the characteristics of the fluid administered and the type of complication.</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">the algorithm was validated and can be used in a practical and objective way by health professionals, in order to promote safety in the care of hospitalized children, with regard to reducing harms caused by infiltration and extravasation.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Santos</LastName>
                        <ForeName>Luciano Marques Dos</ForeName>
                        <Initials>LMD</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0001-7866-6353</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Universidade Estadual de Feira de Santana, Departamento de Saúde, Feira de Santana, BA, Brazil.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Universidade Federal de São Paulo, Escola Paulista de Enfermagem, São Paulo, SP, Brazil.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Nunes</LastName>
                        <ForeName>Katharinne de Jesus</ForeName>
                        <Initials>KJ</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0002-4540-1727</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Universidade Estadual de Feira de Santana, Departamento de Saúde, Feira de Santana, BA, Brazil.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Silva</LastName>
                        <ForeName>Cleonara Sousa Gomes E</ForeName>
                        <Initials>CSGE</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0002-4827-8306</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Universidade Estadual de Feira de Santana, Departamento de Saúde, Feira de Santana, BA, Brazil.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kusahara</LastName>
                        <ForeName>Denise Miyuki</ForeName>
                        <Initials>DM</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0002-9498-0868</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Universidade Federal de São Paulo, Escola Paulista de Enfermagem, São Paulo, SP, Brazil.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Rodrigues</LastName>
                        <ForeName>Elisa da Conceição</ForeName>
                        <Initials>EDC</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0001-6131-8272</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Universidade Federal do Rio de Janeiro, Escola de Enfermagem Anna Nery, Rio de Janeiro, RJ, Brazil.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Avelar</LastName>
                        <ForeName>Ariane Ferreira Machado</ForeName>
                        <Initials>AFM</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0001-7479-8121</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Universidade Federal de São Paulo, Escola Paulista de Enfermagem, São Paulo, SP, Brazil.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <Language>por</Language>
                <Language>spa</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D016454">Review</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>06</Month>
                    <Day>28</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Brazil</Country>
                <MedlineTA>Rev Lat Am Enfermagem</MedlineTA>
                <NlmUniqueID>9420934</NlmUniqueID>
                <ISSNLinking>0104-1169</ISSNLinking>
            </MedlineJournalInfo>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D002406" MajorTopicYN="Y">Catheterization, Peripheral</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D010371" MajorTopicYN="N">Pediatric Nursing</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2020</Year>
                    <Month>04</Month>
                    <Day>08</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2020</Year>
                    <Month>09</Month>
                    <Day>12</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>6</Month>
                    <Day>30</Day>
                    <Hour>12</Hour>
                    <Minute>24</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>7</Month>
                    <Day>1</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>7</Month>
                    <Day>3</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>epublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">34190937</ArticleId>
                <ArticleId IdType="pii">S0104-11692021000100339</ArticleId>
                <ArticleId IdType="doi">10.1590/1518-8345.4314.3435</ArticleId>
                <ArticleId IdType="pmc">PMC8253344</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Cien Saude Colet. 2015 Mar;20(3):925-36</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25760132</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Jpn J Clin Oncol. 2014 Feb;44(2):168-71</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24302758</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rev Bras Enferm. 2020;73(4):e20190300</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32490990</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cochrane Database Syst Rev. 2017 Jul 19;7:CD008404</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28724193</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>World J Clin Oncol. 2016 Feb 10;7(1):87-97</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26862492</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am J Med. 2015 Sep;128(9):943-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25820169</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Turk J Pediatr. 2017;59(2):1621-168</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29276869</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rev Lat Am Enfermagem. 2017 Dec 04;25:e2955</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29211197</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Adv Exp Med Biol. 2019;1148:255-277</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31482503</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pediatr Nurs. 2016 Jan-Feb;42(1):14-20, 49</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27019937</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Adv Nurs. 2003 Feb;41(4):376-82</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12581103</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Hand Surg Am. 2011 Dec;36(12):2060-5; quiz 2066</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22123049</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rev Bras Enferm. 2018 Jul-Aug;71(4):1815-1816</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30156664</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Plast Reconstr Aesthet Surg. 2015 Apr;68(4):505-18</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25618570</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Educ Eval Health Prof. 2020;17:21</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32668826</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Infus Nurs. 2020 Nov/Dec;43(6):319-343</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">33141794</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Vasc Access. 2018 May;19(3):266-271</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29772983</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>BMC Pediatr. 2018 Oct 13;18(1):324</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30316301</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pharmacotherapy. 2014 Jun;34(6):617-32</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24420913</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rev Assoc Med Bras (1992). 2017 Oct;63(10):842-855</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29267485</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rev Bras Enferm. 2020 Jun 08;73(4):e20190471</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32520098</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Clin Nurs. 2017 Jan 19;:</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28102920</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ostomy Wound Manage. 2012 Jul;58(7):40-4</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22798353</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>ANZ J Surg. 2019 Apr;89(4):E122-E126</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28682011</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rev Bras Enferm. 2015 Jan-Feb;68(1):9-14, 13-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25946489</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Acta Paediatr. 2018 Jul;107(7):1240-1246</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29461646</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pediatrics. 2020 Jun;145(Suppl 3):S269-S284</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32482739</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Pharmacother. 2014 Apr 8;48(7):870-886</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24714850</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Infus Nurs. 2009 Jul-Aug;32(4):203-11</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19605999</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Infus Nurs. 2018 Jul/Aug;41(4):247-252</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29958261</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Pharmacother. 2020 Aug;54(8):804-814</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32054312</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Infus Nurs. 2013 Nov-Dec;36(6):392-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24202118</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Oncol Nurs. 2012 Feb;16(1):17-25</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21440502</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Pediatr Nurs. 2017 Jan - Feb;32:47-51</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27651032</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Pediatr Nurs. 2020 Jan - Feb;50:e18-e25</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31648879</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
            <PMID Version="1">33911041</PMID>
            <DateRevised>
                <Year>2022</Year>
                <Month>04</Month>
                <Day>22</Day>
            </DateRevised>
            <Article PubModel="Print">
                <Journal>
                    <ISSN IssnType="Print">2234-7550</ISSN>
                    <JournalIssue CitedMedium="Print">
                        <Volume>47</Volume>
                        <Issue>2</Issue>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>Apr</Month>
                            <Day>30</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Journal of the Korean Association of Oral and Maxillofacial Surgeons</Title>
                    <ISOAbbreviation>J Korean Assoc Oral Maxillofac Surg</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Efficacy of local hyaluronidase administration in guided bone regeneration surgery: a randomized controlled trial.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>91-98</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.5125/jkaoms.2021.47.2.91</ELocationID>
                <Abstract>
                    <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Hyaluronoglucosaminidase (hyaluronidase) increases the local intercellular permeability of the peripheral lymphatic channel and capillaries, which may help reduce edema. In the present study, the effects of hyaluronidase on postoperative edema and pain reduction were evaluated.</AbstractText>
                    <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study included 38 patients who underwent guided bone regeneration (GBR) surgery before implantation. Patients were randomly assigned to either the control group (n=20) or the test group (n=18). Hyaluronidase was injected into the GBR site of subjects in the test group. Postoperative edema was evaluated by measuring the distance between specific facial landmarks immediately after surgery (T1) and 2-4 days after surgery (T2). The degree of pain at T2 and at 10-14 days after surgery (T3) was assessed.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the test group, the degree of swelling was lower than in the control group, however, only two measurements, from the tragus to the mouth corner and from the outer canthus to the mouth corner, showed statistically significant differences (<i>P</i>=0.012 and <i>P</i>=0.001, respectively). The anti-edema effect of hyaluronidase was more effective in the maxilla than in the mandible. In the maxilla, the percentage of facial swelling was significant for three measurements. However, in the mandible, the percentage of facial swelling was significant for only one measurement. Low levels of pain that were similar at T2 and T3 were reported in both groups.</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicate the degree of swelling was lower in the test group and hyaluronidase appeared to be more effective in the maxilla. The degree of pain reduction was similar between groups. Further in vivo and randomized controlled trials with larger sample sizes are warranted.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Kwoen</LastName>
                        <ForeName>Min-Jeong</ForeName>
                        <Initials>MJ</Initials>
                        <Identifier Source="ORCID">https://orcid.org/0000-0002-0246-4090</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Oral and Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Choi</LastName>
                        <ForeName>Yong-Hoon</ForeName>
                        <Initials>YH</Initials>
                        <Identifier Source="ORCID">https://orcid.org/0000-0001-8222-219X</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Conservative Dentistry, Section of Dentistry, Seoul National University Bundang Hospital, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kim</LastName>
                        <ForeName>Keun-Suh</ForeName>
                        <Initials>KS</Initials>
                        <Identifier Source="ORCID">https://orcid.org/0000-0002-5986-4810</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Oral and Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Chang</LastName>
                        <ForeName>Na-Hee</ForeName>
                        <Initials>NH</Initials>
                        <Identifier Source="ORCID">https://orcid.org/0000-0001-8634-571X</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Biomedical Research Institute, Seoul National University Bundang Hospital, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kim</LastName>
                        <ForeName>Young-Kyun</ForeName>
                        <Initials>YK</Initials>
                        <Identifier Source="ORCID">https://orcid.org/0000-0002-7268-3870</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Dentistry and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Lee</LastName>
                        <ForeName>Hyo-Jung</ForeName>
                        <Initials>HJ</Initials>
                        <Identifier Source="ORCID">https://orcid.org/0000-0002-0439-7389</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Oral and Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seoul, Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
            </Article>
            <MedlineJournalInfo>
                <Country>Korea (South)</Country>
                <MedlineTA>J Korean Assoc Oral Maxillofac Surg</MedlineTA>
                <NlmUniqueID>101580242</NlmUniqueID>
                <ISSNLinking>1225-1585</ISSNLinking>
            </MedlineJournalInfo>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Bone graft</Keyword>
                <Keyword MajorTopicYN="N">Guided bone regeneration</Keyword>
                <Keyword MajorTopicYN="N">Hyaluronoglucosaminidase</Keyword>
                <Keyword MajorTopicYN="N">Pain reduction</Keyword>
                <Keyword MajorTopicYN="N">Postoperative edema</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2020</Year>
                    <Month>11</Month>
                    <Day>06</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="revised">
                    <Year>2021</Year>
                    <Month>01</Month>
                    <Day>05</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2021</Year>
                    <Month>01</Month>
                    <Day>11</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>29</Day>
                    <Hour>5</Hour>
                    <Minute>48</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>30</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>30</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33911041</ArticleId>
                <ArticleId IdType="pii">jkaoms.2021.47.2.91</ArticleId>
                <ArticleId IdType="doi">10.5125/jkaoms.2021.47.2.91</ArticleId>
                <ArticleId IdType="pmc">PMC8084749</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>J Oral Maxillofac Surg. 2009 May;67(5):1026-31</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19375013</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Protein Pept Lett. 2018;25(7):663-676</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29956608</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Lasers Med Sci. 2016 Fall;7(4):259-264</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28491263</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Oral Maxillofac Surg. 2004 Jan;62(1):57-61</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14699550</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Int J Oral Maxillofac Surg. 2008 Apr;37(4):341-4</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18272338</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Int J Oral Maxillofac Implants. 2017 Sep 22;33(1):41–50</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28938030</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Exp Med. 1933 Jul 31;58(2):161-81</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19870187</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Arch Craniofac Surg. 2018 Sep;19(3):218-221</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30282434</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pain. 2011 Oct;152(10):2399-2404</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21856077</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Craniofac Surg. 2019 Oct;30(7):e617-e619</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31261329</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Int J Dermatol. 2014 Jun;53(6):777-85</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24168080</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Clin Periodontol. 2005 Feb;32(2):212-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15691354</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Oral Maxillofac Surg. 2018 Aug;76(8):1653-1659</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29654778</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Oral Dis. 2011 Jan;17(1):33-44</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20604872</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Expert Opin Drug Deliv. 2007 Jul;4(4):427-40</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17683255</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Exp Med. 1941 Jan 1;73(1):109-23</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19871061</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Oral Surg Oral Med Oral Pathol. 1983 May;55(5):448-51</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">6575332</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Clin Periodontol. 2003 Sep;30(9):809-18</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12956657</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Inflamm Res. 2016 Jul;65(7):533-42</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26943648</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Oral Implantol. 2010;36(1):25-30</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20218867</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Acta Orthop Scand. 2000 Oct;71(5):496-502</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11186408</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Med Res. 2016 Feb 13;21:5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26873038</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
            <PMID Version="1">33880069</PMID>
            <DateRevised>
                <Year>2022</Year>
                <Month>04</Month>
                <Day>22</Day>
            </DateRevised>
            <Article PubModel="Electronic-eCollection">
                <Journal>
                    <ISSN IssnType="Print">1179-1470</ISSN>
                    <JournalIssue CitedMedium="Print">
                        <Volume>14</Volume>
                        <PubDate>
                            <Year>2021</Year>
                        </PubDate>
                    </JournalIssue>
                    <Title>Medical devices (Auckland, N.Z.)</Title>
                    <ISOAbbreviation>Med Devices (Auckl)</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Evaluation of the Accuracy of a Video and AI Solution to Measure Lower Leg and Foot Volume.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>105-118</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.2147/MDER.S297713</ELocationID>
                <Abstract>
                    <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Peripheral edema, change in foot volume, is a marker of congestion which is regularly assessed in routine clinical care. A novel video and Artificial Intelligence (AI)-based solution used to measure anatomical parameters, including volume and foot length, Heartfelt HF-1, is compared to the laboratory gold standard (water displacement) and a medical disposable measuring tape.</AbstractText>
                    <AbstractText Label="DESIGN SETTING PARTICIPANTS AND MEASUREMENTS" NlmCategory="UNASSIGNED">58 healthy volunteers were measured with the Heartfelt device; 22 were also measured with the water displacement method and 19 with the medical tape. Bland-Altman analysis was performed for both volumes and foot lengths. Left/right foot differences provided covariance-corrected standard error of measurement (ccSEM) and minimum detectable difference (MDD) for each measurement method.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">Heartfelt device measured volumes displayed excellent correlation to the gold standard (water displacement), with Bland-Altman bias of +32mL ±81mL (1 std.dev). Clinically important change in foot volume is approximately 13%. Water displacement yielded ccSEM of ± 32.1mL and MDD of 90mL (6.7% of average foot volume), while the Heartfelt device measurements yielded ccSEM of ±12.6mL and MDD of 35.3mL (2.6% of average foot volume). The majority of differences were attributable to manual positioning of the patient foot in the waterbath.</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study finds that in clinical and non-clinical settings, the Heartfelt device measures foot volume and length more precisely than either the water displacement technique or manual foot length measurements using a medical disposable tape, while having an excellent agreement with these methods.</AbstractText>
                    <CopyrightInformation>© 2021 Chausiaux et al.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Chausiaux</LastName>
                        <ForeName>Oriane</ForeName>
                        <Initials>O</Initials>
                        <Identifier Source="ORCID">0000-0002-2819-7795</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Heartfelt Technologies Ltd, Cambridge, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Williams</LastName>
                        <ForeName>Gareth</ForeName>
                        <Initials>G</Initials>
                        <AffiliationInfo>
                            <Affiliation>Heartfelt Technologies Ltd, Cambridge, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Nieznański</LastName>
                        <ForeName>Michał</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Heartfelt Technologies Ltd, Cambridge, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Bagdu</LastName>
                        <ForeName>Adem</ForeName>
                        <Initials>A</Initials>
                        <AffiliationInfo>
                            <Affiliation>Warwick Medical School, University of Warwick, Coventry, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Downer</LastName>
                        <ForeName>Philip</ForeName>
                        <Initials>P</Initials>
                        <Identifier Source="ORCID">0000-0002-6665-2437</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Heartfelt Technologies Ltd, Cambridge, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Keyser</LastName>
                        <ForeName>Melanie</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Heartfelt Technologies Ltd, Cambridge, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Husheer</LastName>
                        <ForeName>Shamus</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Heartfelt Technologies Ltd, Cambridge, UK.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>04</Month>
                    <Day>13</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>New Zealand</Country>
                <MedlineTA>Med Devices (Auckl)</MedlineTA>
                <NlmUniqueID>101566041</NlmUniqueID>
                <ISSNLinking>1179-1470</ISSNLinking>
            </MedlineJournalInfo>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">-medical device</Keyword>
                <Keyword MajorTopicYN="N">AI</Keyword>
                <Keyword MajorTopicYN="N">congestion</Keyword>
                <Keyword MajorTopicYN="N">heart failure</Keyword>
                <Keyword MajorTopicYN="N">lymphedema</Keyword>
                <Keyword MajorTopicYN="N">peripheral edema</Keyword>
                <Keyword MajorTopicYN="N">renal disease</Keyword>
            </KeywordList>
            <CoiStatement>Dr Oriane Chausiaux and Dr Shamus Husheer are founder-directors of Heartfelt Technologies Ltd and hold stock in the company, Gareth Williams is a director of Heartfelt Technologies Ltd and holds stock options in the company, and all 3 are employed by the company and are inventors on granted patent GB2576770B. Dr Shamus Husheer is the inventor on granted patent GB2542114B. Michał Nieznański, Philip Downer and Dr Melanie Keyser are employees and option holders in the company. Adem Bagdu was an intern in the company during the project (funded by Santander, through the University of Bath, UK). Mr Adem Bagdu reports personal fees from Heartfelt Technologies Ltd, during the conduct of the study. Dr Shamus Husheer reports a patent GB2542114B issued. The authors report no other potential conflicts of interest in this work.</CoiStatement>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2020</Year>
                    <Month>12</Month>
                    <Day>22</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2021</Year>
                    <Month>02</Month>
                    <Day>16</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>21</Day>
                    <Hour>6</Hour>
                    <Minute>41</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>22</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>22</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>epublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33880069</ArticleId>
                <ArticleId IdType="doi">10.2147/MDER.S297713</ArticleId>
                <ArticleId IdType="pii">297713</ArticleId>
                <ArticleId IdType="pmc">PMC8053525</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Lancet. 1986 Feb 8;1(8476):307-10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">2868172</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Orthop Sports Phys Ther. 1999 Oct;29(10):609-15</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10560070</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lymphology. 2017;50(4):197-202</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30248724</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lymphat Res Biol. 2019 Apr;17(2):178-186</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30995190</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Clin Physiol. 2000 Jan;20(1):56-61</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10651793</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Emerg Med Clin North Am. 2019 May;37(2):301-316</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30940374</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Oslo City Hosp. 1981 Jan;31(1):11-5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">6111586</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lymphology. 1994 Jun;27(2):56-70</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8078362</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Sensors (Basel). 2013 Aug 14;13(8):10584-98</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23948874</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lymphat Res Biol. 2020 Oct;18(5):416-421</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32159446</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>BMC Med Res Methodol. 2010 Jan 13;10:5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20070899</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Vasc Surg. 2002 Jan;35(1):8-15</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11802127</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>AACN Adv Crit Care. 2008 Apr-Jun;19(2):223-34</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18560291</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Adv Chronic Kidney Dis. 2017 Sep;24(5):325-331</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29031360</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lymphology. 2003 Sep;36(3):140-3</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14552033</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Heart Fail. 2005 Oct;7(6):953-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16227134</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lymphology. 2005 Mar;38(1):20-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15856683</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Phlebology. 2017 Apr;32(1_suppl):3-19</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28211296</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>IEEE Trans Pattern Anal Mach Intell. 2008 Feb;30(2):328-41</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">18084062</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cardiovasc Diagn Ther. 2017 Jun;7(3):317-324</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28567357</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Int J Cardiol. 2019 Jun 15;285:40-46</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30905515</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Biomed Eng. 1993 Nov;15(6):477-80</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8277752</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Eur J Cardiovasc Nurs. 2007 Mar;6(1):60-5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16784891</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Circulation. 2005 Sep 20;112(12):e154-235</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16160202</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Clin Med Res. 2009 Jun;7(1-2):21-31</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19251582</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):39-45</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26992967</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Skin Res Technol. 2012 Feb;18(1):120-4</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21429012</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Oslo City Hosp. 1981 Dec;31(12):153-5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">7310559</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" Owner="NLM">
            <PMID Version="1">33879816</PMID>
            <DateCompleted>
                <Year>2021</Year>
                <Month>12</Month>
                <Day>03</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2021</Year>
                <Month>12</Month>
                <Day>14</Day>
            </DateRevised>
            <Article PubModel="Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">2045-2322</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>11</Volume>
                        <Issue>1</Issue>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>04</Month>
                            <Day>20</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Scientific reports</Title>
                    <ISOAbbreviation>Sci Rep</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Peripheral vasoreactivity in acute ischemic stroke with hemiplegia.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>8531</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-88050-9</ELocationID>
                <Abstract>
                    <AbstractText>The association between vasomotor tone of the peripheral arteries and cerebral hemisphere function has not been established. This study analyzed the peripheral vasoreactivity of patients with acute ischemic stroke and hemiplegia using a modified Raynaud scan, which is a new technology for blood flow measurement. In this retrospective case-control study, we examined patients with unilateral weakness consistent with ischemic lesions who underwent brain magnetic resonance imaging and modified Raynaud scanning within five days from the onset of symptoms. The modified Raynaud scan was used to quantify the radioactivity of the bilateral fingertips during rest and cooling-heating thermal stress conditions and estimate vasoreactivity based on the change in the blood amount per time under rest-thermal stress. The subjects were classified into the preserved and impaired groups based on their degrees of vasomotor reaction. Based on the modified Raynaud scanning, 37 (mean age = 69.1 ± 10.6) and 32 (mean age = 62.6 ± 11.8) subjects were allocated to the preserved and impaired groups, respectively. Binary logistic regression showed that the affected limb edema (odds ratio (OR) 6.15; confidence interval (CI) 1.40-26.97; p = 0.016) and anterior circulation (OR 3.68; CI 1.01-13.48; p = 0.049) were associated with impaired vasoreactivity. The modified Raynaud scans confirmed that central lesions in the anterior circulation with hemiparesis may influence the vasoreactivity of edematous peripheral arteries. These results may inform treatment and rehabilitation for stroke patients with hemiparesis.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Wang</LastName>
                        <ForeName>Su Jeong</ForeName>
                        <Initials>SJ</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Neurology, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Lee</LastName>
                        <ForeName>Chan-Hyuk</ForeName>
                        <Initials>CH</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Neurology, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kang</LastName>
                        <ForeName>Hyun Goo</ForeName>
                        <Initials>HG</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Neurology, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kim</LastName>
                        <ForeName>Ko Woon</ForeName>
                        <Initials>KW</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Neurology, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kim</LastName>
                        <ForeName>Minjoo</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y" EqualContrib="Y">
                        <LastName>Jeong</LastName>
                        <ForeName>Hwan-Jeong</ForeName>
                        <Initials>HJ</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea. jayjeong@jbnu.ac.kr.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y" EqualContrib="Y">
                        <LastName>Shin</LastName>
                        <ForeName>Byoung-Soo</ForeName>
                        <Initials>BS</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Neurology, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea. sbsoo@jbnu.ac.kr.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea. sbsoo@jbnu.ac.kr.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>04</Month>
                    <Day>20</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>England</Country>
                <MedlineTA>Sci Rep</MedlineTA>
                <NlmUniqueID>101563288</NlmUniqueID>
                <ISSNLinking>2045-2322</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <CommentsCorrectionsList>
                <CommentsCorrections RefType="ErratumIn">
                    <RefSource>Sci Rep. 2021 Sep 15;11(1):18710</RefSource>
                    <PMID Version="1">34526610</PMID>
                </CommentsCorrections>
            </CommentsCorrectionsList>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006429" MajorTopicYN="N">Hemiplegia</DescriptorName>
                    <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000083242" MajorTopicYN="N">Ischemic Stroke</DescriptorName>
                    <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D016491" MajorTopicYN="N">Peripheral Vascular Diseases</DescriptorName>
                    <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                    <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName>
                    <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2020</Year>
                    <Month>10</Month>
                    <Day>16</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2021</Year>
                    <Month>04</Month>
                    <Day>07</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>21</Day>
                    <Hour>6</Hour>
                    <Minute>31</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>22</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>12</Month>
                    <Day>15</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>epublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33879816</ArticleId>
                <ArticleId IdType="doi">10.1038/s41598-021-88050-9</ArticleId>
                <ArticleId IdType="pii">10.1038/s41598-021-88050-9</ArticleId>
                <ArticleId IdType="pmc">PMC8058338</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Disabil Rehabil. 2003 Nov 18;25(22):1265-70</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14617443</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lasers Med Sci. 2009 Jul;24(4):639-51</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19050826</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Rheum Dis. 2014 Jun;73(6):1181-5</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23956248</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Best Pract Res Clin Rheumatol. 2004 Dec;18(6):957-79</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15501192</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pediatr Rheumatol Online J. 2018 Mar 23;16(1):20</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29566759</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Rheumatol. 1997 May;24(5):879-89</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">9150076</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nat Rev Rheumatol. 2012 Aug;8(8):469-79</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22782008</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am J Occup Ther. 2014 Mar-Apr;68(2):203-11</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24581407</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rheumatology (Oxford). 2007 Mar;46(3):533-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17018538</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Br J Hosp Med (Lond). 2019 Nov 2;80(11):658-664</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31707892</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Auton Neurosci. 2004 Nov 30;116(1-2):62-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15556839</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Pharmacol. 2019 Apr 16;10:360</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31073287</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>F1000Res. 2016 May 12;5:</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27239289</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):109-14</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23073231</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mo Med. 2016 Mar-Apr;113(2):123-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27311222</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am J Occup Ther. 1990 Oct;44(10):914-21</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">2248354</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Microvasc Res. 2021 Jan;133:104072</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32949573</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
            <PMID Version="1">33859888</PMID>
            <DateRevised>
                <Year>2021</Year>
                <Month>04</Month>
                <Day>17</Day>
            </DateRevised>
            <Article PubModel="Electronic">
                <Journal>
                    <ISSN IssnType="Print">2168-8184</ISSN>
                    <JournalIssue CitedMedium="Print">
                        <Volume>13</Volume>
                        <Issue>3</Issue>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>Mar</Month>
                            <Day>11</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Cureus</Title>
                    <ISOAbbreviation>Cureus</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Osteopathic Manipulative Treatment to Optimize the Glymphatic Environment in Severe Traumatic Brain Injury Measured With Optic Nerve Sheath Diameter, Intracranial Pressure Monitoring, and Neurological Pupil Index.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>e13823</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.13823</ELocationID>
                <Abstract>
                    <AbstractText>Background Traumatic brain injury (TBI) has a complex pathophysiology that has historically been poorly understood. New evidence on the pathophysiology, molecular biology, and diagnostic studies involved in TBI have shed new light on optimizing rehabilitation and recovery. The goal of this study was to assess the effect of osteopathic manipulative treatment (OMT) on peripheral and central glial lymphatics in patients with severe TBI, brain edema, and elevated intracranial pressure (ICP) by measuring changes in several parameters regularly used in management. Methodology This was a retrospective study at a level II trauma center that occurred in 2018. The study enrolled patients with TBI, increased ICP, or brain edema who had an external ventricular drain placed. Patients previously underwent a 51-minute treatment with OMT with an established protocol. Patients received 51 minutes of OMT to the head, neck, and peripheral lymphatics. The ICP, cerebrospinal fluid (CSF) drainage, optic nerve sheath diameter (ONSD) measured by ultrasonography, and Neurological Pupil Index (NPi) measured by pupillometer were recorded before, during, and after receiving OMT. Results A total of 11 patients were included in the study, and 21 points of data were collected from the patients meeting inclusion criteria who received OMT. There was a mean decrease in the ONSD of 0.62 mm from 6.24 mm to 5.62 mm (P = 0.0001). The mean increase in NPi was 0.18 (P = 0.01). The mean decrease in ICP was 3.33 mmHg (P= 0.0001). There was a significant decrease in CSF output after treatment (P = 0.0001). Each measurement of ICP, ONSD, and NPi demonstrated a decrease in overall CSF volume and pressure after OMT compared to CSF output and ICP prior to OMT. Conclusions This study demonstrates that OMT may help optimize glial lymphatic clearance of CSF and improve brain edema, interstitial waste product removal, NPi, ICP, CSF volume, and ONSD. A holistic approach including OMT may be considered to enhance management in TBI patients. As TBI is a spectrum of disease, utilizing similar techniques may be considered for all forms of TBI including concussions and other diseases with brain edema. The results of this study can better inform future trials to specifically study the effectiveness of OMT in post-concussive treatment and in those with mild-to-moderate TBI.</AbstractText>
                    <CopyrightInformation>Copyright © 2021, Kashyap et al.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Kashyap</LastName>
                        <ForeName>Samir</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Brazdzionis</LastName>
                        <ForeName>James</ForeName>
                        <Initials>J</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Savla</LastName>
                        <ForeName>Paras</ForeName>
                        <Initials>P</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Berry</LastName>
                        <ForeName>James A</ForeName>
                        <Initials>JA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Farr</LastName>
                        <ForeName>Saman</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Patchana</LastName>
                        <ForeName>Tye</ForeName>
                        <Initials>T</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Majeed</LastName>
                        <ForeName>Gohar</ForeName>
                        <Initials>G</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Ghanchi</LastName>
                        <ForeName>Hammad</ForeName>
                        <Initials>H</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Bowen</LastName>
                        <ForeName>Ira</ForeName>
                        <Initials>I</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Wacker</LastName>
                        <ForeName>Margaret Rose</ForeName>
                        <Initials>MR</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Arrowhead Regional Medical Center, Colton, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Miulli</LastName>
                        <ForeName>Dan E</ForeName>
                        <Initials>DE</Initials>
                        <AffiliationInfo>
                            <Affiliation>Neurosurgery, Arrowhead Regional Medical Center, Colton, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>03</Month>
                    <Day>11</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>United States</Country>
                <MedlineTA>Cureus</MedlineTA>
                <NlmUniqueID>101596737</NlmUniqueID>
                <ISSNLinking>2168-8184</ISSNLinking>
            </MedlineJournalInfo>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">glymphatic</Keyword>
                <Keyword MajorTopicYN="N">omt</Keyword>
                <Keyword MajorTopicYN="N">onsd</Keyword>
                <Keyword MajorTopicYN="N">optic nerve sheath</Keyword>
                <Keyword MajorTopicYN="N">osteopathic</Keyword>
                <Keyword MajorTopicYN="N">tbi</Keyword>
            </KeywordList>
            <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>16</Day>
                    <Hour>6</Hour>
                    <Minute>38</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>17</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>17</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>epublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33859888</ArticleId>
                <ArticleId IdType="doi">10.7759/cureus.13823</ArticleId>
                <ArticleId IdType="pmc">PMC8038899</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Neurosci Biobehav Rev. 2018 Jan;84:316-324</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28859995</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Surg Neurol Int. 2011;2:82</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21748035</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neurochem Res. 2015 Dec;40(12):2583-99</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25947369</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Elife. 2017 Aug 21;6:</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28826498</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Cereb Blood Flow Metab. 2017 Oct;37(10):3278-3299</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28816095</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosurg. 2015 Sep;123(3):743-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25955869</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rehabil Res Pract. 2012;2012:659652</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22848836</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Am Osteopath Assoc. 2018 Jun 1;118(6):403-409</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29710088</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Neurochirurgia (Stuttg). 1976 Jan;19(1):33-42</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">1250502</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Oncol Lett. 2013 Mar;5(3):992-996</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23426283</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Neurosci. 2015 Jan 14;35(2):518-26</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25589747</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Head Trauma Rehabil. 2005 Jan-Feb;20(1):76-94</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15668572</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Front Neurol. 2017 Aug 24;8:407</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28883806</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Head Trauma Rehabil. 2015 May-Jun;30(3):E52-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24901324</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Acta Neuropathol. 2018 Mar;135(3):387-407</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29428972</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Am Osteopath Assoc. 2011 Dec;111(12):685-93</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22182954</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Exp Med. 2017 Dec 4;214(12):3645-3667</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29141865</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am J Emerg Med. 2017 Jan;35(1):150-153</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27852525</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Am Osteopath Assoc. 2010 Apr;110(4):232-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20430911</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Clin Neurol Neurosurg. 2011 Oct;113(8):635-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21676532</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Head Trauma Rehabil. 2006 Sep-Oct;21(5):375-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16983222</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Clin Invest. 2017 Sep 1;127(9):3210-3219</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28862640</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
            <PMID Version="1">33855645</PMID>
            <DateRevised>
                <Year>2021</Year>
                <Month>05</Month>
                <Day>02</Day>
            </DateRevised>
            <Article PubModel="Electronic">
                <Journal>
                    <ISSN IssnType="Print">2110-5820</ISSN>
                    <JournalIssue CitedMedium="Print">
                        <Volume>11</Volume>
                        <Issue>1</Issue>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>Apr</Month>
                            <Day>14</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Annals of intensive care</Title>
                    <ISOAbbreviation>Ann Intensive Care</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Monitoring skin blood flow to rapidly identify alterations in tissue perfusion during fluid removal using continuous veno-venous hemofiltration in patients with circulatory shock.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>59</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13613-021-00847-z</ELocationID>
                <Abstract>
                    <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Continuous veno-venous hemofiltration (CVVH) can be used to reduce fluid overload and tissue edema, but excessive fluid removal may impair tissue perfusion. Skin blood flow (SBF) alters rapidly in shock, so its measurement may be useful to help monitor tissue perfusion.</AbstractText>
                    <AbstractText Label="METHODS" NlmCategory="METHODS">In a prospective, observational study in a 35-bed department of intensive care, all patients with shock who required fluid removal with CVVH were considered for inclusion. SBF was measured on the index finger using skin laser Doppler (Periflux 5000, Perimed, Järfälla, Sweden) for 3 min at baseline (before starting fluid removal, T0), and 1, 3 and 6 h after starting fluid removal. The same fluid removal rate was maintained throughout the study period. Patients were grouped according to absence (Group A) or presence (Group B) of altered tissue perfusion, defined as a 10% increase in blood lactate from T0 to T6 with the T6 lactate ≥ 1.5 mmol/l. Receiver operating characteristic curves were constructed and areas under the curve (AUROC) calculated to identify variables predictive of altered tissue perfusion. Data are reported as medians [25th-75th percentiles].</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">We studied 42 patients (31 septic shock, 11 cardiogenic shock); median SOFA score at inclusion was 9 [8-12]. At T0, there were no significant differences in hemodynamic variables, norepinephrine dose, lactate concentration, ScvO<sub>2</sub> or ultrafiltration rate between groups A and B. Cardiac index and MAP did not change over time, but SBF decreased in both groups (p &lt; 0.05) throughout the study period. The baseline SBF was lower (58[35-118] vs 119[57-178] perfusion units [PU], p = 0.03) and the decrease in SBF from T0 to T1 (ΔSBF%) higher (53[39-63] vs 21[12-24]%, p = 0.01) in group B than in group A. Baseline SBF and ΔSBF% predicted altered tissue perfusion with AUROCs of 0.83 and 0.96, respectively, with cut-offs for SBF of ≤ 57 PU (sensitivity 78%, specificity 87%) and ∆SBF% of ≥ 45% (sensitivity 92%, specificity 99%).</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Baseline SBF and its early reduction after initiation of fluid removal using CVVH can predict worsened tissue perfusion, reflected by an increase in blood lactate levels.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Mongkolpun</LastName>
                        <ForeName>Wasineenart</ForeName>
                        <Initials>W</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Bakos</LastName>
                        <ForeName>Péter</ForeName>
                        <Initials>P</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Vincent</LastName>
                        <ForeName>Jean-Louis</ForeName>
                        <Initials>JL</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0001-6011-6951</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. jlvincent@intensive.org.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Creteur</LastName>
                        <ForeName>Jacques</ForeName>
                        <Initials>J</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>04</Month>
                    <Day>14</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Germany</Country>
                <MedlineTA>Ann Intensive Care</MedlineTA>
                <NlmUniqueID>101562873</NlmUniqueID>
                <ISSNLinking>2110-5820</ISSNLinking>
            </MedlineJournalInfo>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Hemodialysis</Keyword>
                <Keyword MajorTopicYN="N">Lactate concentration</Keyword>
                <Keyword MajorTopicYN="N">Laser flowmetry</Keyword>
                <Keyword MajorTopicYN="N">Microcirculation</Keyword>
                <Keyword MajorTopicYN="N">Peripheral perfusion</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2021</Year>
                    <Month>01</Month>
                    <Day>16</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2021</Year>
                    <Month>03</Month>
                    <Day>29</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>15</Day>
                    <Hour>7</Hour>
                    <Minute>38</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>16</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>4</Month>
                    <Day>16</Day>
                    <Hour>6</Hour>
                    <Minute>1</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>epublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33855645</ArticleId>
                <ArticleId IdType="doi">10.1186/s13613-021-00847-z</ArticleId>
                <ArticleId IdType="pii">10.1186/s13613-021-00847-z</ArticleId>
                <ArticleId IdType="pmc">PMC8046875</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Crit Care Med. 2014 Apr;42(4):868-77</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24275513</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Trauma. 2007 Apr;62(4):928-32</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17426550</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>PLoS One. 2017 Nov 27;12(11):e0188548</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29176794</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 2009 Jun;37(6):1961-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19384212</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Intensive Care Med. 2019 Jan;45(1):82-85</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29754310</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>JAMA. 2019 Feb 19;321(7):654-664</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30772908</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 2018 Jun;46(6):e489-e495</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29432347</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>N Engl J Med. 2014 Dec 11;371(24):2309-19</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25494270</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Anesth Analg. 2013 Feb;116(2):351-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">23302972</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>PLoS One. 2019 Jun 3;14(6):e0217857</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31158247</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Microvasc Res. 2010 Mar;79(2):102-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20064535</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>JAMA. 2010 Feb 24;303(8):739-46</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20179283</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Intensive Care. 2014 Oct 11;4:30</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25593746</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Res Pract. 2015;2015:260385</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25954513</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am Rev Respir Dis. 1990 Jul;142(1):2-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">2368971</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 2020 Apr;48(4):443-450</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32205589</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>JAMA. 2016 Feb 23;315(8):801-10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26903338</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Microvasc Res. 2009 Jun;78(1):4-13</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19285089</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2016 Aug 13;20(1):257</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27520452</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Vasc Med. 2001 Nov;6(4):203-10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11958384</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2010;14(1):R25</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20181242</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Intensive Care Med. 2011 May;37(5):801-7</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21373821</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nephrol Dial Transplant. 2018 Jan 1;33(1):149-159</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28444336</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 2018 Oct;46(10):1600-1607</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29985214</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 2006 Feb;34(2):403-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16424721</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2014 Nov 18;18(6):624</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25407408</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1211-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25125374</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>BMC Cardiovasc Disord. 2018 Jan 18;18(1):8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29347907</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Intensive Care. 2016 Dec;6(1):46</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">27207178</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2018 Feb 22;22(1):41</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29467008</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Blood Purif. 2015;40(1):92-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26138662</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Shock. 2018 Jul;50(1):87-95</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28930916</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 1985 Oct;13(10):818-29</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">3928249</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Mayo Clin Proc. 1994 Jun;69(6):564-74</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8189763</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Shock. 2012 Jul;38(1):4-10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22552014</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Shock. 2017 Sep;48(3):294-300</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28248722</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>BMC Nephrol. 2017 Feb 20;18(1):71</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28219329</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Sci Rep. 2017 Aug 17;7(1):8581</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28819317</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Intensive Care Med. 2014 Dec;40(12):1795-815</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">25392034</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>N Engl J Med. 2013 Oct 31;369(18):1726-34</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24171518</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Clin Dermatol. 1995 Jul-Aug;13(4):337-47</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8665442</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Acute Card Care. 2012 Mar;14(1):20-6</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22356569</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Crit Care. 2012 Jun;27(3):283-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21798706</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>JAMA Netw Open. 2019 Jun 5;2(6):e195418</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">31173127</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am J Emerg Med. 2017 Aug;35(8):1136-1141</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28341187</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2017 Oct 18;21(1):255</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29047411</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2011;15(5):R242</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22014216</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Am Rev Respir Dis. 1986 Nov;134(5):873-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">3777684</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>J Cardiovasc Pharmacol. 2000 Nov;36(5):640-8</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11065225</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care Med. 2004 Aug;32(8):1637-42</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15286537</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Intensive Care. 2020 Apr 22;10(1):47</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">32323060</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>PLoS One. 2015 Dec 21;10(12):e0145181</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">26692209</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2013 Sep 11;17(5):R197</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24025259</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ann Intensive Care. 2018 May 3;8(1):60</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">29725778</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Intensive Care Med. 1996 Jul;22(7):707-10</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8844239</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2009;13(3):R92</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19534818</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Intensive Care Med. 2010 Nov;36(11):1882-9</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">20689910</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Intensive Care Med. 2017 Jun;43(6):816-828</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28364303</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nephrol Dial Transplant. 2018 Sep 1;33(9):1636-1642</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">28927232</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Crit Care. 2018 Sep 24;22(1):223</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">30244678</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">33513121</PMID>
            <DateCompleted>
                <Year>2021</Year>
                <Month>09</Month>
                <Day>24</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2021</Year>
                <Month>09</Month>
                <Day>24</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">2168-2208</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>25</Volume>
                        <Issue>8</Issue>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>08</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>IEEE journal of biomedical and health informatics</Title>
                    <ISOAbbreviation>IEEE J Biomed Health Inform</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Non-Invasive Capillary Blood Pressure Measurement Enabling Early Detection and Classification of Venous Congestion.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>2877-2886</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1109/JBHI.2021.3055760</ELocationID>
                <Abstract>
                    <AbstractText>Capillary blood pressure (CBP) is the primary driving force for fluid exchange across microvessels. Subclinical systemic venous congestion prior to overt peripheral edema can directly result in elevated peripheral CBP. Therefore, CBP measurements can enable timely edema control in a variety of clinical cases including venous insufficiency, heart failure and so on. However, currently CBP measurements can be only done invasively and with a complicated experimental setup. In this work, we proposed an opto-mechanical system to achieve non-invasive and automatic CBP measurements through modifying the widely implemented oscillometric technique in home-use arterial blood pressure monitors. The proposed CBP system is featured with a blue light photoplethysmography sensor embedded in finger/toe cuffs to probe skin capillary pulsations. The experimental results demonstrated the proposed CBP system can track local CBP changes induced by different levels of venous congestion. Leveraging the decision tree technique, we demonstrate the use of a multi-site CBP measurement at fingertips and toes to classify four categories of subjects (total N = 40) including patients with peripheral arterial disease, varicose veins and heart failure. Our work demonstrates the promising non-invasive CBP measurement as well as its great potential in realizing point-of-care systems for the management of cardiovascular diseases.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Liu</LastName>
                        <ForeName>Jing</ForeName>
                        <Initials>J</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Yan</LastName>
                        <ForeName>Bryan</ForeName>
                        <Initials>B</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Chen</LastName>
                        <ForeName>Shih-Chi</ForeName>
                        <Initials>SC</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Zhang</LastName>
                        <ForeName>Yuan-Ting</ForeName>
                        <Initials>YT</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Sodini</LastName>
                        <ForeName>Charles</ForeName>
                        <Initials>C</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Zhao</LastName>
                        <ForeName>Ni</ForeName>
                        <Initials>N</Initials>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>08</Month>
                    <Day>05</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>United States</Country>
                <MedlineTA>IEEE J Biomed Health Inform</MedlineTA>
                <NlmUniqueID>101604520</NlmUniqueID>
                <ISSNLinking>2168-2194</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006940" MajorTopicYN="Y">Hyperemia</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D009991" MajorTopicYN="N">Oscillometry</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D014680" MajorTopicYN="N">Veins</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>1</Month>
                    <Day>30</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>9</Month>
                    <Day>25</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>1</Month>
                    <Day>29</Day>
                    <Hour>17</Hour>
                    <Minute>8</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33513121</ArticleId>
                <ArticleId IdType="doi">10.1109/JBHI.2021.3055760</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">33409788</PMID>
            <DateCompleted>
                <Year>2021</Year>
                <Month>06</Month>
                <Day>23</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2021</Year>
                <Month>06</Month>
                <Day>23</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1432-1084</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>31</Volume>
                        <Issue>7</Issue>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>Jul</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>European radiology</Title>
                    <ISOAbbreviation>Eur Radiol</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Deep learning shows good reliability for automatic segmentation and volume measurement of brain hemorrhage, intraventricular extension, and peripheral edema.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>5012-5020</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-020-07558-2</ELocationID>
                <Abstract>
                    <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate for the first time the performance of a deep learning method based on no-new-Net for fully automated segmentation and volumetric measurements of intracerebral hemorrhage (ICH), intraventricular extension of intracerebral hemorrhage (IVH), and perihematomal edema (PHE) in primary ICH on CT.</AbstractText>
                    <AbstractText Label="METHODS" NlmCategory="METHODS">Three hundred and eighty primary ICH patients who underwent CT at hospital arrival were divided into a training cohort (n = 300) and a validation cohort (n = 80). An independent cohort with 80 patients was used for testing. Ground truth (segmentation masks) was manually generated by radiologists. Model performance on lesion segmentation and volumetric measurement of ICH, IVH, and PHE were evaluated by comparing the model results with the segmentations performed by radiologists.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the test cohort, the Dice scores of lesion segmentation were 0.92, 0.79, and 0.71 for ICH, IVH, and PHE, respectively. The sensitivities were 0.93 for ICH, 0.88 for IVH, and 0.81 for PHE. The positive predictive values were 0.92, 0.76, and 0.69 for ICH, IVH, and PHE, respectively. Excellent concordance (concordance correlation coefficients [CCCs] ≥ 0.98) of ICH and IVH and good concordance of PHE (CCCs ≥ 0.92) were demonstrated between manually and automatically measured volumes. The model took approximately 15 s to provide automatic segmentation and volume analysis for each patient.</AbstractText>
                    <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our model demonstrates good reliability for automatic segmentation and volume measurement of ICH, IVH, and PHE in primary ICH, which can be useful to reduce the effort and time of doctors to calculate volumes of ICH, IVH, and PHE.</AbstractText>
                    <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">• Deep learning algorithms can provide automatic and reliable assessment of intracerebral hemorrhage, intraventricular hemorrhage, and perihematomal edema on CT. • Non-contrast CT-based deep learning method can be helpful to provide efficient and accurate measurements of ICH, IVH, and PHE in primary ICH patients, thereby reducing the effort and time of doctors to segment and calculate volumes of ICH, IVH, and PHE in primary ICH patients.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Zhao</LastName>
                        <ForeName>Xianjing</ForeName>
                        <Initials>X</Initials>
                        <AffiliationInfo>
                            <Affiliation>Shanghai Institute of Medical Imaging, Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Jing'an District, Shanghai, 200040, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Chen</LastName>
                        <ForeName>Kaixing</ForeName>
                        <Initials>K</Initials>
                        <AffiliationInfo>
                            <Affiliation>Ping An Technology (Shenzhen) Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Wu</LastName>
                        <ForeName>Ge</ForeName>
                        <Initials>G</Initials>
                        <AffiliationInfo>
                            <Affiliation>Ping An Technology (Shenzhen) Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Zhang</LastName>
                        <ForeName>Guyue</ForeName>
                        <Initials>G</Initials>
                        <AffiliationInfo>
                            <Affiliation>Ping An Technology (Shenzhen) Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Zhou</LastName>
                        <ForeName>Xin</ForeName>
                        <Initials>X</Initials>
                        <AffiliationInfo>
                            <Affiliation>Ping An Technology (Shenzhen) Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Lv</LastName>
                        <ForeName>Chuanfeng</ForeName>
                        <Initials>C</Initials>
                        <AffiliationInfo>
                            <Affiliation>Ping An Technology (Shenzhen) Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Wu</LastName>
                        <ForeName>Shiman</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Jing'an District, Shanghai, 200040, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Chen</LastName>
                        <ForeName>Yun</ForeName>
                        <Initials>Y</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Xie</LastName>
                        <ForeName>Guotong</ForeName>
                        <Initials>G</Initials>
                        <AffiliationInfo>
                            <Affiliation>Ping An Technology (Shenzhen) Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Ping An Health Cloud Company Limited, Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Ping An International Smart City Technology Co., Ltd., Shanghai, China.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Yao</LastName>
                        <ForeName>Zhenwei</ForeName>
                        <Initials>Z</Initials>
                        <Identifier Source="ORCID">http://orcid.org/0000-0002-5681-4308</Identifier>
                        <AffiliationInfo>
                            <Affiliation>Shanghai Institute of Medical Imaging, Shanghai, China. zwyao@fudan.edu.cn.</Affiliation>
                        </AffiliationInfo>
                        <AffiliationInfo>
                            <Affiliation>Department of Radiology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Jing'an District, Shanghai, 200040, China. zwyao@fudan.edu.cn.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <GrantList CompleteYN="Y">
                    <Grant>
                        <GrantID>2019SY061</GrantID>
                        <Agency>Shanghai Municipal Health Commission</Agency>
                        <Country/>
                    </Grant>
                </GrantList>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2021</Year>
                    <Month>01</Month>
                    <Day>06</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Germany</Country>
                <MedlineTA>Eur Radiol</MedlineTA>
                <NlmUniqueID>9114774</NlmUniqueID>
                <ISSNLinking>0938-7994</ISSNLinking>
            </MedlineJournalInfo>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D001929" MajorTopicYN="Y">Brain Edema</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName>
                    <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D020300" MajorTopicYN="N">Intracranial Hemorrhages</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Cerebral hemorrhage</Keyword>
                <Keyword MajorTopicYN="N">Deep learning</Keyword>
                <Keyword MajorTopicYN="N">Edema</Keyword>
                <Keyword MajorTopicYN="N">Tomography, X-ray computed</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2020</Year>
                    <Month>07</Month>
                    <Day>08</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2020</Year>
                    <Month>11</Month>
                    <Day>20</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="revised">
                    <Year>2020</Year>
                    <Month>09</Month>
                    <Day>25</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2021</Year>
                    <Month>1</Month>
                    <Day>8</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>6</Month>
                    <Day>24</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2021</Year>
                    <Month>1</Month>
                    <Day>7</Day>
                    <Hour>6</Hour>
                    <Minute>12</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">33409788</ArticleId>
                <ArticleId IdType="doi">10.1007/s00330-020-07558-2</ArticleId>
                <ArticleId IdType="pii">10.1007/s00330-020-07558-2</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Cordonnier C, Demchuk A, Ziai W, Anderson CS (2018) Intracerebral haemorrhage: current approaches to acute management. Lancet 392:1257–1268</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/S0140-6736(18)31878-6</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pinho J, Costa AS, Araújo JM, Amorim JM, Ferreira C (2019) Intracerebral hemorrhage outcome: a comprehensive update. J Neurol Sci 398:54–66</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.jns.2019.01.013</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Hanley DF (2009) Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 40:1533–1538</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.108.535419</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Irvine H, Male S, Robertson J, Bell C, Bentho O, Streib C (2019) Reduced intracerebral hemorrhage and perihematomal edema volumes in diabetics on sulfonylureas. Stroke 50:995–998</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.118.022301</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Urday S, Kimberly WT, Beslow LA et al (2015) Targeting secondary injury in intracerebral haemorrhage--perihaematomal oedema. Nat Rev Neurol 11:111–122</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1038/nrneurol.2014.264</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ironside N, Chen C-J, Ding D, Mayer SA, Connolly ES Jr (2019) Perihematomal edema after spontaneous intracerebral hemorrhage. Stroke 50:1626–1633</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.119.024965</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Yang J, Arima H, Wu G et al (2015) Prognostic significance of perihematomal edema in acute intracerebral hemorrhage: pooled analysis from the intensive blood pressure reduction in acute cerebral hemorrhage trial studies. Stroke 46:1009–1013</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.114.007154</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Dastur CK, Yu W (2017) Current management of spontaneous intracerebral haemorrhage. Stroke Vasc Neurol 2:21–29</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1136/svn-2016-000047</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Cheung RTF, Zou L-Y (2003) Use of the original, modified, or new intracerebral hemorrhage score to predict mortality and morbidity after intracerebral hemorrhage. Stroke 34:1717–1722</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/01.STR.0000078657.22835.B9</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ziai WC, Carhuapoma JR (2018) Intracerebral hemorrhage. Continuum (Minneap Minn) 24:1603–1622</Citation>
                </Reference>
                <Reference>
                    <Citation>Volbers B, Willfarth W, Kuramatsu JB et al (2016) Impact of perihemorrhagic edema on short-term outcome after intracerebral hemorrhage. Neurocrit Care 24:404–412</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s12028-015-0185-y</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Appelboom G, Bruce SS, Hickman ZL et al (2013) Volume-dependent effect of perihaematomal oedema on outcome for spontaneous intracerebral haemorrhages. J Neurol Neurosurg Psychiatry 84:488–493</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1136/jnnp-2012-303160</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Urday S, Beslow LA, Dai F et al (2016) Rate of perihematomal edema expansion predicts outcome after intracerebral hemorrhage. Crit Care Med 44:790–797</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1097/CCM.0000000000001553</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Yeatts SD, Palesch YY, Moy CS, Selim M (2013) High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care 19:257–266</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s12028-013-9861-y</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Kollmar R, Staykov D, Dörfler A, Schellinger PD, Schwab S, Bardutzky J (2010) Hypothermia reduces perihemorrhagic edema after intracerebral hemorrhage. Stroke 41:1684–1689</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.110.587758</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Freeman WD, Barrett KM, Bestic JM, Meschia JF, Broderick DF, Brott TG (2008) Computer-assisted volumetric analysis compared with ABC/2 method for assessing warfarin-related intracranial hemorrhage volumes. Neurocrit Care 9:307–312</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s12028-008-9089-4</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Huttner HB, Steiner T, Hartmann M et al (2006) Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage. Stroke 37:404–408</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/01.STR.0000198806.67472.5c</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Chang K, Beers AL, Bai HX et al (2019) Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol 21:1412–1422</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1093/neuonc/noz106</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Brugnara G, Isensee F, Neuberger U et al (2020) Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. Eur Radiol 30:2356–2364</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00330-019-06593-y</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Kickingereder P, Isensee F, Tursunova I et al (2019) Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncol 20:728–740</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/S1470-2045(19)30098-1</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ye H, Gao F, Yin Y et al (2019) Precise diagnosis of intracranial hemorrhage and subtypes using a three-dimensional joint convolutional and recurrent neural network. Eur Radiol 29:6191–6201</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1007/s00330-019-06163-2</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ronneberger O, Fischer P, Brox T (2015) U-net: convolutional networks for biomedical image segmentation. Available via https://arxiv.org/abs/1505.04597 . Accessed 18 May 2015</Citation>
                </Reference>
                <Reference>
                    <Citation>Çiçek Ö, Abdulkadir A, Lienkamp SS, Brox T, Ronneberger O (2016) 3D U-Net: learning dense volumetric segmentation from sparse annotation. Available via https://arxiv.org/abs/1606.06650 . Accessed 21 Jun 2016</Citation>
                </Reference>
                <Reference>
                    <Citation>Milletari F, Navab N, Ahmadi S-A (2016) V-net: fully convolutional neural networks for volumetric medical image segmentation. IEEE. Available via https://arxiv.org/abs/1606.04797 . Accessed 15 Jun 2016</Citation>
                </Reference>
                <Reference>
                    <Citation>Casamitjana A, Catà M, Sánchez I, Combalia M, Vilaplana V (2017) Cascaded V-Net using ROI masks for brain tumor segmentation. Available via https://arxiv.org/abs/1812.11588 . Accessed 30 Dec 2018</Citation>
                </Reference>
                <Reference>
                    <Citation>Isensee F, Petersen J, Klein A et al (2018) nnu-net: self-adapting framework for u-net-based medical image segmentation. Available via https://arxiv.org/abs/1809.10486 . Accessed 27 Sep 2018</Citation>
                </Reference>
                <Reference>
                    <Citation>Li X, Chen H, Qi X, Dou Q, Fu C-W, Heng P-A (2018) H-DenseUNet: hybrid densely connected UNet for liver and tumor segmentation from CT volumes. IEEE Trans Med Imaging 37:2663–2674</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1109/TMI.2018.2845918</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Volbers B, Staykov D, Wagner I et al (2011) Semi-automatic volumetric assessment of perihemorrhagic edema with computed tomography. Eur J Neurol 18:1323–1328</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1111/j.1468-1331.2011.03395.x</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Isensee F, Jäger PF, Kohl SAA, Petersen J, Maier-Hein KH (2019) Automated design of deep learning methods for biomedical image segmentation. Available via https://arxiv.org/abs/1904.08128 . Accessed 17 Apr 2019</Citation>
                </Reference>
                <Reference>
                    <Citation>Kingma DP, Ba J (2014) Adam: a method for stochastic optimization. Available via https://arxiv.org/abs/1412.6980 . Accessed 22 Dec 2014</Citation>
                </Reference>
                <Reference>
                    <Citation>Drozdzal M, Vorontsov E, Chartrand G, Kadoury S, Pal C (2016) The importance of skip connections in biomedical image segmentation. Available via https://arxiv.org/abs/1608.04117 . Accessed 14 Aug 2016</Citation>
                </Reference>
                <Reference>
                    <Citation>Chen L-C, Papandreou G, Kokkinos I, Murphy K, Yuille AL (2017) DeepLab: semantic image segmentation with deep convolutional nets, atrous convolution, and fully connected CRFs. Available via https://arxiv.org/abs/1606.00915 . Accessed 2 Jun 2016</Citation>
                </Reference>
                <Reference>
                    <Citation>Zhao X, Wu Y, Song G, Li Z, Zhang Y, Fan Y (2018) A deep learning model integrating FCNNs and CRFs for brain tumor segmentation. Med Image Anal 43:98–111</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.media.2017.10.002</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Patel A, Schreuder F, Klijn CJM et al (2019) Intracerebral haemorrhage segmentation in non-contrast CT. Sci Rep 9:17858</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1038/s41598-019-54491-6</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ironside N, Chen CJ, Mutasa S et al (2019) Fully automated segmentation algorithm for hematoma volumetric analysis in spontaneous intracerebral hemorrhage. Stroke 50:3416–3423</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.119.026561</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Dhar R, Falcone GJ, Chen Y et al (2020) Deep learning for automated measurement of hemorrhage and perihematomal edema in supratentorial intracerebral hemorrhage. Stroke 51:648–651</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.119.027657</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Chang PD, Kuoy E, Grinband J et al (2018) Hybrid 3D/2D convolutional neural network for hemorrhage evaluation on head CT. AJNR Am J Neuroradiol 39:1609–1616</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.3174/ajnr.A5742</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Davis SM, Broderick J, Hennerici M et al (2006) Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66:1175–1181</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1212/01.wnl.0000208408.98482.99</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Al-Shahi Salman R, Frantzias J, Lee RJ et al (2018) Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol 17:885–894</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/S1474-4422(18)30253-9</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Morotti A, Boulouis G, Dowlatshahi D et al (2019) Standards for detecting, interpreting, and reporting noncontrast computed tomographic markers of intracerebral hemorrhage expansion. Ann Neurol 86:480–492</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1002/ana.25563</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Hallevi H, Dar NS, Barreto AD et al (2009) The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications. Crit Care Med 37:969–974 e961</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1097/CCM.0b013e318198683a</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Chan E, Anderson CS, Wang X et al (2015) Significance of intraventricular hemorrhage in acute intracerebral hemorrhage: intensive blood pressure reduction in acute cerebral hemorrhage trial results. Stroke 46:653–658</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.114.008470</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ironside N, Chen CJ, Mutasa S et al (2020) Fully automated segmentation algorithm for perihematomal edema volumetry after spontaneous intracerebral hemorrhage. Stroke 51:815–823</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1161/STROKEAHA.119.026764</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lin L, Dou Q, Jin YM et al (2019) Deep learning for automated contouring of primary tumor volumes by MRI for nasopharyngeal carcinoma. Radiology 291:677–686</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1148/radiol.2019182012</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Rudie JD, Weiss DA, Saluja R et al (2019) Multi-disease segmentation of gliomas and white matter hyperintensities in the BraTS data using a 3D convolutional neural network. Front Comput Neurosci 13:84</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.3389/fncom.2019.00084</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Egger C, Opfer R, Wang C et al (2017) MRI FLAIR lesion segmentation in multiple sclerosis: does automated segmentation hold up with manual annotation? Neuroimage Clin 13:264–270</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1016/j.nicl.2016.11.020</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Castro DC, Walker I, Glocker B (2020) Causality matters in medical imaging. Nat Commun 11:3673</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="doi">10.1038/s41467-020-17478-w</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" Owner="NLM">
            <PMID Version="1">32890711</PMID>
            <DateCompleted>
                <Year>2021</Year>
                <Month>02</Month>
                <Day>26</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2021</Year>
                <Month>02</Month>
                <Day>26</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1872-7573</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>265</Volume>
                        <PubDate>
                            <Year>2021</Year>
                            <Month>Jan</Month>
                            <Day>30</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Journal of ethnopharmacology</Title>
                    <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Anti-inflammatory and antinociceptive activity of Siparuna guianensis Aublet, an amazonian plant traditionally used by indigenous communities.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>113344</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(20)33226-8</ELocationID>
                <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2020.113344</ELocationID>
                <Abstract>
                    <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Siparuna guianensis Aublet leaves, known as negramina, are used by indigenous and local communities in Brazil and other countries in the Americas to treat pain and inflammatory diseases.</AbstractText>
                    <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">To characterize the chemical constituents and to evaluate the antioxidant, anti-inflammatory, antinociceptive and locomotor activities of the dichloromethane fraction (DF) of S. guianensis leaves. Also, an acute oral toxicity test was accomplished.</AbstractText>
                    <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The chemical characterization of DF was performed by ultra-high pressure liquid chromatography (UHPLC) analyses coupled with a high-resolution mass spectrometer. The antioxidant potential of DF was investigated using nitric oxide (NO) and hydroxyl radical (OH) scavenging test. The evaluation study of the anti-inflammatory activity was carried out in vitro by NO measurement in stimulated macrophages and, in vivo, by croton oil-induced ear edema, LPS-induced peritonitis, and zymosan-induced arthritis in mice. Different mechanisms of central and peripheral nociception were stimulated by acetic acid-induced writhing, formalin, and tail-flick tests. Besides that, the open field assay was performed.</AbstractText>
                    <AbstractText Label="RESULTS" NlmCategory="RESULTS">UHPLC analyses of DF showed the presence of a mixture of glycosylated and methoxylated flavonoids. DF was able to scavenge NO and OH radicals in vitro and showed anti-inflammatory activity by inhibiting NO production in LPS-stimulated murine macrophages. Oral administration of DF considerably inhibited the ear edema after croton oil application and reduced the leukocyte infiltrated in LPS-induced peritonitis. In the inflammatory intra-articular zymosan-induced process, DF showed a significant reduction in the inflammatory area and of the cells in the synovial and connective tissues adjacent to the joint. Also, DF was able to reduce the intra-articular edema. In nociception models, the oral administration of DF considerably inhibited the acetic acid-induced writhings. The formalin test showed that DF attenuated the licking time in both phases, which suggested that DF reduce the nociception by central and peripheral mechanisms. In the tail-flick test, DF showed no activity. Besides that, DF did not affect the animal locomotion, and no acute toxicity was observed.</AbstractText>
                    <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For the first time, the anti-inflammatory and antinociceptive activities of S. guianensis were reported, supporting its ethnopharmacological uses for some inflammatory diseases and painful conditions.</AbstractText>
                    <CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Conegundes</LastName>
                        <ForeName>Jessica Leiras Mota</ForeName>
                        <Initials>JLM</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: jessicaleiras26@gmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Silva</LastName>
                        <ForeName>Josiane Mello da</ForeName>
                        <Initials>JMD</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: jmsjf@yahoo.com.br.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Mendes</LastName>
                        <ForeName>Renata de Freitas</ForeName>
                        <Initials>RF</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: renatinhafmendes@gmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Fernandes</LastName>
                        <ForeName>Maria Fernanda</ForeName>
                        <Initials>MF</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: mf_mariafernanda@hotmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Pinto</LastName>
                        <ForeName>Nícolas de Castro Campos</ForeName>
                        <Initials>NCC</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: nickbioquimica@hotmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Almeida</LastName>
                        <ForeName>Maycon Alcantara de</ForeName>
                        <Initials>MA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: maycon.jf@hotmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Dib</LastName>
                        <ForeName>Paula Ribeiro Braga</ForeName>
                        <Initials>PRB</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Parasitology, Microbiology, and Immunology, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: paularibeirodib@hotmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Andrade</LastName>
                        <ForeName>Rafaela de Oliveira</ForeName>
                        <Initials>RO</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Morphology, Biological Sciences Institute, Federal University of Juiz de Fora, 36036 900, Juiz de Fora, MG, Brazil. Electronic address: rafaandrade@gmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Rodrigues</LastName>
                        <ForeName>Matheus Nehrer</ForeName>
                        <Initials>MN</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Morphology, Biological Sciences Institute, Federal University of Juiz de Fora, 36036 900, Juiz de Fora, MG, Brazil. Electronic address: matheusnehrer@hotmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Castañon</LastName>
                        <ForeName>Maria Christina Marques Nogueira</ForeName>
                        <Initials>MCMN</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Morphology, Biological Sciences Institute, Federal University of Juiz de Fora, 36036 900, Juiz de Fora, MG, Brazil. Electronic address: christina.nogueira@terra.com.br.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Macedo</LastName>
                        <ForeName>Gilson Costa</ForeName>
                        <Initials>GC</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Parasitology, Microbiology, and Immunology, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: gcmbio@gmail.com.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Scio</LastName>
                        <ForeName>Elita</ForeName>
                        <Initials>E</Initials>
                        <AffiliationInfo>
                            <Affiliation>Laboratory of Bioactive Natural Products, Department of Biochemistry, Biological Science Institute, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil. Electronic address: elita.scio@ufjf.edu.br.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2020</Year>
                    <Month>09</Month>
                    <Day>03</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>Ireland</Country>
                <MedlineTA>J Ethnopharmacol</MedlineTA>
                <NlmUniqueID>7903310</NlmUniqueID>
                <ISSNLinking>0378-8741</ISSNLinking>
            </MedlineJournalInfo>
            <ChemicalList>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>31C4KY9ESH</RegistryNumber>
                    <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
                </Chemical>
            </ChemicalList>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
                    <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
                    <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
                    <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
                    <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
                    <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
                    <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
                    <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000073571" MajorTopicYN="N">Laurales</DescriptorName>
                    <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName>
                    <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
                    <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                    <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008519" MajorTopicYN="N">Medicine, Traditional</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
                    <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D059225" MajorTopicYN="N">Nociception</DescriptorName>
                    <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
                    <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
                    <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">Anti-inflammatory</Keyword>
                <Keyword MajorTopicYN="N">Antinociceptive</Keyword>
                <Keyword MajorTopicYN="N">Chemical characterization</Keyword>
                <Keyword MajorTopicYN="N">Flavonoids glycosides</Keyword>
                <Keyword MajorTopicYN="N">Siparuna guianensis</Keyword>
            </KeywordList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2019</Year>
                    <Month>11</Month>
                    <Day>28</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="revised">
                    <Year>2020</Year>
                    <Month>08</Month>
                    <Day>18</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2020</Year>
                    <Month>08</Month>
                    <Day>26</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2020</Year>
                    <Month>9</Month>
                    <Day>6</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2021</Year>
                    <Month>2</Month>
                    <Day>27</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2020</Year>
                    <Month>9</Month>
                    <Day>5</Day>
                    <Hour>20</Hour>
                    <Minute>7</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">32890711</ArticleId>
                <ArticleId IdType="pii">S0378-8741(20)33226-8</ArticleId>
                <ArticleId IdType="doi">10.1016/j.jep.2020.113344</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
            <PMID Version="1">32182144</PMID>
            <DateCompleted>
                <Year>2021</Year>
                <Month>04</Month>
                <Day>27</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2021</Year>
                <Month>04</Month>
                <Day>27</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1557-8682</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>21</Volume>
                        <Issue>2</Issue>
                        <PubDate>
                            <Year>2020</Year>
                            <Month>06</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>High altitude medicine &amp; biology</Title>
                    <ISOAbbreviation>High Alt Med Biol</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Rapid Ascent to 4559 m Is Associated with Increased Plasma Components of the Vascular Endothelial Glycocalyx and May Be Associated with Acute Mountain Sickness.</ArticleTitle>
                <Pagination>
                    <MedlinePgn>176-183</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1089/ham.2019.0081</ELocationID>
                <Abstract>
                    <AbstractText>
                        <b>
                            <i>Background:</i>
                        </b> The stress of high altitude alters vascular permeability, which may be related to structural changes in the endothelial glycocalyx. We aimed to study these changes by measuring plasma concentrations of several glycocalyx components upon exposure to high altitude. <b>
                        <i>Methods:</i>
                    </b> Plasma collected from 17 subjects at low altitude (423 m) and at three time points (7, 20, and 44 hours) after rapid ascent to high altitude (4559 m) were evaluated for concentrations of three glycocalyx components: syndecan-1, intercellular adhesion molecule-1 (ICAM-1), and heparan sulfate. Vital signs and echocardiographic measurement of systolic pulmonary artery pressure (sPAP) and cardiac output were also obtained at low and high altitudes. <b>
                    <i>Results:</i>
                </b> Mean age of the study population was 35.5 ± 11.2 years with a body mass index of 22.7 ± 2.5 kg/m<sup>2</sup>. Concentrations of ICAM-1 and heparan sulfate increased from baseline to 7 hours after arrival at high altitude; the ICAM-1 rise persisted at 20 hours. Syndecan-1 concentrations were increased only at 44 hours. Increased ICAM-1 concentrations correlated with sPAP and peripheral edema. Elevations in heparan sulfate appeared to correlate with acute mountain sickness (AMS). <b>
                <i>Conclusions:</i>
            </b> Levels of circulating glycocalyx components increase after exposure to high altitude and may correlate with AMS. Measuring plasma concentrations of various glycocalyx components could serve as a useful tool for further evaluation of vascular endothelial injury and repair in illness at high altitude.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Swenson</LastName>
            <ForeName>Kai Erik</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Pulmonary and Critical Care Medicine, Stanford University, Palo Alto, California, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Berger</LastName>
            <ForeName>Marc Moritz</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology, Perioperative and General Critical Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sareban</LastName>
            <ForeName>Mahdi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Research Institute of Molecular Sports Medicine and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Macholz</LastName>
            <ForeName>Franziska</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology, Perioperative and General Critical Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology, Perioperative and General Critical Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Schiefer</LastName>
            <ForeName>Lisa Maria</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology, Perioperative and General Critical Care Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mairbäurl</LastName>
            <ForeName>Heimo</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Sports Medicine, Department of Internal Medicine VII, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Swenson</LastName>
            <ForeName>Erik Richard</ForeName>
            <Initials>ER</Initials>
            <AffiliationInfo>
                <Affiliation>Pulmonary, Critical Care and Sleep Medicine, VA Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2020</Year>
        <Month>03</Month>
        <Day>17</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>High Alt Med Biol</MedlineTA>
    <NlmUniqueID>100901183</NlmUniqueID>
    <ISSNLinking>1527-0297</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000531" MajorTopicYN="N">Altitude</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000532" MajorTopicYN="Y">Altitude Sickness</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019276" MajorTopicYN="Y">Glycocalyx</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="Y">ICAM-1</Keyword>
    <Keyword MajorTopicYN="Y">acute mountain sickness</Keyword>
    <Keyword MajorTopicYN="Y">altitude</Keyword>
    <Keyword MajorTopicYN="Y">glycocalyx</Keyword>
    <Keyword MajorTopicYN="Y">heparan sulfate</Keyword>
    <Keyword MajorTopicYN="Y">syndecan-1</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2020</Year>
        <Month>3</Month>
        <Day>18</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2021</Year>
        <Month>4</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2020</Year>
        <Month>3</Month>
        <Day>18</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">32182144</ArticleId>
    <ArticleId IdType="doi">10.1089/ham.2019.0081</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">31578673</PMID>
<DateCompleted>
    <Year>2020</Year>
    <Month>04</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>12</Month>
    <Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1573-2584</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>51</Volume>
            <Issue>11</Issue>
            <PubDate>
                <Year>2019</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>International urology and nephrology</Title>
        <ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>2015-2025</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-019-02292-1</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Mammalian target of rapamycin (mTOR) inhibitors were previously considered a potential therapy for autosomal dominant polycystic kidney disease (ADPKD), but prior studies remained controversial about their efficacy. We performed an updated meta-analysis regarding the therapeutic and adverse effects of mTOR inhibitors in patients with ADPKD.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched Cochrane Library, PubMed, EMBASE, and Medline for randomized controlled trials (RCTs) comparing mTOR inhibitors to placebo in ADPKD patients up to August 2019. We calculated weighted mean differences (WMDs) for total kidney volume (TKV), estimated glomerular filtration rates (eGFRs), and weighted odds ratios (ORs) for treatment-related complications between the treatment and the placebo groups, using the random effects model.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">We retrieved a total of 9 RCTs enrolling 784 ADPKD patients receiving rapamycin, sirolimus, or everolimus between 2009 and 2016. The WMDs of TKV and eGFR from baseline to the last measurement were - 31.54 mL (95% confidence interval [CI] - 76.79 to 13.71 mL) and 2.81 mL/min/1.73 m<sup>2</sup> (95% CI - 1.85 to 7.46 mL/min/1.73 m<sup>2</sup>), respectively. Patients receiving mTOR inhibitors had a significantly increased risk of any adverse effects (OR 5.92, 95% CI 3.53-9.94), with the most common ones being aphthous stomatitis (OR 15.45, 95% CI 9.68-24.66) and peripheral edema (OR 3.49, 95% CI 1.31-9.27) compared to placebo users.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">mTOR inhibitors did not significantly influence renal progression in patients with ADPKD, but were associated with a higher risk of complications. Whether mTOR inhibitors can be an add-on option or second-line agents remain undetermined.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Chun-Hung</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Orthopedics, Far Eastern Memorial Hospital, New Taipei City, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chao</LastName>
            <ForeName>Chia-Ter</ForeName>
            <Initials>CT</Initials>
            <Identifier Source="ORCID">http://orcid.org/0000-0003-2892-7986</Identifier>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, National Taiwan University Hospital BeiHu Branch, National Taiwan University College of Medicine, Taipei, Taiwan. b88401084@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Graduate Institute of Toxicology, National Taiwan University College of Medicine, No. 1, Section 1 Jen-Ai Rd., Taipei, 10051, Taiwan. b88401084@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Mei-Yi</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Nephrology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Primary Care Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lo</LastName>
            <ForeName>Wei-Cheng</ForeName>
            <Initials>WC</Initials>
            <AffiliationInfo>
                <Affiliation>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Tsu-Chen</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
                <Affiliation>School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Mai-Szu</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Nephrology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D017418">Meta-Analysis</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2019</Year>
        <Month>10</Month>
        <Day>01</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Netherlands</Country>
    <MedlineTA>Int Urol Nephrol</MedlineTA>
    <NlmUniqueID>0262521</NlmUniqueID>
    <ISSNLinking>0301-1623</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>EC 2.7.11.1</RegistryNumber>
        <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016891" MajorTopicYN="N">Polycystic Kidney, Autosomal Dominant</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Autosomal dominant polycystic kidney disease</Keyword>
    <Keyword MajorTopicYN="N">End-stage renal disease</Keyword>
    <Keyword MajorTopicYN="N">Estimated glomerular filtration rate</Keyword>
    <Keyword MajorTopicYN="N">Mammalian target of rapamycin</Keyword>
    <Keyword MajorTopicYN="N">Total kidney volume</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2019</Year>
        <Month>05</Month>
        <Day>03</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2019</Year>
        <Month>09</Month>
        <Day>17</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2019</Year>
        <Month>10</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2020</Year>
        <Month>4</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2019</Year>
        <Month>10</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">31578673</ArticleId>
    <ArticleId IdType="doi">10.1007/s11255-019-02292-1</ArticleId>
    <ArticleId IdType="pii">10.1007/s11255-019-02292-1</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Clin J Am Soc Nephrol. 2010 Jul;5(7):1312-29</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20498248</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Soc Nephrol. 2008 Mar;19(3):631-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18199797</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Soc Nephrol. 2012 May;23(5):842-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22343118</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Exp Nephrol. 2017 Apr;21(2):203-211</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27278932</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hepatol. 2013 Jul;59(1):153-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23499726</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1993 Jul 29;329(5):332-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8321262</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 2009 Nov;24(11):3334-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19525519</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin J Am Soc Nephrol. 2014 May;9(5):881-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24721888</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cochrane Database Syst Rev. 2015 Jul 14;(7):CD010294</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26171904</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Soc Nephrol. 2010 Jun;21(6):1031-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20466742</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Invest. 2007 Mar;117(3):730-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17290308</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Transplant Proc. 2018 Jul - Aug;50(6):1863-1867</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30056917</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2010 Aug 26;363(9):820-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20581391</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Q J Med. 1991 Jun;79(290):477-85</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1946928</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 2012 Sep;27(9):3560-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22785114</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Trends Mol Med. 2014 May;20(5):251-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24491980</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2015 May 16;385(9981):1993-2002</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26090645</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Blood Press Res. 2007;30(4):253-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17596700</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Transplant Proc. 2012 Dec;44(10):2936-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23195001</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cell Mol Med. 2017 Aug;21(8):1619-1635</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28244683</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22344503</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Nephrol. 2017 Dec;13(12):750-768</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28989174</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephron Clin Pract. 2013;124(1-2):10-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24022660</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drug Saf. 2019 Jul;42(7):813-825</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30868436</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 2017 Aug 1;32(8):1356-1363</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27325254</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 2015 Oct;88(4):699-710</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26200945</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hum Genet. 2016 Jun 2;98(6):1193-1207</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27259053</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Nephrol. 2013 May;9(5):249-50</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23567275</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin J Am Soc Nephrol. 2016 May 6;11(5):785-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26912555</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Invest. 2014 Jun;124(6):2315-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24892705</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrology (Carlton). 2014 Apr;19(4):217-26</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24460701</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2010 Aug 26;363(9):830-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20581392</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Nephrol. 2014 Aug;10(8):455-65</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24935705</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">30999027</PMID>
<DateCompleted>
    <Year>2020</Year>
    <Month>02</Month>
    <Day>07</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>02</Month>
    <Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1873-1635</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>70</Volume>
            <PubDate>
                <Year>2019</Year>
                <Month>05</Month>
            </PubDate>
        </JournalIssue>
        <Title>Progress in retinal and eye research</Title>
        <ISOAbbreviation>Prog Retin Eye Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Retinal oximetry: Metabolic imaging for diseases of the retina and brain.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1-22</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="pii" ValidYN="Y">S1350-9462(18)30080-6</ELocationID>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.preteyeres.2019.04.001</ELocationID>
    <Abstract>
        <AbstractText>Retinal oximetry imaging of retinal blood vessels measures oxygen saturation of hemoglobin. The imaging technology is non-invasive and reproducible with remarkably low variability on test-retest studies and in healthy cohorts. Pathophysiological principles and novel biomarkers in several retinal diseases have been discovered, as well as possible applications for systemic and brain disease. In diabetic retinopathy, retinal venous oxygen saturation is elevated and arteriovenous difference progressively reduced in advanced stages of retinopathy compared with healthy persons. This correlates with pathophysiology of diabetic retinopathy where hypoxia stimulates VEGF production. Laser treatment and vitrectomy both improve retinal oximetry values, which correlate with clinical outcome. The oximetry biomarker may allow automatic measurement of severity of diabetic retinopathy and predict its response to treatment. Central retinal vein occlusion is characterized by retinal hypoxia, which is evident in retinal oximetry. The retinal hypoxia seen on oximetry correlates with the extent of peripheral ischemia, visual acuity and thickness of macular edema. This biomarker may help diagnose and measure severity of vein occlusion and degree of retinal ischemia. Glaucomatous retinal atrophy is associated with reduced oxygen consumption resulting in reduced arteriovenous difference and higher retinal venous saturation. The oximetry findings correlate with worse visual field, thinner nerve fiber layer and smaller optic disc rim. This provides an objective biomarker for glaucomatous damage. In retinitis pigmentosa, an association exists between advanced atrophy, worse visual field and higher retinal venous oxygen saturation, lower arteriovenous difference. This biomarker may allow measurement of severity and progression of retinitis pigmentosa and other atrophic retinal diseases. Retinal oximetry offers visible light imaging of systemic and central nervous system vessels. It senses hypoxia in cardiac and pulmonary diseases. Oximetry biomarkers have been discovered in Alzheimer's disease and multiple sclerosis and oxygen levels in the retina correspond well with brain.</AbstractText>
        <CopyrightInformation>Copyright © 2019. Published by Elsevier Ltd.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Stefánsson</LastName>
            <ForeName>Einar</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland; Oxymap ehf, Reykjavik, Iceland. Electronic address: einarste@landspitali.is.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Olafsdottir</LastName>
            <ForeName>Olof Birna</ForeName>
            <Initials>OB</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Eliasdottir</LastName>
            <ForeName>Thorunn S</ForeName>
            <Initials>TS</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vehmeijer</LastName>
            <ForeName>Wouter</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
                <Affiliation>Leiden University, Leiden, the Netherlands.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Einarsdottir</LastName>
            <ForeName>Anna Bryndis</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland; Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bek</LastName>
            <ForeName>Toke</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Torp</LastName>
            <ForeName>Thomas Lee</ForeName>
            <Initials>TL</Initials>
            <AffiliationInfo>
                <Affiliation>Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Grauslund</LastName>
            <ForeName>Jakob</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Eysteinsson</LastName>
            <ForeName>Thor</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Karlsson</LastName>
            <ForeName>Robert Arnar</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland; Oxymap ehf, Reykjavik, Iceland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Van Keer</LastName>
            <ForeName>Karel</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
                <Affiliation>University of Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Stalmans</LastName>
            <ForeName>Ingeborg</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
                <Affiliation>University of Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vandewalle</LastName>
            <ForeName>Evelien</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
                <Affiliation>University of Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Todorova</LastName>
            <ForeName>Margarita G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
                <Affiliation>University of Basel, Department of Ophthalmology, Basel, Switzerland; Cantonal Hospital St.Gallen, Department of Ophthalmology, St. Gallen, Switzerland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hammer</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Universitätsklinikum Jena, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Garhöfer</LastName>
            <ForeName>Gerhard</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Clinical Pharmacology, Medical University of Vienna, Austria.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Schmetterer</LastName>
            <ForeName>Leopold</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
                <Affiliation>Singapore Eye Research Institute, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Austria.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Šín</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hardarson</LastName>
            <ForeName>Sveinn Hakon</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
                <Affiliation>University of Iceland, Reykjavik, Iceland.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2019</Year>
        <Month>04</Month>
        <Day>15</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Prog Retin Eye Res</MedlineTA>
    <NlmUniqueID>9431859</NlmUniqueID>
    <ISSNLinking>1350-9462</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>S88TT14065</RegistryNumber>
        <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010092" MajorTopicYN="Y">Oximetry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012164" MajorTopicYN="N">Retinal Diseases</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012171" MajorTopicYN="N">Retinal Vessels</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014794" MajorTopicYN="N">Visual Fields</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="Y">Alzheimer's disease</Keyword>
    <Keyword MajorTopicYN="Y">Biomarker</Keyword>
    <Keyword MajorTopicYN="Y">Brain</Keyword>
    <Keyword MajorTopicYN="Y">Cardiac output</Keyword>
    <Keyword MajorTopicYN="Y">Central circulation</Keyword>
    <Keyword MajorTopicYN="Y">Classification</Keyword>
    <Keyword MajorTopicYN="Y">Diabetic retinopathy</Keyword>
    <Keyword MajorTopicYN="Y">Eye</Keyword>
    <Keyword MajorTopicYN="Y">Glaucoma</Keyword>
    <Keyword MajorTopicYN="Y">Heart</Keyword>
    <Keyword MajorTopicYN="Y">Multiple sclerosis</Keyword>
    <Keyword MajorTopicYN="Y">Oxygen</Keyword>
    <Keyword MajorTopicYN="Y">Progression of glaucoma</Keyword>
    <Keyword MajorTopicYN="Y">Retina</Keyword>
    <Keyword MajorTopicYN="Y">Retinal atrophy</Keyword>
    <Keyword MajorTopicYN="Y">Retinal dystrophy</Keyword>
    <Keyword MajorTopicYN="Y">Retinal oximetry</Keyword>
    <Keyword MajorTopicYN="Y">Retinal vein occlusion, retinal ischemia</Keyword>
    <Keyword MajorTopicYN="Y">Retinitis pigmentosa</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2018</Year>
        <Month>12</Month>
        <Day>21</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2019</Year>
        <Month>03</Month>
        <Day>27</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2019</Year>
        <Month>04</Month>
        <Day>10</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2019</Year>
        <Month>4</Month>
        <Day>19</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2020</Year>
        <Month>2</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2019</Year>
        <Month>4</Month>
        <Day>19</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">30999027</ArticleId>
    <ArticleId IdType="pii">S1350-9462(18)30080-6</ArticleId>
    <ArticleId IdType="doi">10.1016/j.preteyeres.2019.04.001</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">30441682</PMID>
<DateCompleted>
    <Year>2019</Year>
    <Month>10</Month>
    <Day>29</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>09</Month>
    <Day>28</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">2694-0604</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>2018</Volume>
            <PubDate>
                <Year>2018</Year>
                <Month>Jul</Month>
            </PubDate>
        </JournalIssue>
        <Title>Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference</Title>
        <ISOAbbreviation>Annu Int Conf IEEE Eng Med Biol Soc</ISOAbbreviation>
    </Journal>
    <ArticleTitle>AERO: An Objective Peripheral Edema Measurement Device.</ArticleTitle>
    <Pagination>
        <MedlinePgn>5914-5917</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1109/EMBC.2018.8513657</ELocationID>
    <Abstract>
        <AbstractText>Peripheral edema is of ten assessed by medical prof essionals to gain insights about development of many patient conditions. Currently, doctors assess edema by pushing on the swollen area of a patient. The difficulty with this method is the inconsistency assessment results between different physicians due to the subjective nature of the practice. The proposed solution uses AERO (or Air Edema RepOrting), a mobile, handheld device consisting of a high-speed camera with a macro lens, LED light, and compressed air to create edema indentation and capture images of the skin /tissue response. A MATLAB program analyzes these images and determines the correct level of edema. AERO was tested with a LifeformOR pitting edema trainer (four pieces of skin sample that represent the four edema levels). Various system configurations, such as the air pressure, camera to sample distance, and air incidence angle, were examined and optimal parameters were identified. Results demonstrated that AERO was able to distinguish the four levels of edema sample pads. This solution can potentially provide a quantified, standard evaluation of peripheral edema for both home and health care environments.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Williams</LastName>
            <ForeName>Keith</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Muhong</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hardin</LastName>
            <ForeName>Sonya</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>George</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Jianchu</ForeName>
            <Initials>J</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Annu Int Conf IEEE Eng Med Biol Soc</MedlineTA>
    <NlmUniqueID>101763872</NlmUniqueID>
    <ISSNLinking>2375-7477</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2018</Year>
        <Month>11</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2018</Year>
        <Month>11</Month>
        <Day>18</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2019</Year>
        <Month>10</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">30441682</ArticleId>
    <ArticleId IdType="doi">10.1109/EMBC.2018.8513657</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">29759062</PMID>
<DateCompleted>
    <Year>2019</Year>
    <Month>04</Month>
    <Day>15</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>04</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1742-2094</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2018</Year>
                <Month>May</Month>
                <Day>14</Day>
            </PubDate>
        </JournalIssue>
        <Title>Journal of neuroinflammation</Title>
        <ISOAbbreviation>J Neuroinflammation</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury.</ArticleTitle>
    <Pagination>
        <MedlinePgn>142</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-018-1166-9</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute neurological insults caused by infection, systemic inflammation, ischemia, or traumatic injury are often associated with breakdown of the blood-brain barrier (BBB) followed by infiltration of peripheral immune cells, cytotoxic proteins, and water. BBB breakdown and extravasation of these peripheral components into the brain parenchyma result in inflammation, oxidative stress, edema, excitotoxicity, and neurodegeneration. These downstream consequences of BBB dysfunction can drive pathophysiological processes and play a substantial role in the morbidity and mortality of acute and chronic neurological insults, and contribute to long-term sequelae. Preserving or rescuing BBB integrity and homeostasis therefore represents a translational research area of high therapeutic potential.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Induction of general and localized BBB disruption in mice was carried out using systemic administration of LPS and focal photothrombotic ischemic insult, respectively, in the presence and absence of the monoacylglycerol lipase (MAGL) inhibitor, CPD-4645. The effects of CPD-4645 treatment were assessed by gene expression analysis performed on neurovascular-enriched brain fractions, cytokine and inflammatory mediator measurement, and functional assessment of BBB permeability. The mechanism of action of CPD-4645 was studied pharmacologically using inverse agonists/antagonists of the cannabinoid receptors CB1 and CB2.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Here, we demonstrate that the neurovasculature exhibits a unique transcriptional signature following inflammatory insults, and pharmacological inhibition of MAGL using a newly characterized inhibitor rescues the transcriptional profile of brain vasculature and restores its functional homeostasis. This pronounced effect of MAGL inhibition on blood-brain barrier permeability is evident following both systemic inflammatory and localized ischemic insults. Mechanistically, the protective effects of the MAGL inhibitor are partially mediated by cannabinoid receptor signaling in the ischemic brain insult.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results support considering MAGL inhibitors as potential therapeutics for BBB dysfunction and cerebral edema associated with inflammatory brain insults.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Piro</LastName>
            <ForeName>Justin R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA. JPiro1000@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Abbvie Inc., 200 Sidney St., Cambridge, MA, 02139, USA. JPiro1000@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Suidan</LastName>
            <ForeName>Georgette L</ForeName>
            <Initials>GL</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Biogen, 225 Binney St., Cambridge, MA, 02142, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Quan</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pi</LastName>
            <ForeName>YeQing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Biogen, 225 Binney St., Cambridge, MA, 02142, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>O'Neill</LastName>
            <ForeName>Sharon M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Biogen, 225 Binney St., Cambridge, MA, 02142, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ilardi</LastName>
            <ForeName>Marissa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: NYU School of Medicine, 550 1st Ave., New York, NY, 10016, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pozdnyakov</LastName>
            <ForeName>Nikolay</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lanz</LastName>
            <ForeName>Thomas A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Biogen, 225 Binney St., Cambridge, MA, 02142, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Xi</LastName>
            <ForeName>Hualin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Abbvie Inc., 200 Sidney St., Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bell</LastName>
            <ForeName>Robert D</ForeName>
            <Initials>RD</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Samad</LastName>
            <ForeName>Tarek A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
                <Affiliation>Pfizer Worldwide Research &amp; Development, Cambridge, MA, 02139, USA. samad.tarek@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Present Address: Sanofi R&amp;D, 49 New York Ave., Framingham, MA, 01701, USA. samad.tarek@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2018</Year>
        <Month>05</Month>
        <Day>14</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>J Neuroinflammation</MedlineTA>
    <NlmUniqueID>101222974</NlmUniqueID>
    <ISSNLinking>1742-2094</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D001095">Arachidonic Acids</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D063388">Endocannabinoids</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D005989">Glycerides</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>8D239QDW64</RegistryNumber>
        <NameOfSubstance UI="C094503">glyceryl 2-arachidonate</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 3.1.1.23</RegistryNumber>
        <NameOfSubstance UI="D008994">Monoacylglycerol Lipases</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001095" MajorTopicYN="N">Arachidonic Acids</DescriptorName>
        <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002199" MajorTopicYN="N">Capillary Permeability</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D063388" MajorTopicYN="N">Endocannabinoids</DescriptorName>
        <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005989" MajorTopicYN="N">Glycerides</DescriptorName>
        <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008994" MajorTopicYN="N">Monoacylglycerol Lipases</DescriptorName>
        <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">2-arachidonoylglycerol</Keyword>
    <Keyword MajorTopicYN="N">Blood-brain barrier</Keyword>
    <Keyword MajorTopicYN="N">Monoacylglycerol lipase</Keyword>
    <Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
    <Keyword MajorTopicYN="N">Neurovasculature</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2018</Year>
        <Month>02</Month>
        <Day>02</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>04</Month>
        <Day>18</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2018</Year>
        <Month>5</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2018</Year>
        <Month>5</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2019</Year>
        <Month>4</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29759062</ArticleId>
    <ArticleId IdType="doi">10.1186/s12974-018-1166-9</ArticleId>
    <ArticleId IdType="pii">10.1186/s12974-018-1166-9</ArticleId>
    <ArticleId IdType="pmc">PMC5952841</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Eur Neurol. 2005;53(4):188-93</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15956787</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2112-20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23825365</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 2015 Mar 1;32(5):297-306</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25166905</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Bioinformatics. 2010 Jan 1;26(1):139-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19910308</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Exp Immunol. 2002 May;128(2):245-54</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11985514</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Chem Biol. 2009 Jan;5(1):37-44</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19029917</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>PLoS Pathog. 2010 Apr 29;6(4):e1000874</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20442866</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell Mol Neurobiol. 2000 Apr;20(2):131-47</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10696506</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 2011 Nov 11;334(6057):809-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22021672</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood. 2010 Nov 25;116(22):4712-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20716766</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroinflammation. 2015 Apr 28;12:81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25927213</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>BMC Neurosci. 2010 Feb 02;11:12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20122276</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>EMBO Rep. 2010 Feb;11(2):97-105</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20075988</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 2013 Apr 1;30(7):565-79</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23151067</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neuron. 2010 Nov 4;68(3):409-27</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21040844</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood. 2009 Jun 4;113(23):6015-22</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19349621</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurobiol Dis. 2006 May;22(2):257-64</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16364651</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Genome Biol. 2014 Feb 03;15(2):R29</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24485249</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosci. 2017 Jan 4;37(1):129-140</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28053036</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroinflammation. 2012 Jun 29;9:150</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22747709</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biochem J. 2004 Feb 1;377(Pt 3):787-95</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14561220</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cerebrovasc Dis. 2011;32(6):517-27</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22104408</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell. 2015 Nov 19;163(5):1064-1078</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26590417</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nature. 2012 May 16;485(7399):512-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22622580</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2016 Sep;36(9):1481-507</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27323783</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Atherosclerosis. 2008 Feb;196 (2):514-22</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17606262</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mol Pharmacol. 2010 Dec;78(6):996-1003</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20855465</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Genome Biol. 2010;11(3):R25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20196867</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Expert Opin Investig Drugs. 2006 Apr;15(4):351-65</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16548785</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroinflammation. 2013 Oct 31;10 :133</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24176075</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2015 Mar 31;35(4):706</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25826320</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nucleic Acids Res. 2015 Apr 20;43(7):e47</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25605792</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 2006 May 9;1088(1):19-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16630594</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain. 2016 Feb;139(Pt 2):563-77</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26493635</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res Brain Res Rev. 2001 Oct;36(2-3):249-57</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11690622</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Behav Immun. 2017 Feb;60:1-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26995317</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell Res. 2009 Jan;19(1):116-27</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19114994</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Leukoc Biol. 2010 May;87(5):779-89</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20130219</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Exp Neurol. 2013 Dec;250:43-51</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24056042</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell Rep. 2012 Jun 28;1(6):617-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22813736</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Neurol. 1997 Mar;41(3):326-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9066353</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chem Biol. 2007 Dec;14 (12 ):1347-56</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18096503</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Behav Immun. 2009 May;23(4):507-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19486646</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurobiol Dis. 2010 Jan;37(1):13-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19664713</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2017 Jan;37(1):85-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26661237</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 2015 Oct 14;1623:30-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25916577</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Matrix Biol. 2015 May-Jul;44-46:70-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25622912</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurobiol Dis. 2012 Dec;48(3):495-506</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22782081</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pharmacol Exp Ther. 2005 Apr;313(1):352-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15579492</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Epilepsia. 2018 Jan;59(1):79-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29171003</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Matrix Biol. 2010 May;29(4):304-16</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20096780</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Infect Dis. 2000 Jul;31(1):80-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10913401</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">29726641</PMID>
<DateCompleted>
    <Year>2018</Year>
    <Month>10</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1009-3591</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>8</Issue>
            <PubDate>
                <Year>2017</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zhonghua nan ke xue = National journal of andrology</Title>
        <ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Impact of deep slow-wave sleep deprivation on oxidative stress response of the testis tissue in rats].</ArticleTitle>
    <Pagination>
        <MedlinePgn>687-691</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the influence of deep slow-wave sleep deprivation on the oxidative stress of testicular tissue in rats.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-six 5-week-old male Wistar rats were equally randomized into deep slow-wave sleep deprivation group (SD1), deep slow-wave sleep and duration sleep deprivation group ( SD2), and a cage control group (CC). The rat model of deep slow-wave sleep deprivation was established using the flowerpot technique. The rats in the SD1 group were interfered every 24 minutes and deprived of 12 hours of sleep at night, those in the SD2 group deprived of 8 minutes of sleep at an interval of 24 minutes and 12 hours of sleep at night, and those in the CC group exposed to 12 hours of daylight and 12 hours of darkness. After 28 days, all the rats were executed for measurement of the testis volume and protein content, determination of the methane dicarboxylic aldehyde (MDA) level and activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and observation of the pathological changes in the testicular tissue under the microscope.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the CC group, the rats in the SD1 and SD2 groups showed significantly reduced body weight (［268.5 ± 1.6］ vs ［248.1 ± 25.1］and［232.9 ± 10.1］g, P&lt;0.05) and increased relative testis mass (［50.0 ± 1.3］ vs ［57.9 ± 6.1］ and ［54.9 ± 3.5］ ×10⁻², P&lt;0.05). Statistically significant differences were found between the CC and SD2 groups in the contents of protein (［6.3 ± 1.4］ vs ［4.5 ± 0.9］ gpro/L, P&lt;0.05) and MDA (［1.1 ± 0.1］ vs ［1.3 ± 0.3］ nmol/mgpro, P&lt;0.05) and the activities of SOD (［104.3 ± 33.1］ vs ［135.2 ± 26.9］ U/mgpro, P&lt;0.05) and GSH-Px (［15.6 ± 4.0］ vs ［21.7 ± 4.3］ U/mgpro, P&lt;0.05), but not between the CC and SD1 groups (P&gt;0.05). The lumens in the testis were narrowed, with obvious hyperplasia, hyperemia and edema in the peripheral interstitial tissue, but no significant pathologic changes were observed in the testis tissue of the SD1 group.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term deprivation of deep slow-wave sleep impairs the structure of the testis tissue and induces oxidative stress response in rats.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
                <Affiliation>Research Institute of Endocrinology / Key Laboratory of Hormones and Development / Key Laboratory for Metabolic Diseases, Hospital of Metabolic Diseases, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>The Second School of Clinical Medicine, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Yu-Han</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qi-Jin</ForeName>
            <Initials>QJ</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Mei-Wen</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zi-Han</ForeName>
            <Initials>ZH</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Yi-Wei</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hai-Zheng</ForeName>
            <Initials>HZ</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xue-Qian</ForeName>
            <Initials>XQ</Initials>
            <AffiliationInfo>
                <Affiliation>School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Lai-Xiang</ForeName>
            <Initials>LX</Initials>
            <AffiliationInfo>
                <Affiliation>Research Institute of Endocrinology / Key Laboratory of Hormones and Development / Key Laboratory for Metabolic Diseases, Hospital of Metabolic Diseases, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>chi</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>China</Country>
    <MedlineTA>Zhonghua Nan Ke Xue</MedlineTA>
    <NlmUniqueID>101093592</NlmUniqueID>
    <ISSNLinking>1009-3591</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>4Y8F71G49Q</RegistryNumber>
        <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.11.1.9</RegistryNumber>
        <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.15.1.1</RegistryNumber>
        <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008315" MajorTopicYN="N">Malondialdehyde</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<OtherAbstract Type="Publisher" Language="chi">
    <AbstractText>目的：研究深慢波睡眠剥夺对大鼠睾丸组织氧化应激反应的影响。 方法：36只5周龄健康雄性Wistar大鼠，随机分为深慢波睡眠时相剥夺组（SD1组）、深慢波睡眠时相及时长剥夺组（SD2组）组和空白对照组（CC组），每组12只，利用小平台水环境建立深慢波睡眠剥夺模型。SD1组每间隔24 min干扰1次，SD2组每间隔24 min剥夺睡眠8 min；夜间都进行12 h的完全睡眠剥夺。CC组模拟正常的12 h光照、12 h黑暗时间。28 d后，大鼠股动脉放血，留取睾丸组织进行称重，测定睾丸组织中蛋白含量、丙二醛（MDA）、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物岐化酶（SOD）水平，显微镜下观察睾丸病理结构的改变。结果：SD1、SD2组大鼠的终末体质量［（248.1±25.1） g、（232.9±10.1） g］均下降，与CC组［（268.5± 1.6）g］相比差异有统计学意义（P均&lt;0.05）；与CC组相比，SD2组睾丸相对质量明显升高［（54.9±3.5）×10⁻² vs （50.0±1.3）×10⁻²，P&lt;0.05］。与CC组相比，SD2组睾丸组织蛋白含量、MDA含量、SOD活性和GSH-Px均有显著差异［蛋白含量：（4.5±0.9）g pro/L vs 6.3±1.4）g pro/L； MDA含量: （1.3±0.3）nmol/mg pro vs （1.1±0.1）nmol/mg pro；SOD活性：（135.2±26.9）U/mg pro vs （104.3±33.1）U/mg pro； GSH-Px活性： （21.7±4.3）U/mg pro vs（15.6±4.0）U/mg pro，P均&lt;0.05］，而与SD1组比较差异无统计学意义。SD1组睾丸病理学改变不明显，但SD2组睾丸生精小管管腔变小，周围间质部分增加，间质充血水肿明显。结论：长期深慢波睡眠剥夺对大鼠睾丸组织结构产生损伤并引起氧化应激反应。.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">flowerpot technique</Keyword>
    <Keyword MajorTopicYN="N">oxidative stress</Keyword>
    <Keyword MajorTopicYN="N">rat</Keyword>
    <Keyword MajorTopicYN="N">sleep deprivation</Keyword>
    <Keyword MajorTopicYN="N">testis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2018</Year>
        <Month>5</Month>
        <Day>5</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2018</Year>
        <Month>5</Month>
        <Day>5</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2018</Year>
        <Month>10</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29726641</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">29411010</PMID>
<DateCompleted>
    <Year>2018</Year>
    <Month>08</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>08</Month>
    <Day>06</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1552-5783</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>59</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2018</Year>
                <Month>02</Month>
                <Day>01</Day>
            </PubDate>
        </JournalIssue>
        <Title>Investigative ophthalmology &amp; visual science</Title>
        <ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Discovery of a Cynomolgus Monkey Family With Retinitis Pigmentosa.</ArticleTitle>
    <Pagination>
        <MedlinePgn>826-830</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.17-22958</ELocationID>
    <Abstract>
        <AbstractText Label="Purpose">To accelerate the development of new therapies, an inherited retinal degeneration model in a nonhuman primate would be useful to confirm the efficacy in preclinical studies. In this study, we describe the discovery of retinitis pigmentosa in a cynomolgus monkey (Macaca fascicularis) pedigree.</AbstractText>
        <AbstractText Label="Methods">First, screening with fundus photography was performed on 1443 monkeys at the Tsukuba Primate Research Center. Ophthalmic examinations, such as indirect ophthalmoscopy, ERGs using RETeval, and optic coherent tomography (OCT) measurement, were then performed to confirm diagnosis.</AbstractText>
        <AbstractText Label="Results">Retinal degeneration with cystoid macular edema was observed in both eyes of one 14-year-old female monkey. In her examinations, the full-field ERGs were nonrecordable and the outer layer of the retina in the parafoveal area was not visible on OCT imaging. Moreover, less frequent pigmentary retinal anomalies also were observed in her 3-year-old nephew. His full-field ERGs were almost nonrecordable and the outer layer was not visible in the peripheral retina. His father was her cousin (the son of her mother's older brother) and his mother was her younger half-sibling sister with a different father.</AbstractText>
        <AbstractText Label="Conclusions">The hereditary nature is highly probable (autosomal recessive inheritance suspected). However, whole-exome analysis performed identified no pathogenic mutations in these monkeys.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ikeda</LastName>
            <ForeName>Yasuhiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Ocular Pathology and Imaging Science, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nishiguchi</LastName>
            <ForeName>Koji M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Miya</LastName>
            <ForeName>Fuyuki</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medical Science Mathematics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shimozawa</LastName>
            <ForeName>Nobuhiro</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tsukuba, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Funatsu</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nakatake</LastName>
            <ForeName>Shunji</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fujiwara</LastName>
            <ForeName>Kohta</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tachibana</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Murakami</LastName>
            <ForeName>Yusuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hisatomi</LastName>
            <ForeName>Toshio</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Shigeo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yasutomi</LastName>
            <ForeName>Yasuhiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tsukuba, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tsunoda</LastName>
            <ForeName>Tatsuhiko</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medical Science Mathematics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nakazawa</LastName>
            <ForeName>Toru</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ishibashi</LastName>
            <ForeName>Tatsuro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sonoda</LastName>
            <ForeName>Koh-Hei</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Graduate School Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
    <NlmUniqueID>7703701</NlmUniqueID>
    <ISSNLinking>0146-0404</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004596" MajorTopicYN="N">Electroretinography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName>
        <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009887" MajorTopicYN="N">Ophthalmoscopy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012174" MajorTopicYN="N">Retinitis Pigmentosa</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000073359" MajorTopicYN="N">Whole Exome Sequencing</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2018</Year>
        <Month>2</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2018</Year>
        <Month>2</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2018</Year>
        <Month>8</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29411010</ArticleId>
    <ArticleId IdType="pii">2672463</ArticleId>
    <ArticleId IdType="doi">10.1167/iovs.17-22958</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">29293163</PMID>
<DateCompleted>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>01</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1528-1159</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>14</Issue>
            <PubDate>
                <Year>2018</Year>
                <Month>07</Month>
                <Day>15</Day>
            </PubDate>
        </JournalIssue>
        <Title>Spine</Title>
        <ISOAbbreviation>Spine (Phila Pa 1976)</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Investigation of the Effect of Cervical Radiculopathy on Peripheral Nerves of the Upper Extremity With High-Resolution Ultrasonography.</ArticleTitle>
    <Pagination>
        <MedlinePgn>E798-E803</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1097/BRS.0000000000002539</ELocationID>
    <Abstract>
        <AbstractText Label="STUDY DESIGN">Prospective, cross-sectional observational study.</AbstractText>
        <AbstractText Label="OBJECTIVE">We aimed to investigate the effects of chronic cervical radiculopathy (CR) on the cross-sectional area (CSA) values of the cervical nerve roots (CNRs), median, ulnar, and radial nerves with high-resolution ultrasonography.</AbstractText>
        <AbstractText Label="SUMMARY OF BACKGROUND DATA">Symptomatic nerve roots are wider than asymptomatic nerve roots due to the presence of edema. Peripheral nerves have also been shown to develop edema, fibrosis, and changes distal to the affected nerve as a result of mechanical compression. In addition according to "double-crush syndrome" hypothesis, the peripheral nerves are more sensitive to pressure, and a proximal nerve lesion makes the distal segment of the nerve more susceptible to anatomic deterioration by causing interruption in the axoplasmic conduction due to compression.</AbstractText>
        <AbstractText Label="METHODS">Forty patients with chronic CR were included to the study. Both affected CNRs and the contralateral nerve roots (control group) were evaluated with high-resolution ultrasonography. Ulnar and median nerve CSA measurements were performed at four measurement points and radial nerve measurements at a single measurement point.</AbstractText>
        <AbstractText Label="RESULTS">CSA measurements were statistically significantly higher at the CNR of the affected side compared to the unaffected side. There was no statistically significant difference when affected and unaffected sides were compared in terms of measurements performed from median, ulnar, and radial nerves at all measurement points.</AbstractText>
        <AbstractText Label="CONCLUSION">The results of the present study indicate that the changes in the CNR caused by CR do not have any effect on the peripheral nerves. We did not find any affection in peripheral nerve CSA that might have been suggestive of double-crush syndrome in CR.</AbstractText>
        <AbstractText Label="LEVEL OF EVIDENCE">2.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Metin Ökmen</LastName>
            <ForeName>Burcu</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physical Medicine and Rehabilitation, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ökmen</LastName>
            <ForeName>Korgün</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology and Reanimation, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Altan</LastName>
            <ForeName>Lale</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physical Medicine and Rehabilitation, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology and Reanimation, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Uludag University, Bursa, Turkey.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D064888">Observational Study</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Spine (Phila Pa 1976)</MedlineTA>
    <NlmUniqueID>7610646</NlmUniqueID>
    <ISSNLinking>0362-2436</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011843" MajorTopicYN="N">Radiculopathy</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013126" MajorTopicYN="N">Spinal Nerve Roots</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018084" MajorTopicYN="N">Ultrasonography, Interventional</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D034941" MajorTopicYN="N">Upper Extremity</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2018</Year>
        <Month>1</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2018</Year>
        <Month>11</Month>
        <Day>18</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2018</Year>
        <Month>1</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29293163</ArticleId>
    <ArticleId IdType="doi">10.1097/BRS.0000000000002539</ArticleId>
    <ArticleId IdType="pii">00007632-201807150-00005</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Abbed KM, Coumans JV. Cervical radiculopathy: pathophysiology, presentation, and clinical evaluation. Neurosurgery 2007; 60 (suppl):28–34.</Citation>
    </Reference>
    <Reference>
        <Citation>Thoomes EJ, Scholten-Peeters GG, De Boer AJ, et al. Lack of uniform diagnostic criteria for cervical radiculopathy in conservative intervention studies: a systematic review. Eur Spine J 2012; 8:1459–1470.</Citation>
    </Reference>
    <Reference>
        <Citation>Yoon SH. Cervical radiculopathy. Phys Med Rehabil Clin N Am 2011; 2:439–446.</Citation>
    </Reference>
    <Reference>
        <Citation>Carette S, Fehlings MG. Clinical practice. Cervical radiculopathy. N Engl J Med 2005; 353:392–399.</Citation>
    </Reference>
    <Reference>
        <Citation>Sugawara O, Atsuta Y, Iwahara T, et al. The effects of mechanical compression and hypoxia on nerve root and dorsal root ganglia. An analysis of ectopic firing using an in vitro model. Spine (Phila Pa 1976) 1996; 21:2089–2094.</Citation>
    </Reference>
    <Reference>
        <Citation>Byun WM, Kim JW, Lee JK. Differentiation between symptomatic and asymptomatic extraforaminal stenosis in lumbosacral transitional vertebra: Role of three-dimensional magnetic resonance lumbosacral radiculography. Korean J Radiol 2012; 13:403–411.</Citation>
    </Reference>
    <Reference>
        <Citation>Byun WM, Ahn SH, Ahn MW. Value of 3D MR lumbosacral radiculography in the diagnosis of symptomatic chemical radiculitis. Am J Neuroradiol 2012; 33:529–534.</Citation>
    </Reference>
    <Reference>
        <Citation>Kim E, Yoon JS, Kang HJ. Ultrasonographic cross-sectional area of spinal nerve roots in cervical radiculopathy: a pilot study. Am J Phys Med Rehabil 2015; 94:159–164.</Citation>
    </Reference>
    <Reference>
        <Citation>Takeuchi M, Wakao N, Hirasawa A, et al. Ultrasonography has a diagnostic value in the assessment of cervical radiculopathy: a prospective pilot study. Eur Radiol 2017; 27:3467–3473.</Citation>
    </Reference>
    <Reference>
        <Citation>Upton AR, McComas AJ. The double crush in nerve entrapment syndromes. Lancet 1973; 2:359–362.</Citation>
    </Reference>
    <Reference>
        <Citation>Hurst LC, Weissberg D, Carroll RE. The relationship of the double crush to carpal tunnel syndrome (an analysis of 1000 cases of carpal tunnel syndrome). J Hand Surg 1985; 10:202–204.</Citation>
    </Reference>
    <Reference>
        <Citation>Baba H, Maezawa Y, Uchida K, et al. Cervical myeloradiculopathy with entrapment neuropathy: a study based on the double-crush concept. Spinal Cord 1998; 36:399–404.</Citation>
    </Reference>
    <Reference>
        <Citation>Morgan G, Wilbourn AJ. Cervical radiculopathy and coexisting distal entrapment neuropathies: double-crush syndromes? Neurology 1998; 50:78–83.</Citation>
    </Reference>
    <Reference>
        <Citation>Wessel LE, Fufa DT, Canham RB, et al. Outcomes following peripheral nerve decompression with and without associated double crush syndrome: a case control study. Plast Reconstr Surg 2017; 139:119–127.</Citation>
    </Reference>
    <Reference>
        <Citation>Klauser AS, Halpern EJ, De Zordo T, et al. Carpal tunnel syndrome assessment with US: value of additional cross-sectional area measurements of the median nerve in patients versus healthy volunteers. Radiology 2009; 250:171–177.</Citation>
    </Reference>
    <Reference>
        <Citation>Beekman R, Schoemaker MC, Van Der Plas JP, et al. Diagnostic value of high-resolution sonography in ulnar neuropathy at the elbow. Neurology 2004; 62:767–773.</Citation>
    </Reference>
    <Reference>
        <Citation>Rao R. Neck pain, cervical radiculopathy, and cervical myelopathy: pathophysiology, natural history, and clinical evaluation. Instr Course Lect 2003; 52:479–488.</Citation>
    </Reference>
    <Reference>
        <Citation>Haun DW, Cho JC, Kettner NW. Normative cross-sectional area of the C5-C8 nerve roots using ultrasonography. Ultrasound Med Biol 2010; 36:1422–1430.</Citation>
    </Reference>
    <Reference>
        <Citation>Won SJ, Kim BJ, Park KS, et al. Measurement of cross-sectional area of cervical roots and brachial plexus trunks. Muscle Nerve 2012; 46:711–716.</Citation>
    </Reference>
    <Reference>
        <Citation>Simon NG, Ralph JW, Poncelet AN, et al. A comparison of ultrasonographic and electrophysiologic ’inching’ in ulnar neuropathy at the elbow. Clin Neurophysiol 2015; 126:391–398.</Citation>
    </Reference>
    <Reference>
        <Citation>Dahlin LB. Aspects on pathophysiology of nerve entrapments and nerve compression injuries. Neurosurg Clin N Am 1991; 2:21–29.</Citation>
    </Reference>
    <Reference>
        <Citation>Lundborg G, Dahlin LB. Anatomy, function and pathophysiology of peripheral nerves and nerve compression. Hand Clin 1996; 12:185–193.</Citation>
    </Reference>
    <Reference>
        <Citation>Uğurlu FG, Tiftik T, Kara M, et al. Ultrasonographic evaluation of the median and sciatic nerves in hemiplegic patients after stroke. Am J Phys Med Rehabil 2015; 94:429–435.</Citation>
    </Reference>
    <Reference>
        <Citation>Cartwright MS, Walker FO, Griffin LP, et al. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44:346–351.</Citation>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
<PMID Version="1">29270515</PMID>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
    <Journal>
        <ISSN IssnType="Electronic">2468-0249</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>2</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2017</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>Kidney international reports</Title>
        <ISOAbbreviation>Kidney Int Rep</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Right Ventricular Function, Peripheral Edema, and Acute Kidney Injury in Critical Illness.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1059-1065</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ekir.2017.05.017</ELocationID>
    <Abstract>
        <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The cardiorenal syndrome generally focuses on left ventricular function, and the importance of the right ventricle as a determinant of renal function is described less frequently. In a cohort of critically ill patients with echocardiographic measurements obtained within 24 hours of admission to the intensive care unit, we examined the association of right ventricular function with acute kidney injury (AKI) and AKI-associated mortality. We also examined whether clinical measurement of volume overload modified the association between ventricular function and AKI in a subpopulation with documented admission physical examinations.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Among 1879 critically ill patients with echocardiographic ventricular measurements, 43% (<i>n</i> = 807) had ventricular dysfunction-21% (<i>n</i> = 388), 9% (<i>n</i> = 167), and 13% (<i>n</i> = 252) with isolated left ventricular dysfunction, isolated right ventricular dysfunction, and biventricular dysfunction, respectively. Overall, ventricular dysfunction was associated with a 43% higher adjusted risk of AKI (95% confidence interval [CI] 1.14-1.80; <i>P</i> = 0.002) compared with those with normal biventricular function, whereas isolated left ventricular dysfunction, isolated right ventricular dysfunction, and biventricular dysfunction were associated with a 1.34 (95% CI 1.00-1.77, <i>P</i> = 0.05), 1.35 (95% CI 0.90-2.10, <i>P</i> = 0.14) and 1.67 (95% CI 1.23-2.31, <i>P</i> = 0.002) higher adjusted risk. Although an episode of AKI was associated with an approximately 2-fold greater risk of hospital mortality in those with isolated left ventricular dysfunction and biventricular dysfunction, in those with isolated right ventricular dysfunction, AKI was associated with a 7.85-fold greater risk of death (95% CI 2.89-21.3, <i>P</i> &lt; 0.001). Independent of ventricular function, peripheral edema was an important determinant of AKI.</AbstractText>
        <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Like left ventricular function, right ventricular function is an important determinant of AKI and AKI-associated mortality. Volume overload, independently of ventricular function, is a risk factor for AKI. Whether establishment of euvolemia might mitigate AKI risk will require further study.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
                <Affiliation>Beth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Joon</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Alistair E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
                <Affiliation>Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mark</LastName>
            <ForeName>Roger G</ForeName>
            <Initials>RG</Initials>
            <AffiliationInfo>
                <Affiliation>Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Celi</LastName>
            <ForeName>Leo Anthony</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
                <Affiliation>Beth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Danziger</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Beth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>R01 EB017205</GrantID>
            <Acronym>EB</Acronym>
            <Agency>NIBIB NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2017</Year>
        <Month>06</Month>
        <Day>10</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Kidney Int Rep</MedlineTA>
    <NlmUniqueID>101684752</NlmUniqueID>
    <ISSNLinking>2468-0249</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">acute kidney injury</Keyword>
    <Keyword MajorTopicYN="N">congestion</Keyword>
    <Keyword MajorTopicYN="N">edema</Keyword>
    <Keyword MajorTopicYN="N">left ventricle</Keyword>
    <Keyword MajorTopicYN="N">right ventricle</Keyword>
    <Keyword MajorTopicYN="N">volume overload</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2017</Year>
        <Month>05</Month>
        <Day>15</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2017</Year>
        <Month>05</Month>
        <Day>28</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29270515</ArticleId>
    <ArticleId IdType="doi">10.1016/j.ekir.2017.05.017</ArticleId>
    <ArticleId IdType="pii">S2468-0249(17)30152-3</ArticleId>
    <ArticleId IdType="pmc">PMC5733885</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Am J Physiol. 1949 Apr;157(1):1-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18130215</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 2008 Jan;36(1 Suppl):S75-88</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18158481</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Card Fail. 2011 Jul;17(7):533-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21703524</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Public Health. 2015 Feb;25 Suppl 1:15-20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25690125</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Cardiol. 2010 Feb 15;105(4):511-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20152246</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Am Thorac Soc. 2016 May;13(5):705-11</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26966784</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 1984 Jun;54(6):719-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6733867</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Kidney Dis. 2013 May;61(5):649-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23499048</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cleve Clin J Med. 2006 Jun;73 Suppl 2:S8-13; discussion S30-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16786907</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Intern Med. 2015 Apr;277(4):468-77</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24931482</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Heart Fail. 2012 Mar;14 (3):287-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22357576</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2005 Jan;26(1):11-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15615794</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin J Am Soc Nephrol. 2016 Apr 7;11(4):602-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26787777</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Card Fail. 2008 Dec;14(10):824-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19041045</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Diagn Res. 2015 Mar;9(3):OC05-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25954646</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 2014 Sep;42(9):2109-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24810531</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 2008 Apr;34(4):707-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18157662</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 2013 Mar;83(3):384-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23254894</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ J. 2013;77(10):2612-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23856712</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Physiol. 1931 Apr 24;71(4):381-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16994187</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2009 Feb 17;53(7):589-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19215833</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>BMJ Open. 2015 May 22;5(5):e007466</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26002690</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Crit Care. 2012 Jun;27(3):319.e9-15</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21855287</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Intern Med. 1984 Apr;100(4):483-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6703540</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 2012 Dec;27(12):4263-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23045432</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Trauma. 1999 Dec;47(6):1000-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10608524</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2003 Apr 17;348(16):1546-54</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12700374</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Care. 2009 Jun;47(6):626-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19433995</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Physiol. 1931 Jun 6;72(1):49-61</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16994199</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 1999 Mar;27(3):540-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10199533</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">29248780</PMID>
<DateCompleted>
    <Year>2018</Year>
    <Month>05</Month>
    <Day>14</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>05</Month>
    <Day>14</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1878-8769</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>111</Volume>
            <PubDate>
                <Year>2018</Year>
                <Month>Mar</Month>
            </PubDate>
        </JournalIssue>
        <Title>World neurosurgery</Title>
        <ISOAbbreviation>World Neurosurg</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Correlation of Lactate Concentration in Peripheral Plasma and Cerebrospinal Fluid with Glasgow Outcome Scale for Patients with Tuberculous Meningitis Complicated by Acute Hydrocephalus Treated with Fluid Diversions.</ArticleTitle>
    <Pagination>
        <MedlinePgn>e178-e182</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="pii" ValidYN="Y">S1878-8750(17)32123-X</ELocationID>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.wneu.2017.12.007</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tuberculous meningitis (TBM) is an endemic infectious disease in developing countries, and it can become a serious illness in children. Treatment of TBM is more difficult and prone to failure than treatment of pulmonary tuberculosis. TBM causes hydrocephalus, cerebral edema, increased intracranial pressure, global ischemia, and neurologic deficits, which disturb cellular metabolism and increase lactate levels. A reliable, widely available clinical indicator of TBM severity is needed. Successful treatment of TBM is assessed using the Glasgow Outcome Scale (GOS).</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">This prospective cohort study included 34 patients with TBM and acute hydrocephalus who had undergone fluid diversions and were admitted to Dr. Hasan Sadikin Hospital in Bandung from 2014 to 2015. A portable machine for blood glucose measurement was used to measure lactate concentrations. Statistical significance was defined as P ≤ 0.05.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Average levels of plasma and cerebrospinal fluid (CSF) lactate were 1.99 ± 0.70 mmol/L and 3.04 ± 1.05 mmol/L, respectively. A significantly higher level of lactate was observed in CSF compared with plasma. Preoperative plasma lactate was negatively correlated to GOS (r = -0.539; P = 0.013), and CSF lactate was negatively correlated to GOS (r = -0.412; P = 0.027). Average lactate levels in CSF (central) were higher than plasma (peripheral) levels. GOS scale of patients decreased with increased plasma and CSF lactate levels.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Examination of plasma and CSF lactate levels should be included in routine examinations to determine extent of cellular damage and GOS score in patients with TBM and acute hydrocephalus who have undergone fluid diversions.</AbstractText>
        <CopyrightInformation>Copyright © 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Faried</LastName>
            <ForeName>Ahmad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital, Bandung, Indonesia. Electronic address: faried.fkup@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Arief</LastName>
            <ForeName>Gusman</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital, Bandung, Indonesia.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Arifin</LastName>
            <ForeName>Muhammad Z</ForeName>
            <Initials>MZ</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital, Bandung, Indonesia.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nataprawira</LastName>
            <ForeName>Heda M</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Child Health, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin Hospital, Bandung, Indonesia.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>14</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>World Neurosurg</MedlineTA>
    <NlmUniqueID>101528275</NlmUniqueID>
    <ISSNLinking>1878-8750</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>33X04XA5AT</RegistryNumber>
        <NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002557" MajorTopicYN="N">Cerebrospinal Fluid Shunts</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D023261" MajorTopicYN="Y">Glasgow Outcome Scale</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006849" MajorTopicYN="N">Hydrocephalus</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014390" MajorTopicYN="N">Tuberculosis, Meningeal</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Acute hydrocephalus</Keyword>
    <Keyword MajorTopicYN="N">Glasgow Outcome Scale</Keyword>
    <Keyword MajorTopicYN="N">Plasma lactate and cerebrospinal fluid lactate level</Keyword>
    <Keyword MajorTopicYN="N">Tuberculous meningitis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2017</Year>
        <Month>08</Month>
        <Day>09</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>03</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>05</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>19</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2018</Year>
        <Month>5</Month>
        <Day>15</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>18</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29248780</ArticleId>
    <ArticleId IdType="pii">S1878-8750(17)32123-X</ArticleId>
    <ArticleId IdType="doi">10.1016/j.wneu.2017.12.007</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">28954021</PMID>
<DateCompleted>
    <Year>2017</Year>
    <Month>12</Month>
    <Day>04</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1678-2925</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <Issue>4</Issue>
            <PubDate>
                <MedlineDate>2017 Jul-Aug</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Arquivos brasileiros de oftalmologia</Title>
        <ISOAbbreviation>Arq Bras Oftalmol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Alternative ways to optimize treatment for retinal vein occlusion with peripheral capillary non-perfusion: a pilot study.</ArticleTitle>
    <Pagination>
        <MedlinePgn>224-228</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="pii" ValidYN="Y">S0004-27492017000400224</ELocationID>
    <ELocationID EIdType="doi" ValidYN="Y">10.5935/0004-2749.20170055</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE:" NlmCategory="UNASSIGNED">We compared the efficacy and safety of ranibizumab versus ranibizumab plus scatter laser photocoagulation (SLP) in patients with chronic post-central retinal vein occlusion (CRVO) macular edema (ME).</AbstractText>
        <AbstractText Label="METHODS:" NlmCategory="UNASSIGNED">This prospective non-randomized pilot study included 250 patients with peripheral retinal ischemia and CRVO-related ME. The mean follow-up period was 24.5 ± 6.5 months. The clinical assessments conducted included best corrected visual acuity, optical coherence tomography, and multi-field fluorescein angiography with measurement of the ischemic area. The study population comprised two comparable patient groups with peripheral retinal ischemia that received different treatments for post-CRVO ME: ranibizumab with peripheral SLP of capillary non-perfusion areas (Group 1); and Lucentis® monotherapy (Group 2). Data analyses were performed using Statistica 7 software suite and included the estimation of х ± δ values and their dispersion and covariation coefficients at different stages of the study.</AbstractText>
        <AbstractText Label="RESULTS:" NlmCategory="UNASSIGNED">Clinically significant retinal ischemia was detected in 175 (70%) patients, occupying an average of 435.12 ± 225.13 mm2, i.e., 167.15 ± 45.16 optic disc areas. Peripheral ischemia was found in 125 patients, representing 50% of all patients with CRVO and 71.4% of all patients with ischemic CRVO. The mean number of ranibizumab injections in patients who underwent SLP was 3.5 ± 1.6. Patients treated with ranibizumab monotherapy for 24 months received 10.6 ± 2.5 injections. Functional and anatomic results were comparable in the two groups.</AbstractText>
        <AbstractText Label="CONCLUSIONS:" NlmCategory="UNASSIGNED">The combination of ranibizumab injections and peripheral SLP in capillary non-perfusion areas can significantly decrease the number of injections and reduce neovascular complications.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Tultseva</LastName>
            <ForeName>Svetlana N</ForeName>
            <Initials>SN</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Astakhov</LastName>
            <ForeName>Yury S</ForeName>
            <Initials>YS</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Novikov</LastName>
            <ForeName>Sergei A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nechiporenko</LastName>
            <ForeName>Pavel A</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lisochkina</LastName>
            <ForeName>Alla B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ovnanyan</LastName>
            <ForeName>Andranik Y</ForeName>
            <Initials>AY</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Astakhov</LastName>
            <ForeName>Sergei Y</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Brazil</Country>
    <MedlineTA>Arq Bras Oftalmol</MedlineTA>
    <NlmUniqueID>0400645</NlmUniqueID>
    <ISSNLinking>0004-2749</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>ZL1R02VT79</RegistryNumber>
        <NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017075" MajorTopicYN="N">Laser Coagulation</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012170" MajorTopicYN="N">Retinal Vein Occlusion</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2016</Year>
        <Month>11</Month>
        <Day>16</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2017</Year>
        <Month>02</Month>
        <Day>05</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2017</Year>
        <Month>9</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2017</Year>
        <Month>9</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>5</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">28954021</ArticleId>
    <ArticleId IdType="pii">S0004-27492017000400224</ArticleId>
    <ArticleId IdType="doi">10.5935/0004-2749.20170055</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">28688009</PMID>
<DateCompleted>
    <Year>2019</Year>
    <Month>05</Month>
    <Day>14</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>05</Month>
    <Day>14</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1573-2614</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2018</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of clinical monitoring and computing</Title>
        <ISOAbbreviation>J Clin Monit Comput</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Comparing volume-clamp method and intra-arterial blood pressure measurements in patients with atrial fibrillation admitted to the intensive or medium care unit.</ArticleTitle>
    <Pagination>
        <MedlinePgn>439-446</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10877-017-0044-9</ELocationID>
    <Abstract>
        <AbstractText>International guidelines highlight the importance of blood pressure (BP) in patients with atrial fibrillation (AF). However, BP measurement in AF is complicated by beat-to-beat fluctuation. Automated BP measurement devices are not validated for patients with AF and no consensus exists on how to measure BP in AF manually. Beat-to-beat BP measurement using the volume-clamp method (VCM) could represent a non-invasive method to accurately assess BP, but has not been validated in AF. 31 admitted patients with sustained AF and 10 control patients with sinus rhythm underwent simultaneous intra-arterial and non-invasive BP measurement using a VCM monitor (Nexfin<sup>®</sup>, BMEYE, Amsterdam, The Netherlands). Patients with compromised peripheral perfusion, high doses of vasopressor drugs or peripheral edema were excluded. Differences in systolic, diastolic and mean BP of 5 (standard deviation; SD 8) mmHg (accuracy and precision) between both methods were considered acceptable. Additionally, the magnitude of beat-to-beat fluctuations in systolic BP of both methods was compared. In AF, the differences between noninvasive and invasive BP were -4 (SD 12), +1 (SD 7) and 0 (SD 8) mmHg for systolic, diastolic and mean BP respectively. Absolute differences in beat-to-beat BP fluctuations were 1.5 (IQR 0.8-3.8) mmHg. Accuracy of VCM in AF was similar to sinus rhythm. In conclusion, in patients with AF, accurate and precise measurement of non-invasive beat-to-beat BP measurement using the VCM is possible, the one exception being the precision of systolic BP. Beat-to-beat variability can be accurately reproduced.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Berkelmans</LastName>
            <ForeName>G F N</ForeName>
            <Initials>GFN</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Vascular Medicine, University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands. GFN.Berkelmans@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kuipers</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, Zaans Medical Center, Zaandam, The Netherlands.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Westerhof</LastName>
            <ForeName>B E</ForeName>
            <Initials>BE</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Laboratory for Clinical Cardiovascular Physiology, Center for Heart Failure Research, Academic Medical Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Spoelstra-de Man</LastName>
            <ForeName>A M E</ForeName>
            <Initials>AME</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Intensive Care, VU University Medical Centre, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Smulders</LastName>
            <ForeName>Y M</ForeName>
            <Initials>YM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2017</Year>
        <Month>07</Month>
        <Day>07</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Netherlands</Country>
    <MedlineTA>J Clin Monit Comput</MedlineTA>
    <NlmUniqueID>9806357</NlmUniqueID>
    <ISSNLinking>1387-1307</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D062186" MajorTopicYN="Y">Arterial Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003971" MajorTopicYN="N">Diastole</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Atrial fibrillation</Keyword>
    <Keyword MajorTopicYN="N">Blood pressure</Keyword>
    <Keyword MajorTopicYN="N">Noninvasive measurement</Keyword>
    <Keyword MajorTopicYN="N">Validation</Keyword>
    <Keyword MajorTopicYN="N">Volume clamp method</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2017</Year>
        <Month>04</Month>
        <Day>05</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2017</Year>
        <Month>07</Month>
        <Day>04</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2017</Year>
        <Month>7</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2019</Year>
        <Month>5</Month>
        <Day>15</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2017</Year>
        <Month>7</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">28688009</ArticleId>
    <ArticleId IdType="doi">10.1007/s10877-017-0044-9</ArticleId>
    <ArticleId IdType="pii">10.1007/s10877-017-0044-9</ArticleId>
    <ArticleId IdType="pmc">PMC5943389</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Hypertens. 2012 Nov;30(11):2074-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22914573</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Anaesth. 2013 Aug;111(2):178-84</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23485882</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Med. 2010 Jun;123(6):484-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20569748</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 2012 May;116(5):1092-103</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22415387</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press Monit. 2012 Aug;17(4):171-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22781635</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2014 Dec 2;130(23):e199-267</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24682347</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>BMJ. 1990 Jan 20;300(6718):162-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2105795</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2012 Dec 15;380(9859):2224-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23245609</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2010 Mar 13;375(9718):906-15</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20226989</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 1983 Jul;53(1):96-104</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6861300</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Anaesth. 2012 Oct;109(4):514-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22750726</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press Monit. 2011 Oct;16(5):246-51</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21885960</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2009 Feb 28;373(9665):739-45</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19249635</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anaesthesia. 2010 Nov;65(11):1119-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20860647</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Heart Assoc. 2013 Jun 21;2(3):e000250</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23782923</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 2010 Nov;138(5):1093-100</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20299623</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Anaesth. 2012 Oct;109(4):609-15</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22907342</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet Neurol. 2010 May;9(5):469-80</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20227347</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2009 Apr;22(4):378-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19180062</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2012 Nov;33(21):2719-47</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22922413</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cardiovasc Res. 1998 Jun;38(3):605-16</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9747429</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2013 Sep;62(3):579-84</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23897073</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2015 Jan 27;131(4):e29-322</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25520374</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Anesth. 2012 Jun;24(4):304-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22608585</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Anaesth. 2015 Oct;115(4):540-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26385663</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 2015 Jan;122(1):208-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25611656</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 2016 Sep;42(9):1350-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27155605</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JAMA. 2001 May 9;285(18):2370-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11343485</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
<PMID Version="1">28299615</PMID>
<DateRevised>
    <Year>2020</Year>
    <Month>09</Month>
    <Day>29</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1092-8464</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>19</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2017</Year>
                <Month>Mar</Month>
            </PubDate>
        </JournalIssue>
        <Title>Current treatment options in cardiovascular medicine</Title>
        <ISOAbbreviation>Curr Treat Options Cardiovasc Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Remote Monitoring in Heart Failure: the Current State.</ArticleTitle>
    <Pagination>
        <MedlinePgn>22</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11936-017-0519-5</ELocationID>
    <Abstract>
        <AbstractText Label="OPINION STATEMENT" NlmCategory="UNASSIGNED">The treatment of congestive heart failure is an expensive undertaking with much of this cost occurring as a result of hospitalization. It is not surprising that many remote monitoring strategies have been developed to help patients maintain clinical stability by avoiding congestion. Most of these have failed. It seems very unlikely that these failures were the result of any one underlying false assumption but rather from the fact that heart failure is a progressive, deadly disease and that human behavior is hard to modify. One lesson that does stand out from the myriad of methods to detect congestion is that surrogates of congestion, such as weight and impedance, are not reliable or actionable enough to influence outcomes. Too many factors influence these surrogates to successfully and confidently use them to affect HF hospitalization. Surrogates are often attractive because they can be inexpensively measured and followed. They are, however, indirect estimations of congestion, and due to the lack specificity, the time and expense expended affecting the surrogate do not provide enough benefit to warrant its use. We know that high filling pressures cause transudation of fluid into tissues and that pulmonary edema and peripheral edema drive patients to seek medical assistance. Direct measurement of these filling pressures appears to be the sole remote monitoring modality that shows a benefit in altering the course of the disease in these patients. Congestive heart failure is such a serious problem and the consequences of hospitalization so onerous in terms of patient well-being and costs to society that actual hemodynamic monitoring, despite its costs, is beneficial in carefully selected high-risk patients. Those patients who benefit are ones with a prior hospitalization and ongoing New York Heart Association (NYHA) class III symptoms. Patients with NYHA class I and II symptoms do not require hemodynamic monitoring because they largely have normal hemodynamics. Those with NYHA class IV symptoms do not benefit because their hemodynamics are so deranged that they cannot be substantially altered except by mechanical circulatory support or heart transplantation. Finally, hemodynamic monitoring offers substantial hope to those patients with normal ejection fraction (EF) heart failure, a large group for whom medical therapy has largely been a failure. These patients have not benefited from the neurohormonal revolution that improved the lives of their brothers and sisters with reduced ejection fractions. Hemodynamic stabilization improves the condition of both but more so of the normal EF cohort. This is an important observation that will help us design future trials for the 50% of heart failure patients with normal systolic function.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Mohan</LastName>
            <ForeName>Rajeev C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
                <Affiliation>Advanced Heart Failure and Mechanical Circulatory Support Program, Pulmonary Hypertension Program, Division of Cardiology, Scripps Clinic, 9898 Genesee Avenue, AMP Suite #300, La Jolla, CA, 92037, USA. Mohan.rajeev@scrippshealth.org.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Heywood</LastName>
            <ForeName>J Thomas</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
                <Affiliation>Advanced Heart Failure and Mechanical Circulatory Support Program, Pulmonary Hypertension Program, Division of Cardiology, Scripps Clinic, 9898 Genesee Avenue, AMP Suite #300, La Jolla, CA, 92037, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Small</LastName>
            <ForeName>Roy S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
                <Affiliation>Cardiology, Lancaster Heart and Vascular Institute, Lancaster General Hospital/Penn Medicine, Lancaster, PA, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Curr Treat Options Cardiovasc Med</MedlineTA>
    <NlmUniqueID>9815942</NlmUniqueID>
    <ISSNLinking>1092-8464</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Heart failure</Keyword>
    <Keyword MajorTopicYN="N">Hemodynamic monitoring</Keyword>
    <Keyword MajorTopicYN="N">Remote monitoring</Keyword>
    <Keyword MajorTopicYN="N">Telemonitoring</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2017</Year>
        <Month>3</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2017</Year>
        <Month>3</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>3</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">28299615</ArticleId>
    <ArticleId IdType="doi">10.1007/s11936-017-0519-5</ArticleId>
    <ArticleId IdType="pii">10.1007/s11936-017-0519-5</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Am Coll Cardiol. 2002 Jan 2;39(1):83-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11755291</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Med Internet Res. 2013 Aug 21;15(8):e167</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23965236</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Europace. 2015 Aug;17(8):1276-81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25983310</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Med Internet Res. 2015 Mar 12;17(3):e63</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25768664</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2011 Feb 19;377(9766):658-66</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21315441</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2010 Apr 27;55(17):1803-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20413029</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Card Fail. 2016 Nov;22(11):875-883</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27133201</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2005 Aug 9;112(6):841-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16061743</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Card Fail. 2011 Apr;17(4):282-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21440865</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2011 May 3;123(17):1873-80</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21444883</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Cardiol. 2007 May 21;99(10A):3G-10G</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17512421</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Med Internet Res. 2015 Apr 22;17(4):e101</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25903278</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2010 Dec 9;363(24):2301-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21080835</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2008 Mar 18;51(11):1073-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18342224</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2009 Oct 27;54(18):1683-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19850208</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2016 Jan 30;387(10017):453-61</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26560249</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2012 Sep;33(17):2189-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22677137</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Heart Fail. 2013 May;6(3):606-19</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23616602</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Telemed Telecare. 2014 Jan;20(1):11-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24352899</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2016 Jan 26;133(4):e38-360</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26673558</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Card Fail. 2009 Aug;15(6):475-81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19643357</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2013 Jan 29;61(4):391-403</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23219302</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JACC Heart Fail. 2016 May;4(5):333-44</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26874388</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JACC Heart Fail. 2014 Apr;2(2):97-112</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24720916</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2011 Mar 1;123(8):933-44</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21262990</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2014 Aug 16;384(9943):583-590</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25131977</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2016 Nov 1;37(41):3154-3163</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26984864</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JAMA Intern Med. 2016 Mar;176(3):310-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26857383</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Heart Fail. 2014 Nov;7(6):935-44</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25286913</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">28269250</PMID>
<DateCompleted>
    <Year>2017</Year>
    <Month>07</Month>
    <Day>04</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>09</Month>
    <Day>28</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">2694-0604</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>2016</Volume>
            <PubDate>
                <Year>2016</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference</Title>
        <ISOAbbreviation>Annu Int Conf IEEE Eng Med Biol Soc</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Design of peripheral edema measurement device for home use.</ArticleTitle>
    <Pagination>
        <MedlinePgn>4387-4390</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1109/EMBC.2016.7591699</ELocationID>
    <Abstract>
        <AbstractText>Due to improvements in cardiovascular care, more patients are living longer but ultimately developing heart failure. It is important for patients with chronic conditions, like heart failure, to self-manage and monitor their symptoms. One symptoms that can be indicative of worsening heart failure is peripheral edema. Therefore, we present a concept for a HeartSMART system capable of edema measurement in the home with remote connection to and feedback from providers. The goal of the system is to provide a tool for heart failure patients to manage their disease. The work presented herein describes the system design and preliminary testing using simulated edema models. The system uses displacement and force sensors and mimics the gold standard finger indentation performed by care providers. The results for the edema models (foam) show increasing displacement with edema severity.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>George</LastName>
            <ForeName>Stephanie M</ForeName>
            <Initials>SM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Langley</LastName>
            <ForeName>Brandon D</ForeName>
            <Initials>BD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Weaver</LastName>
            <ForeName>Elizabeth M B</ForeName>
            <Initials>EM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hardin</LastName>
            <ForeName>Sonya R</ForeName>
            <Initials>SR</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jianchu Yao</LastName>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Annu Int Conf IEEE Eng Med Biol Soc</MedlineTA>
    <NlmUniqueID>101763872</NlmUniqueID>
    <ISSNLinking>2375-7477</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006798" MajorTopicYN="Y">Housing</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2017</Year>
        <Month>3</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2017</Year>
        <Month>3</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>7</Month>
        <Day>5</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">28269250</ArticleId>
    <ArticleId IdType="doi">10.1109/EMBC.2016.7591699</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27592219</PMID>
<DateCompleted>
    <Year>2018</Year>
    <Month>07</Month>
    <Day>05</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1095-9319</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>109</Volume>
            <PubDate>
                <Year>2017</Year>
                <Month>01</Month>
            </PubDate>
        </JournalIssue>
        <Title>Microvascular research</Title>
        <ISOAbbreviation>Microvasc Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A novel method for measuring hydraulic conductivity at the human blood-nerve barrier in vitro.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1-6</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="pii" ValidYN="Y">S0026-2862(16)30136-4</ELocationID>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mvr.2016.08.005</ELocationID>
    <Abstract>
        <AbstractText>Microvascular barrier permeability to water is an essential biophysical property required for the homeostatic maintenance of unique tissue microenvironments. This is of particular importance in peripheral nerves where strict control of ionic concentrations is needed for axonal signal transduction. Previous studies have associated inflammation, trauma, toxin exposure and metabolic disease with increases in water influx and hydrostatic pressure in peripheral nerves with resultant endoneurial edema that may impair axonal function. The regulation of water permeability across endoneurial microvessels that form the blood-nerve barrier (BNB) is poorly understood. Variations exist in apparatus and methods used to measure hydraulic conductivity. The objective of the study was to develop a simplified hydraulic conductivity system using commercially available components to evaluate the BNB. We determined the mean hydraulic conductivity of cultured confluent primary and immortalized human endoneurial endothelial cell layers as 2.00×10<sup>-7</sup> and 2.17×10<sup>-7</sup>cm/s/cm H₂O respectively, consistent with restrictive microvascular endothelial cells in vitro. We also determined the mean hydraulic conductivity of immortalized human brain microvascular endothelial cell layers, a commonly used blood-brain barrier (BBB) cell line, as 0.20×10<sup>-7</sup>cm/s/cm H₂O, implying a mean 10-fold higher resistance to transendothelial water flux in the brain compared to peripheral nerves. To our knowledge, this is the first reported measurement of human BNB and BBB hydraulic conductivities. This model represents an important tool to further characterize the human BNB and deduce the molecular determinants and signaling mechanisms responsible for BNB hydraulic conductivity in normal and disease states in vitro.</AbstractText>
        <CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Helton</LastName>
            <ForeName>E Scott</ForeName>
            <Initials>ES</Initials>
            <AffiliationInfo>
                <Affiliation>Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Palladino</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ubogu</LastName>
            <ForeName>Eroboghene E</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
                <Affiliation>Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, United States. Electronic address: eeubogu@uabmc.edu.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>R01 NS075212</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>08</Month>
        <Day>31</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Microvasc Res</MedlineTA>
    <NlmUniqueID>0165035</NlmUniqueID>
    <ISSNLinking>0026-2862</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000952">Antigens, Polyomavirus Transforming</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>059QF0KO0R</RegistryNumber>
        <NameOfSubstance UI="D014867">Water</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000952" MajorTopicYN="N">Antigens, Polyomavirus Transforming</DescriptorName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D049428" MajorTopicYN="Y">Blood-Nerve Barrier</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002463" MajorTopicYN="N">Cell Membrane Permeability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003584" MajorTopicYN="Y">Cytological Techniques</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
        <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012756" MajorTopicYN="N">Sheep</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019108" MajorTopicYN="N">Tight Junctions</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="Y">Blood-brain barrier</Keyword>
    <Keyword MajorTopicYN="Y">Blood-nerve barrier</Keyword>
    <Keyword MajorTopicYN="Y">Bubble tracker</Keyword>
    <Keyword MajorTopicYN="Y">Diffusion chamber</Keyword>
    <Keyword MajorTopicYN="Y">Endoneurial endothelial cells</Keyword>
    <Keyword MajorTopicYN="Y">Hydraulic conductivity</Keyword>
    <Keyword MajorTopicYN="Y">Peripheral nerves</Keyword>
    <Keyword MajorTopicYN="Y">Transendothelial water flux</Keyword>
</KeywordList>
<CoiStatement>POTENTIAL CONFLICTS OF INTEREST E.S.H. and S.D. have nothing to disclose.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2016</Year>
        <Month>05</Month>
        <Day>31</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2016</Year>
        <Month>08</Month>
        <Day>30</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2016</Year>
        <Month>08</Month>
        <Day>31</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>10</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2018</Year>
        <Month>7</Month>
        <Day>6</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>9</Month>
        <Day>5</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">27592219</ArticleId>
    <ArticleId IdType="pii">S0026-2862(16)30136-4</ArticleId>
    <ArticleId IdType="doi">10.1016/j.mvr.2016.08.005</ArticleId>
    <ArticleId IdType="pmc">PMC5164953</ArticleId>
    <ArticleId IdType="mid">NIHMS815461</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Neuropathol Exp Neurol. 2010 Jan;69(1):82-97</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20010300</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1451-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19286951</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Microb Pathog. 2001 Jan;30(1):19-28</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11162182</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Invest Dermatol. 1989 Aug;93(2 Suppl):62S-67S</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2546995</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol. 1993 Aug;265(2 Pt 1):C439-46</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8368273</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroinflammation. 2016 Jan 06;13:3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26732309</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res Bull. 2000 May 1;52(1):1-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10779695</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Natl Acad Sci U S A. 1988 Jul;85(13):4879-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3387444</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acta Neuropathol. 2015 Oct;130(4):445-68</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26264608</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Rev Esp Anestesiol Reanim. 2000 Dec;47(10):464-75</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11171467</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acta Orthop Scand. 1983 Apr;54(2):312-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6846011</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Microvasc Res. 2001 Mar;61(2):203-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11254400</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Rev Esp Anestesiol Reanim. 2003 Feb;50(2):80-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12712870</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5705-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8202551</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 1978 Jun 16;148(2):510-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">656947</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Rev Neurobiol. 1990;5(3):265-311</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2168810</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Microvasc Res. 2012 May;83(3):298-310</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22326552</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Eye Res. 1997 Aug;16(8):761-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9255504</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Opin Crit Care. 2013 Aug;19(4):282-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23743590</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1051-64</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25659484</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Anat. 1994 Oct;185 ( Pt 2):259-66</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7961132</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell Mol Neurobiol. 2013 Mar;33(2):175-86</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23104242</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Microvasc Res. 2006 Mar;71(2):135-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16530229</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Biomed Eng. 2014 Apr;42(4):763-75</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24264601</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Biomed Eng. 2010 Aug;38(8):2499-511</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20361260</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 1977 Feb 18;122(2):373-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">837238</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Vasc Res. 2013;50(4):289-303</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23839247</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Microvasc Res. 2000 Mar;59(2):265-77</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10684732</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cardiovasc Res. 2010 Jul 15;87(2):320-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20543206</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acta Neuropathol. 2011 Mar;121(3):291-312</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21136068</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol. 1997 Jan;272(1 Pt 1):L38-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9038900</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol. 1991 Jun;260(6 Pt 1):L571-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2058698</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Neurol. 1980 Oct;8(4):392-401</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6254435</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">29638060</PMID>
<DateCompleted>
    <Year>2018</Year>
    <Month>05</Month>
    <Day>09</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>05</Month>
    <Day>09</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0001-6837</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>73</Volume>
            <Issue>5</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>Acta poloniae pharmaceutica</Title>
        <ISOAbbreviation>Acta Pol Pharm</ISOAbbreviation>
    </Journal>
    <ArticleTitle>SYNTHESIS AND IMMUNOREGULATORY PROPERTIES OF SELECTED 5-AMINO-3-METHYL-4-ISOXAZOLECARBOXYLIC ACID BENZYLAMIDES.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1201-1211</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The aim of the study was to characterize a series of isoxazole derivatives in several immunological tests in vitro and in vivo, in mouse and human models. The human model included measurement of: viability of peripheral blood mononuclear cells (PBMC), phytohemagglutinin A (PHA)-induced proliferation of PBMC, production of tumor necrosis factor a (TNF a) in whole blood cultures stimulated with lipopolysaccharide (LPS) and growth of SW-948 and L1210 tumor cell lines. Experiments in mice encompassed the following tests: secondary, humoral immune response splenocytes to sheep erythrocytes (SRBC) in vitiv, delayed type hypersensitivity (DTH) to ovalbumin (OVA) and carrageenan-induced foot edema. All compounds were non-toxic against PMBC and displayed differential, dose-dependent suppressive properties in the model of PHA- induced PMBC proliferation. They also exhibited differential, mostly inhibitory effects on TNF a production. The inhibitory actions on growth of tumor cell lines were moderate. M05 (5-amino-3-methyl-N-(4-methyl-benzyl)-4-isoxazolecarboxamide) was most suppressive in the proliferation and TNF a production tests, it was, therefore, selected for in vitro and in vivo studies in the mouse models. The compound inhibited the humoral immune response in vitro, stimulated the inductive phase of DTH in vivo, although it inhibited the eliciting phase of that response. The compound also inhibited the carrageenan skin reaction. M05 combines strong anti-proliferative and anti-inflammatory activities, it is therefore attractive for further studies in more advanced animal models as a potential therapeutic.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Maczynski</LastName>
            <ForeName>Marcin</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Artym</LastName>
            <ForeName>Jolanta</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kocieba</LastName>
            <ForeName>Maja</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sockacka-Cwikla</LastName>
            <ForeName>Aleksandra</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Drozd-Szczygiel</LastName>
            <ForeName>Ewa</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ryng</LastName>
            <ForeName>Stanislaw</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zimecki</LastName>
            <ForeName>Michal</ForeName>
            <Initials>M</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Poland</Country>
    <MedlineTA>Acta Pol Pharm</MedlineTA>
    <NlmUniqueID>2985167R</NlmUniqueID>
    <ISSNLinking>0001-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>
        <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007939" MajorTopicYN="N">Leukemia L1210</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
        <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2018</Year>
        <Month>4</Month>
        <Day>12</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>9</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>9</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">29638060</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">27367530</PMID>
<DateCompleted>
    <Year>2017</Year>
    <Month>01</Month>
    <Day>30</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1744-8344</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>9</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>Expert review of cardiovascular therapy</Title>
        <ISOAbbreviation>Expert Rev Cardiovasc Ther</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Endovascular treatment for chronic pulmonary hypertension: a focus on angioplasty for chronic thromboembolic pulmonary hypertension.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1089-94</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1080/14779072.2016.1208083</ELocationID>
    <Abstract>
        <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Percutaneous transluminal pulmonary angioplasty (PTPA) was introduced for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in the late 20(th) century, and first attempts in collective patients were made in 2001 with beneficial effects but a moderate amount of complications. It was refined around 2010, and has been recently established as an effective and safe treatment.</AbstractText>
        <AbstractText Label="AREAS COVERED" NlmCategory="METHODS">The indication was originally inoperable CTEPH with peripheral lesions, but has now widened to symptomatic or hypoxic patients. The lesion is typically a meshwork-like structure of organized thrombi and is sometimes not seen as a stenosis angiographically, necessitating other means of investigation such as measurement of distal pressure. The technique to treat lesions is the same as for coronary angioplasty except in several ways. Expert commentary: The effects of PTPA are comparable to those of surgical endarterectomy, and the complications of reperfusion pulmonary edema and vascular injury are now controlled by several strategies and based on experience.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Satoh</LastName>
            <ForeName>Toru</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kataoka</LastName>
            <ForeName>Masaharu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>b Division of Cardiology, Department of Medicine , Keio University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Inami</LastName>
            <ForeName>Takumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ishiguro</LastName>
            <ForeName>Haruhisa</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yanagisawa</LastName>
            <ForeName>Ryoji</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shimura</LastName>
            <ForeName>Nobuhiko</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shigeta</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yoshino</LastName>
            <ForeName>Hideaki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
                <Affiliation>a Division of Cardiology, Department of Medicine , Kyorin University School of Medicine , Tokyo , Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>07</Month>
        <Day>20</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Expert Rev Cardiovasc Ther</MedlineTA>
    <NlmUniqueID>101182328</NlmUniqueID>
    <ISSNLinking>1477-9072</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000792" MajorTopicYN="N">Angiography</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000800" MajorTopicYN="N">Angioplasty, Balloon</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004691" MajorTopicYN="N">Endarterectomy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Balloon pulmonary angioplasty</Keyword>
    <Keyword MajorTopicYN="N">chronic thromboembolic pulmonary hypertension</Keyword>
    <Keyword MajorTopicYN="N">percutaneous transluminal pulmonary angioplasty</Keyword>
    <Keyword MajorTopicYN="N">pressure wire</Keyword>
    <Keyword MajorTopicYN="N">pulmonary edema</Keyword>
    <Keyword MajorTopicYN="N">pulmonary endarterectomy</Keyword>
    <Keyword MajorTopicYN="N">pulmonary injury</Keyword>
    <Keyword MajorTopicYN="N">pulmonary stenosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>7</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>7</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>1</Month>
        <Day>31</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">27367530</ArticleId>
    <ArticleId IdType="doi">10.1080/14779072.2016.1208083</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27222246</PMID>
<DateCompleted>
    <Year>2017</Year>
    <Month>11</Month>
    <Day>20</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1879-291X</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>9</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>09</Month>
            </PubDate>
        </JournalIssue>
        <Title>Ultrasound in medicine &amp; biology</Title>
        <ISOAbbreviation>Ultrasound Med Biol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Design and Testing of a Single-Element Ultrasound Viscoelastography System for Point-of-Care Edema Quantification.</ArticleTitle>
    <Pagination>
        <MedlinePgn>2209-19</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ultrasmedbio.2016.04.013</ELocationID>
    <ELocationID EIdType="pii" ValidYN="Y">S0301-5629(16)30050-3</ELocationID>
    <Abstract>
        <AbstractText>Management of fluid overload in patients with end-stage renal disease represents a unique challenge to clinical practice because of the lack of accurate and objective measurement methods. Currently, peripheral edema is subjectively assessed by palpation of the patient's extremities, ostensibly a qualitative indication of tissue viscoelastic properties. New robust quantitative estimates of tissue fluid content would allow clinicians to better guide treatment, minimizing reactive treatment decision making. Ultrasound viscoelastography (UVE) can be used to estimate strain in viscoelastic tissue, deriving material properties that can help guide treatment. We are developing and testing a simple, low-cost UVE system using a single-element imaging transducer that is simpler and less computationally demanding than array-based systems. This benchtop validation study tested the feasibility of using the UVE system by measuring the mechanical properties of a tissue-mimicking material under large strains. We generated depth-dependent creep curves and viscoelastic parameter maps of time constants and elastic moduli for the Kelvin model of viscoelasticity. During testing, the UVE system performed well, with mean UVE-measured strain matching standard mechanical testing with maximum absolute errors ≤4%. Motion tracking revealed high correlation and signal-to-noise ratios, indicating that the system is reliable.</AbstractText>
        <CopyrightInformation>Copyright © 2016 World Federation for Ultrasound in Medicine &amp; Biology. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Pitre</LastName>
            <ForeName>John J</ForeName>
            <Initials>JJ</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
                <Affiliation>Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Koziol</LastName>
            <ForeName>Leo B</ForeName>
            <Initials>LB</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Veterans Affairs Medical Center, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kruger</LastName>
            <ForeName>Grant H</ForeName>
            <Initials>GH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan, USA; Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vollmer</LastName>
            <ForeName>Alan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Veterans Affairs Medical Center, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ophir</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Ultrasonics Laboratory, Department of Diagnostic and Interventional Imaging, University of Texas Medical School, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ammann</LastName>
            <ForeName>Jean-Jacques</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physics, Universidad de Santiago, Santiago, Chile; G.E.A. Universitas SpA, Santiago, Chile.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Weitzel</LastName>
            <ForeName>William F</ForeName>
            <Initials>WF</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Veterans Affairs Medical Center, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bull</LastName>
            <ForeName>Joseph L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: joebull@umich.edu.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>I01 BX001684</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>05</Month>
        <Day>21</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Ultrasound Med Biol</MedlineTA>
    <NlmUniqueID>0410553</NlmUniqueID>
    <ISSNLinking>0301-5629</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055119" MajorTopicYN="N">Elastic Modulus</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D054459" MajorTopicYN="N">Elasticity Imaging Techniques</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019047" MajorTopicYN="N">Phantoms, Imaging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014783" MajorTopicYN="N">Viscosity</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="Y">Creep experiment</Keyword>
    <Keyword MajorTopicYN="Y">Edema</Keyword>
    <Keyword MajorTopicYN="Y">End-stage renal disease</Keyword>
    <Keyword MajorTopicYN="Y">Point-of-care</Keyword>
    <Keyword MajorTopicYN="Y">Poroelasticity</Keyword>
    <Keyword MajorTopicYN="Y">Speckle tracking</Keyword>
    <Keyword MajorTopicYN="Y">Srain imaging</Keyword>
    <Keyword MajorTopicYN="Y">Ultrasound</Keyword>
    <Keyword MajorTopicYN="Y">Viscoelastography</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>28</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2016</Year>
        <Month>03</Month>
        <Day>08</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2016</Year>
        <Month>04</Month>
        <Day>18</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>5</Month>
        <Day>26</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>5</Month>
        <Day>26</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>11</Month>
        <Day>29</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">27222246</ArticleId>
    <ArticleId IdType="pii">S0301-5629(16)30050-3</ArticleId>
    <ArticleId IdType="doi">10.1016/j.ultrasmedbio.2016.04.013</ArticleId>
    <ArticleId IdType="pmc">PMC4983502</ArticleId>
    <ArticleId IdType="mid">NIHMS789365</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Ultrasound Med Biol. 2008 May;34(5):809-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18384929</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 1998 Oct;24(8):1183-99</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9833588</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>IEEE Trans Ultrason Ferroelectr Freq Control. 1997;44(1):164-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18244114</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Phys Med Biol. 2007 Jun 7;52(11):3241-59</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17505100</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 2006 Apr;32(4):547-67</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16616601</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acad Radiol. 2008 Dec;15(12):1526-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19000869</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Phys Med Biol. 2004 Sep 21;49(18):4395-405</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15509073</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrason Imaging. 1991 Apr;13(2):111-34</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1858217</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):393-404</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15838608</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Biomech Eng. 1984 May;106(2):165-73</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6738022</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Phys Med Biol. 2007 May 7;52(9):2425-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17440244</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Med Imaging Rev. 2011 Nov;7(4):313-327</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22754425</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 2006 Dec;32(12):1869-85</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17169699</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 1992;18(8):667-73</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1440988</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Phys Med Biol. 2007 Nov 7;52(21):6525-41</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17951860</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Interface Focus. 2011 Aug 6;1(4):540-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22866230</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Radiol Oncol. 2012 Dec;46(4):284-95</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23412910</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 2008 Apr;34(4):617-29</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18222033</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 2004 Feb;30(2):215-28</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14998674</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ultrasound Med Biol. 2005 Jun;31(6):803-16</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15936496</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27154237</PMID>
<DateCompleted>
    <Year>2017</Year>
    <Month>05</Month>
    <Day>15</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1741-0444</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>55</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2017</Year>
                <Month>Feb</Month>
            </PubDate>
        </JournalIssue>
        <Title>Medical &amp; biological engineering &amp; computing</Title>
        <ISOAbbreviation>Med Biol Eng Comput</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Bilateral photoplethysmography for arterial steal detection in arteriovenous fistula using a fractional-order decision-making quantizer.</ArticleTitle>
    <Pagination>
        <MedlinePgn>257-270</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11517-016-1503-z</ELocationID>
    <Abstract>
        <AbstractText>As inflow and outflow stenoses worsen, both flow resistance and pressure increase in the stenotic vascular access. During dialysis, when blood flow decreases, it may retrograde from the peripheral artery through the palmar arch to the arterial anastomosis site. Arterial steal syndrome (ASS) causes distal hypoperfusion, resulting in hand ischemia or extremity pain and edema. Hence, this study proposes the bilateral photoplethysmography (PPG) for ASS detection in arteriovenous fistulas. The decision-making quantizer utilizes the fractional-order feature extraction method and a non-cooperative game (NCG) framework to evaluate the ASS risk level. Bilateral asynchronous PPG signals have significant differences in the rise time and amplitude in relation to the degree of stenosis. The fractional-order self-synchronization error formulation is a feature extraction method used to quantify bilateral differences in blood flow changes between the dexter and sinister PPG signals. The NCG model as a method of decision-making is then employed to evaluate the ASS risk level. Using an acoustic Doppler measurement, the resistive (Res) index is also used to evaluate the vascular access stenosis at the arterial anastomosis site. In contrast with alternative methods including the high-sensitivity C-reactive protein level or Res index, our experimental results indicate that the proposed decision-making quantizer is more efficient in preventing ASS during hemodialysis treatment.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jian-Xing</ForeName>
            <Initials>JX</Initials>
            <AffiliationInfo>
                <Affiliation>National Synchrotron Radiation Research Center, Hsinchu Science Park, Hsinchu, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Guan-Chun</ForeName>
            <Initials>GC</Initials>
            <AffiliationInfo>
                <Affiliation>National Synchrotron Radiation Research Center, Hsinchu Science Park, Hsinchu, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Ming-Jui</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan City, 71051, Taiwan. wmr216@yahoo.com.tw.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Chia-Hung</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Electrical Engineering, Kao-Yuan University, Kaohsiung City, 82151, Taiwan. eechl53@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Tainsong</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Biomedical Engineering, National Cheng Kung University, Tainan City, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>05</Month>
        <Day>06</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Med Biol Eng Comput</MedlineTA>
    <NlmUniqueID>7704869</NlmUniqueID>
    <ISSNLinking>0140-0118</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001164" MajorTopicYN="N">Arteriovenous Fistula</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003658" MajorTopicYN="Y">Decision Making, Computer-Assisted</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008955" MajorTopicYN="N">Models, Cardiovascular</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017156" MajorTopicYN="N">Photoplethysmography</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012815" MajorTopicYN="Y">Signal Processing, Computer-Assisted</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014652" MajorTopicYN="N">Vascular Diseases</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Arterial steal syndrome (ASS)</Keyword>
    <Keyword MajorTopicYN="N">Fractional-order self-synchronization error formulation</Keyword>
    <Keyword MajorTopicYN="N">Non-cooperative game (NCG)</Keyword>
    <Keyword MajorTopicYN="N">Photoplethysmography (PPG)</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2015</Year>
        <Month>03</Month>
        <Day>04</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2016</Year>
        <Month>03</Month>
        <Day>28</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>5</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>5</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>5</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">27154237</ArticleId>
    <ArticleId IdType="doi">10.1007/s11517-016-1503-z</ArticleId>
    <ArticleId IdType="pii">10.1007/s11517-016-1503-z</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Med Biol Eng Comput. 1988 Mar;26(2):153-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3067002</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Physiol Meas. 2005 Oct;26(5):811-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16088070</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int J Nephrol. 2011;2011:639840</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21603104</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cardiovasc Res. 2006 Jul 1;71(1):30-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16624260</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2011 Feb;57(2):231-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21149827</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Biol Eng Comput. 2015 May;53(5):393-403</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25681949</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Vasc Endovasc Surg. 2004 Jan;27(1):1-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14652830</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2003 Jan 28;107(3):363-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12551853</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Biol Eng Comput. 2005 Mar;43(2):252-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15865136</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Healthc Technol Lett. 2015 May 01;2(3):64-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26609407</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Magn Reson Imaging. 2011 Apr;33(4):839-46</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21448948</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Kidney Dis. 2009 Jun;53(6):1024-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19394732</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin J Am Soc Nephrol. 2007 Jan;2(1):175-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17699402</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Diabetes Care. 2006 Feb;29(2):329-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16443882</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 2011 Dec;26(12 ):3908-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21421591</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 2009 May;24(5):1574-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19131355</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Biochem. 2011 Sep;44(13):1080-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21704026</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Biol Eng Comput. 2013 Sep;51(9):1011-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23645205</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>IEEE J Biomed Health Inform. 2014 Mar;18(2):703-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24058032</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Biol Chem. 2014 May 16;289(20):14283-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24711458</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Biol Eng Comput. 1987 Nov;25(6):661-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2974911</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Trends Pharmacol Sci. 2006 Sep;27(9):503-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16876881</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Vasc Surg. 2013 Nov;58(5):1259-66</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23830159</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">27030654</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>07</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>02</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1009-2587</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>32</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>Mar</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns</Title>
        <ISOAbbreviation>Zhonghua Shao Shang Za Zhi</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Effects of San-huang-sheng-fu oil on peripheral circulatory disorders and foot ulcers in diabetic rats and the mechanisms].</ArticleTitle>
    <Pagination>
        <MedlinePgn>168-75</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.1009-2587.2016.03.009</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effects of San-huang-sheng-fu oil (S) on peripheral circulatory disorders and foot ulcers in diabetic rats and the relevant mechanisms.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">(1) Twenty-five Wistar rats were divided into non-diabetes (N), diabetes and sham treatment (DS), metformin (M), S, and combined treatment (CT) groups according to the random number table, with 5 rats in each group. Rats in group N were injected with sodium citrate buffer solution, while rats in the other 4 groups were injected with 10 mg/mL streptozotocin to induce diabetes. In post injection week (PIW) 3, feet of rats in all the 5 groups received an ice-cold stimulation to induce peripheral circulatory disorders. From PIW 9 to 12, rats in groups N and DS were gavaged with saline and applied with sesame oil on pelma of both hind limbs; rats in group M were gavaged with diluted M and applied with sesame oil on pelma of both hind limbs; rats in group S were gavaged with saline and applied with S on pelma of both hind limbs; rats in group CT were gavaged with diluted M and applied with S on pelma of both hind limbs. In PIW 9 before treatment (hereinafter referred to as before treatment) and post treatment week (PTW) 1, 2, and 3, plantar temperature and hot pain threshold of rats were detected by infrared thermometer and foot tester respectively. (2) Another 25 rats were divided and induced with diabetes (expect for group N) as above. In PIW 9, rats in the 5 groups were inflicted with foot ulcer in the left pelma of hind limb by steam and received the corresponding treatment. On post treatment day (PTD) 3, 7, 21, and 35, the general condition and area of wounds were observed and measured respectively. All the rats were sacrificed on PTD 35, and wound tissue was collected for histomorphological observation and determination of expressions of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) using HE staining and immunohistochemical staining respectively. Data were processed with analysis of variance for repeated measurement, one-way analysis of variance, and Bonferroni post hoc test.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">(1) The experiment of peripheral circulatory disorders in diabetes. Compared with the plantar temperature of rats in group N, except for that in group CT in PTW 2 and groups M, S, and CT in PTW 3 (with t values from 0.258 to 2.647, P values above 0.05), the plantar temperature of rats with diabetes in the 4 groups at each time point was lowered significantly (with t values from 2.811 to 6.066, P values below 0.05). Compared with the plantar temperature of rats in group DS, except for that in group CT in PTW 2 and 3 significantly increased (with t values respectively 3.419 and 2.863, P values below 0.05), the plantar temperature of rats in groups M, S, and CT showed no significant difference at each time point (with t values from 0.128 to 1.654, P values above 0.05). The plantar hot pain threshold of rats was significantly decreased in group N than in the other 4 groups before treatment and group S in PTW 1 (with t values from 2.836 to 4.456, P values below 0.05). The plantar hot pain thresholds of rats in groups M, S, and CT were close to the hot pain threshold in group DS (with t values from 0.312 to 1.611, P values above 0.05). (2) The experiment of diabetic foot ulcers. Edema existed in all the wounds of rats on PTD 3. The wound areas of all the rats continued to increase with swelling and scar formation on PTD 7. On PTD 21, the scar of rats in groups N, S, and CT fell off; the wounds of rats in group DS were still swollen; scar of rats did not fall off with dark red in the skin around the wound in group M. On PTD 35, wounds of rats in groups N, S, and CT were nearly healed; while wounds of rats in groups DS and M were still swollen and the scar around the wound failed to fall off. On PTD 3 and 7, the wound areas of rats with diabetes in the 4 groups were close to those in group N (with t values from 0.111 to 1.476, P values above 0.05). On PTD 21, the wound area of rats in group DS was significantly larger than that in group N (t=5.502, P&lt;0.01), while the wound areas of rats with diabetes in the other 3 groups were close to the area in group N (with t values from 0.544 to 1.676, P values above 0.05). On PTD 21, the wound area of rats in group M was close to that in group DS (t=1.895, P&gt;0.05), while the wound areas of rats in groups S and CT were significantly smaller than the area in group DS (with t values respectively 5.809 and 3.426, P&lt;0.05 or P&lt;0.01). On PTD 35, the wound areas of rats in groups DS and M were significantly larger than the area in group N (with t values respectively 8.495 and 4.108, P values below 0.01), while the wound areas of rats in groups S and CT were close to the area in group N (with t values respectively 0.291 and 2.195, P values above 0.05). On PTD 35, the wound area of rats in group M was close to that in group DS (t=0.897, P&gt;0.05); while the wound areas of rats in groups S and CT were significantly smaller than the area in group DS (with t values respectively 6.923 and 6.583, P values below 0.01). On PTD 35, the structures of wound tissue were in better integrity with less inflammatory cells and more regularly arranged collagen fibers around the wounds of rats in groups N, S, and CT than in groups DS and M. On PTD 35, the expression levels of COX-2 and VEGF in the wounds of rats in group DS [respectively (222±89)% and (55±12)%] were close to those in group M [respectively (137±24)% and (94±36)%, with t values respectively 3.046 and 2.653, P values above 0.05]. On PTD 35, the expression level of COX-2 in the wounds of rats in group DS was significantly higher than the expression levels of COX-2 in groups N, S, and CT [respectively (100±35)%, (91±42)%, and (109±17)%, with t values from 4.039 to 4.653, P values below 0.01], while the expression level of VEGF in the wounds of rats in group DS was significantly lower than the expression levels of VEGF in groups N, S, and CT [respectively (100±28)%, (143±12)%, and (120±13)%, with t values from 3.363 to 5.905, P&lt;0.05 or P&lt;0.01].</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">S can improve the plantar temperature decrease and pain dysesthesia of rats caused by diabetic peripheral circulatory disorders. It also can promote wound healing of diabetic foot ulcers in rats with down-regulation of COX-2 and up-regulation of VEGF.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratory of Pharmacology, College of Pharmacy, South-Central University for Nationalities, Wuhan 430074, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Y J</ForeName>
            <Initials>YJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Y S</ForeName>
            <Initials>YS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>X J</ForeName>
            <Initials>XJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>H B</ForeName>
            <Initials>HB</Initials>
        </Author>
    </AuthorList>
    <Language>chi</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>China</Country>
    <MedlineTA>Zhonghua Shao Shang Za Zhi</MedlineTA>
    <NlmUniqueID>100959418</NlmUniqueID>
    <ISSNLinking>1009-2587</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C000591275">San-Huang</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C467498">vascular endothelial growth factor A, rat</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.99.1</RegistryNumber>
        <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.99.1</RegistryNumber>
        <NameOfSubstance UI="C489691">Ptgs2 protein, rat</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002921" MajorTopicYN="N">Cicatrix</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017719" MajorTopicYN="N">Diabetic Foot</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>4</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>4</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>7</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">27030654</ArticleId>
    <ArticleId IdType="doi">10.3760/cma.j.issn.1009-2587.2016.03.009</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27020890</PMID>
<DateCompleted>
    <Year>2017</Year>
    <Month>02</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1556-2891</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>06</Month>
            </PubDate>
        </JournalIssue>
        <Title>Forensic science, medicine, and pathology</Title>
        <ISOAbbreviation>Forensic Sci Med Pathol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Reliability of body size measurements obtained at autopsy: impact on the pathologic assessment of the heart.</ArticleTitle>
    <Pagination>
        <MedlinePgn>139-45</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12024-016-9773-1</ELocationID>
    <Abstract>
        <AbstractText>Purpose Assessment of body size at autopsy is important for interpreting organ weight measurements and in some cases body identification. The reliability of post-mortem body size measurements, the causes for perturbations in these measurements from their corresponding pre-mortem values, and the impact of such perturbations on heart weight interpretation have not been fully explored. Methods Autopsy body length and weight measurements and pre-mortem height and body weight measurements were compared in 132 autopsies. Clinical records were evaluated for peripheral edema and serum albumin levels. Causes of death, body cavity fluid collections, and heart weights were obtained from the autopsy reports. A subset of patients underwent quantitative post-mortem computed tomography assessment of anasarca. Results At autopsy, body weight differed from the pre-mortem value by 11 ± 1 %, compared with -0.2 ± 0.3 % for body length (P &lt; 0.0001). The percent change in body weight at autopsy correlated with the presence of peripheral edema (14 ± 2 % vs. 7 ± 2 %, P = 0.01), serum albumin &lt; 3.0 g/dL (16 ± 2 % vs. 7 ± 2 %, P = 0.001), and the degree of anasarca (P = 0.01). In 4 % of autopsies, heart weights were abnormal based on the pre-mortem body weight, but would be classified as normal based on the elevated post-mortem body weight. Conclusions At autopsy, body weight is a less reliable parameter than body length in correlating with the corresponding pre-mortem measurement. Autopsy body weights are elevated in part due to peripheral edema/anasarca. Alterations in body weight at autopsy can confound the interpretation of organ weight measurements.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>McCormack</LastName>
            <ForeName>Carmen A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Simches Research Building Room 8236, 185 Cambridge Street CPZN, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lo Gullo</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology, University of Milano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>The Division of Thoracic Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kalra</LastName>
            <ForeName>Mannudeep K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
                <Affiliation>The Division of Thoracic Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Louissaint</LastName>
            <ForeName>Abner</ForeName>
            <Initials>A</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
                <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Simches Research Building Room 8236, 185 Cambridge Street CPZN, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Stone</LastName>
            <ForeName>James R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Simches Research Building Room 8236, 185 Cambridge Street CPZN, Boston, MA, 02114, USA. jrstone@partners.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA. jrstone@partners.org.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>03</Month>
        <Day>29</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Forensic Sci Med Pathol</MedlineTA>
    <NlmUniqueID>101236111</NlmUniqueID>
    <ISSNLinking>1547-769X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001344" MajorTopicYN="Y">Autopsy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001827" MajorTopicYN="Y">Body Height</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001835" MajorTopicYN="Y">Body Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D049429" MajorTopicYN="N">Forensic Pathology</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Autopsy</Keyword>
    <Keyword MajorTopicYN="N">Body length</Keyword>
    <Keyword MajorTopicYN="N">Body size</Keyword>
    <Keyword MajorTopicYN="N">Body weight</Keyword>
    <Keyword MajorTopicYN="N">Edema</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="accepted">
        <Year>2016</Year>
        <Month>03</Month>
        <Day>14</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>3</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>3</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2017</Year>
        <Month>2</Month>
        <Day>6</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">27020890</ArticleId>
    <ArticleId IdType="doi">10.1007/s12024-016-9773-1</ArticleId>
    <ArticleId IdType="pii">10.1007/s12024-016-9773-1</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Forensic Sci. 2013 May;58(3):811-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23488801</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Forensic Med Pathol. 1990 Sep;11(3):202-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2220704</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Forensic Sci Med Pathol. 2015 Dec;11(4):488-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26541472</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hum Biol. 1993;5(3):291-296</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28548411</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mayo Clin Proc. 1988 Feb;63(2):137-46</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3276974</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Virchows Arch. 2008 Jan;452(1):11-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17952460</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Forensic Med Pathol. 2012 Dec;33(4):362-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22182983</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Comput Assist Tomogr. 2014 Mar-Apr;38(2):293-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24632938</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Forensic Sci Int. 2001 Jun 15;119(2):149-54</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11376980</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Pathol. 2011 Apr;64(4):358-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21059599</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Jpn Circ J. 1979 Feb;43(2):77-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">449022</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1966 Mar;33(3):450-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4221929</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26892302</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>19</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>04</Month>
    <Day>23</Day>
</DateRevised>
<Article PubModel="Electronic">
    <Journal>
        <ISSN IssnType="Electronic">2045-2322</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <PubDate>
                <Year>2016</Year>
                <Month>Feb</Month>
                <Day>19</Day>
            </PubDate>
        </JournalIssue>
        <Title>Scientific reports</Title>
        <ISOAbbreviation>Sci Rep</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Elevated pulmonary artery pressure and brain natriuretic peptide in high altitude pulmonary edema susceptible non-mountaineers.</ArticleTitle>
    <Pagination>
        <MedlinePgn>21357</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep21357</ELocationID>
    <Abstract>
        <AbstractText>Exaggerated pulmonary pressor response to hypoxia is a pathgonomic feature observed in high altitude pulmonary edema (HAPE) susceptible mountaineers. It was investigated whether measurement of basal pulmonary artery pressure (Ppa) and brain natriuretic peptide (BNP) could improve identification of HAPE susceptible subjects in a non-mountaineer population. We studied BNP levels, baseline hemodynamics and the response to hypoxia (FIo2 = 0.12 for 30 min duration at sea level) in 11 HAPE resistant (no past history of HAPE, Control) and 11 HAPE susceptible (past history of HAPE, HAPE-S) subjects. Baseline Ppa (19.31 ± 3.63 vs 15.68 ± 2.79 mm Hg, p &lt; 0.05) and plasma BNP levels (52.39 ± 32.9 vs 15.05 ± 9.6 pg/ml, p &lt; 0.05) were high and stroke volume was less (p &lt; 0.05) in HAPE-S subjects compared to control. Acute hypoxia produced an exaggerated increase in heart rate (p &lt; 0.05), mean arterial pressure (p &lt; 0.05) and Ppa (28.2 ± 5.8 vs 19.33 ± 3.74 mm Hg, p &lt; 0.05) and fall in peripheral oxygen saturation (p &lt; 0.05) in HAPE-S compared to control. Receiver operating characteristic (ROC) curves showed that Ppa response to acute hypoxia was the best variable to identify HAPE susceptibility (AUC 0.92) but BNP levels provided comparable information (AUC 0.85). BNP levels are easy to determine and may represent an important marker for the determination of HAPE susceptibility.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Rajinder K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Himashree</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Krishan</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Soree</LastName>
            <ForeName>Poonam</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Desiraju</LastName>
            <ForeName>Koundinya</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
                <Affiliation>CSIR Institute of Genomics and Integrated Biology, Mall Road, Delhi 110007, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Agrawal</LastName>
            <ForeName>Anurag</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>CSIR Institute of Genomics and Integrated Biology, Mall Road, Delhi 110007, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ghosh</LastName>
            <ForeName>Dishari</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Dass</LastName>
            <ForeName>Deepak</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Reddy</LastName>
            <ForeName>Prassana K</ForeName>
            <Initials>PK</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Panjwani</LastName>
            <ForeName>Usha</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Shashi Bala</ForeName>
            <Initials>SB</Initials>
            <AffiliationInfo>
                <Affiliation>Defence Institute of Physiology and Allied Sciences. Timarpur, Delhi-110054, India.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>02</Month>
        <Day>19</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Sci Rep</MedlineTA>
    <NlmUniqueID>101563288</NlmUniqueID>
    <ISSNLinking>2045-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>114471-18-0</RegistryNumber>
        <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
    </Chemical>
</ChemicalList>
<SupplMeshList>
    <SupplMeshName Type="Disease" UI="C535833">Pulmonary edema of mountaineers</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000532" MajorTopicYN="N">Altitude Sickness</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000886" MajorTopicYN="N">Anthropometry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2015</Year>
        <Month>05</Month>
        <Day>18</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2016</Year>
        <Month>01</Month>
        <Day>13</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>2</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>2</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>12</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26892302</ArticleId>
    <ArticleId IdType="pii">srep21357</ArticleId>
    <ArticleId IdType="doi">10.1038/srep21357</ArticleId>
    <ArticleId IdType="pmc">PMC4759542</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Eur Respir J. 1995 Nov;8(11):1825-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8620946</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 2000 Mar 31;86(6):671-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10747003</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Respir Crit Care Med. 2005 Sep 15;172(6):763-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15947284</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 1994 Aug;77(2):912-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8002547</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Respir Crit Care Med. 2001 Feb;163(2):368-73</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11179108</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H856-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14604853</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1995 Jul 27;333(4):214-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7540722</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2013 Jun 13;368(24):2294-302</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23758234</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2001 Apr 24;103(16):2078-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11319198</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1999 Apr 6;99(13):1713-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10190881</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Respir Physiol Neurobiol. 2009 Dec 31;169(3):297-302</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19770072</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Respir J. 1998 Mar;11(3):643-50</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9596116</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Pharmacol. 2013 Jul;169(5):1035-47</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23517027</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1984 Oct;70(4):657-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6478568</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 1998 Jan;31(1):202-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9426041</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 2005 Nov;99(5):1796-801</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16024527</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Compr Physiol. 2012 Oct;2(4):2753-73</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23720264</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Semin Respir Crit Care Med. 2005 Aug;26(4):385-93</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16121315</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am Rev Respir Dis. 1969 Sep;100(3):334-41</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5822044</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2009 Apr 7;119(13):1747-57</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19307479</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol. 1998 Apr;274(4 Pt 1):L517-26</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9575869</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am Heart J. 1987 May;113(5):1114-22</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3578005</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Heart. 2003 Feb;89(2):225-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12527688</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 1996 Aug;81(2):911-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8872663</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2000 Mar 15;35(4):980-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10732898</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Sci (Lond). 2013 Apr;124(7):479-89</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23130672</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1964 Mar;29:393-408</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14131411</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):412-20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3774020</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>High Alt Med Biol. 2012 Jun;13(2):105-11</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22724613</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 1989 Nov;67(5):1982-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2532195</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JAMA. 2002 May 1;287(17):2228-35</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11980523</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 1987 Nov;92(5):814-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3665594</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1971 Nov;44(5):759-70</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5115068</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 1993 Jan;103(1):111-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8417862</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 1996 Aug;81(2):922-32</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8872664</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 1996 Jun;109(6):1446-51</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8769491</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 1988 Dec;65(6):2632-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2975278</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Appl Physiol (1985). 1986 Jul;61(1):260-70</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3090012</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1985 Nov;72(5):957-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4042303</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drug Des Devel Ther. 2009 Dec 29;3:269-87</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20054445</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br Heart J. 1969 Jan;31(1):52-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5764965</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol. 1993 Jul;265(1 Pt 1):L87-92</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8338186</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26878472</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>14</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1874-1754</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>209</Volume>
            <PubDate>
                <Year>2016</Year>
                <Month>Apr</Month>
                <Day>15</Day>
            </PubDate>
        </JournalIssue>
        <Title>International journal of cardiology</Title>
        <ISOAbbreviation>Int J Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Cholecystokinin in plasma predicts cardiovascular mortality in elderly females.</ArticleTitle>
    <Pagination>
        <MedlinePgn>37-41</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2016.02.038</ELocationID>
    <ELocationID EIdType="pii" ValidYN="Y">S0167-5273(16)30253-4</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cholecystokinin (CCK) and gastrin are related gastrointestinal hormones with documented cardiovascular effects of exogenous administration. It is unknown whether measurement of endogenous CCK or gastrin in plasma contains information regarding cardiovascular mortality.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Mortality risk was evaluated using Cox proportional hazard regression and Kaplan-Meier analyses. Elderly patients in a primary care setting with symptoms of cardiac disease, i.e. shortness of breath, peripheral edema, and/or fatigue, were evaluated (n=470). Primary care patients were followed for 13years (from 1999); the 5-year all-cause and cardiovascular mortality was used as end point.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">In univariate analysis, patients in the 4th CCK quartile had an increased risk of 5-year cardiovascular mortality (hazard ratio 3.9, 95% confidence interval: 2.1-7.0, p&lt;0.0001). In multivariate analysis including established factors associated with cardiovascular mortality, CCK concentrations in the 4th quartile were still associated with increased 5-year cardiovascular mortality risk (HR 3.1, 95% C.I.: 1.7-5.7, p=0.0004), even when including 4th quartile NT-proBNP concentrations in the same model. We observed a marked difference between the genders, where CCK concentrations in the 4th quartile were associated with a higher 5-year cardiovascular mortality in female patients (HR 8.99, 95% C.I.: 3.49-102.82, p=0.0007) compared to men (1.47, 95% C.I.: 0.7-3.3, p=0.35). In contrast, no significant information was obtained from 4th quartile gastrin concentrations on 5-year cardiovascular mortality risk.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CCK in plasma is an independent marker of cardiovascular mortality in elderly female patients. The study thus introduces measurement of plasma CCK in gender-specific cardiovascular risk assessment.</AbstractText>
        <CopyrightInformation>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Goetze</LastName>
            <ForeName>Jens P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: JPG@dadlnet.dk.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rehfeld</LastName>
            <ForeName>Jens F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Alehagen</LastName>
            <ForeName>Urban</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Cardiology, Linköping University, Linköping, Sweden; Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2016</Year>
        <Month>02</Month>
        <Day>03</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Netherlands</Country>
    <MedlineTA>Int J Cardiol</MedlineTA>
    <NlmUniqueID>8200291</NlmUniqueID>
    <ISSNLinking>0167-5273</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>9011-97-6</RegistryNumber>
        <NameOfSubstance UI="D002766">Cholecystokinin</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002766" MajorTopicYN="N">Cholecystokinin</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015150" MajorTopicYN="N">Echocardiography, Doppler</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName>
        <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">ANP</Keyword>
    <Keyword MajorTopicYN="N">Atrial natriuretic peptide</Keyword>
    <Keyword MajorTopicYN="N">B-type natriuretic peptide</Keyword>
    <Keyword MajorTopicYN="N">BNP</Keyword>
    <Keyword MajorTopicYN="N">Cholecystokinin</Keyword>
    <Keyword MajorTopicYN="N">Heart failure</Keyword>
    <Keyword MajorTopicYN="N">Prognosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>26</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2015</Year>
        <Month>12</Month>
        <Day>15</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2016</Year>
        <Month>02</Month>
        <Day>02</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>2</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>2</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>12</Month>
        <Day>15</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26878472</ArticleId>
    <ArticleId IdType="pii">S0167-5273(16)30253-4</ArticleId>
    <ArticleId IdType="doi">10.1016/j.ijcard.2016.02.038</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26841413</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>13</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1940-9990</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>IEEE transactions on biomedical circuits and systems</Title>
        <ISOAbbreviation>IEEE Trans Biomed Circuits Syst</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A Robust System for Longitudinal Knee Joint Edema and Blood Flow Assessment Based on Vector Bioimpedance Measurements.</ArticleTitle>
    <Pagination>
        <MedlinePgn>545-55</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1109/TBCAS.2015.2487300</ELocationID>
    <Abstract>
        <AbstractText>We present a robust vector bioimpedance measurement system for longitudinal knee joint health assessment, capable of acquiring high resolution static (slowly varying over the course of hours to days) and dynamic (rapidly varying on the order of milli-seconds) bioresistance and bioreactance signals. Occupying an area of 78×90 mm(2) and consuming 0.25 W when supplied with ±5 V, the front-end achieves a dynamic range of 345 Ω and noise floor of 0.018 mΩrms (resistive) and 0.055 mΩrms (reactive) within a bandwidth of 0.1-20 Hz. A microcontroller allows real-time calibration to minimize errors due to environmental variability (e.g., temperature) that can be experienced outside of lab environments, and enables data storage on a micro secure digital card. The acquired signals are then processed using customized physiology-driven algorithms to extract musculoskeletal (edema) and cardiovascular (local blood volume pulse) features from the knee joint. In a feasibility study, we found statistically significant differences between the injured and contralateral static knee impedance measures for two subjects with recent unilateral knee injury compared to seven controls. Specifically, the impedance was lower for the injured knees, supporting the physiological expectations for increased edema and damaged cell membranes. In a second feasibility study, we demonstrate the sensitivity of the dynamic impedance measures with a cold-pressor test, with a 20 mΩ decrease in the pulsatile resistance associated with increased downstream peripheral vascular resistance. The proposed system will serve as a foundation for future efforts aimed at quantifying joint health status continuously during normal daily life. </AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Hersek</LastName>
            <ForeName>Sinan</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Töreyin</LastName>
            <ForeName>Hakan</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Inan</LastName>
            <ForeName>Omer T</ForeName>
            <Initials>OT</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2015</Year>
        <Month>12</Month>
        <Day>24</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>IEEE Trans Biomed Circuits Syst</MedlineTA>
    <NlmUniqueID>101312520</NlmUniqueID>
    <ISSNLinking>1932-4545</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015374" MajorTopicYN="N">Biosensing Techniques</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017097" MajorTopicYN="N">Electric Impedance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007719" MajorTopicYN="N">Knee Joint</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2016</Year>
        <Month>2</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2016</Year>
        <Month>2</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>12</Month>
        <Day>15</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26841413</ArticleId>
    <ArticleId IdType="doi">10.1109/TBCAS.2015.2487300</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26583760</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>08</Month>
    <Day>30</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>04</Month>
    <Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1527-1315</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>279</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2016</Year>
                <Month>May</Month>
            </PubDate>
        </JournalIssue>
        <Title>Radiology</Title>
        <ISOAbbreviation>Radiology</ISOAbbreviation>
    </Journal>
    <ArticleTitle>MR Imaging of Brachial Plexus and Limb-Girdle Muscles in Patients with Amyotrophic Lateral Sclerosis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>553-61</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1148/radiol.2015150559</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess brachial plexus magnetic resonance (MR) imaging features and limb-girdle muscle abnormalities as signs of muscle denervation in patients with amyotrophic lateral sclerosis (ALS).</AbstractText>
        <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This study was approved by the local ethical committees on human studies, and written informed consent was obtained from all subjects before enrollment. By using an optimized protocol of brachial plexus MR imaging, brachial plexus and limb-girdle muscle abnormalities were evaluated in 23 patients with ALS and clinical and neurophysiologically active involvement of the upper limbs and were compared with MR images in 12 age-matched healthy individuals. Nerve root and limb-girdle muscle abnormalities were visually evaluated by two experienced observers. A region of interest-based analysis was performed to measure nerve root volume and T2 signal intensity. Measures obtained at visual inspection were analyzed by using the Wald χ(2) test. Mean T2 signal intensity and volume values of the regions of interest were compared between groups by using a hierarchical linear model, accounting for the repeated measurement design.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The level of interrater agreement was very strong (κ = 0.77-1). T2 hyperintensity and volume alterations of C5, C6, and C7 nerve roots were observed in patients with ALS (P &lt; .001 to .03). Increased T2 signal intensity of nerve roots was associated with faster disease progression (upper-limb Medical Research Council scale progression rate, r = 0.40; 95% confidence interval: 0.001, 0.73). Limb-girdle muscle alterations (ie, T2 signal intensity alteration, edema, atrophy) and fat infiltration also were found, in particular, in the supraspinatus muscle, showing more frequent T2 signal intensity alterations and edema (P = .01) relative to the subscapularis and infraspinatus muscles.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Increased T2 signal intensity and volume of brachial nerve roots do not exclude a diagnosis of ALS and suggest involvement of the peripheral nervous system in the ALS pathogenetic cascade. MR imaging of the peripheral nervous system and the limb-girdle muscle may be useful for monitoring the evolution of ALS and distinguishing patients with ALS from those with inflammatory neuropathy, respectively.</AbstractText>
        <CopyrightInformation>(©) RSNA, 2015.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Gerevini</LastName>
            <ForeName>Simonetta</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Agosta</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Riva</LastName>
            <ForeName>Nilo</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Spinelli</LastName>
            <ForeName>Edoardo G</ForeName>
            <Initials>EG</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pagani</LastName>
            <ForeName>Elisabetta</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Caliendo</LastName>
            <ForeName>Giandomenico</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chaabane</LastName>
            <ForeName>Linda</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Copetti</LastName>
            <ForeName>Massimiliano</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Quattrini</LastName>
            <ForeName>Angelo</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Comi</LastName>
            <ForeName>Giancarlo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Falini</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Filippi</LastName>
            <ForeName>Massimo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>From the Department of Neuroradiology (S.G., G.Caliendo, A.F.), Neuroimaging Research Unit (F.A., E.G.S., E.P., M.F.), Department of Neurology (N.R., E.G.S., G.Comi, M.F.), and Neuropathology Unit (N.R., L.C., A.Q.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy; and Biostatistics Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (M.C.).</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>18</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Radiology</MedlineTA>
    <NlmUniqueID>0401260</NlmUniqueID>
    <ISSNLinking>0033-8419</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020516" MajorTopicYN="N">Brachial Plexus Neuropathies</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
        <QualifierName UI="Q000294" MajorTopicYN="Y">innervation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>8</Month>
        <Day>31</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26583760</ArticleId>
    <ArticleId IdType="doi">10.1148/radiol.2015150559</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26550694</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>09</Month>
    <Day>21</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>01</Month>
    <Day>31</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1095-953X</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>85</Volume>
            <PubDate>
                <Year>2016</Year>
                <Month>Jan</Month>
            </PubDate>
        </JournalIssue>
        <Title>Neurobiology of disease</Title>
        <ISOAbbreviation>Neurobiol Dis</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Recombinant Slit2 attenuates neuroinflammation after surgical brain injury by inhibiting peripheral immune cell infiltration via Robo1-srGAP1 pathway in a rat model.</ArticleTitle>
    <Pagination>
        <MedlinePgn>164-173</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="pii" ValidYN="Y">S0969-9961(15)30082-6</ELocationID>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2015.11.003</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Peripheral immune cell infiltration to the brain tissue at the perisurgical site can promote neuroinflammation after surgical brain injury (SBI). Slit2, an extracellular matrix protein, has been reported to reduce leukocyte migration. This study evaluated the effect of recombinant Slit2 and the role of its receptor roundabout1 (Robo1) and its downstream mediator Slit-Robo GTPase activating protein 1 (srGAP1)-Cdc42 on peripheral immune cell infiltration after SBI in a rat model.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and fifty-three adult male Sprague-Dawley rats (280-350 g) were used. Partial resection of right frontal lobe was performed to induce SBI. Slit2 siRNA was administered by intracerebroventricular injection 24h before SBI. Recombinant Slit2 was injected intraperitoneally 1h before SBI. Recombinant Robo1 used as a decoy receptor was co-administered with recombinant Slit2. srGAP1 siRNA was administered by intracerebroventricular injection 24h before SBI. Post-assessments included brain water content measurement, neurological tests, ELISA, Western blot, immunohistochemistry, and Cdc42 activity assay.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Endogenous Slit2 was increased after SBI. Robo1 was expressed by peripheral immune cells. Endogenous Slit2 knockdown worsened brain edema after SBI. Recombinant Slit2 administration reduced brain edema, neurological deficits, and pro-inflammatory cytokines after SBI. Recombinant Slit2 reduced peripheral immune cell markers cluster of differentiation 45 (CD45) and myeloperoxidase (MPO), as well as Cdc42 activity in the perisurgical brain tissue which was reversed by recombinant Robo1 co-administration and srGAP1 siRNA.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Recombinant Slit2 improved outcomes by reducing neuroinflammation after SBI, possibly by decreasing peripheral immune cell infiltration to the perisurgical site through Robo1-srGAP1 mediated inhibition of Cdc42 activity. These results suggest that Slit2 may be beneficial to reduce SBI-induced neuroinflammation.</AbstractText>
        <CopyrightInformation>Copyright © 2015 Elsevier Inc. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Sherchan</LastName>
            <ForeName>Prativa</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.; Department of Anesthesiology, Loma Linda University, CA 92354, U.S.A.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuechun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Akyol</LastName>
            <ForeName>Onat</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jiping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>John H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.; Department of Anesthesiology, Loma Linda University, CA 92354, U.S.A.; Department of Neurosurgery, Loma Linda University, CA 92354, U.S.A.. Electronic address: johnzhang3910@yahoo.com.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>R01 NS084921</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>10</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Neurobiol Dis</MedlineTA>
    <NlmUniqueID>9500169</NlmUniqueID>
    <ISSNLinking>0969-9961</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C490016">roundabout protein</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C499133">tGAP1 protein, rat</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>R6FXH13RRC</RegistryNumber>
        <NameOfSubstance UI="C118487">Slit homolog 2 protein</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName>
        <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        <QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020690" MajorTopicYN="N">GTPase-Activating Proteins</DescriptorName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D057967" MajorTopicYN="N">Infusions, Intraventricular</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName>
        <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Brain edema</Keyword>
    <Keyword MajorTopicYN="N">Cdc42</Keyword>
    <Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
    <Keyword MajorTopicYN="N">Peripheral immune cell infiltration</Keyword>
    <Keyword MajorTopicYN="N">Robo1</Keyword>
    <Keyword MajorTopicYN="N">Slit2</Keyword>
    <Keyword MajorTopicYN="N">Surgical brain injury</Keyword>
    <Keyword MajorTopicYN="N">srGAP1</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2015</Year>
        <Month>08</Month>
        <Day>06</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>29</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>05</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>10</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>10</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>9</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26550694</ArticleId>
    <ArticleId IdType="pii">S0969-9961(15)30082-6</ArticleId>
    <ArticleId IdType="doi">10.1016/j.nbd.2015.11.003</ArticleId>
    <ArticleId IdType="pmc">PMC4688150</ArticleId>
    <ArticleId IdType="mid">NIHMS738016</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Ann Neurol. 2014 Feb;75(2):209-19</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24273204</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurooncol. 2008 Mar;87(1):1-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17968499</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood. 2012 Oct 25;120(17):3563-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22932798</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Leukoc Biol. 2009 Dec;86(6):1403-15</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19759280</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Behav Brain Res. 2014 May 1;264:151-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24518201</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Prog Neurobiol. 2002 Dec;68(5):311-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12531232</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biomed Res Int. 2014;2014:672409</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25309917</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 2008 Jun 18;1215:218-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18479673</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Sci Transl Med. 2010 Mar 17;2(23):23ra19</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20375003</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Neurosci. 2003 Dec;4(12):941-56</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14682358</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell. 2001 Oct 19;107(2):209-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11672528</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Cell Biol. 2009 Nov;11(11):1325-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19855388</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2007 May;27(5):894-908</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17033693</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Opin Genet Dev. 2002 Oct;12(5):583-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12200164</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 1995 Apr;26(4):627-34; discussion 635</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7709410</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 2011 Feb;42(2):477-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21193742</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Glia. 2003 Apr 15;42(2):130-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12655597</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Immunol. 2010 Nov 15;185(10):6294-305</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20944010</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neuro Oncol. 2009 Dec;11(6):779-89</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20008733</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Opin Crit Care. 2011 Apr;17(2):122-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21326097</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Med. 2008 Apr;14(4):448-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18345009</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 2012 Jun;40(6):1908-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22488000</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Exp Neurol. 2007 Oct;207(2):186-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17714707</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2006 May 2;113(17):2105-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16636173</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Immunol. 2003 Jul;3(7):569-81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12876559</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2008 Jun;28(6):1235-48</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18364727</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosurg. 2012 Jan;116(1):246-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22017304</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Surg Neurol. 2007 Jan;67(1):15-20; discussion 20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17210286</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Med. 2009 Aug;15(8):844-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19661986</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Comp Neurol. 2002 Jan 7;442(2):130-55</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11754167</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biochem J. 2000 Jun 1;348 Pt 2:241-55</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10816416</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nature. 2001 Apr 19;410(6831):948-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11309622</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Immunol. 2014 Jan 1;192(1):385-93</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24272999</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Semin Immunol. 1999 Apr;11(2):125-37</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10329499</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Opin Anaesthesiol. 2002 Oct;15(5):477-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17019241</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>BMJ Open. 2014;4(4):e004921</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24760352</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurosurgery. 2007 Nov;61(5):1067-75; discussion 1075-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18091283</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurobiol Dis. 2013 Oct;58:296-307</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23816751</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Pathol. 2004 Jul;165(1):341-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15215188</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 2010 Aug;41(8):1783-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20616319</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Behav Brain Res. 2015 Sep 1;290:161-71</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25975171</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 2014 Jun;45(6):1807-14</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24757104</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Adv Cancer Res. 2012;114:187-235</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22588058</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosurg. 2007 Apr;106(4):680-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17432722</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Leukoc Biol. 2007 Sep;82(3):465-76</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17565045</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Inj. 2014;28(12):1594-601</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25093611</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26310790</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>06</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1532-429X</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <PubDate>
                <Year>2015</Year>
                <Month>Aug</Month>
                <Day>27</Day>
            </PubDate>
        </JournalIssue>
        <Title>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</Title>
        <ISOAbbreviation>J Cardiovasc Magn Reson</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Increased myocardial extracellular volume in active idiopathic systemic capillary leak syndrome.</ArticleTitle>
    <Pagination>
        <MedlinePgn>76</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12968-015-0181-6</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Systemic Capillary Leak Syndrome (SCLS) is a rare disorder of unknown etiology presenting as recurrent episodes of shock and peripheral edema due to leakage of fluid into soft tissues. Insights into SCLS pathogenesis are few due to the scarcity of cases, and the etiology of vascular barrier disruption in SCLS is unknown. Recent advances in cardiovascular magnetic resonance (CMR) allow for the quantitative assessment of the myocardial extracellular volume (ECV), which can be increased in conditions causing myocardial edema. We hypothesized that measurement of myocardial ECV may detect myocardial vascular leak in patients with SCLS.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-six subjects underwent a standard CMR examination at the NIH Clinical Center from 2009 until 2014: 20 patients with acute intermittent SCLS, six subjects with chronic SCLS, and 30 unaffected controls. Standard volumetric measurements; late gadolinium enhancement imaging and pre- and post-contrast T1 mapping were performed. ECV was calculated by calibration of pre- and post-contrast T1 values with blood hematocrit.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Demographics and cardiac parameters were similar in both groups. There was no significant valvular disorder in either group. Subjects with chronic SCLS had higher pre-contrast myocardial T1 compared to healthy controls (T1: 1027 ± 44 v. 971 ± 41, respectively; p = 0.03) and higher myocardial ECV than patients with acute intermittent SCLS or controls: 33.8 ± 4.6, 26.9 ± 2.6, 26 ± 2.4, respectively; p = 0.007 v. acute intermittent; P = 0.0005 v. controls). When patients with chronic disease were analyzed together with five patients with acute intermittent disease who had just experienced an acute SCLS flare, ECV values were significantly higher than in subjects with acute intermittent SCLS in remission or age-matched controls and (31.2 ± 4.6 %, 26.5 ± 2.7 %, 26 ± 2.4 %, respectively; p = 0.01 v. remission, p = 0.001 v. controls). By contrast, T1 values did not distinguish these three subgroups (1008 ± 40, 978 ± 40, 971 ± 41, respectively, p = 0.2, active v. remission; p = 0.06 active v. controls). Abundant myocardial edema without evidence of acute inflammation was detected in cardiac tissue postmortem in one patient.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with active SCLS have significantly higher myocardial ECV than age-matched controls or SCLS patients in remission, which correlated with histopathological findings in one patient.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ertel</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Medstar Washington Hospital Center, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pratt</LastName>
            <ForeName>Drew</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kellman</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Leung</LastName>
            <ForeName>Steve</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bandettini</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Lauren M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
                <Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive Room 4154, Bethesda, MD, 20892-8305, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Young</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive Room 4154, Bethesda, MD, 20892-8305, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nelson</LastName>
            <ForeName>Celeste</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
                <Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive Room 4154, Bethesda, MD, 20892-8305, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Arai</LastName>
            <ForeName>Andrew E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
                <Affiliation>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Druey</LastName>
            <ForeName>Kirk M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
                <Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive Room 4154, Bethesda, MD, 20892-8305, USA. kdruey@niaid.nih.gov.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2015</Year>
        <Month>08</Month>
        <Day>27</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>J Cardiovasc Magn Reson</MedlineTA>
    <NlmUniqueID>9815616</NlmUniqueID>
    <ISSNLinking>1097-6647</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019559" MajorTopicYN="N">Capillary Leak Syndrome</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004489" MajorTopicYN="N">Edema, Cardiac</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019028" MajorTopicYN="Y">Magnetic Resonance Imaging, Cine</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008396" MajorTopicYN="N" Type="Geographic">Maryland</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2015</Year>
        <Month>03</Month>
        <Day>10</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2015</Year>
        <Month>08</Month>
        <Day>11</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>8</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>8</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>6</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26310790</ArticleId>
    <ArticleId IdType="doi">10.1186/s12968-015-0181-6</ArticleId>
    <ArticleId IdType="pii">10.1186/s12968-015-0181-6</ArticleId>
    <ArticleId IdType="pmc">PMC4551171</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Ann Intern Med. 2011 Apr 5;154(7):464-71</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21464348</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Magn Reson Med. 2002 Feb;47(2):372-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11810682</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JACC Cardiovasc Imaging. 2011 Feb;4(2):157-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21329900</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Respir Crit Care Med. 2014 May 1;189(9):1145-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24787070</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JACC Cardiovasc Imaging. 2008 Sep;1(5):652-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19356496</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mayo Clin Proc. 2010 Oct;85(10):905-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20634497</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JACC Cardiovasc Imaging. 2012 Sep;5(9):897-907</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22974802</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Radiology. 1999 Jun;211(3):698-708</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10352594</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Magn Reson. 2014;16:21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24593856</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Magn Reson Imaging. 2007 Oct;26(4):1081-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17896383</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Intern Med. 1999 Jun 1;130(11):905-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10375339</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JACC Cardiovasc Imaging. 2013 Apr;6(4):488-97</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23498672</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Intern Med. 2010 Jul 20;153(2):90-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20643990</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Magn Reson. 2012;14:64</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22967246</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood. 2012 May 3;119(18):4321-32</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22411873</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2010 Jul 13;122(2):138-44</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20585010</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Magn Reson. 2012;14:76</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23107451</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Rev Med Interne. 2011 May;32(5):e69-71</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20621395</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Magn Reson. 2012;14:63</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22963517</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Med. 2015 Jan;128(1):91-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25193271</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Cardiol. 2013 Mar 1;111(5):717-22</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23228924</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 1999 Mar;25(3):334-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10229177</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J Acute Cardiovasc Care. 2012 Sep;1(3):248-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24062914</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Rheum Dis. 1996 Sep;55(9):603-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8882128</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">26050057</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>13</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>12</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1538-8646</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>4</Issue>
            <PubDate>
                <MedlineDate>2015 Jul-Aug</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Dimensions of critical care nursing : DCCN</Title>
        <ISOAbbreviation>Dimens Crit Care Nurs</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A Pilot Study: Comparison of Arm Versus Ankle Noninvasive Blood Pressure Measurement at 2 Different Levels of Backrest Elevation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>232-5</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1097/DCC.0000000000000126</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Standard practice for obtaining noninvasive blood pressure includes arm blood pressure (BP) cuff placement at the level of the heart; however, some critical care patients cannot have BPs taken in their arm because of various conditions, and ankle BPs are frequently used as substitutes.</AbstractText>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to determine if there was a significant variation between upper arm and ankle BP measurements at different backrest elevations with consideration of peripheral edema factors.</AbstractText>
        <AbstractText Label="METHODOLOGY" NlmCategory="METHODS">After institutional review board approval was obtained, a pilot study was implemented to evaluate noninvasive BP measurements of the arm and ankle with backrest elevation at 0° and 30° in a population of medical intensive care unit patients. Participants served as their own controls and were randomly assigned to left- versus right-side BP readings. Data were also collected on presence of arm versus ankle edema.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 30 participants enrolled in the study and provided 120 BP measurements. Blood pressure readings were analyzed in terms of diastolic and systolic findings as well as backrest elevations and edema presence. Thirteen participants presented with either arm or ankle edema. There was a statistical difference between the systolic arm and ankle BP measurements in the 0° (P = .008) and 30° (P &lt; .001) backrest elevation positions. The correlation between arm and ankle diastolic BP is greater for participants without ankle edema (P = .038, r = 0.54) than for participants with ankle edema (P = .650, r = 0.14), but it is not statistically significant (P = .47).</AbstractText>
        <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Even though ankle BPs are often substituted for arm BPs when the arm is unable to be used, ankle BPs and arm BPs are not interchangeable. Adjustments in backrest elevation and considerations of edema do not normalize the differences. Blood pressures obtained from the ankle are significantly greater than those obtained from the arm. This information needs to be considered when arms are not available and legs are used as surrogates for the upper arm.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Henley</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>Nicole Henley, BSN, RN, CCRN, is Clinician IV at the medical intensive care unit at the University of Virginia Health System in Charlottesville. Beth D. Quatrara, DNP, RN, CMSRN, ACNS-BC, is director of Nursing Research for the Professional Nursing Staff Organization at the University of Virginia Health System in Charlottesville. Mark Conaway, PhD, is a professor at the Division of Translational Research and Applied Statistics, Department of Public Health Sciences, at the University of Virginia Health System in Charlottesville.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Quatrara</LastName>
            <ForeName>Beth D</ForeName>
            <Initials>BD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Conaway</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Dimens Crit Care Nurs</MedlineTA>
    <NlmUniqueID>8211489</NlmUniqueID>
    <ISSNLinking>0730-4625</ISSNLinking>
</MedlineJournalInfo>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000842" MajorTopicYN="N">Ankle</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>6</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>6</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>12</Month>
        <Day>15</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">26050057</ArticleId>
    <ArticleId IdType="doi">10.1097/DCC.0000000000000126</ArticleId>
    <ArticleId IdType="pii">00003465-201507000-00010</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
<PMID Version="1">25733986</PMID>
<DateCompleted>
    <Year>2015</Year>
    <Month>03</Month>
    <Day>03</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>09</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Print">2005-3711</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>57</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2015</Year>
                <Month>Feb</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of Korean Neurosurgical Society</Title>
        <ISOAbbreviation>J Korean Neurosurg Soc</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Change in plasma vascular endothelial growth factor after gamma knife radiosurgery for meningioma: a preliminary study.</ArticleTitle>
    <Pagination>
        <MedlinePgn>77-81</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.3340/jkns.2015.57.2.77</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to investigate changes in the plasma level of vascular endothelial growth factor (VEGF) after Gamma Knife radiosurgery (GKRS) for the treatment of meningioma.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Fourteen patients with meningiomas had peripheral venous blood collected at the time of GKRS and at 1 week, 1 month, 3 month and 6 month visits. Plasma VEGF levels were measured using commercially available enzyme-linked immunosorbent assay. For controls, peripheral blood samples were obtained from 20 healthy volunteers.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean plasma VEGF level (29.6 pg/mL) in patients with meningiomas before GKRS was significantly lower than that of the control group (62.4 pg/mL, p=0.019). At 1 week after GKRS, the mean plasma VEGF levels decreased to 23.4 pg/mL, and dropped to 13.9 pg/mL at 1 month, 14.8 pg/mL at 3 months, then increased to 27.7 pg/mL at 6 months. Two patients (14.3%) with peritumoral edema (PTE) showed a level of VEGF 6 months after GKRS higher than their preradiosurgical level. There was no significant association found in an analysis of correlation between PTE and tumor size, marginal dose, age, and sex.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study is first in demonstrating changes of plasma VEGF after stereotactic radiosurgery (SRS) for meningioma. This study may provide a stimulus for more work related to whether measurement of plasma level has a correlation with tumor response after SRS for meningioma.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Seong-Hyun</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Jeong-Hyun</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Sung-Kyoo</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2015</Year>
        <Month>02</Month>
        <Day>26</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Korea (South)</Country>
    <MedlineTA>J Korean Neurosurg Soc</MedlineTA>
    <NlmUniqueID>101467054</NlmUniqueID>
    <ISSNLinking>1225-8245</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Gamma Knife radiosurgery</Keyword>
    <Keyword MajorTopicYN="N">Meningioma</Keyword>
    <Keyword MajorTopicYN="N">Stereotactic radiosurgery</Keyword>
    <Keyword MajorTopicYN="N">Vascular endothelial growth factor</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2014</Year>
        <Month>05</Month>
        <Day>08</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2014</Year>
        <Month>09</Month>
        <Day>23</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2014</Year>
        <Month>09</Month>
        <Day>26</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>3</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>3</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2015</Year>
        <Month>3</Month>
        <Day>4</Day>
        <Hour>6</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">25733986</ArticleId>
    <ArticleId IdType="doi">10.3340/jkns.2015.57.2.77</ArticleId>
    <ArticleId IdType="pmc">PMC4345197</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Cancer. 1999 Jan 1;85(1):178-87</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9921991</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stereotact Funct Neurosurg. 1996;66 Suppl 1:129-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9032853</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosurg. 2006 Dec;105 Suppl:120-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18503344</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Cancer Res. 1996 May;2(5):821-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9816236</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosurg. 1999 Jul;91(1):44-50</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10389879</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurosurgery. 2010 Dec;67(6):1703-8; discussion 1708</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21107201</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>BJU Int. 2007 Jul;100(1):209-14</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17428240</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurooncol. 2007 May;83(1):33-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17245625</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurosurgery. 1998 Sep;43(3):405-13; discussion 413-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9733295</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 1983 Feb 25;219(4587):983-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6823562</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stereotact Funct Neurosurg. 1999;72 Suppl 1:60-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10681692</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stereotact Funct Neurosurg. 1996;66 Suppl 1:142-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9032855</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anticancer Res. 2009 Feb;29(2):731-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19331229</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 2008 Aug;39(8):2274-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18535271</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurol Neurosurg Psychiatry. 2003 Feb;74(2):226-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12531956</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Surg. 2001 Feb;233(2):227-35</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11176129</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neuropathol. 2012 Sep-Oct;31(5):352-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22541785</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurosurg Focus. 2003 May 15;14(5):e5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15669816</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">25626722</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>01</Month>
    <Day>29</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1432-1459</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>262</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2015</Year>
            </PubDate>
        </JournalIssue>
        <Title>Journal of neurology</Title>
        <ISOAbbreviation>J Neurol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Nerve ultrasound for differentiation between amyotrophic lateral sclerosis and multifocal motor neuropathy.</ArticleTitle>
    <Pagination>
        <MedlinePgn>870-80</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-015-7648-0</ELocationID>
    <Abstract>
        <AbstractText>Ultrasound is useful for non-invasive visualization of focal nerve pathologies probably resulting from demyelination, remyelination, edema or inflammation. In patients with progressive muscle weakness, differentiation between multifocal motor neuropathy (MMN) and amyotrophic lateral sclerosis (ALS) is essential regarding therapy and prognosis. Therefore, the objective of this study was to investigate whether nerve ultrasound can differentiate between ALS and MMN. Systematic ultrasound measurements of peripheral nerves and the 6th cervical nerve root (C6) were performed in 17 patients with ALS, in 8 patients with MMN and in 28 healthy controls. Nerve conduction studies of corresponding nerves were undertaken in MMN and ALS patients. Electromyography was performed in ALS patients according to revised El-Escorial criteria. ANOVA and unpaired t test with Bonferroni correction revealed significant differences in cross-sectional areas (CSA) of different nerves and C6 diameter between the groups. Nerve enlargement was found significantly more frequently in MMN than in other groups (p &lt; 0.001). Receiver operating characteristics analysis revealed detection of enlarged nerves/roots in at least four measurement points to serve as a good marker to differentiate MMN from ALS with a sensitivity of 87.5% and a specificity of 94.1%. Ultrasonic focal nerve enlargement in MMN was often not colocalized with areas of conduction blocks found in nerve conduction studies. Systematic ultrasound measurements in different nerves and nerve roots are valuable for detecting focal nerve enlargement in MMN, generally not found in ALS and thus could serve as a diagnostic marker to differentiate between both entities in addition to electrodiagnostic studies.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Grimm</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurology, Neuromuscular Center, Basel University Hospital, University Basel, Petersgraben 4, 4000, Basel, Switzerland, alexander.grimm@usb.ch.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Décard</LastName>
            <ForeName>Bernhard F</ForeName>
            <Initials>BF</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Athanasopoulou</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Schweikert</LastName>
            <ForeName>Kathi</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sinnreich</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Axer</LastName>
            <ForeName>Hubertus</ForeName>
            <Initials>H</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <DataBankList CompleteYN="Y">
        <DataBank>
            <DataBankName>DRKS</DataBankName>
            <AccessionNumberList>
                <AccessionNumber>DRKS0005253</AccessionNumber>
            </AccessionNumberList>
        </DataBank>
    </DataBankList>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2015</Year>
        <Month>01</Month>
        <Day>28</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>J Neurol</MedlineTA>
    <NlmUniqueID>0423161</NlmUniqueID>
    <ISSNLinking>0340-5354</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002574" MajorTopicYN="N">Cervical Vertebrae</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011115" MajorTopicYN="N">Polyneuropathies</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013126" MajorTopicYN="N">Spinal Nerve Roots</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2014</Year>
        <Month>11</Month>
        <Day>25</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2015</Year>
        <Month>01</Month>
        <Day>13</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2015</Year>
        <Month>01</Month>
        <Day>12</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>1</Month>
        <Day>29</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>1</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>1</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">25626722</ArticleId>
    <ArticleId IdType="doi">10.1007/s00415-015-7648-0</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Ultraschall Med. 2014 Oct;35(5):459-67</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24764211</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2009 Jul;40(1):98-102</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19533637</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 1991 Sep;14(9):869-71; discussion 867-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1922183</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2009 Dec;40(6):960-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19697380</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neurophysiol. 2008 Mar;119(3):497-503</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18164242</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Peripher Nerv Syst. 2013 Sep;18(3):232-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24028191</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroimaging. 2015 Mar-Apr;25(2):207-16</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24593005</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Peripher Nerv Syst. 2014 Jun;19(2):165-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24862982</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 1996 Feb;19(2):163-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8559164</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Peripher Nerv Syst. 2014 Sep;19(3):234-41</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25418824</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2012 May;45(5):730-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22499101</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11464847</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Neurol. 1988 Jul;24(1):73-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2843079</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2013 Jun;47(6):790-804</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23629869</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2014 Dec;50(6):976-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24634226</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neurophysiol. 2014 Jan;125(1):160-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24099922</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurol Sci. 1994 Jul;124 Suppl:96-107</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7807156</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroimmunol. 2001 Apr 2;115(1-2):4-18</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11282149</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurology. 2005 Jul 26;65(2):305-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16043806</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neuromuscul Disord. 2012 Jul;22(7):627-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22513319</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurology. 2006 Jul 25;67(2):280-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16864821</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurol Sci. 2014 Dec 15;347(1-2):44-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25262016</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2013 Mar;47(3):443-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23281131</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2011 Sep;44(3):346-51</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21815172</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neurol Neurosurg. 2010 Feb;112(2):103-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19931253</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurology. 1995 Aug;45(8):1570-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7644057</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Ultrasound. 2002 Sep;30(7):433-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12210462</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurology. 1997 May;48(5):1218-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9153446</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Neurol. 2011 Oct 11;7(11):639-49</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21989247</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neurophysiol. 2015 Apr;126(4):820-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25204706</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2011 Dec;44(6):862-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22102454</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1277-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25209417</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurol. 2013 Dec;260(12 ):3115-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24101129</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2007 Mar;35(3):379-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17058272</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neurophysiol. 2014 Sep;125(9):1906-11</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24657162</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 2013 Apr;73(5):397-406</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23516024</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>AJR Am J Roentgenol. 2002 Jun;178(6):1553-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12034637</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Neurophysiol. 2013 Sep;124(9):1881-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23583024</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Muscle Nerve. 2013 Mar;47(3):385-95</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23381770</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Peripher Nerv Syst. 2010 Dec;15(4):295-301</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21199100</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
<PMID Version="1">25610552</PMID>
<DateCompleted>
    <Year>2015</Year>
    <Month>01</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>10</Month>
    <Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Print">2008-5117</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2014</Year>
            </PubDate>
        </JournalIssue>
        <Title>Journal of cardiovascular and thoracic research</Title>
        <ISOAbbreviation>J Cardiovasc Thorac Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Effect of peripheral edema on oscillometric blood pressure measurement.</ArticleTitle>
    <Pagination>
        <MedlinePgn>217-21</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.15171/jcvtr.2014.015</ELocationID>
    <Abstract>
        <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Blood pressure (BP) measurement is essential for epidemiological studies and clinical decisions. It seems that tissue characteristics can affect BP results and we try to find edema effect on BP results taken by different methods.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">BP of 55 children before open heart surgery were measured and compared according to three methods: Arterial as standard and reference, oscillometric and auscultatory methods. Peripheral edema as a tissue characteristic was defined in higher than +2 as marked edema and in equal or lower than +2 as no edema.</AbstractText>
        <AbstractText Label="STATISTICAL ANALYSES" NlmCategory="METHODS">data was expressed as Mean and 95% of confidence interval (CI 95%). Comparison of two groups was performed by T independent test and of more than two groups by ANOVA test. Mann-Whitney U and paired T-test were used for serially comparisons of changes. P less than 0.05 was considered significant.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty five children aged 29.4±3.9 months were divided into two groups: 10 children with peripheral edema beyond +2 and 45 cases without edema. Oscillometric method overestimated systolic BP and the Mean (CI 95%) difference of oscillometric to arterial was 4.8 (8/-1, P=0.02) in edematous and 4.2 (7/1, p=0.004) in non edematous. Oscillometric method underestimated diastolic BP as -9 (-1.8/-16.5, P=0.03) in edematous group and 2.6 (-0.7/+5, P= 0.2) in non edematous compared to arterial method.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Oscillometric device standards cannot cover all specific clinical conditions. It underestimates diastolic BP significantly in edematous children, which was 9.2 mmHg in average beyond the acceptable standards.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ghaffari</LastName>
            <ForeName>Shamsi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Malaki</LastName>
            <ForeName>Majid</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rezaeifar</LastName>
            <ForeName>Afshin</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Abdollahi Fakhim</LastName>
            <ForeName>Shahin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Otorhinolaryngology, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2014</Year>
        <Month>12</Month>
        <Day>30</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Iran</Country>
    <MedlineTA>J Cardiovasc Thorac Res</MedlineTA>
    <NlmUniqueID>101528712</NlmUniqueID>
    <ISSNLinking>2008-5117</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">Auscultatory</Keyword>
    <Keyword MajorTopicYN="N">Blood Pressure</Keyword>
    <Keyword MajorTopicYN="N">Edema</Keyword>
    <Keyword MajorTopicYN="N">Oscillometric</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2014</Year>
        <Month>09</Month>
        <Day>21</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2014</Year>
        <Month>12</Month>
        <Day>12</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2015</Year>
        <Month>1</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2015</Year>
        <Month>1</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2015</Year>
        <Month>1</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">25610552</ArticleId>
    <ArticleId IdType="doi">10.15171/jcvtr.2014.015</ArticleId>
    <ArticleId IdType="pmc">PMC4291599</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Arch Pediatr Adolesc Med. 2001 Jan;155(1):50-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11177062</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1987 Jan;79(1):1-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3797155</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Paediatr Anaesth. 2009 Nov;19(11):1048-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19796350</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int J Rheumatol. 2012;2012:590845</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22518163</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Eng Phys. 2011 Dec;33(10 ):1287-92</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21752691</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press Monit. 2007 Dec;12(6):377-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18277314</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press Monit. 2006 Feb;11(1):27-32</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16410738</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Cardiol. 2010 Aug 1;106(3):386-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20643251</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Paediatr Child Health. 2000 Feb;36(1):41-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10723690</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>East Mediterr Health J. 2005 Sep-Nov;11(5-6):968-76</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16761667</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):956-63</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17143128</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press Monit. 2001 Dec;6(6):287-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12055403</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Angiology. 2006 Jan-Feb;57(1):41-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16444455</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 2000 Feb;28(2):371-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10708169</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press Monit. 2002 Dec;7(6):319-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12488652</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1993 Nov;88(5 Pt 1):2460-70</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8222141</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hypertens. 1991 Feb;9(2):109-14</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1849524</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2011 Jun;24(6):628-34</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21350431</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Blood Press Res. 2008;31(1):63-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18259097</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">25539576</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>08</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1472-6882</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <PubDate>
                <Year>2014</Year>
                <Month>Dec</Month>
                <Day>23</Day>
            </PubDate>
        </JournalIssue>
        <Title>BMC complementary and alternative medicine</Title>
        <ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Chemical composition, antinociceptive, anti-inflammatory and redox properties in vitro of the essential oil from Remirea maritima Aubl. (Cyperaceae).</ArticleTitle>
    <Pagination>
        <MedlinePgn>514</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-514</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present study was carried out to evaluate antioxidant, antinociceptive and anti-inflammatory activities of essential oil from R. maritima (RMO) in experimental protocols.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">The essential oil from the roots and rhizomes of RMO were obtained by hydrodistillation using a Clevenger apparatus, and analyzed by gas chromatography/mass spectrometry (GC/MS). Here, we evaluated free radical scavenging activities and antioxidant potential of RMO using in vitro assays for scavenging activity against hydroxyl radicals, hydrogen peroxide, superoxide radicals, and nitric oxide. The total reactive antioxidant potential (TRAP) and total antioxidant reactivity (TAR) indexes and in vitro lipoperoxidation were also evaluated. The ability of RMO to prevent lipid peroxidation was measured by quantifying thiobarbituric acid-reactive substances (TBARS). NO radical generated at physiological pH was found to be inhibited by RMO, that showed scavenging effect upon SNP-induced NO production at all concentrations. Antinociceptive and anti-inflammatory properties were evaluated by acetic acid writhing reflex, Formalin-induced nociception and Carrageenan-induced edema test.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The majors compounds identified was remirol (43.2%), cyperene (13.8%), iso-evodionol (5.8%), cyperotundone (5.7%), caryophyllene oxide (4.9%), and rotundene (4.6%). At the TRAP assay, RMO concentration of 1 mg.mL(-1) showed anti-oxidant effects and at concentration of 1 and 10 ng.mL(-1) RMO showed pro-oxidant effect. RMO at 1 mg.mL(-1) also showed significant anti-oxidant capacity in TAR measurement. Concentrations of RMO from 1 ng.mL(-1) to 100 μg.mL(-1) enhanced the AAPH-induced lipoperoxidation. RMO reduced deoxyribose oxidative damage, induced by the Fenton reaction induction system, at concentrations from 1 ng.mL(-1) to 100 μg.mL(-1). We observed that RMO caused a significant increase in rate of adrenaline auto-oxidation. On the other hand RMO did not present any scavenging effect in H2O2 formation in vitro. The results of this study revealed that RMO has both peripheral and central analgesic properties. The RMO, all doses, orally (p.o.) administered significantly inhibited (p &lt; 0.05, p &lt; 0.01 and p &lt; 0.001) the acetic acid-induced writhings and two phases of formalin-induced nociception in mice.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The RMO demonstrated antioxidant and analgesic profile which may be related to the composition of the oil.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Rabelo</LastName>
            <ForeName>Alessandra Silva</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. alessandrarabelo@hotmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Serafini</LastName>
            <ForeName>Mairim Russo</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. maiserafini@hotmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rabelo</LastName>
            <ForeName>Thallita Kelly</ForeName>
            <Initials>TK</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. thallitarabelo@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>de Melo</LastName>
            <ForeName>Marcelia Garcez Dória</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. marceliagdmelo@bol.com.br.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>da Silva Prado</LastName>
            <ForeName>Douglas</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. maiserafini@gmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gelain</LastName>
            <ForeName>Daniel Pens</ForeName>
            <Initials>DP</Initials>
            <AffiliationInfo>
                <Affiliation>Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, 13083-970, Porto Alegre, Rio Grande do Sul, Brazil. dgelain@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Moreira</LastName>
            <ForeName>José Claudio Fonseca</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
                <Affiliation>Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, 13083-970, Porto Alegre, Rio Grande do Sul, Brazil. 00006866@ufrgs.br.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>dos Santos Bezerra</LastName>
            <ForeName>Marília</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. lilinhabezerra@hotmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>da Silva</LastName>
            <ForeName>Thanany Brasil</ForeName>
            <Initials>TB</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Pesquisa em Química Orgânica de Sergipe (LABORGANICS), Departamento de Química, Universidade Federal de Sergipe, 49100-000, São Cristóvão, Sergipe, Brazil. gmartesanato@hotmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Costa</LastName>
            <ForeName>Emmanoel Vilaça</ForeName>
            <Initials>EV</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Pesquisa em Química Orgânica de Sergipe (LABORGANICS), Departamento de Química, Universidade Federal de Sergipe, 49100-000, São Cristóvão, Sergipe, Brazil. lucindoju@hotmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>de Lima Nogueira</LastName>
            <ForeName>Paulo Cesar</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Pesquisa em Química Orgânica de Sergipe (LABORGANICS), Departamento de Química, Universidade Federal de Sergipe, 49100-000, São Cristóvão, Sergipe, Brazil. pclimanog@yahoo.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>de Souza Moraes</LastName>
            <ForeName>Valéria Regina</ForeName>
            <Initials>VR</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Pesquisa em Química Orgânica de Sergipe (LABORGANICS), Departamento de Química, Universidade Federal de Sergipe, 49100-000, São Cristóvão, Sergipe, Brazil. left.ufs@hotmail.com.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>do Nascimento Prata</LastName>
            <ForeName>Ana Paula</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Sistemática Vegetal, Departamento de Biologia, Universidade Federal de Sergipe, 49100-000, São Cristóvão, Sergipe, Brazil. adrianoasa7@2001.com.br.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Quintans</LastName>
            <ForeName>Lucindo José</ForeName>
            <Initials>LJ</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. lucindo_junior@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Araújo</LastName>
            <ForeName>Adriano Antunes Souza</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratório de Ensaios Farmacêuticos e Toxicidade, Universidade Federal de Sergipe (LeFT/UFS), 49100-000, São Cristóvão, Sergipe, Brazil. adriasa2001@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2014</Year>
        <Month>12</Month>
        <Day>23</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>BMC Complement Altern Med</MedlineTA>
    <NlmUniqueID>101088661</NlmUniqueID>
    <ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D009822">Oils, Volatile</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010938">Plant Oils</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.15.1.1</RegistryNumber>
        <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D029785" MajorTopicYN="N">Cyperaceae</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008401" MajorTopicYN="N">Gas Chromatography-Mass Spectrometry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009822" MajorTopicYN="N">Oils, Volatile</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010938" MajorTopicYN="N">Plant Oils</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2013</Year>
        <Month>11</Month>
        <Day>05</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2014</Year>
        <Month>12</Month>
        <Day>10</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2014</Year>
        <Month>12</Month>
        <Day>26</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2014</Year>
        <Month>12</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>8</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">25539576</ArticleId>
    <ArticleId IdType="doi">10.1186/1472-6882-14-514</ArticleId>
    <ArticleId IdType="pii">1472-6882-14-514</ArticleId>
    <ArticleId IdType="pmc">PMC4528852</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Phytother Res. 2007 Apr;21(4):308-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17199238</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Soc Exp Biol Med. 1962 Dec;111:544-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14001233</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Phytother Res. 2006 Oct;20(10):896-900</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16909442</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Ethnopharmacol. 2007 Apr 4;110(3):526-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17097249</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Clin Nutr. 1993 Nov;47(11):759-64</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8287845</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Free Radic Res Commun. 1992;17(5):299-311</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1483581</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Chromatogr. 1963 Aug;11:463-71</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14062605</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biol Pharm Bull. 2007 Aug;30(8):1488-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17666809</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Food Chem Toxicol. 2008 Feb;46(2):446-75</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17996351</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anal Biochem. 2009 Feb 1;385(1):107-14</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19027710</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Magn Reson Chem. 2009 Jun;47(6):527-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19288546</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Food Chem Toxicol. 2009 Sep;47(9):2338-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19540900</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Orofac Pain. 2010 Summer;24(3):305-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20664833</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Basic Clin Pharmacol Toxicol. 2010 Dec;107(6):949-57</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20849525</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Toxicol In Vitro. 2011 Mar;25(2):462-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21111802</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Med Food. 2011 Oct;14(10):1159-66</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21548805</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Med Food. 2011 Nov;14(11):1389-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21663477</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Ethnopharmacol. 2013 Jan 9;145(1):11-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23123264</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Pharmacol. 1980 Jan 11;61(1):17-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7353582</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Methods Enzymol. 1984;105:121-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6727660</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Fed Proc. 1987 Jan;46(1):118-26</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3100339</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pain. 1987 Jul;30(1):103-14</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3614974</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Methods Enzymol. 1990;186:1-85</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2172697</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Methods Enzymol. 1990;186:421-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2233309</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pain. 1990 Aug;42(2):235-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2247320</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biochem Pharmacol. 1992 Jul 22;44(2):205-14</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1322662</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pain. 1992 Oct;51(1):5-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1454405</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Life Sci. 2006 Mar 27;78(18):2033-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16487545</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">25293500</PMID>
<DateCompleted>
    <Year>2016</Year>
    <Month>05</Month>
    <Day>25</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1756-185X</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2015</Year>
                <Month>Jul</Month>
            </PubDate>
        </JournalIssue>
        <Title>International journal of rheumatic diseases</Title>
        <ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Correlation of structural abnormalities of the wrist and metacarpophalangeal joints evaluated by high-resolution peripheral quantitative computed tomography, 3 Tesla magnetic resonance imaging and conventional radiographs in rheumatoid arthritis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>628-39</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.12495</ELocationID>
    <Abstract>
        <AbstractText Label="AIM" NlmCategory="OBJECTIVE">In rheumatoid arthritis (RA) hands, we applied high-resolution peripheral quantitative computed tomography (HR-pQCT) and 3 Tesla (3 T) magnetic resonance imaging (MRI), which are new methods for erosion detection and bone marrow edema (BME) quantification. We compared the erosion measurements between these techniques with conventional radiographs (CR) in order to examine their significance for evaluating structural abnormalities.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">In 16 RA patients, HR-pQCT of metacarpophalangeal and wrist joints, 3 T MRI of wrist joints, as well as CR in both hands and feet were performed. Ten patients had 1-year follow-up CR. CRs were graded according to the modified Sharp score (MSS). Bone erosions were evaluated in HR-pQCT and MRI. BME pattern was quantified from MRI for volume, signal change and total burden.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The erosion detection sensitivity of MRI was 85.7% and CR was 60.9% when HR-pQCT was considered as a reference method. The smallest dimensions of erosion detected by HR-pQCT, MRI and CR were 0.09, 0.14 and 0.66 cm, respectively. Baseline total MSS was correlated with HR-pQCT erosion measures, MRI erosion measures and MRI BME volume (P &lt; 0.05). The mean difference between baseline and 1-year follow-up MSS (delta MSS) was 1.2. A trend was observed toward a correlation between delta MSS and MRI BME volume and burden.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates that HR-pQCT detects more and smaller bone erosions compared to MRI and CR. In addition, 3 T MRI can provide quantitative measurement of BME. Combination of HR-pQCT and MRI modalities may provide powerful tools to evaluate joint inflammation and bone damage in RA.</AbstractText>
        <CopyrightInformation>© 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Chan Hee</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Division of Rheumatology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang-si, South Korea.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Srikhum</LastName>
            <ForeName>Waraporn</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Radiology, Thammasat University, Pathumthani, Thailand.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Burghardt</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Virayavanich</LastName>
            <ForeName>Warapat</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Department of Radiology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Imboden</LastName>
            <ForeName>John B</ForeName>
            <Initials>JB</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medicine, University of California, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
                <Affiliation>Division of Rheumatology, San Francisco General Hospital, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Link</LastName>
            <ForeName>Thomas M</ForeName>
            <Initials>TM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaojuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2014</Year>
        <Month>10</Month>
        <Day>08</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Int J Rheum Dis</MedlineTA>
    <NlmUniqueID>101474930</NlmUniqueID>
    <ISSNLinking>1756-1841</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001855" MajorTopicYN="N">Bone Marrow Diseases</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008662" MajorTopicYN="N">Metacarpophalangeal Joint</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014057" MajorTopicYN="Y">Tomography, X-Ray Computed</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014955" MajorTopicYN="N">Wrist Joint</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">3 Tesla magnetic resonance imaging</Keyword>
    <Keyword MajorTopicYN="N">conventional radiograph</Keyword>
    <Keyword MajorTopicYN="N">erosion</Keyword>
    <Keyword MajorTopicYN="N">high-resolution peripheral quantitative computed tomography</Keyword>
    <Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2014</Year>
        <Month>10</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2014</Year>
        <Month>10</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2016</Year>
        <Month>5</Month>
        <Day>26</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">25293500</ArticleId>
    <ArticleId IdType="doi">10.1111/1756-185X.12495</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
<PMID Version="1">25225586</PMID>
<DateCompleted>
    <Year>2014</Year>
    <Month>09</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>04</Month>
    <Day>08</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1920-8642</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2014</Year>
            </PubDate>
        </JournalIssue>
        <Title>World journal of emergency medicine</Title>
        <ISOAbbreviation>World J Emerg Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Risk assessment of ischemic stroke associated pneumonia.</ArticleTitle>
    <Pagination>
        <MedlinePgn>209-13</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.5847/wjem.j.1920-8642.2014.03.009</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cerebral stroke is a disease with a high disability rate and a high fatality rate. This study was undertaken to assess the risk of stroke associated pneumonia (SAP) in patients with ischemic stroke using A2DS2 score.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Altogether 1 279 patients with ischemic stroke who were treated in our department from 2009 to 2011 were retrospectively analyzed with A2DS2 score. A2DS2 score was calculated as follows: age ≥75 years=1, atrial fibrillation=1, dysphagia=2, male sex=1; stroke severity: NIHSS score 0-4=0, 5-15=3, ≥16=5. The patients were divided into three groups according to A2DS2 score: 620 in score 0 group, 383 in score 1-9 group, and 276 in score ≥10 group. The three groups were comparatively analyzed. The diagnostic criteria for SAP were as follows: newly emerging lesions or progressively infiltrating lesions on post-stroke chest images combined with more than two of the following clinical symptoms of infection: (1) fever ≥38 °C; (2) newly occurred cough, productive cough or exacerbation of preexisting respiratory tract symptoms with or without chest pain; (3) signs of pulmonary consolidation and/or wet rales; (4) peripheral white blood cell count ≥10×10(9)/L or ≤4×10(9)/L with or without nuclear shift to left, while excluding some diseases with clinical manifestations similar to pneumonia, such as tuberculosis, pulmonary tumors, non-infectious interstitial lung disease, pulmonary edema, pulmonary embolism and atelectasis. The incidence and mortality of SAP as well as the correlation with ischemic stroke site were analyzed in the three groups respectively. Mean± standard deviation was used to represent measurement data with normal distribution and Student's t test was used. The chi-square test was used to calculate the percentage for enumeration data.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of SAP was significantly higher in the A2DS2 score≥10 group than that in the score 1-9 and score 0 groups (71.7% vs. 22.7%, 71.7% vs. 3.7%, respectively), whereas the mortality in the score≥10 group was significantly higher than that in the score 1-9 and score 0 groups (16.7% vs. 4.96%, 16.7% vs. 0.3%, respectively). The incidences of cerebral infarction in posterior circulation and cross-MCA, ACA distribution areas were significantly higher than those in the SAP group and in the non-SAP group (35.1% vs.10.1%, 11.4% vs. 7.5%, respectively). The incidence of non-fermentative bacteria infection was significantly increased in the score≥10 group.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A2DS2 score provides a basis for risk stratification of SAP. The prevention of SAP needs to be strengthened in acute ischemic stroke patients with a A2DS2 score≥10.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurology, Wuhan Central Hospital, Wuhan 430014, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lin-Hong</ForeName>
            <Initials>LH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurology, Wuhan Central Hospital, Wuhan 430014, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Wu-Ping</ForeName>
            <Initials>WP</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurology, Wuhan Central Hospital, Wuhan 430014, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Jun-Min</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurology, Wuhan Central Hospital, Wuhan 430014, China.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>China</Country>
    <MedlineTA>World J Emerg Med</MedlineTA>
    <NlmUniqueID>101549691</NlmUniqueID>
    <ISSNLinking>1920-8642</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
    <Keyword MajorTopicYN="N">A2DS2 scoring tool</Keyword>
    <Keyword MajorTopicYN="N">Function of deglutition</Keyword>
    <Keyword MajorTopicYN="N">Ischemic stroke</Keyword>
    <Keyword MajorTopicYN="N">Location of ischemic stroke</Keyword>
    <Keyword MajorTopicYN="N">NIHSS scoring</Keyword>
    <Keyword MajorTopicYN="N">Non-fermentative bacteria</Keyword>
    <Keyword MajorTopicYN="N">Risk stratification</Keyword>
    <Keyword MajorTopicYN="N">Stroke associated pneumonia</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2014</Year>
        <Month>02</Month>
        <Day>13</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2014</Year>
        <Month>06</Month>
        <Day>16</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2014</Year>
        <Month>9</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2014</Year>
        <Month>9</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2014</Year>
        <Month>9</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">25225586</ArticleId>
    <ArticleId IdType="doi">10.5847/wjem.j.issn.1920-8642.2014.03.009</ArticleId>
    <ArticleId IdType="pii">wjem-5-209</ArticleId>
    <ArticleId IdType="pmc">PMC4163809</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1225-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23024353</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Oral Rehabil. 2013 Jun;40(6):472-80</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23607530</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int J Antimicrob Agents. 2011 Jan;37(1):10-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20869853</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurol. 2007 Oct;254(10):1323-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17361338</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Zhonghua Nan Ke Xue. 2009 Jan;15(1):60-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19288753</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Physiol Sci. 2014 Jan;64(1):65-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24142459</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurology. 2003 Feb 25;60(4):620-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12601102</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Zhonghua Nei Ke Za Zhi. 2011 Mar;50(3):191-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21600078</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 2012 Oct;43(10):2617-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22798325</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Diet Assoc. 2003 Mar;103(3):381-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12616266</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 2007 Feb;38(2 Suppl):770-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17261736</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet Neurol. 2008 Apr;7(4):341-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18339349</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurology. 2007 May 29;68(22):1938-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17536051</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">24846392</PMID>
<DateCompleted>
    <Year>2015</Year>
    <Month>01</Month>
    <Day>15</Day>
</DateCompleted>
<DateRevised>
    <Year>2014</Year>
    <Month>06</Month>
    <Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1361-6579</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2014</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Physiological measurement</Title>
        <ISOAbbreviation>Physiol Meas</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Bioelectrical impedance spectroscopy as a fluid management system in heart failure.</ArticleTitle>
    <Pagination>
        <MedlinePgn>917-30</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1088/0967-3334/35/6/917</ELocationID>
    <Abstract>
        <AbstractText>Episodes of hospitalization for heart failure patients are frequent and are often accompanied by fluid accumulations. The change of the body impedance, measured by bioimpendace spectroscopy, is an indicator of the water content. The hypothesis was that it is possible to detect edema from the impedance data. First, a finite integration technique was applied to test the feasibility and allowed a theoretical analysis of current flows through the body. Based on the results of the simulations, a clinical study was designed and conducted. The segmental impedances of 25 patients suffering from heart failure were monitored over their recompensation process. The mean age of the patients was 73.8 and their mean body mass index was 28.6. From these raw data the model parameters from the Cole model were deduced by an automatic fitting algorithm. These model data were used to classify the edema status of the patient. The baseline values of the regression lines of the extra- and intracellular resistance from the transthoracic measurement and the baseline value of the regression line of the extracellular resistance from the foot-to-foot measurement were identified as important parameters for the detection of peripheral edema. The rate of change of the imaginary impedance at the characteristic frequency and the mean intracellular resistance from the foot-to-foot measurement were identified as important parameters for the detection of pulmonary edema. To classify the data, two decision trees were considered: One should detect pulmonary edema (n(pulmonary) = 13, n(none) = 12) and the other peripheral edema (n(peripheral) = 12, n(none) = 13). Peripheral edema could be detected with a sensitivity of 100% and a specificity of 90%. The detection of pulmonary edema showed a sensitivity of 92.31% and a specificity of 100%. The leave-one-out cross-validation-error for the peripheral edema detection was 12% and 8% for the detection of pulmonary edema. This enables the application of BIS as an early warning system for cardiac decompensation with the potential to optimize patient care.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Weyer</LastName>
            <ForeName>Sören</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Philips Chair of Medical Information Technology, RWTH Aachen University, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zink</LastName>
            <ForeName>Matthias Daniel</ForeName>
            <Initials>MD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wartzek</LastName>
            <ForeName>Tobias</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Leicht</LastName>
            <ForeName>Lennart</ForeName>
            <Initials>L</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mischke</LastName>
            <ForeName>Karl</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vollmer</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Leonhardt</LastName>
            <ForeName>Steffen</ForeName>
            <Initials>S</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2014</Year>
        <Month>05</Month>
        <Day>20</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Physiol Meas</MedlineTA>
    <NlmUniqueID>9306921</NlmUniqueID>
    <ISSNLinking>0967-3334</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>114471-18-0</RegistryNumber>
        <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001826" MajorTopicYN="N">Body Fluids</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003663" MajorTopicYN="N">Decision Trees</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D058266" MajorTopicYN="N">Dielectric Spectroscopy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017097" MajorTopicYN="N">Electric Impedance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004566" MajorTopicYN="N">Electrodes</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2014</Year>
        <Month>5</Month>
        <Day>22</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2014</Year>
        <Month>5</Month>
        <Day>23</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2015</Year>
        <Month>1</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">24846392</ArticleId>
    <ArticleId IdType="doi">10.1088/0967-3334/35/6/917</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23588112</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>10</Month>
    <Day>28</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>07</Month>
    <Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1097-6809</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>58</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2013</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of vascular surgery</Title>
        <ISOAbbreviation>J Vasc Surg</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The influence of patient and wound variables on healing of venous leg ulcers in a randomized controlled trial of growth-arrested allogeneic keratinocytes and fibroblasts.</ArticleTitle>
    <Pagination>
        <MedlinePgn>433-9</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvs.2012.12.055</ELocationID>
    <ELocationID EIdType="pii" ValidYN="Y">S0741-5214(13)00063-3</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine patient and wound variables presumed to influence healing outcomes in the context of therapeutic trials for chronic venous leg ulcers.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">This double-blind, vehicle-controlled study was conducted with randomized assignment to one of four cell therapy dose groups (n = 46, 43, 44, 45) or vehicle control (n = 50). A 2-week run-in period was used to exclude rapid healers and those with infection or uncontrolled edema. This was a multicenter (ambulatory, private, hospital-based and university-based practices, and wound care centers in North America) study. Adults ≥ 18 years old with chronic venous insufficiency associated with an uninfected venous leg ulcer (2-12 cm(2) area, 6-104 weeks' duration) were included in the study. Excluded were pregnant or lactating women, wounds with exposed muscle, tendon or bone, patients unable to tolerate compression bandages, or patients who had exclusionary medical conditions or exposure to certain products. Exclusion during run-in included patients with infection, uncontrolled severe edema or with healing rates ≥ 0.349 cm/2 wk. Screen fail rate was 37% (134/362), and the withdrawal rate was~10% (23 of 228). Growth-arrested neonatal dermal fibroblasts and keratinocytes were delivered via pump spray in a fibrin sealant-based matrix, plus a foam dressing and four-layer compression bandaging. Treatment continued for 12 weeks or until healed, whichever occurred first. Patient demographic and wound-related variables were evaluated for influence on complete wound healing in all patients, as well as the subsets of treated and control patients.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Wound duration (P = .004) and the presence of specific quantities of certain bacterial species (P &lt; .001) affected healing in the vehicle group, while healing in the cell-treated groups was influenced by wound duration (P = .012), wound area (P = .026), wound location (P = .011), and specific quantities of certain bacterial species (P = .002). Age, sex, race, diabetes, HbA1C, peripheral neuropathy, and serum prealbumin did not significantly affect healing. Body mass index was positively associated with healing in cell-treated patients.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Wound duration is a quantifiable surrogate for one or more undefined variables that can have a profound negative effect on venous leg ulcer healing. Although cell therapy overcame barriers to healing, the only specific barrier identified was the presence of certain bacterial species. Interventional trials of potentially effective new therapies can be most informative when patients with suspected barriers to healing are included. The specific measurement of candidate barriers such as microbial pathogens, wound inflammatory state, and fibroblast function should be considered in future randomized trials to improve our understanding of the basis for chronicity.</AbstractText>
        <CopyrightInformation>Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Lantis</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <Suffix>2nd</Suffix>
            <AffiliationInfo>
                <Affiliation>Division of Vascular and Endovascular Surgery, St. Luke's Roosevelt Hospital Center, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Marston</LastName>
            <ForeName>William A</ForeName>
            <Initials>WA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Farber</LastName>
            <ForeName>Alik</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kirsner</LastName>
            <ForeName>Robert S</ForeName>
            <Initials>RS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuxin</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Tommy D</ForeName>
            <Initials>TD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cargill</LastName>
            <ForeName>D Innes</ForeName>
            <Initials>DI</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Slade</LastName>
            <ForeName>Herbert B</ForeName>
            <Initials>HB</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016448">Multicenter Study</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2013</Year>
        <Month>04</Month>
        <Day>12</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Vasc Surg</MedlineTA>
    <NlmUniqueID>8407742</NlmUniqueID>
    <ISSNLinking>0741-5214</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015718">Fibrin Tissue Adhesive</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D059447" MajorTopicYN="Y">Cell Cycle Checkpoints</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D058128" MajorTopicYN="N">Compression Bandages</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003646" MajorTopicYN="N">Debridement</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015718" MajorTopicYN="N">Fibrin Tissue Adhesive</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
        <QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName>
        <QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009779" MajorTopicYN="N">Occlusive Dressings</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014647" MajorTopicYN="N">Varicose Ulcer</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014689" MajorTopicYN="N">Venous Insufficiency</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014946" MajorTopicYN="N">Wound Infection</DescriptorName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2012</Year>
        <Month>09</Month>
        <Day>21</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>13</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2012</Year>
        <Month>12</Month>
        <Day>22</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2013</Year>
        <Month>4</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2013</Year>
        <Month>4</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>10</Month>
        <Day>29</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23588112</ArticleId>
    <ArticleId IdType="pii">S0741-5214(13)00063-3</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jvs.2012.12.055</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23448451</PMID>
<DateCompleted>
    <Year>2014</Year>
    <Month>04</Month>
    <Day>01</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1873-4286</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>33</Issue>
            <PubDate>
                <Year>2013</Year>
            </PubDate>
        </JournalIssue>
        <Title>Current pharmaceutical design</Title>
        <ISOAbbreviation>Curr Pharm Des</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Anderson-Fabry disease: a multiorgan disease.</ArticleTitle>
    <Pagination>
        <MedlinePgn>5974-96</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A. FD causes glycolipids, such as globotriaosylceramide (Gb3), to accumulate in the vascular endothelium of several organs (Fig. 2), including the skin, kidneys, nervous system, and heart, thereby triggering inflammation and fibrosis. These processes generally result in organ dysfunction, which is usually the first clinical evidence of FD. Patients with classic FD have various symptoms, eg, acroparesthesias, hypohidrosis, angiokeratomas, corneal opacities, cerebrovascular lesions, cardiac disorders, andrenal dysfunction.However, evolving knowledge about the natural course of disease suggests that it is more appropriate to describe FD as a disease with a wide spectrum of heterogeneously progressive clinical phenotypes. Indeed, most female heterozygotes develop symptoms due to yet undetermined mechanisms and a high percentage of females develops vital organ involvement including the kidneys, heart and/or brain about a decade later than males. Renal failure is a serious complication of this disease. Fabry nephropathy lesions are present and progress in childhood while the disease commonly remains silent by routine clinical measures. Early and timely diagnosis of Fabry nephropathy is crucial since late initiation of enzyme replacement therapy may not halt progressive renal dysfunction. This may be challenging due to difficulties in diagnosis of Fabry disease in children and absence of a sensitive non-invasive biomarker of early Fabry nephropathy. Accurate measurement of glomerular filtration rate and regular assessment for proteinuria and microalbuminuria are useful, though not sensitive enough to detect early lesions in the kidney. The principal clinical manifestations in Fabry disease consist of artery associated complications (such as cerebral disease and nephropathy), but the pathophysiology of this specific vasculopathy is unclear. Several studies indicate that the specific vascular lesions that are present in Fabry disease occur as a result of vascular dysfunction with major components being endothelial dysfunction, alterations in cerebral perfusion and a pro-thrombotic phenotype. Fabry cardiac involvement has several clinical manifestations (Table 10): concentric left ventricular hypertrophy without left ventricular dilation and severe loss of left ventricular systolic function, mitral and aortic valvulopathy, disorders of the atrioventricular conduction or repolarization, and compromised diastolic function. The neurological manifestations of Fabry disease include both peripheral nervous system and CNS involvement, with globotriaosylceramide accumulation found in Schwann cells and dorsal root ganglia together with deposits in CNS neurones. The main involvement of the CNS is attributable to cerebrovasculopathy, with an increased incidence of stroke. The abnormal neuronal accumulation of glycosphingolipid appears to have little clinical effect on the natural history of Fabry disease, with the possible exception of some reported mild cognitive abnormalities. The pathogenesis of Fabry vasculopathy remains poorly understood, but probably relates, in part, to abnormal functional control of the vessels, secondary to endothelial dysfunction as a consequence of α-galactosidase A deficiency. The diagnosis of Fabry disease is made in hemizygous males after the detection of the presence of angiokeratomas (Fig. 19 A, B), irregularities in sweating, edema, scant body hair, painful sensations, and of cardiovascular, intestinal, renal, ophthalmologic, phlebologic, and respiratory involvement. A deficiency of alpha-gal A in serum, leukocytes, tears, tissue specimens, or cultured skin fibroblasts further supports the diagnosis in male patients. Since heterozygous women show angiokeratomas in only about 30% of cases and may have alpha-gal A levels within normal range, genetic analysis is recommended. The resultant storage of undegraded glycolipids leads to the progressive development of potentially life-threatening manifestations affecting multiple organ systems in the body. The Mainz Severity Score Index (MSSI) (Table 12), a scoring system for patients with Fabry disease has been proven to be representative in patients with 'classic' Fabry disease and may be useful for monitoring clinical improvement in patients receiving enzyme replacement therapy. The MSSI of patients with AFD was significantly higher than that of patients with other severe debilitating diseases.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Tuttolomondo</LastName>
            <ForeName>Antonino</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Italy. bruno.tuttolomondo@unipa.it.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pecoraro</LastName>
            <ForeName>Rosaria</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Simonetta</LastName>
            <ForeName>Irene</ForeName>
            <Initials>I</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Miceli</LastName>
            <ForeName>Salvatore</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pinto</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Licata</LastName>
            <ForeName>Giuseppe</ForeName>
            <Initials>G</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United Arab Emirates</Country>
    <MedlineTA>Curr Pharm Des</MedlineTA>
    <NlmUniqueID>9602487</NlmUniqueID>
    <ISSNLinking>1381-6128</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList>
    <SupplMeshName Type="Disease" UI="C567062">Fabry Disease, Cardiac Variant</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D056947" MajorTopicYN="N">Enzyme Replacement Therapy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000795" MajorTopicYN="N">Fabry Disease</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>16</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2013</Year>
        <Month>02</Month>
        <Day>15</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2013</Year>
        <Month>3</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2013</Year>
        <Month>3</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2014</Year>
        <Month>4</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23448451</ArticleId>
    <ArticleId IdType="pii">CPD-EPUB-20130219-14</ArticleId>
    <ArticleId IdType="doi">10.2174/13816128113199990352</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23418386</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>10</Month>
    <Day>29</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Print">0315-162X</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2013</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>The Journal of rheumatology</Title>
        <ISOAbbreviation>J Rheumatol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Quantitative and semiquantitative bone erosion assessment on high-resolution peripheral quantitative computed tomography in rheumatoid arthritis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>408-16</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.120780</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To develop novel quantitative and semiquantitative bone erosion measures at metacarpophalangeal (MCP) and wrist joints in patients with rheumatoid arthritis (RA) using high-resolution peripheral quantitative computed tomography (HR-pQCT), and to correlate these measurements with disease duration and bone marrow edema (BME) patterns derived from magnetic resonance imaging (MRI).</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Sixteen patients with RA and 7 healthy subjects underwent hand and wrist HR-pQCT and 3-Tesla MRI. Bone erosions of the MCP2, MCP3, and distal radius were evaluated by measuring maximal erosion dimension on axial slices, which is a simple and fast measurement, and then were graded (grades 0-3) based on the maximal dimension. Correlation coefficients were calculated between (1) sum maximal dimensions, highest grades, and sum grades of bone erosions; (2) erosion measures and the clinical evaluation; (3) erosion measures and BME volume in distal radius.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The inter- and intrareader agreements of maximal erosion dimensions were excellent (intraclass correlation coefficients 0.89, 0.99, and root mean square error 9.4%, 4.7%, respectively). Highest grades and sum grades were significantly correlated to sum maximal dimensions of all erosions. Number of erosions, sum maximal erosion dimensions, highest grades, and sum grades correlated significantly with disease duration. Number of erosions, sum maximal dimensions, and erosion grading of the distal radius correlated significantly with BME volume.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HR-pQCT provides a sensitive method with high reader agreement in assessment of structural bone damage in RA. The good correlation of erosion measures with disease duration as well as BME volume suggests that they could become feasible measures of erosions in RA.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Srikhum</LastName>
            <ForeName>Waraporn</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
                <Affiliation>Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, UCSF (University of California, San Francisco), CA, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Virayavanich</LastName>
            <ForeName>Warapat</ForeName>
            <Initials>W</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Burghardt</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Link</LastName>
            <ForeName>Thomas M</ForeName>
            <Initials>TM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Imboden</LastName>
            <ForeName>John B</ForeName>
            <Initials>JB</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaojuan</ForeName>
            <Initials>X</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2013</Year>
        <Month>02</Month>
        <Day>15</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Canada</Country>
    <MedlineTA>J Rheumatol</MedlineTA>
    <NlmUniqueID>7501984</NlmUniqueID>
    <ISSNLinking>0315-162X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
    <CommentsCorrections RefType="CommentIn">
        <RefSource>Nat Rev Rheumatol. 2013 Jul;9(7):385-6</RefSource>
        <PMID Version="1">23752941</PMID>
    </CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006225" MajorTopicYN="N">Hand</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011884" MajorTopicYN="N">Radius</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014955" MajorTopicYN="N">Wrist Joint</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2013</Year>
        <Month>2</Month>
        <Day>19</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2013</Year>
        <Month>2</Month>
        <Day>19</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>10</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23418386</ArticleId>
    <ArticleId IdType="pii">jrheum.120780</ArticleId>
    <ArticleId IdType="doi">10.3899/jrheum.120780</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23386736</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>05</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1600-0455</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2013</Year>
                <Month>Apr</Month>
                <Day>01</Day>
            </PubDate>
        </JournalIssue>
        <Title>Acta radiologica (Stockholm, Sweden : 1987)</Title>
        <ISOAbbreviation>Acta Radiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>MR imaging of primary sclerosing cholangitis: additional value of diffusion-weighted imaging and ADC measurement.</ArticleTitle>
    <Pagination>
        <MedlinePgn>242-8</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1177/0284185112471792</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Primary sclerosing cholangitis (PSC) is a cholestatic liver disease with chronic inflammation and progressive destruction of biliary tree. Magnetic resonance (MR) examination with diffusion-weighted imaging (DWI) allows analysis of morphological liver parenchymal changes and non-invasive assessment of liver fibrosis. Moreover, MR cholangiopancreatography (MRCP), as a part of standard MR protocol, provides insight into bile duct irregularities.</AbstractText>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate MR and MRCP findings in patients with primary sclerosing cholangitis and to determine the value of DWI in the assessment of liver fibrosis.</AbstractText>
        <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The following MR findings were reviewed in 38 patients: abnormalities in liver parenchyma signal intensity, changes in liver morphology, lymphadenopathy, signs of portal hypertension, and irregularities of intra- and extrahepatic bile ducts. Apparent diffusion coefficient (ADC) was calculated for six locations in the liver for b = 800 s/mm(2).</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">T2-weighted hyperintensity was seen as peripheral wedge-shaped areas in 42.1% and as periportal edema in 28.9% of patients. Increased enhancement of liver parenchyma on arterial-phase imaging was observed in six (15.8%) patients. Caudate lobe hypertrophy was present in 10 (26.3%), while spherical liver shape was noted in 7.9% of patients. Liver cirrhosis was seen in 34.2% of patients; the most common pattern was micronodular cirrhosis (61.5%). Other findings included lymphadenopathy (28.9%), signs of portal hypertension (36.7%), and bile duct irregularities (78.9%). The mean ADCs (x10(-3)mm(2)/s) were significantly different at stage I vs. stages III and IV, and stage II vs. stage IV. No significant difference was found between stages II and III. For prediction of stage ≥II and stage ≥III, areas under receiver-operating characteristic curves were 0.891 and 0.887, respectively.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MR with MRCP is a necessary diagnostic procedure for diagnosis of PSC and evaluation of disease severity. Moreover, DWI could be used in continuation with standard MR sequences for the evaluation of liver fibrosis stage and distribution.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kovač</LastName>
            <ForeName>Jelena Djokić</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
                <Affiliation>Center for Radiology and Magnetic Resonance Imaging, Clinical Center Serbia, Belgrade, Serbia. jelenadjokic2003@yahoo.co.uk</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ješić</LastName>
            <ForeName>Rada</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Stanisavljević</LastName>
            <ForeName>Dejana</ForeName>
            <Initials>D</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kovač</LastName>
            <ForeName>Bojan</ForeName>
            <Initials>B</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Maksimovic</LastName>
            <ForeName>Ružica</ForeName>
            <Initials>R</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2013</Year>
        <Month>02</Month>
        <Day>05</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Acta Radiol</MedlineTA>
    <NlmUniqueID>8706123</NlmUniqueID>
    <ISSNLinking>0284-1851</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015209" MajorTopicYN="N">Cholangitis, Sclerosing</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007090" MajorTopicYN="N">Image Interpretation, Computer-Assisted</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2013</Year>
        <Month>2</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2013</Year>
        <Month>2</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>5</Month>
        <Day>17</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23386736</ArticleId>
    <ArticleId IdType="pii">0284185112471792</ArticleId>
    <ArticleId IdType="doi">10.1177/0284185112471792</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23126349</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>04</Month>
    <Day>30</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>12</Month>
    <Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1751-7176</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>11</Issue>
            <PubDate>
                <Year>2012</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of clinical hypertension (Greenwich, Conn.)</Title>
        <ISOAbbreviation>J Clin Hypertens (Greenwich)</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.</ArticleTitle>
    <Pagination>
        <MedlinePgn>773-8</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1111/jch.12004</ELocationID>
    <Abstract>
        <AbstractText>Postmenopausal women are at greater risk for hypertension-related cardiovascular disease. Antihypertensive therapy may help alleviate arterial stiffness that represents a potential modifiable risk factor of hypertension. This randomized controlled study investigated the difference between an angiotensin receptor blocker and a calcium channel blocker in reducing arterial stiffness. Overall, 125 postmenopausal hypertensive women (age, 61.4 ± 6 years; systolic blood pressure/diastolic blood pressure [SBP/DBP], 158 ± 11/92 ± 9 mm Hg) were randomized to valsartan 320 mg ± hydrochlorothiazide (HCTZ) (n = 63) or amlodipine 10 mg ± HCTZ (n = 62). The primary outcome was carotid-to-femoral pulse wave velocity (PWV) changes after 38 weeks of treatment. Both treatments lowered peripheral blood pressure (BP) (-22.9/-10.9 mm Hg for valsartan and -25.2/-11.7 mm Hg for amlodipine, P = not significant) and central BP (-15.7/-7.6 mm Hg for valsartan and -19.2/-10.3 mm Hg for amlodipine, P&lt;.05 for central DBP). Both treatments similarly reduced the carotid-femoral PWV (-1.9 vs -1.7 m/s; P = not significant). Amlodipine was associated with a higher incidence of peripheral edema compared with the valsartan group (77% vs 14%, P&lt;.001). BP lowering in postmenopausal women led to a reduction in arterial stiffness as assessed by PWV measurement. Both regimens reduced PWV to a similar degree after 38 weeks of treatment despite differences in central BP lowering, suggesting that the effect of valsartan on PWV is mediated through nonhemodynamic effects.</AbstractText>
        <CopyrightInformation>© 2012 Wiley Periodicals, Inc.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Hayoz</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medicine, Hospital Cantonal Fribourg, Fribourg, Switzerland. hayozd@h-fr.ch</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zappe</LastName>
            <ForeName>Dion H</ForeName>
            <Initials>DH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Meyer</LastName>
            <ForeName>Marie A R</ForeName>
            <Initials>MA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Baek</LastName>
            <ForeName>Inyoung</ForeName>
            <Initials>I</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kandra</LastName>
            <ForeName>Albert</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Joly</LastName>
            <ForeName>Marie P</ForeName>
            <Initials>MP</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mazzolai</LastName>
            <ForeName>Lucia</ForeName>
            <Initials>L</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Haesler</LastName>
            <ForeName>Erik</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Periard</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2012</Year>
        <Month>09</Month>
        <Day>12</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Clin Hypertens (Greenwich)</MedlineTA>
    <NlmUniqueID>100888554</NlmUniqueID>
    <ISSNLinking>1524-6175</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>1J444QC288</RegistryNumber>
        <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>80M03YXJ7I</RegistryNumber>
        <NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>HG18B9YRS7</RegistryNumber>
        <NameOfSubstance UI="D014633">Valine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D063177" MajorTopicYN="Y">Pulse Wave Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName>
        <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000068756" MajorTopicYN="N">Valsartan</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D059289" MajorTopicYN="N">Vascular Stiffness</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>5</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23126349</ArticleId>
    <ArticleId IdType="doi">10.1111/jch.12004</ArticleId>
    <ArticleId IdType="pmc">PMC8108841</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Hypertens. 2007 Feb;25(2):415-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17211249</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Hypertens (Greenwich). 2007 Mar;9(3):168-78</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17341993</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hypertens Suppl. 1998 Jan;16(1):S17-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9534092</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 2009 Aug 18;54(8):705-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19679248</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2002 Apr;15(4 Pt 1):321-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11991217</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2002 Oct 15;106(16):2085-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12379578</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 1996 Mar 16;347(9003):714-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8602000</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1993 Nov;88(5 Pt 1):2460-70</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8222141</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2001 Oct;38(4):949-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11641315</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2008 Jun;51(6):1617-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18426991</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2005 Jul;46(1):244-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15911747</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hypertens. 2002 Nov;20(11):2165-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12409954</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2001 Mar;37(3):943-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11244022</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2004 Jan;17(1):82-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14700519</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press. 2004;13(5):272-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15545149</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2001 Nov;38(5):1049-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11711496</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1999 May 11;99(18):2434-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10318666</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2007 Jan;49(1):69-75</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17159087</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2004 Dec;17(12 Pt 2):39S-48S</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15607434</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Exp Pharmacol Physiol. 2005 Mar;32(3):210-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15743405</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Coll Cardiol. 1992 Oct;20(4):952-63</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1527307</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Menopause. 2006 Mar-Apr;13(2):265-79</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16645540</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2011 May;57(5):911-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21403086</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Exp Hypertens. 2008 Apr;30(3):267-76</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18425706</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ J. 2004 Dec;68(12):1194-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15564706</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2006 Nov;27(21):2588-605</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17000623</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hypertens. 2001 Dec;19(12):2205-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11725165</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2002 Jun 18;105(24):2817-20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12070106</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23114464</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>03</Month>
    <Day>14</Day>
</DateCompleted>
<DateRevised>
    <Year>2012</Year>
    <Month>11</Month>
    <Day>01</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1878-3619</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2012</Year>
            </PubDate>
        </JournalIssue>
        <Title>Bio-medical materials and engineering</Title>
        <ISOAbbreviation>Biomed Mater Eng</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Application of the laser Doppler flowmeter for measurement of blood pressure and functional parameters of microcirculation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>351-9</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.3233/BME-2012-0724</ELocationID>
    <Abstract>
        <AbstractText>The laser Doppler flowmeter has become an effective tool for the clinical study of microcirculation with non-invasive measurements and excellent velocity resolution. Microcirculation flow measurements cannot be used as reference criteria for circulation function. Thus, the relative change in fingertip microcirculation was measured through inflation and deflation of an automatic sphygmomanometer wrapped around the arm, and the blood pressure and functional parameters of circulation, such as biological zero (BZ), peak flow (PF) and time to peak flow (tp), were determined. For 50 healthy participants, the correlation coefficients for the laser Doppler flowmeter and oscillometric results were 0.950 and 0.838 for systolic and diastolic pressure, respectively. The mean and standard errors for both methods fell within the range specified in the Association for the Advancement of Medical Instrumentation standards. The BZ of an edema patient was about 5 times higher than normal. For patients with peripheral arterial occlusive disease (PAOD), the PF could not be determined, and the tp was about twice the normal value. The accuracy of blood pressure measurements using the laser Doppler flowmeter was comparable to that of the commonly used oscillometric sphygmomanometer, and the physiological circulation functional parameters were useful in identifying signs of edema and PAOD.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Chang-Lin</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Electrical Engineering, National Tsing Hua University, Hsinchu, Taiwan. hulong@itri.org.tw</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Zhan-Sheng</ForeName>
            <Initials>ZS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yen-Yu</ForeName>
            <Initials>YY</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Yuan-Hsiang</ForeName>
            <Initials>YH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Mei-Feng</ForeName>
            <Initials>MF</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Meng-Lin</ForeName>
            <Initials>ML</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Netherlands</Country>
    <MedlineTA>Biomed Mater Eng</MedlineTA>
    <NlmUniqueID>9104021</NlmUniqueID>
    <ISSNLinking>0959-2989</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList>
    <SupplMeshName Type="Disease" UI="C564658">Peripheral Arterial Occlusive Disease 1</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001157" MajorTopicYN="N">Arterial Occlusive Diseases</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017078" MajorTopicYN="N">Laser-Doppler Flowmetry</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008833" MajorTopicYN="Y">Microcirculation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D058729" MajorTopicYN="N">Peripheral Arterial Disease</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>3</Month>
        <Day>15</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23114464</ArticleId>
    <ArticleId IdType="pii">034N76170P041121</ArticleId>
    <ArticleId IdType="doi">10.3233/BME-2012-0724</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23106194</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>04</Month>
    <Day>23</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1556-9535</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2013</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Cutaneous and ocular toxicology</Title>
        <ISOAbbreviation>Cutan Ocul Toxicol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Endothelial cell damage following sulfur mustard exposure in rabbits and its association with the delayed-onset ocular lesions.</ArticleTitle>
    <Pagination>
        <MedlinePgn>115-23</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.3109/15569527.2012.717571</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Ocular injuries following exposure to the toxic agent sulfur mustard (SM) are characterized by acute corneal erosions and inflammation of the anterior segment that may be followed by delayed corneal injuries, expressed clinically by neovascularization and epithelial defects. The present study aimed to investigate the effects of SM on corneal endothelium (CE) during the acute and delayed phase in relation to the development of the long-term pathology.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Rabbit eyes were exposed to SM vapor. A clinical follow-up including pachymetry for measurement of corneal thickness were conducted up to 3 months following exposure. In vivo analysis of corneal endothelium in the central and peripheral cornea was carried out, using a contact specular microscopy. Morphometric analysis of cell area and number of cells was performed, to include the acute and delayed phases. Eyes were taken for histology at different time points following exposure (1 h to 3 months). TUNEL staining (Terminal deoxynucleotidyl transferase dUTP nick end labeling) was conducted for detection of apoptosis during the acute phase.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">SM induced acute corneal erosions and prolonged anterior segment inflammation. Corneal thickness increased within hours, declined after few days but remained higher compared to baseline value for months after the exposure, indicating a chronic edema. Apoptotic alterations were first observed at 6 h resulting in a significant decline in the number of endothelial cells at 24-48 h following exposure. Healing of the endothelium was relatively fast and at one week the Descemet's membrane was resurfaced, yet, the density and morphology of the cells was often abnormal. Moreover, histological evaluation revealed deformation and enlargement of many cells (polymegathism and pleomorphism), thickening and double layered Descemet's membrane. These changes were more pronounced in corneas displaying delayed pathology.</AbstractText>
        <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">SM induced apoptotic cell death of endothelial cells that was accompanied by corneal edema. The impaired healing of the endothelium, including the decrease in endothelial cell density was associated with the delayed-onset injuries. Since human corneal endothelium is almost amitotic, endothelium toxicity should be taken into consideration when testing potential treatments against ocular injuries following SM exposure.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kadar</LastName>
            <ForeName>Tamar</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Pharmacology, Israel Institute for Biological Research, Ness-Ziona, Israel. tamark@iibr.gov.il</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Maayan</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Liat</ForeName>
            <Initials>L</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fishbine</LastName>
            <ForeName>Eliezer</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sahar</LastName>
            <ForeName>Rita</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Brandeis</LastName>
            <ForeName>Rachel</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Dachir</LastName>
            <ForeName>Shlomit</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Amir</LastName>
            <ForeName>Adina</ForeName>
            <Initials>A</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2012</Year>
        <Month>10</Month>
        <Day>30</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Cutan Ocul Toxicol</MedlineTA>
    <NlmUniqueID>101266892</NlmUniqueID>
    <ISSNLinking>1556-9527</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D002619">Chemical Warfare Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>T8KEC9FH9P</RegistryNumber>
        <NameOfSubstance UI="D009151">Mustard Gas</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002619" MajorTopicYN="N">Chemical Warfare Agents</DescriptorName>
        <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004728" MajorTopicYN="N">Endothelium, Corneal</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005131" MajorTopicYN="N">Eye Injuries</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009151" MajorTopicYN="N">Mustard Gas</DescriptorName>
        <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>10</Month>
        <Day>31</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>10</Month>
        <Day>31</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>4</Month>
        <Day>24</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">23106194</ArticleId>
    <ArticleId IdType="doi">10.3109/15569527.2012.717571</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22674428</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>11</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1573-2622</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>125</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2012</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Documenta ophthalmologica. Advances in ophthalmology</Title>
        <ISOAbbreviation>Doc Ophthalmol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Gyrate atrophy: clinical and genetic findings in a female without arginine-restricted diet during her first 39 years of life and report of a new OAT gene mutation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>81-9</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10633-012-9335-0</ELocationID>
    <Abstract>
        <AbstractText>We report the clinical and genetic data obtained at a 17-year follow-up examination of a patient with gyrate atrophy, without an arginine-restricted diet. Patient examinations included visual acuity (VA), perimetry, biomicroscopy, funduscopy, fundus photography, fundus autofluorescence (FAF), spectral-domain optical coherence tomography (OCT), and standard full-field electroretinography (ERG). Blood samples were taken for measurement of serum ornithine level and molecular genetic analysis of the OAT gene. The female was 22 years of age when gyrate atrophy was diagnosed based on peripheral chorioretinal atrophy and an increased ornithine level. Reexamination after 17 years revealed a reduced VA (0.25 OU), dense cataract, extensive peripheral chorioretinal atrophy, a further increased ornithine level, but only slow progression of visual field constriction, and still detectable ERG amplitudes. FAF was absent in the atrophic periphery and almost homogeneous at the posterior pole except parafoveally. OCT showed interruption of the foveal inner/outer segment junction and parafoveal microcystoid spaces. After cataract surgery, VA increased to the same values as those found at the age of 22 years (0.5 OD, 0.6 OS). Molecular analysis revealed a new deletion c.532_536delTGGGG (p.Trp178X) and a known mutation c.897C&gt;G (p.Tyr299X) in the OAT gene. Although the patient had refused to diet during her first 39 years of life, the gyrate atrophy showed a very slow progression. FAF allows evaluating the integrity of the retinal pigment epithelium and may help to delimit gyrate atrophy from choroideremia. Interruption of foveal inner/outer segment junction and cystoid macula edema appears in gyrate atrophy.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Renner</LastName>
            <ForeName>Agnes B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
                <Affiliation>Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. a.renner@berlin.de</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Walter</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fiebig</LastName>
            <ForeName>Britta S</ForeName>
            <Initials>BS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jägle</LastName>
            <ForeName>Herbert</ForeName>
            <Initials>H</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2012</Year>
        <Month>06</Month>
        <Day>07</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Netherlands</Country>
    <MedlineTA>Doc Ophthalmol</MedlineTA>
    <NlmUniqueID>0370667</NlmUniqueID>
    <ISSNLinking>0012-4486</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>94ZLA3W45F</RegistryNumber>
        <NameOfSubstance UI="D001120">Arginine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>E524N2IXA3</RegistryNumber>
        <NameOfSubstance UI="D009952">Ornithine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 2.6.1.13</RegistryNumber>
        <NameOfSubstance UI="D009953">Ornithine-Oxo-Acid Transaminase</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018753" MajorTopicYN="Y">Diet, Protein-Restricted</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004596" MajorTopicYN="N">Electroretinography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015799" MajorTopicYN="N">Gyrate Atrophy</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName>
        <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009952" MajorTopicYN="N">Ornithine</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009953" MajorTopicYN="N">Ornithine-Oxo-Acid Transaminase</DescriptorName>
        <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D058609" MajorTopicYN="N">Visual Field Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014794" MajorTopicYN="N">Visual Fields</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2011</Year>
        <Month>10</Month>
        <Day>28</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2012</Year>
        <Month>05</Month>
        <Day>21</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>6</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>6</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>11</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">22674428</ArticleId>
    <ArticleId IdType="doi">10.1007/s10633-012-9335-0</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Ophthalmology. 2006 Nov;113(11):2066.e1-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16935340</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Doc Ophthalmol. 2009 Feb;118(1):69-77</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19030905</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Biol Chem. 1988 Oct 5;263(28):14288-95</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3170546</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Ophthalmol. 2002 Feb;120(2):146-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11831916</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Trans Am Ophthalmol Soc. 1975;73:153-71</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1246803</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Ophthalmol. 1991 Nov;109(11):1539-48</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1755734</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Ophthalmol. 1990 Jun;74(6):363-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2378845</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 2001 Apr;108(4):721-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11297489</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Ophthalmol. 1980 Feb;89(2):219-22</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7355975</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int Ophthalmol. 1981 Aug;4(1-2):23-32</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7028650</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hum Genet. 1988 Feb;42(2):365-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2893548</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Ophthalmol. 2009 Jul;127(7):907-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19597113</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Ophthalmol. 2005 Jul;140(1):147-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16038665</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurochem Res. 1984 Apr;9(4):555-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6462326</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Ophthalmol. 2004 Jul;122(7):982-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15249361</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4096-104</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18487380</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 1993 Jan 29;259(5095):680-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8430317</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Ophthalmol. 1974 Jan;58(1):3-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4841281</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 1985 Dec;92(12):1719-27</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4088625</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Retina. 1989;9(2):139-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2772421</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arq Bras Oftalmol. 2007 Sep-Oct;70(5):858-61</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18157315</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cytogenet Cell Genet. 1988;48(2):126-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3197452</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Ophthalmol. 2001 May;119(5):667-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11346393</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 2009 Jun;116(6):1201-9.e1-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19376587</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Ophthalmol. 1974 Nov;58(11):907-16</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4457103</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mol Vis. 1998 Nov 05;4:24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9815288</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Ophthalmol. 1986 Aug;70(8):612-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3741829</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Invest Ophthalmol Vis Sci. 1983 Apr;24(4):432-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6832916</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acta Ophthalmol (Copenh). 1987 Feb;65(1):101-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3577698</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 1973 May 12;1(7811):1031-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4122112</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 1981 Apr;88(4):292-301</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7254775</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 1985 Mar;92(3):394-401</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3991128</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 1981 Apr;88(4):325-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7254778</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 1980 Dec 5;210(4474):1128-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7444439</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Invest. 1980 Feb;65(2):371-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7356686</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 1981 Apr;88(4):307-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6973117</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 1978 Apr 14;200(4338):200-1</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">635581</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Inherit Metab Dis. 2004;27(2):187-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15159649</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hum Genet. 1992 Jul;51(1):81-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1609808</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Comp Biochem Physiol B. 1987;88(1):35-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3677612</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22570147</PMID>
<DateCompleted>
    <Year>2013</Year>
    <Month>01</Month>
    <Day>31</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1097-0142</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>118</Volume>
            <Issue>21</Issue>
            <PubDate>
                <Year>2012</Year>
                <Month>Nov</Month>
                <Day>01</Day>
            </PubDate>
        </JournalIssue>
        <Title>Cancer</Title>
        <ISOAbbreviation>Cancer</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.</ArticleTitle>
    <Pagination>
        <MedlinePgn>5403-13</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.27526</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models. The authors conducted a phase 1 study to determine the recommended phase 2 dose, safety, tolerability, and pharmacokinetics of efatutazone.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Patients with advanced solid malignancies and no curative therapeutic options were enrolled to receive a given dose of efatutazone, administered orally (PO) twice daily for 6 weeks, in a 3 + 3 intercohort dose-escalation trial. After the third patient, patients with diabetes mellitus were excluded. Efatutazone dosing continued until disease progression or unacceptable toxicity, with measurement of efatutazone pharmacokinetics and plasma adiponectin levels.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-one patients received efatutazone at doses ranging from 0.10 to 1.15 mg PO twice daily. Dose escalation stopped when maximal impact on PPARγ-related biomarkers had been reached before any protocol-defined maximum-tolerated dose level. On the basis of a population pharmacokinetic/pharmacodynamic analysis, the recommended phase 2 dose was 0.5 mg PO twice daily. A majority of patients experienced peripheral edema (53.3%), often requiring diuretics. Three episodes of dose-limiting toxicities, related to fluid retention, were noted in the 0.10-, 0.25-, and 1.15-mg cohorts. Of 31 treated patients, 27 were evaluable for response. A sustained partial response (PR; 690 days on therapy) was observed in a patient with myxoid liposarcoma. Ten additional patients had stable disease (SD) for ≥60 days. Exposures were approximately dose proportional, and adiponectin levels increased after 4 weeks of treatment at all dose levels. Immunohistochemistry of archived specimens demonstrated that PPARγ and retinoid X receptor expression levels were significantly greater in patients with SD for ≥60 days or PR (P = .0079), suggesting a predictive biomarker.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Efatutazone demonstrates acceptable tolerability with evidence of disease control in patients with advanced malignancies.</AbstractText>
        <CopyrightInformation>Copyright © 2012 American Cancer Society.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Pishvaian</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
                <Affiliation>Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA. pishvaim@georgetown.edu</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Marshall</LastName>
            <ForeName>John L</ForeName>
            <Initials>JL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wagner</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Jimmy J</ForeName>
            <Initials>JJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Malik</LastName>
            <ForeName>Shakun</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cotarla</LastName>
            <ForeName>Ion</ForeName>
            <Initials>I</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Deeken</LastName>
            <ForeName>John F</ForeName>
            <Initials>JF</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>A Ruth</ForeName>
            <Initials>AR</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Daniel</LastName>
            <ForeName>Hirut</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Halim</LastName>
            <ForeName>Abdel-Baset</ForeName>
            <Initials>AB</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zahir</LastName>
            <ForeName>Hamim</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Copigneaux</LastName>
            <ForeName>Catherine</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Kejian</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Beckman</LastName>
            <ForeName>Robert A</ForeName>
            <Initials>RA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Demetri</LastName>
            <ForeName>George D</ForeName>
            <Initials>GD</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <DataBankList CompleteYN="Y">
        <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
                <AccessionNumber>NCT00408434</AccessionNumber>
            </AccessionNumberList>
        </DataBank>
    </DataBankList>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>P30 CA051008</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2012</Year>
        <Month>05</Month>
        <Day>08</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Cancer</MedlineTA>
    <NlmUniqueID>0374236</NlmUniqueID>
    <ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>M17ILL71MC</RegistryNumber>
        <NameOfSubstance UI="C510342">efatutazone</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020714" MajorTopicYN="N">Maximum Tolerated Dose</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D047495" MajorTopicYN="N">PPAR gamma</DescriptorName>
        <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2011</Year>
        <Month>09</Month>
        <Day>05</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>13</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2012</Year>
        <Month>02</Month>
        <Day>09</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>5</Month>
        <Day>10</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>5</Month>
        <Day>10</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2013</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">22570147</ArticleId>
    <ArticleId IdType="doi">10.1002/cncr.27526</ArticleId>
    <ArticleId IdType="pmc">PMC3726261</ArticleId>
    <ArticleId IdType="mid">NIHMS480086</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Lab Clin Med. 2002 Jul;140(1):17-26</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12080324</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cancer Res. 2002 Jun 1;62(11):3282-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12036946</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Cancer. 2008 Aug;44(12):1734-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18511262</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2002 May 14;105(19):2296-302</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12010913</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>PPAR Res. 2008;2008:156875</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18509496</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11087869</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Digestion. 2001;64(2):75-80</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11684819</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Pharmacol Ther. 2007 Sep;82(3):275-81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17361126</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Oncol. 2007 Apr 20;25(12):1476-81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17442990</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Gastroenterology. 1998 Nov;115(5):1049-55</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9797355</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10984506</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>PPAR Res. 2008;2008:309469</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18596912</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int J Cancer. 2001 Nov 1;94(3):335-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11745411</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nature. 2000 May 25;405(6785):421-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10839530</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Med. 1998 Sep;4(9):1046-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9734398</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Biol Chem. 2001 Oct 12;276(41):37731-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11459852</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cancer Res. 1998 Aug 1;58(15):3344-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9699665</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10097144</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mol Pharmacol. 2008 Mar;73(3):709-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18055759</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Cancer. 2000 Nov;83(10):1394-400</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11044367</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>PLoS One. 2008 Jul 02;3(7):e2569</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18596980</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mol Cancer Ther. 2002 Mar;1(5):357-63</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12489852</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biochim Biophys Acta. 2010 Mar;1804(3):581-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19778642</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell. 1994 Dec 30;79(7):1147-56</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8001151</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Annu Rev Med. 2002;53:409-35</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11818483</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Oncogene. 2006 Apr 13;25(16):2304-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16331265</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Biol Chem. 2001 Dec 14;276(50):47131-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11668172</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8990192</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neoplasia. 1999 Oct;1(4):330-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10935488</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Biol Chem. 2004 Aug 20;279(34):35583-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15190077</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22382312</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>06</Month>
    <Day>29</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>07</Month>
    <Day>20</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1347-5215</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2012</Year>
            </PubDate>
        </JournalIssue>
        <Title>Biological &amp; pharmaceutical bulletin</Title>
        <ISOAbbreviation>Biol Pharm Bull</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice.</ArticleTitle>
    <Pagination>
        <MedlinePgn>280-8</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Human serum albumin (HSA) is used as an important plasma volume expander in clinical practice. However, the infused HSA may extravasate into the interstitial space and induce peripheral edema in treating the critical illness related to marked increase in capillary permeability. Such poor intravascular retention also demands a frequent administration of HSA. We hypothesize that increasing the molecular weight of HSA by PEGylation may be a potential approach to decrease capillary permeability of HSA. In the present study, HSA was PEGylated in a site-specific manner and the PEGylated HSA carrying one chain of polyethylene glycol (PEG) (20 kDa) per HSA molecule was obtained. The purity, PEGylated site and secondary structure of the modified protein were characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), thiol group blockage method and circular dichroism (CD) measurement, respectively. In addition, the pharmacokinetics in normal mice was investigated, vascular permeability of the PEGylated HSA was evaluated in lipopolysaccharide (LPS)-induced lung injury mouse model and the pharmacodynamics was investigated in LPS-induced sepsis model with systemic capillary leakage. The results showed that the biological half-life of the modified HSA was approximately 2.3 times of that of the native HSA, PEG-HSA had a lower vascular permeability and better recovery in blood pressure and haemodilution was observed in rats treated with PEG-HSA. From the results it can be inferred that the chemically well-defined and molecularly homogeneous PEGylated HSA is superior to HSA in treating capillary permeability increase related illness because of its longer biological half-life and lower vascular permeability.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Shandong University, China.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yan-Na</ForeName>
            <Initials>YN</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Hai-Ning</ForeName>
            <Initials>HN</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jin-Feng</ForeName>
            <Initials>JF</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Huan-Li</ForeName>
            <Initials>HL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Guang-Li</ForeName>
            <Initials>GL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Feng-Shan</ForeName>
            <Initials>FS</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Japan</Country>
    <MedlineTA>Biol Pharm Bull</MedlineTA>
    <NlmUniqueID>9311984</NlmUniqueID>
    <ISSNLinking>0918-6158</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010952">Plasma Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
        <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006400" MajorTopicYN="N">Hematocrit</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010952" MajorTopicYN="N">Plasma Substitutes</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>3</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>3</Month>
        <Day>3</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>6</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">22382312</ArticleId>
    <ArticleId IdType="pii">JST.JSTAGE/bpb/35.280</ArticleId>
    <ArticleId IdType="doi">10.1248/bpb.35.280</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22269349</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>06</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1742-2094</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
                <Year>2012</Year>
                <Month>Jan</Month>
                <Day>23</Day>
            </PubDate>
        </JournalIssue>
        <Title>Journal of neuroinflammation</Title>
        <ISOAbbreviation>J Neuroinflammation</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice.</ArticleTitle>
    <Pagination>
        <MedlinePgn>17</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1186/1742-2094-9-17</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brain edema as a result of secondary injury following traumatic brain injury (TBI) is a major clinical concern. Neutrophils are known to cause increased vascular permeability leading to edema formation in peripheral tissue, but their role in the pathology following TBI remains unclear.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">In this study we used controlled cortical impact (CCI) as a model for TBI and investigated the role of neutrophils in the response to injury. The outcome of mice that were depleted of neutrophils using an anti-Gr-1 antibody was compared to that in mice with intact neutrophil count. The effect of neutrophil depletion on blood-brain barrier function was assessed by Evan's blue dye extravasation, and analysis of brain water content was used as a measurement of brain edema formation (24 and 48 hours after CCI). Lesion volume was measured 7 and 14 days after CCI. Immunohistochemistry was used to assess cell death, using a marker for cleaved caspase-3 at 24 hours after injury, and microglial/macrophage activation 7 days after CCI. Data were analyzed using Mann-Whitney test for non-parametric data.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Neutrophil depletion did not significantly affect Evan's blue extravasation at any time-point after CCI. However, neutrophil-depleted mice exhibited a decreased water content both at 24 and 48 hours after CCI indicating reduced edema formation. Furthermore, brain tissue loss was attenuated in neutropenic mice at 7 and 14 days after injury. Additionally, these mice had a significantly reduced number of activated microglia/macrophages 7 days after CCI, and of cleaved caspase-3 positive cells 24 h after injury.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that neutrophils are involved in the edema formation, but not the extravasation of large proteins, as well as contributing to cell death and tissue loss following TBI in mice.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kenne</LastName>
            <ForeName>Ellinor</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Erlandsson</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lindbom</LastName>
            <ForeName>Lennart</ForeName>
            <Initials>L</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hillered</LastName>
            <ForeName>Lars</ForeName>
            <Initials>L</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Clausen</LastName>
            <ForeName>Fredrik</ForeName>
            <Initials>F</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2012</Year>
        <Month>01</Month>
        <Day>23</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>J Neuroinflammation</MedlineTA>
    <NlmUniqueID>101222974</NlmUniqueID>
    <ISSNLinking>1742-2094</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000950">Antigens, Ly</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C480309">Ly6G antigen, mouse</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>059QF0KO0R</RegistryNumber>
        <NameOfSubstance UI="D014867">Water</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>45PG892GO1</RegistryNumber>
        <NameOfSubstance UI="D005070">Evans Blue</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 3.4.22.-</RegistryNumber>
        <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000950" MajorTopicYN="N">Antigens, Ly</DescriptorName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005070" MajorTopicYN="N">Evans Blue</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020556" MajorTopicYN="N">Neutrophil Infiltration</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2011</Year>
        <Month>09</Month>
        <Day>23</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2012</Year>
        <Month>01</Month>
        <Day>23</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>1</Month>
        <Day>25</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>1</Month>
        <Day>25</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>6</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">22269349</ArticleId>
    <ArticleId IdType="pii">1742-2094-9-17</ArticleId>
    <ArticleId IdType="doi">10.1186/1742-2094-9-17</ArticleId>
    <ArticleId IdType="pmc">PMC3292978</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Neurotrauma. 2007 Aug;24(8):1295-307</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17711391</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood. 1987 Jan;69(1):338-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3539230</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Exp Neurol. 2002 Jan;173(1):168-81</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11771949</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuropathol Exp Neurol. 2011 Mar;70(3):218-35</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21293296</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurosci Lett. 2004 Feb 26;357(1):21-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15036604</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2003 Dec;23(12):1430-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14663338</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res Bull. 2010 Oct 30;83(5):272-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20638460</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroinflammation. 2009 Nov 04;6:32</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19889224</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 1997 Nov;17(11):1210-20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9390653</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 1996 Jun;13(6):333-41</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8835801</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acta Neurochir Suppl. 1998;71:212-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9779187</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Leukoc Biol. 1997 Mar;61(3):279-85</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9060450</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurosurgery. 1998 Feb;42(2):291-8; discussion 298-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9482179</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chem Immunol Allergy. 2003;83:146-66</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12947983</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Leukoc Biol. 2010 May;87(5):779-89</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20130219</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Respir J. 2008 Aug;32(2):405-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18321926</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 1993 Jul;77(1):141-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8317722</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 2000 Oct;17(10):871-90</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11063054</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosci. 1995 Dec;15(12):8223-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8613756</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertens Res. 2010 Jul;33(7):703-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20485441</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 1990 Winter;7(4):207-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2127947</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Inj. 2009 Jun;23(6):577-84</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19484631</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Neurosci. 2009 Aug;30(3):385-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19614750</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 2002 Sep;19(9):1039-50</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12482117</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroimmunol. 1997 Feb;72(2):169-77</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9042110</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Trauma. 1993 Sep;35(3):415-22</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8371301</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Semin Immunopathol. 2009 Nov;31(4):497-511</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19779720</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosci. 2000 Sep 15;20(18):7037-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10995849</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosci Methods. 1991 Oct;39(3):253-62</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1787745</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cereb Blood Flow Metab. 2001 Nov;21(11):1259-67</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11702041</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nature. 1981 Feb 19;289(5799):646-50</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7464931</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neuroscience. 2004;129(4):1021-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15561417</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Rev Immunol. 2009 Jun;9(6):429-39</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19461673</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 1994 Sep 12;656(2):344-52</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7820595</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 1994 Jun;11(3):303-15</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7996584</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood. 2008 Aug 15;112(4):1461-71</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18490516</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Neurobiol Dis. 2010 Nov;40(2):394-403</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20621186</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 1994 Oct;11(5):499-506</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7861443</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Neurosci. 2011 Jul;34(1):110-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21623956</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurochem. 2007 Aug;102(3):900-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17561941</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 1999 Jul;16(7):583-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10447070</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurosci Res. 1998 May 1;52(3):342-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9590442</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neurotrauma. 1995 Dec;12(6):1015-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8742130</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res Brain Res Rev. 2005 Apr;48(2):388-99</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15850678</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Stroke. 1994 Jul;25(7):1469-75</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8023364</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Neuroinflammation. 2008 Jun 30;5:28</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18590543</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann N Y Acad Sci. 2010 Oct;1207:123-33</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20955435</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22265424</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>08</Month>
    <Day>31</Day>
</DateCompleted>
<DateRevised>
    <Year>2012</Year>
    <Month>04</Month>
    <Day>23</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1532-8430</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>3</Issue>
            <PubDate>
                <MedlineDate>2012 May-Jun</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Journal of electrocardiology</Title>
        <ISOAbbreviation>J Electrocardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>T-wave alternans and the confounding role of the T-wave amplitude.</ArticleTitle>
    <Pagination>
        <MedlinePgn>294-5</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jelectrocard.2011.12.002</ELocationID>
    <Abstract>
        <AbstractText>The interpretation of the electrocardiogram (ECG) T-wave alternans (TWA) as positive or negative depends on its magnitude, regardless whether the frequency domain or the time domain analysis is employed. The author argues that a number of cardiac and extracardiac influences can confound the magnitude of TWA. The amplitude of the ECG T waves, considered in the measurement/calculation of TWA, and possibly myocardial edema are examples of cardiac influences. Peripheral edema with its effect in attenuating the amplitude of all components of the ECG, including the T waves, is an example of extracardiac influence. Another concern is the variation in the evolution of the T-wave amplitudes during the 3- to 6-month period after an acute myocardial infarction, and whether such variation confounds the results of the TWA testing, which often is undertaken at that time bracket. The T-wave amplitude changes may impact the sensitivity and specificity of TWA testing after an acute myocardial infarction. Perhaps the measured TWA magnitude should be adjusted to the amplitude of the T waves or voltage-time integral of the J-T interval, depending on the method used for the calculation of TWA. These issues need to be considered and investigated in an effort to render TWA testing more reliable in predicting sudden cardiac death.</AbstractText>
        <CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Madias</LastName>
            <ForeName>John E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
                <Affiliation>Mount Sinai School of Medicine of the New York University, New York, NY, USA. madiasj@nychhc.org</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2012</Year>
        <Month>01</Month>
        <Day>20</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Electrocardiol</MedlineTA>
    <NlmUniqueID>0153605</NlmUniqueID>
    <ISSNLinking>0022-0736</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D016757" MajorTopicYN="N">Death, Sudden, Cardiac</DescriptorName>
        <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2011</Year>
        <Month>11</Month>
        <Day>16</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2012</Year>
        <Month>1</Month>
        <Day>24</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2012</Year>
        <Month>1</Month>
        <Day>24</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>9</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">22265424</ArticleId>
    <ArticleId IdType="pii">S0022-0736(11)00516-4</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jelectrocard.2011.12.002</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22160952</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>02</Month>
    <Day>01</Day>
</DateCompleted>
<DateRevised>
    <Year>2012</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1439-4413</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>136</Volume>
            <Issue>50</Issue>
            <PubDate>
                <Year>2011</Year>
                <Month>Dec</Month>
            </PubDate>
        </JournalIssue>
        <Title>Deutsche medizinische Wochenschrift (1946)</Title>
        <ISOAbbreviation>Dtsch Med Wochenschr</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[70-year-old woman with cardiac hypertrophy and severe pulmonary hypertension: pre- or postcapillary?].</ArticleTitle>
    <Pagination>
        <MedlinePgn>2594-8</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0031-1292855</ELocationID>
    <Abstract>
        <AbstractText Label="HISTORY AND ADMISSION FINDINGS" NlmCategory="METHODS">A 70-year-old female patient was admitted with progressive dyspnea and peripheral edema. The patient had a medical history of myocardial hypertrophy, diastolic dysfunction and concomitant pulmonary hypertension (PH).</AbstractText>
        <AbstractText Label="INVESTIGATIONS" NlmCategory="METHODS">The physical exam was suggestive of cardiac decompensation. Echocardiography showed myocardial hypertrophy, an enlarged left atrium as well as enlarged right-sided heart chambers. A prominent tricuspid regurgitation jet was present, and the estimated systolic right ventricular pressure was 65 mmHg. Invasive hemodynamic measurements showed a marked pressure elevation in the pulmonary circulation (mean PAP 51 mmHg), combined with an elevated left ventricular end-diastolic pressure (LVEDP) of 30 mmHg and a profound increase in the transpulmonary gradient (TPG, 21 mmHg).</AbstractText>
        <AbstractText Label="TREATMENT AND COURSE" NlmCategory="METHODS">The synopsis of these findings led to the diagnosis of postcapillary PH with a prominent precapillary involvement and cardiac decompensation. Due to signs of volume overload, an adequate diuretic therapy was initiated. The patient was recompensated and lost 7 kg of weight, which was associated with substantial clinical improvement. At invasive follow-up hemodynamic measurement, the patient's PAP was substantially decreased and almost reached normal values. The previously diagnosed precapillary involvement had disappeared.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PH is a frequent phenomenon in patients with systolic and diastolic heart failure, and might initially appear as a combination of pre- and postcapillary involvement. The patients' volume status has a major influence on pulmonary hemodynamics. An adequate therapy of the underlying heart failure, especially an adequate diuresis, may have marked beneficial effects on pulmonary hemodynamics. Hemodynamic measurements should always be performed in compensated status.</AbstractText>
        <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Dumitrescu</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
                <Affiliation>Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Köln</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gerhardt</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Viethen</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Erdmann</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rosenkranz</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>70-jährige Patientin mit Myokardhypertrophie und schwerer pulmonaler Hypertonie: Prä- oder postkapillär?</VernacularTitle>
    <ArticleDate DateType="Electronic">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>07</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
    <NlmUniqueID>0006723</NlmUniqueID>
    <ISSNLinking>0012-0472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006328" MajorTopicYN="N">Cardiac Catheterization</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006332" MajorTopicYN="N">Cardiomegaly</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004489" MajorTopicYN="N">Edema, Cardiac</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D054144" MajorTopicYN="N">Heart Failure, Diastolic</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011669" MajorTopicYN="N">Pulmonary Wedge Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014262" MajorTopicYN="N">Tricuspid Valve Insufficiency</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>14</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>14</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>2</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">22160952</ArticleId>
    <ArticleId IdType="doi">10.1055/s-0031-1292855</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21928263</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>07</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1724-6016</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>3</Issue>
            <PubDate>
                <MedlineDate>2012 May-Jun</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>European journal of ophthalmology</Title>
        <ISOAbbreviation>Eur J Ophthalmol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Multifocal electroretinograms in age-related macular degeneration before and after photodynamic therapy.</ArticleTitle>
    <Pagination>
        <MedlinePgn>412-6</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.5301/ejo.5000031</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate multifocal electroretinograms (mfERG) and macular retinal thickness before and after photodynamic therapy (PDT) for predominantly classic choroidal neovascularization (CNV) (classic type) and occult with no classic CNV (occult type).</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Recording of mfERG and measurement of macular retinal thickness were performed before and after PDT in 19 patients (19 eyes) with the classic type and 24 (26 eyes) with the occult type. The evaluation items were the amplitude of the first negative wave (N1), the amplitude from the peak of the negative wave to that of the following positive wave (P1), and the peak latencies of the negative and positive waves.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with mfERG before PDT, that after PDT showed a significant decrease in the P1 latency in the central area (31.1 ± 1.9 ms before and 29.6 ± 1.6 ms after PDT) for the classic type and significant decreases in both the central (32.0 ± 2.0 ms before and 30.5 ± 2.4 ms after PDT) and peripheral (30.2 ± 2.0 ms before and 29.5 ± 2.0 ms after PDT) areas for the occult type. Optical coherence tomography showed significant decreases in macular retinal thickness in both groups (464 and 314 µm before and after PDT, respectively, for the classic type and 516 and 340 µm for the occult type).</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After PDT, retinal function evaluated by mfERG improved for both the classic and occult types, and the recovery of P1 latency may be due to improvement in retinal edema.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kojima</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Nara Medical University, Kashihara Nara, Japan. cozimasa@yahoo.co.jp</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yukawa</LastName>
            <ForeName>Eiichi</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shimoyama</LastName>
            <ForeName>Kimie</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nochioka</LastName>
            <ForeName>Katsunori</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tsujinaka</LastName>
            <ForeName>Hiroki</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Matsuura</LastName>
            <ForeName>Toyoaki</ForeName>
            <Initials>T</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Eur J Ophthalmol</MedlineTA>
    <NlmUniqueID>9110772</NlmUniqueID>
    <ISSNLinking>1120-6721</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0X9PA28K43</RegistryNumber>
        <NameOfSubstance UI="D000077362">Verteporfin</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>IX6J1063HV</RegistryNumber>
        <NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004596" MajorTopicYN="Y">Electroretinography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011166" MajorTopicYN="N">Porphyrins</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000077362" MajorTopicYN="N">Verteporfin</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D057135" MajorTopicYN="N">Wet Macular Degeneration</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="accepted">
        <Year>2011</Year>
        <Month>06</Month>
        <Day>22</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2011</Year>
        <Month>9</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2011</Year>
        <Month>9</Month>
        <Day>20</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>7</Month>
        <Day>25</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">21928263</ArticleId>
    <ArticleId IdType="pii">79854744-6584-4524-A1B6-957D60443F9C</ArticleId>
    <ArticleId IdType="doi">10.5301/ejo.5000031</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21784887</PMID>
<DateCompleted>
    <Year>2011</Year>
    <Month>11</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1521-0103</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>339</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2011</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>The Journal of pharmacology and experimental therapeutics</Title>
        <ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.</ArticleTitle>
    <Pagination>
        <MedlinePgn>307-12</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.111.182402</ELocationID>
    <Abstract>
        <AbstractText>We examined a novel therapeutic approach for hypertension, a small-molecule direct inhibitor of smooth muscle myosin, CK-2018448 (CK-448), which is an N,N'-alkylurea (U.S. Patent Publication 2009-0275537 A1) in conscious dogs with renal hypertension and compared its efficacy with that of a calcium channel blocker, amlodipine. Dogs were instrumented with a miniature left ventricular pressure gauge, an aortic pressure catheter, and ultrasonic flow probes in the ascending aorta and renal and iliac arteries for measurement of cardiac output and regional blood flow. In the hypertensive state, mean arterial pressure increased from 101 ± 3.8 to 142 ± 1.9 mm Hg. At the doses selected, CK-448 and amlodipine increased cardiac output similarly (30 ± 11% versus 33 ± 6.4%) and similarly reduced mean arterial pressure (-22 ± 3.6% versus -16 ± 3.4%) and total peripheral resistance (-36 ± 5.9% versus -37 ± 5.8%). CK-448 had the greatest vasodilator effect in the renal bed, where renal blood flow increased by 46 ± 9.0%, versus 11 ± 3.4% for amlodipine (p &lt; 0.01). CK-488 produced significantly less vasodilation in the limb, where iliac blood flow did not change; in contrast, it rose by 48 ± 12% with amlodipine (p &lt; 0.01). The minimal effects on limb blood flow could limit the development of peripheral edema, an adverse side effect of Ca(2+) channel blockers. In addition, in a rodent model of hypertension, oral administration of a smooth muscle myosin inhibitor resulted in a sustained antihypertensive effect. Thus, the smooth muscle myosin inhibitor's preferential effect on renal blood flow makes this drug mechanism particularly appealing, because many patients with hypertension have renal insufficiency, and patients with heart failure could benefit from afterload reduction coupled with enhanced renal blood flow.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Cell Biology and Molecular Medicine and the Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ho</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Abarzúa</LastName>
            <ForeName>Patricio</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Dhar</LastName>
            <ForeName>Sunil K</ForeName>
            <Initials>SK</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Zhiheng</ForeName>
            <Initials>Z</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pannirselvam</LastName>
            <ForeName>Malar</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Morgans</LastName>
            <ForeName>David J</ForeName>
            <Initials>DJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Malik</LastName>
            <ForeName>Fady I</ForeName>
            <Initials>FI</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vatner</LastName>
            <ForeName>Stephen F</ForeName>
            <Initials>SF</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>R37 HL033107</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>T32 HL069752</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>R01 HL033107</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>R01 HL106511</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL0-93481-02</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL0-69752-07</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>AG0--27211--04</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL0-33107-27</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL0--69020-10</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL10-1420-01</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL10-2472-01</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>R01 HL093481</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2011</Year>
        <Month>07</Month>
        <Day>22</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
    <NlmUniqueID>0376362</NlmUniqueID>
    <ISSNLinking>0022-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C568079">CK 2018448</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>1J444QC288</RegistryNumber>
        <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>8W8T17847W</RegistryNumber>
        <NameOfSubstance UI="D014508">Urea</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 3.6.4.1</RegistryNumber>
        <NameOfSubstance UI="D009218">Myosins</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007083" MajorTopicYN="N">Iliac Artery</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009218" MajorTopicYN="N">Myosins</DescriptorName>
        <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011918" MajorTopicYN="N">Rats, Inbred SHR</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012079" MajorTopicYN="N">Renal Circulation</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName>
        <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2011</Year>
        <Month>7</Month>
        <Day>26</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2011</Year>
        <Month>7</Month>
        <Day>26</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>13</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">21784887</ArticleId>
    <ArticleId IdType="pii">jpet.111.182402</ArticleId>
    <ArticleId IdType="doi">10.1124/jpet.111.182402</ArticleId>
    <ArticleId IdType="pmc">PMC3186291</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Eur Heart J. 1992 Jun;13 Suppl A:26-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1396848</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol Cell Physiol. 2010 May;298(5):C1118-26</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20164381</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 1980 Sep;47(3):356-65</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6157500</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 2000 Feb;35(2):621-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10679507</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 1987 Nov;61(5):678-86</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2822279</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Angiology. 1997 Mar;48(3):203-13</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9071195</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 1985 May-Jun;7(3 Pt 2):I55-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2987125</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Heart Fail. 2010 Jul;3(4):522-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20498236</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Braz J Med Biol Res. 2005 Jan;38(1):119-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15665998</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int J Cardiol. 1991 Mar;30(3):303-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1829064</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 2011 Mar 18;331(6023):1439-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21415352</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hypertens Suppl. 1989 Sep;7(4):S161-7; discussion S168</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2681592</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Pharmacol. 1987;10 Suppl 1:S121-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2442504</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Cell Biol. 2001 Nov;3(11):1025-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11715025</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Cardiol Rep. 2002 Nov;4(6):479-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12379167</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Cell Biol. 2000 Jun;2(6):371-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10854329</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 1985 May-Jun;7(3 Pt 1):380-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3158603</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Physiol. 1988 Dec;255(6 Pt 2):H1525-34</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3202211</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2010 Feb 23;121(7):e46-e215</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20019324</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Med. 1984 May 31;76(5B):38-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6375361</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pharmacol Exp Ther. 1993 May;265(2):1026-37</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8496801</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 1991 Feb;68(2):555-67</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1991355</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2002 Nov;15(11):932-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12441211</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21704694</PMID>
<DateCompleted>
    <Year>2011</Year>
    <Month>12</Month>
    <Day>27</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1872-7573</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>137</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2011</Year>
                <Month>Sep</Month>
                <Day>01</Day>
            </PubDate>
        </JournalIssue>
        <Title>Journal of ethnopharmacology</Title>
        <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Anti-inflammatory effects of methanol extract of Antrodia cinnamomea mycelia both in vitro and in vivo.</ArticleTitle>
    <Pagination>
        <MedlinePgn>575-84</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2011.06.009</ELocationID>
    <Abstract>
        <AbstractText Label="AIMS OF THE STUDY" NlmCategory="OBJECTIVE">Antrodia cinnamomea is a folk medicinal mushroom commonly used in Taiwan for the treatment of several types of cancers and inflammatory disorders. This study aimed to explore the folk use of Antrodia cinnamomea on pharmacological grounds to characterize the scientific basis of anti-inflammatory activity.</AbstractText>
        <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The in vitro anti-inflammatory activity of methanol extract of liquid cultured mycelia of Antrodia cinnamomea (MEMAC) was judged by the measurement of the produced levels of pro-inflammatory cytokines and mediators in lipopolysaccharide (LPS)-stimulated RAW264.7 cells and human peripheral blood mononuclear cells (PBMCs). The in vivo anti-inflammatory activity of MEMAC was evaluated using carrageenan-induced hind paw edema in mice, the activities of catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) in the liver and the levels of malondialdehyde (MDA) and nitrite oxide (NO) in the edema paw. The levels of serum NO and TNF-α were measured. The MEMAC was administered at the concentrations of 100, 200, and 400mg/kg body weight of mouse.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">MEMAC inhibited the production of LPS-induced pro-inflammatory cytokines (TNF-α and IL-6) and mediators (NO and PGE2) in RAW264.7 cells and human PBMCs. Data from Western blotting showed that MEMAC decreased the levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein expression in LPS-stimulated RAW264.7 macrophages. In vivo, MEMAC showed significant (p&lt;0.05) anti-inflammatory activity by reducing the edema volume in carrageenan-induced paw edema in mice. MEMAC (400mg/kg) also reduced the carrageenan-induced leukocyte migration (50.92±5.71%). Further, MEMAC increased the activities of CAT, SOD, and GPx in the liver tissue and decreased the levels of serum NO and TNF-α after carrageenan administration.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results showed that MEMAC has the anti-inflammatory property both in vitro and in vivo, suggesting that it may be a potential preventive or therapeutic candidate for the treatment of inflammatory disorders.</AbstractText>
        <CopyrightInformation>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Chi-Luan</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
                <Affiliation>Taiwan Seed Improvement and propagation Station, Council of Agriculture, Propagation Technology Section, Taichung, Taiwan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Chia-Chuan</ForeName>
            <Initials>CC</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Shyh-Shyun</ForeName>
            <Initials>SS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kuo</LastName>
            <ForeName>Chao-Lin</ForeName>
            <Initials>CL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Shih-Lan</ForeName>
            <Initials>SL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Jeng-Shyan</ForeName>
            <Initials>JS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Guan-Jhong</ForeName>
            <Initials>GJ</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2011</Year>
        <Month>06</Month>
        <Day>16</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Ireland</Country>
    <MedlineTA>J Ethnopharmacol</MedlineTA>
    <NlmUniqueID>7903310</NlmUniqueID>
    <ISSNLinking>0378-8741</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D012997">Solvents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>31C4KY9ESH</RegistryNumber>
        <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>4Y8F71G49Q</RegistryNumber>
        <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>9000-07-1</RegistryNumber>
        <NameOfSubstance UI="D002351">Carrageenan</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.11.1.6</RegistryNumber>
        <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.11.1.9</RegistryNumber>
        <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.13.39</RegistryNumber>
        <NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.13.39</RegistryNumber>
        <NameOfSubstance UI="C496317">Nos2 protein, mouse</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.99.-</RegistryNumber>
        <NameOfSubstance UI="C077623">Ptgs2 protein, mouse</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.99.1</RegistryNumber>
        <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.15.1.1</RegistryNumber>
        <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>K7Q1JQR04M</RegistryNumber>
        <NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>Y4S76JWI15</RegistryNumber>
        <NameOfSubstance UI="D000432">Methanol</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055491" MajorTopicYN="Y">Antrodia</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002351" MajorTopicYN="N">Carrageenan</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002374" MajorTopicYN="N">Catalase</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008315" MajorTopicYN="N">Malondialdehyde</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008519" MajorTopicYN="N">Medicine, Traditional</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000432" MajorTopicYN="N">Methanol</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D025282" MajorTopicYN="N">Mycelium</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012997" MajorTopicYN="N">Solvents</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2011</Year>
        <Month>02</Month>
        <Day>25</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2011</Year>
        <Month>05</Month>
        <Day>26</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2011</Year>
        <Month>06</Month>
        <Day>09</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2011</Year>
        <Month>6</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2011</Year>
        <Month>6</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>28</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">21704694</ArticleId>
    <ArticleId IdType="pii">S0378-8741(11)00426-0</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jep.2011.06.009</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21640687</PMID>
<DateCompleted>
    <Year>2011</Year>
    <Month>12</Month>
    <Day>20</Day>
</DateCompleted>
<DateRevised>
    <Year>2012</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Print">1933-1711</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>5</Issue>
            <PubDate>
                <MedlineDate>2011 Sep-Oct</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Journal of the American Society of Hypertension : JASH</Title>
        <ISOAbbreviation>J Am Soc Hypertens</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Effects of the L/N-type calcium channel antagonist cilnidipine on morning blood pressure control and peripheral edema formation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>410-6</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jash.2011.03.008</ELocationID>
    <Abstract>
        <AbstractText>The L/N-type calcium channel blocker cilnidipine has unique effects including sympathetic nerve suppression and the balanced vasodilatation of arteries and veins that may alleviate morning hypertension (MHT) or peripheral edema caused by calcium channel antagonists. We used ambulatory blood pressure monitoring (ABPM) and a unique peripheral edema measurement to evaluate the effect of morning and bedtime cilnidipine in patients with MHT. Forty-three patients with MHT (60 ± 12 years) were randomly assigned to a morning or bedtime cilnidipine (10-20 mg/day). MHT was defined as a mean systolic blood pressure (SBP) ≥ 135 mm Hg by ABPM within 2 hours after awaking. After 3 months, greater SBP reductions were observed in the bedtime administration group (versus the morning administration group) at 3:30-6:00 AM (-24 ± 20 mm Hg vs. -10 ± 4 mm Hg; P &lt; .05) and at 6:30-9:00 AM (-26 ± 15 mm Hg vs. -14 ± 17 mm Hg; P &lt; .05). Although physical examinations showed leg edema in 16% of the patients, quantitative evaluations did not reveal significant volume gains. Cilnidipine had a greater effect on MHT, without causing significant leg edema, when administered at bedtime.</AbstractText>
        <CopyrightInformation>Copyright © 2011 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Narita</LastName>
            <ForeName>Sumito</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Cardiology, Saiseikai Futsukaichi Hospital, Chikushino, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yoshioka</LastName>
            <ForeName>Yasuko</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ide</LastName>
            <ForeName>Atsumi</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kadokami</LastName>
            <ForeName>Toshiaki</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Momii</LastName>
            <ForeName>Hidetoshi</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Masayoshi</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ando</LastName>
            <ForeName>Shin-ichi</ForeName>
            <Initials>S</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2011</Year>
        <Month>06</Month>
        <Day>02</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Am Soc Hypertens</MedlineTA>
    <NlmUniqueID>101312518</NlmUniqueID>
    <ISSNLinking>1878-7436</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D004095">Dihydropyridines</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>97T5AZ1JIP</RegistryNumber>
        <NameOfSubstance UI="C065927">cilnidipine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018660" MajorTopicYN="N">Blood Pressure Monitoring, Ambulatory</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004095" MajorTopicYN="N">Dihydropyridines</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013564" MajorTopicYN="N">Sympathetic Nervous System</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2011</Year>
        <Month>01</Month>
        <Day>26</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2011</Year>
        <Month>03</Month>
        <Day>20</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2011</Year>
        <Month>03</Month>
        <Day>21</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2011</Year>
        <Month>6</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2011</Year>
        <Month>6</Month>
        <Day>7</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2011</Year>
        <Month>12</Month>
        <Day>21</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">21640687</ArticleId>
    <ArticleId IdType="pii">S1933-1711(11)00098-2</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jash.2011.03.008</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21478799</PMID>
<DateCompleted>
    <Year>2012</Year>
    <Month>05</Month>
    <Day>10</Day>
</DateCompleted>
<DateRevised>
    <Year>2011</Year>
    <Month>11</Month>
    <Day>09</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1529-7535</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2011</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title>
        <ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Comparison of bedside and laboratory blood glucose estimations in critically ill children with shock.</ArticleTitle>
    <Pagination>
        <MedlinePgn>e297-301</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0b013e3182192804</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Bedside glucometers are often used for frequent glucose measurements on capillary blood in critically ill children. However, there are concerns that capillary blood glucose estimations may not be accurate in children with shock and peripheral edema. The objective of this study was to compare simultaneously obtained laboratory values of arterial or central venous blood glucose with capillary blood glucose estimation using a glucometer in children with shock.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective observational study.</AbstractText>
        <AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary pediatric intensive care unit in a children's hospital in Chennai.</AbstractText>
        <AbstractText Label="PATIENTS" NlmCategory="METHODS">All children admitted between July 2007 and September 2008 with shock as defined by the American College of Critical Care Medicine criteria were eligible for inclusion.</AbstractText>
        <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">None.</AbstractText>
        <AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Three hundred thirty-seven sets of simultaneous measurements were obtained from 52 children (age range, 3 months to 18 yrs; average Pediatric Risk of Mortality III score 9.6). The mean blood glucose measurement using capillary blood on a bedside glucometer was 135 ± 67 mg/dL (7.5 ± 3.7 mmol/L). The mean laboratory glucose was 130 ± 67 mg/dL (7.2 ± 3.7 mmol/L). The correlation coefficient between the measurements was 0.94. There were no differences between those with and without peripheral edema. Using Bland-Altman plots, the mean difference between capillary samples vs. laboratory glucose was 6 mg/dL (0.3 mmol/L). The spread was wider at the higher ends of blood glucose values.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Capillary blood glucose estimation in children with shock was similar to the laboratory measurement in the midranges of glucose values.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ramachandran</LastName>
            <ForeName>Bala</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
                <Affiliation>Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sethuraman</LastName>
            <ForeName>Ramaswami</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ravikumar</LastName>
            <ForeName>Karnam G</ForeName>
            <Initials>KG</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kissoon</LastName>
            <ForeName>Niranjan</ForeName>
            <Initials>N</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Pediatr Crit Care Med</MedlineTA>
    <NlmUniqueID>100954653</NlmUniqueID>
    <ISSNLinking>1529-7535</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003955" MajorTopicYN="N">Diagnostic Tests, Routine</DescriptorName>
        <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007755" MajorTopicYN="N">Laboratories, Hospital</DescriptorName>
        <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019095" MajorTopicYN="N">Point-of-Care Systems</DescriptorName>
        <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012772" MajorTopicYN="Y">Shock, Septic</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2011</Year>
        <Month>4</Month>
        <Day>12</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2011</Year>
        <Month>4</Month>
        <Day>12</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2012</Year>
        <Month>5</Month>
        <Day>11</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">21478799</ArticleId>
    <ArticleId IdType="doi">10.1097/PCC.0b013e3182192804</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21069358</PMID>
<DateCompleted>
    <Year>2011</Year>
    <Month>07</Month>
    <Day>26</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1861-0692</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2011</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>Clinical research in cardiology : official journal of the German Cardiac Society</Title>
        <ISOAbbreviation>Clin Res Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure.</ArticleTitle>
    <Pagination>
        <MedlinePgn>335-42</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00392-010-0248-1</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Atrial fibrillation (AF) and acute congestive heart failure (aCHF) are characterized by an adverse cardiac remodeling. Arrhythmogenic or structural remodeling can be caused by interstitial fibrosis. Transforming growth factor beta 1 (TGF-beta 1) represents a central regulator of cardiac fibrosis. This study investigates serum levels of TGF-beta 1 in patients with AF and aCHF.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">401 patients presenting with symptoms of dyspnea or peripheral edema were prospectively enrolled. Blood samples for measurement of TGF-beta 1 (R&amp;D Systems, Inc.) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) (DadeBehring ltd.) were collected after the initial clinical evaluation.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Median TGF-beta 1 levels were lower in patients with AF (21.0 ng/ml, interquartile range (IR) 15.4-27.6 ng/ml, n = 107) compared to those without (25.0 ng/ml, IR 18.5-31.6 ng/ml, n = 294) (p = 0.009). Patients with aCHF had lower TGF-beta 1 levels (median 22.0 ng/ml, IR 15.6-27.1 ng/ml, n = 122) than those without (median 24.9 ng/ml, IR 18.1-31.9 ng/ml, n = 279) (p = 0.0005). In logistic regression models TGF-beta 1 was still associated with AF (odds ratio (OR) 3.00, 95% CI 1.37-6.61, p = 0.0001) and aCHF (OR 3.98, 95% CI 1.55-10.19, p = 0.004). TGF-beta 1 inversely correlated with left atrial diameter (r = -0.30, p = 0.007) and NT-proBNP (r = -0.14, p = 0.007).</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low serum levels of TGF-beta 1 are associated with AF and aCHF. This decrease may result from a higher consumption of TGF-beta 1 within the impaired myocardium or antifibrotic functions of natriuretic peptides.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Behnes</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>First Department of Medicine, University Medical Centre Mannheim, Medical Faculty of Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany. michael.behnes@umm.de</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hoffmann</LastName>
            <ForeName>Ursula</ForeName>
            <Initials>U</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lang</LastName>
            <ForeName>Siegfried</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Weiss</LastName>
            <ForeName>Christel</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ahmad-Nejad</LastName>
            <ForeName>Parviz</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Neumaier</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Borggrefe</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Brueckmann</LastName>
            <ForeName>Martina</ForeName>
            <Initials>M</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2010</Year>
        <Month>11</Month>
        <Day>11</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Clin Res Cardiol</MedlineTA>
    <NlmUniqueID>101264123</NlmUniqueID>
    <ISSNLinking>1861-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>114471-18-0</RegistryNumber>
        <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2010</Year>
        <Month>05</Month>
        <Day>30</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2010</Year>
        <Month>10</Month>
        <Day>20</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2010</Year>
        <Month>11</Month>
        <Day>12</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2010</Year>
        <Month>11</Month>
        <Day>12</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2011</Year>
        <Month>7</Month>
        <Day>27</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">21069358</ArticleId>
    <ArticleId IdType="doi">10.1007/s00392-010-0248-1</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Curr Opin Cardiol. 2000 May;15(3):128-35</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10952417</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Heart Fail Rev. 2000 Jun;5(2):119-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16228139</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Europace. 2009 Jul;11(7):860-85</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19531542</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Heart Rhythm. 2007 Mar;4(3 Suppl):S24-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17336879</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2009 Jan 10;373(9658):155-66</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19135613</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Biochim Biophys Acta. 2008 Apr;1782(4):197-228</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18313409</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Exp Pharmacol Physiol. 2008 Mar;35(3):335-41</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18290874</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 2002 Jan;61(1):324-35</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11786115</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2009 Feb;98(2):101-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18975023</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 2004 Jan 27;109(3):363-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14732752</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2008 Jun;97(6):389-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18322636</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell Mol Life Sci. 2006 Nov;63(22):2584-96</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17013566</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2000 May 4;342(18):1350-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10793168</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Int J Cardiol. 2009 Jun 26;135(2):165-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18603317</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Naunyn Schmiedebergs Arch Pharmacol. 2010 Mar;381(3):195-206</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19784635</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2009 Jan;98(1):25-32</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18853096</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Med Hypotheses. 2008;70(2):317-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17689021</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1997 Dec 2;96(11):4065-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9403633</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Radiology. 1983 Sep;148(3):839-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6878708</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Can J Physiol Pharmacol. 2001 Aug;79(8):723-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11558681</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cardiovasc Res. 2007 May 1;74(2):207-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16919613</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 2007 Oct 25;357(17):1767-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17960018</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cardiovasc Res. 2006 Feb 1;69(2):318-28</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16289003</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nat Med. 2007 Aug;13(8):952-61</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17660828</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Heart Valve Dis. 2008 Sep;17(5):557-65</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18980090</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Cell Mol Life Sci. 2008 May;65(10):1489-508</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18322650</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 2008 Feb 1;102(2):185-92</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17991884</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Endocrinol Invest. 2007 May;30(5):350-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17598964</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2008 Feb;97(2):124-30</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18046529</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Pharmacol. 2008 Oct;52(4):293-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18791467</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2009 Mar;98(3):189-94</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19034378</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Immunology. 2006 May;118(1):10-24</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16630019</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2008 Nov;97(11):820-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18648726</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circ Res. 2010 Mar 19;106(5):992-1003</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20075334</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Lancet. 2006 Jan 28;367(9507):356-67</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16443044</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2010 Oct;31(19):2369-429</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20802247</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur Heart J. 2008 Oct;29(19):2388-442</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18799522</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Res Cardiol. 2008 Feb;97(2):98-104</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17938849</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Trends Cell Biol. 2008 Sep;18(9):430-42</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18706811</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20534929</PMID>
<DateCompleted>
    <Year>2010</Year>
    <Month>09</Month>
    <Day>15</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>20</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1998-3689</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>58</Volume>
            <Issue>4</Issue>
            <PubDate>
                <MedlineDate>2010 Jul-Aug</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Indian journal of ophthalmology</Title>
        <ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Misleading Goldmann applanation tonometry in a post-LASIK eye with interface fluid syndrome.</ArticleTitle>
    <Pagination>
        <MedlinePgn>333-5</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.4103/0301-4738.64133</ELocationID>
    <Abstract>
        <AbstractText>A 21-year-old myope presented with decreased vision and corneal edema following vitreoretinal surgery for retinal detachment. While intraocular pressure (IOP) measurement with Goldmann applanation tonometer (GAT) was low, the digital tonometry indicated raised pressures. An interface fluid syndrome (IFS) was suspected and confirmed by clinical exam and optical coherence tomography. A tonopen used to measure IOP through the peripheral cornea revealed elevated IOP which was the cause of the interface fluid. Treatment with IOP-lowering agents resulted in complete resolution of the interface fluid. This case is being reported to highlight the fact that IFS should be suspected when there is LASIK flap edema and IOP readings using GAT are low and that GAT is not an optimal method to measure IOP in this condition. Alternative methods like tonopen or Schiotz tonometry can be used.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Senthil</LastName>
            <ForeName>Sirisha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>LV Prasad Eye Institute, LV Prasad Marg, Banjara Hills, Hyderabad-500 034, India.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rathi</LastName>
            <ForeName>Varsha</ForeName>
            <Initials>V</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Garudadri</LastName>
            <ForeName>Chandrasekhar</ForeName>
            <Initials>C</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>India</Country>
    <MedlineTA>Indian J Ophthalmol</MedlineTA>
    <NlmUniqueID>0405376</NlmUniqueID>
    <ISSNLinking>0301-4738</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007429" MajorTopicYN="N">Intraocular Pressure</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020731" MajorTopicYN="N">Keratomileusis, Laser In Situ</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009216" MajorTopicYN="N">Myopia</DescriptorName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014065" MajorTopicYN="N">Tonometry, Ocular</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014821" MajorTopicYN="N">Vitrectomy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2010</Year>
        <Month>6</Month>
        <Day>11</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2010</Year>
        <Month>6</Month>
        <Day>11</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2010</Year>
        <Month>9</Month>
        <Day>16</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">20534929</ArticleId>
    <ArticleId IdType="pii">IndianJOphthalmol_2010_58_4_333_64133</ArticleId>
    <ArticleId IdType="doi">10.4103/0301-4738.64133</ArticleId>
    <ArticleId IdType="pmc">PMC2907040</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Cataract Refract Surg. 1999 Jul;25(7):1009-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10404381</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 2007 Oct;114(10):1848-59</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17908592</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cataract Refract Surg. 2006 Sep;32(9):1560-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16931273</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug;39(4 Suppl):S80-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18777878</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cataract Refract Surg. 2002 Feb;28(2):356-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11821221</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cataract Refract Surg. 1999 Apr;25(4):486-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10198852</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ophthalmology. 2002 Apr;109(4):659-65</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11927421</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cataract Refract Surg. 2005 Apr;31(4):853-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15899468</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Refract Surg. 2006 May;22(5):441-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16722481</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20428000</PMID>
<DateCompleted>
    <Year>2010</Year>
    <Month>08</Month>
    <Day>13</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>12</Month>
    <Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1662-2782</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>164</Volume>
            <PubDate>
                <Year>2010</Year>
            </PubDate>
        </JournalIssue>
        <Title>Contributions to nephrology</Title>
        <ISOAbbreviation>Contrib Nephrol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Bioelectric impedance measurement for fluid status assessment.</ArticleTitle>
    <Pagination>
        <MedlinePgn>143-152</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1159/000313727</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adequacy of body fluid volume improves short- and long-term outcomes inpatients with heart and kidney disorders. Bioelectrical impedance vector analysis (BIVA) has the potential to be used as a routine method at the bedside for assessment and management of body fluids.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Impedance (Z vector) is a combination of resistance, R (function of intra- and extracellular fluid volume) and reactance, Xc (function of the dielectric material of tissue cells), with the best signal to noise ratio at 50 kHz. BIVA allows a direct assessment of body fluid volume through patterns of vector distribution on the R-Xc plane without the knowledge of the body weight. Reference tolerance ellipses (50, 75 and 95%) for the individual vector were previously calculated in the healthy population.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">We determined the optimal vector distribution in patients undergoing hemodialysis without hypotension or intradialytic symptoms. Most vectors lay within the reference 75% tolerance ellipse of the healthy population indicating full electrical restoration of tissues. We also determined the optimal vector distribution of patients undergoing continuous ambulatory peritoneal dialysis without edema and with a residual urine output. The vector distribution was close to the distribution of both healthy subjects and pre-session distribution of hemodialysis patients. We established the relationship between central venous pressure and BIVA in critically ill patients. Shorter vectors (overhydration) were associated with increasing venous pressure, whereas longer vectors were associated with decreasing venous pressure. The association between BIVA and NT-proBNP has been evaluated in patients with acute cardiac-related dyspnea. In the 'gray zone' of NT-proBNP values between 'ruling out' and 'ruling in' acute heart failure, BIVA detected latent peripheral congestion.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Simple patterns of BIVA allow detection, monitoring, and control of hydration status using vector displacement for the feedback on treatment.</AbstractText>
        <CopyrightInformation>Copyright (c) 64\C S. Karger AG, Basel.</CopyrightInformation>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Piccoli</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medical and Surgical Sciences, Nephrology Clinic, University of Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D023361">Validation Study</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2010</Year>
        <Month>04</Month>
        <Day>20</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Switzerland</Country>
    <MedlineTA>Contrib Nephrol</MedlineTA>
    <NlmUniqueID>7513582</NlmUniqueID>
    <ISSNLinking>0302-5144</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000886" MajorTopicYN="N">Anthropometry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016477" MajorTopicYN="N">Artifacts</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017097" MajorTopicYN="Y">Electric Impedance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051437" MajorTopicYN="N">Renal Insufficiency</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014882" MajorTopicYN="Y">Water-Electrolyte Balance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014883" MajorTopicYN="N">Water-Electrolyte Imbalance</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2010</Year>
        <Month>4</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2010</Year>
        <Month>4</Month>
        <Day>30</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2010</Year>
        <Month>8</Month>
        <Day>14</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">20428000</ArticleId>
    <ArticleId IdType="pii">000313727</ArticleId>
    <ArticleId IdType="doi">10.1159/000313727</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20370378</PMID>
<DateCompleted>
    <Year>2010</Year>
    <Month>09</Month>
    <Day>08</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1473-4877</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2010</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Current medical research and opinion</Title>
        <ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1321-31</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1185/03007991003715079</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the efficacy and general safety of rivoglitazone, a novel thiazolidinedione, as a treatment for type 2 diabetes in a dose-ranging study over a period of up to 6 months.</AbstractText>
        <AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">A 26-week, randomized, double-blind, double-dummy, placebo- and active comparator (pioglitazone 45 mg)-controlled study designed to evaluate the efficacy and safety of once-daily rivoglitazone 1, 2, or 3 mg in subjects with type 2 diabetes. The study was conducted in adults with type 2 diabetes (glycated hemoglobin [HbA(1c)] &gt;or=7.0% and &lt;10.5%) who were either naïve to prior antidiabetes drug treatment or discontinued pre-study antidiabetes medications and were switched to study medication. A total of 441 subjects were randomized, using an equal allocation schedule to one of five treatment arms, including placebo. The primary efficacy measurement was the change in HbA(1c) from baseline to week 26 in the intent-to-treat population (last observation carried forward), for drug treatments minus placebo (placebo-subtracted).</AbstractText>
        <AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Identifier NCT00143520.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of early discontinuations was &gt;50%, with most cases being related to a lack of efficacy (highest on placebo) or adverse experiences (highest on rivoglitazone 3 mg). Rivoglitazone 1, 2, and 3 mg and pioglitazone 45 mg were more effective than placebo in reducing HbA(1c) from baseline to week 26 (placebo-subtracted change from baseline: -0.55% [p = 0.0034], -0.99% [p &lt; 0.0001], -1.10% [p &lt; 0.0001], and -0.59% [p = 0.0016], respectively). In general, all treatments were safe. The most common drug-related adverse events reported with rivoglitazone were peripheral edema and weight gain; incidences increased with dose and were higher with rivoglitazone 2 and 3 mg than with pioglitazone or rivoglitazone 1 mg.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Rivoglitazone is a potent thiazolidinedione agent with demonstrated glycemic benefits over a 6-month period in subjects with type 2 diabetes. Once-daily doses of 1, 2, and 3 mg rivoglitazone demonstrated HbA(1c) reduction similar or superior to those observed for pioglitazone 45 mg. Limitations in generalizing from this study include a modest sample size and a high rate of discontinuation prior to the last scheduled visit.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Truitt</LastName>
            <ForeName>Kenneth E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
                <Affiliation>Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA. ktruitt@dsi.com</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Goldberg</LastName>
            <ForeName>Ronald B</ForeName>
            <Initials>RB</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rosenstock</LastName>
            <ForeName>Julio</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chou</LastName>
            <ForeName>Hubert S</ForeName>
            <Initials>HS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Merante</LastName>
            <ForeName>Domenico</ForeName>
            <Initials>D</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Triscari</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Antonia C</ForeName>
            <Initials>AC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <DataBankList CompleteYN="Y">
        <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
                <AccessionNumber>NCT00143520</AccessionNumber>
            </AccessionNumberList>
        </DataBank>
    </DataBankList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016448">Multicenter Study</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Curr Med Res Opin</MedlineTA>
    <NlmUniqueID>0351014</NlmUniqueID>
    <ISSNLinking>0300-7995</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>3A3N0634Q6</RegistryNumber>
        <NameOfSubstance UI="C521549">rivoglitazone</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>X4OV71U42S</RegistryNumber>
        <NameOfSubstance UI="D000077205">Pioglitazone</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000077205" MajorTopicYN="N">Pioglitazone</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2010</Year>
        <Month>4</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2010</Year>
        <Month>4</Month>
        <Day>8</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2010</Year>
        <Month>9</Month>
        <Day>9</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">20370378</ArticleId>
    <ArticleId IdType="doi">10.1185/03007991003715079</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20175949</PMID>
<DateCompleted>
    <Year>2010</Year>
    <Month>07</Month>
    <Day>01</Day>
</DateCompleted>
<DateRevised>
    <Year>2010</Year>
    <Month>02</Month>
    <Day>23</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1603-9629</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>57</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2010</Year>
                <Month>Jan</Month>
            </PubDate>
        </JournalIssue>
        <Title>Danish medical bulletin</Title>
        <ISOAbbreviation>Dan Med Bull</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Experimental studies of pneumococcal meningitis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>B4119</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>This thesis summarizes experimental meningitis research conducted at Statens Serum Institut in collaboration with the Copenhagen HIV programme and the Danish Research Centre for Magnetic Resonance between 2001 and 2007. Previous experimental studies had shown that the host inflammatory response in invasive infections contributed significantly to an extremely poor outcome despite initiation of efficient antimicrobial chemotherapy. Consequently, we aimed to investigate and clarify how the course of disease in pneumococcal meningitis was modulated by local meningeal inflammation and concomitant systemic infection and inflammation. Experimental studies were based on the development of a rat model of pneumococcal meningitis, refined and optimized to closely resemble the human disease, mimicking disease severity, outcome, focal- and global brain injury and brain pathophysiology. These endpoints were evaluated by the development of a clinical score system, definition of outcomes and measurement of hearing loss by otoacoustic emission. The investigation of in-vitro and in-vivo brain pathology with histology and MRI revealed an injury pattern similar to that found clinically. Additionally, MRI enabled the study of parameters closely related to the cerebral pathophysiology of meningitis (brain oedema, blood brain barrier (BBB) permeability, focal brain injury and hydrocephalus). Modulation of the inflammatory host response was achieved by initiation of treatment prior to infection: 1) G-CSF treatment increased the peripheral availability of leukocytes, 2) Selectin blocker fucoidin attenuated meningeal leukocyte accumulation and 3) A serotype specific Ab augmented systemic pneumococcal phagocytosis. The studies revealed a dual role of the inflammatory response in pneumococcal meningitis. Whilst focal brain injury appeared to result from local meningeal infectious processes, clinical disease severity and outcome appeared determined by systemic infection. Furthermore systemic disease contributed significantly to BBB permeability and brain ventricle expansion. Ventricle expansion was also associated with clinical appearance. An augmented systemic host response limited pneumococcal bacteraemia and protected from fatal outcome, but did not reduce occurrence of focal brain injury. Thus, our findings suggest that meningitis sequelae arise from local disease complications whereas fatal outcome is accelerated by systemic infection. Understanding of the relationship and interplay between septicaemia, intracranial pressure, ventricle expansion and brain edema could help optimize the treatment of these disease complications by, for example, improved systemic infection control. New therapeutic approaches to improve survival and neurological outcome from pneumococcal meningitis may be achieved through identification of the pathogen factors that initiate and prolong extensive systemic and local inflammation. Investigation of genomic differences and protein expression between pneumococcal serotypes or between identical serotypes with different virulence are considered crucial to this progress. Future progress may also be achieved by disease prevention with pneumococcal vaccines. Randomized trials of treatment strategies including bacteriostatic agents, antioxidants or more specific anti-inflammatory agents are realistic possibilities in the near future.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Brandt</LastName>
            <ForeName>Christian T</ForeName>
            <Initials>CT</Initials>
            <AffiliationInfo>
                <Affiliation>National Center for Antimicrobials and Infection Control, Statens Serum Institut, Denmark. ctb@ssi.dk</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Denmark</Country>
    <MedlineTA>Dan Med Bull</MedlineTA>
    <NlmUniqueID>0066040</NlmUniqueID>
    <ISSNLinking>0907-8916</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>
        <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003051" MajorTopicYN="N">Cochlea</DescriptorName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006319" MajorTopicYN="N">Hearing Loss, Sensorineural</DescriptorName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008586" MajorTopicYN="N">Meningitis, Pneumococcal</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009345" MajorTopicYN="N">Neisseria meningitidis</DescriptorName>
        <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
        <QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012703" MajorTopicYN="N">Serotyping</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>222</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2010</Year>
        <Month>2</Month>
        <Day>24</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2010</Year>
        <Month>2</Month>
        <Day>24</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2010</Year>
        <Month>7</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">20175949</ArticleId>
    <ArticleId IdType="pii">B4119</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20085941</PMID>
<DateCompleted>
    <Year>2010</Year>
    <Month>03</Month>
    <Day>23</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>10</Month>
    <Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1527-7755</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2010</Year>
                <Month>Feb</Month>
                <Day>20</Day>
            </PubDate>
        </JournalIssue>
        <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
        <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1031-7</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2009.23.8220</ELocationID>
    <Abstract>
        <AbstractText>PURPOSE To assess the efficacy and tolerability of bortezomib with or without dexamethasone and to define prognostic factors for patients with primary systemic light chain (AL) amyloidosis treated with bortezomib or both. PATIENTS AND METHODS Ninety-four patients from three centers were analyzed: 19% received the combination as first-line treatment, 81% had a median of two previous therapies, and 69% had refractory disease, while most patients had symptomatic heart involvement or elevated serum N-terminal pro-brain natriuretic peptide (NT-proBNP). Results A hematologic response was achieved in 71% within a median of 52 days, including 25% complete responses (CRs). Previously untreated patients had a 47% CR rate. Age 65 years or younger (P = .043) and twice weekly administration of bortezomib (P = .041) were associated with higher response rates. A cardiac response was documented in 29% of patients, in most as sustained improvement of functional class and less often as a decrease in wall thickness. Hematologic responses were associated with a cardiac response and NT-proBNP reduction. After a median follow-up of 12 months, 29% of patients had organ progression and 27% had hematologic progression. Median survival has not been reached and the 1-year survival rate is 76%. Baseline NT-proBNP was independently associated with survival (P = .001), while in a landmark analysis, survival was associated with NT-proBNP reduction of &gt; or = 30% (P = .006) and achievement of hematologic response (P = .001). Toxicity was manageable and mostly consisted of neuropathy, orthostasis, peripheral edema, and constipation or diarrhea. CONCLUSION Bortezomib with or without dexamethasone is active in AL amyloidosis and induces rapid responses and high rates of hematologic and organ responses. Serial measurement of cardiac biomarkers is a powerful predictor of outcome.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kastritis</LastName>
            <ForeName>Efstathios</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Clinical Therapeutics, University of Athens School of Medicine, 80 Vas. Sofias Ave, 115 28, Athens, Greece.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wechalekar</LastName>
            <ForeName>Ashutosh D</ForeName>
            <Initials>AD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Dimopoulos</LastName>
            <ForeName>Meletios A</ForeName>
            <Initials>MA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Merlini</LastName>
            <ForeName>Giampaolo</ForeName>
            <Initials>G</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hawkins</LastName>
            <ForeName>Philip N</ForeName>
            <Initials>PN</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Perfetti</LastName>
            <ForeName>Vittorio</ForeName>
            <Initials>V</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gillmore</LastName>
            <ForeName>Julian D</ForeName>
            <Initials>JD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Palladini</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>G7900510</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016448">Multicenter Study</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2010</Year>
        <Month>01</Month>
        <Day>19</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Clin Oncol</MedlineTA>
    <NlmUniqueID>8309333</NlmUniqueID>
    <ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D001897">Boronic Acids</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>69G8BD63PP</RegistryNumber>
        <NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>7S5I7G3JQL</RegistryNumber>
        <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
    <CommentsCorrections RefType="CommentIn">
        <RefSource>Clin J Am Soc Nephrol. 2010 Nov;5(11):1912-5</RefSource>
        <PMID Version="1">20947791</PMID>
    </CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001897" MajorTopicYN="N">Boronic Acids</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="entrez">
        <Year>2010</Year>
        <Month>1</Month>
        <Day>21</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2010</Year>
        <Month>1</Month>
        <Day>21</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2010</Year>
        <Month>3</Month>
        <Day>24</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">20085941</ArticleId>
    <ArticleId IdType="pii">JCO.2009.23.8220</ArticleId>
    <ArticleId IdType="doi">10.1200/JCO.2009.23.8220</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">19944662</PMID>
<DateCompleted>
    <Year>2010</Year>
    <Month>05</Month>
    <Day>12</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1877-0568</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>95</Volume>
            <Issue>8</Issue>
            <PubDate>
                <Year>2009</Year>
                <Month>Dec</Month>
            </PubDate>
        </JournalIssue>
        <Title>Orthopaedics &amp; traumatology, surgery &amp; research : OTSR</Title>
        <ISOAbbreviation>Orthop Traumatol Surg Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Common peroneal nerve palsy following TNF-based isolated limb perfusion for irresectable extremity desmoid tumor.</ArticleTitle>
    <Pagination>
        <MedlinePgn>639-44</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.otsr.2009.09.009</ELocationID>
    <Abstract>
        <AbstractText>Hyperthermic isolated limb perfusion (ILP) (2 mg, TNF-alpha and 100mg, melphalan) was performed for an irresectable right thigh desmoid tumor with calf extension in a 49-year-old man. The patient had a history of four resections since the age of 19 years. Local ILP toxicity appeared with extensive edema and common peroneal neurologic impairment including paresis that remained severe 10 months later. One of the most troublesome side effects of perfusion is peripheral nerve damage, which has been reported at a rate of between 1 and 48% of perfused patients. ILP is an effective treatment in recurrence situations or where resection threatens loss of function; it, however, requires administration in specialized centers, progress in standardization and close monitoring to avoid locoregional toxicity, the mechanisms of which merit further investigation. Emergency compartmental pressure measurement may indicate fasciotomy, can be of great interest.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Drouet</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Neurology Department, Desgenettes Military Teaching Hospital, 108, boulevard Pinel, 69275 Lyon cedex 3, France. drouetalain@yahoo.fr</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Le Moigne</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Have</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Blondet</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jacquin</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chauvin</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>France</Country>
    <MedlineTA>Orthop Traumatol Surg Res</MedlineTA>
    <NlmUniqueID>101494830</NlmUniqueID>
    <ISSNLinking>1877-0568</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>Q41OR9510P</RegistryNumber>
        <NameOfSubstance UI="D008558">Melphalan</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010478" MajorTopicYN="N">Chemotherapy, Cancer, Regional Perfusion</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018222" MajorTopicYN="N">Fibromatosis, Aggressive</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008558" MajorTopicYN="N">Melphalan</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010543" MajorTopicYN="N">Peroneal Nerve</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012983" MajorTopicYN="N">Soft Tissue Neoplasms</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013848" MajorTopicYN="N">Thigh</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2008</Year>
        <Month>09</Month>
        <Day>25</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2009</Year>
        <Month>05</Month>
        <Day>18</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2009</Year>
        <Month>09</Month>
        <Day>01</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2009</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2009</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2010</Year>
        <Month>5</Month>
        <Day>13</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">19944662</ArticleId>
    <ArticleId IdType="pii">S1877-0568(09)00167-4</ArticleId>
    <ArticleId IdType="doi">10.1016/j.otsr.2009.09.009</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">19027832</PMID>
<DateCompleted>
    <Year>2009</Year>
    <Month>03</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2015</Year>
    <Month>11</Month>
    <Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1873-2747</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>78</Volume>
            <Issue>4-5</Issue>
            <PubDate>
                <Year>2009</Year>
                <Month>Mar</Month>
                <Day>16</Day>
            </PubDate>
        </JournalIssue>
        <Title>Brain research bulletin</Title>
        <ISOAbbreviation>Brain Res Bull</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Serum S100B, brain edema, and hematoma formation in a rat model of collagenase-induced hemorrhagic stroke.</ArticleTitle>
    <Pagination>
        <MedlinePgn>158-63</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brainresbull.2008.10.012</ELocationID>
    <Abstract>
        <AbstractText>S100B, a 21-kD Ca(2+) binding protein expressed in Schwann cells and astroglia, has often been reported as a promising biomarker for ischemic stroke. In addition to ischemic stroke, the peripheral S100B level may also be useful as a biomarker for intracerebral hemorrhage (ICH). However, the kinetics and characterization of peripheral S100B in patients or experimental animal models with ICH have not been carefully examined. The present study investigated the kinetics and characteristics of the serum S100B level in a rat collagenase-induced ICH model. The serum S100B kinetics and the time-course of brain edema and hematoma formation were examined. Then, the correlations between the elevated serum S100B level and brain edema or hematoma formation were investigated. A transient elevation of serum S100B that peaked at 6 h after ICH induction was observed. The single measurement of serum S100B at 6 h after ICH induction was significantly correlated with brain edema formation and the maximal extent of the hematoma volumes. These results suggest the significance of serum S100B as a biomarker of brain damage resulting from ICH.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
                <Affiliation>Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan. yu.tanaka@po.rd.taisho.co.jp</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Marumo</LastName>
            <ForeName>Toshiyuki</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shibuta</LastName>
            <ForeName>Hiromi</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Omura</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Shigeru</ForeName>
            <Initials>S</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2008</Year>
        <Month>11</Month>
        <Day>21</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Brain Res Bull</MedlineTA>
    <NlmUniqueID>7605818</NlmUniqueID>
    <ISSNLinking>0361-9230</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C579158">S100b protein, rat</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 3.4.24.-</RegistryNumber>
        <NameOfSubstance UI="D017364">Collagenases</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017364" MajorTopicYN="N">Collagenases</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006406" MajorTopicYN="N">Hematoma</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D064568" MajorTopicYN="N">S100 Calcium Binding Protein beta Subunit</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2008</Year>
        <Month>04</Month>
        <Day>07</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2008</Year>
        <Month>10</Month>
        <Day>23</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2008</Year>
        <Month>10</Month>
        <Day>23</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>11</Month>
        <Day>26</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2009</Year>
        <Month>3</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>11</Month>
        <Day>26</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">19027832</ArticleId>
    <ArticleId IdType="pii">S0361-9230(08)00369-9</ArticleId>
    <ArticleId IdType="doi">10.1016/j.brainresbull.2008.10.012</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18980090</PMID>
<DateCompleted>
    <Year>2009</Year>
    <Month>01</Month>
    <Day>23</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0966-8519</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>5</Issue>
            <PubDate>
                <Year>2008</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>The Journal of heart valve disease</Title>
        <ISOAbbreviation>J Heart Valve Dis</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema.</ArticleTitle>
    <Pagination>
        <MedlinePgn>557-65</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="BACKGROUND AND AIM OF THE STUDY" NlmCategory="OBJECTIVE">The study aim was to perform a comprehensive evaluation of the association between N-terminal pro B-type natriuretic peptide (NT-proBNP) and the severity of heart valve diseases in a typical clinical population presenting with acute dyspnea or peripheral edema.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Among 401 eligible patients, 210 demonstrated evaluable complete echocardiographic examinations. Plasma levels of NT-proBNP were measured after the initial clinical evaluation.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with a prior valve replacement had higher plasma levels of NT-proBNP (median 3,366 pg/ml; n = 10) compared to all other patients (median 931 pg/ml; n = 200) (p &lt; 0.05). In univariable analyses, NT-proBNP levels correlated with multiple valve diseases (r = 0.5; p &lt; 0.001) and the severities of specific heart valve diseases, including aortic valve stenosis (AS) and regurgitation (AR), tricuspid (TR) and mitral valve regurgitation (MR) (p &lt; 0.001). Within multivariable linear regression models, multiple heart valve diseases (Beta = 0.21; T = 3.56; p = 0.0001) and specifically valve regurgitations (AR (Beta = 0.16; T = 2.54; p = 0.012), MR (Beta = 0.36; T = 5.55; p = 0.0001), TR (Beta = 0.17; T = 2.55; p = 0.012)) were associated with increasing plasma levels of NT-proBNP. Patients with NT-proBNP plasma levels &gt; 1,100 pg/ml showed the highest risk for future clinical events (odds ratio (OR) 4.86; p = 0.02), followed by patients with TR (OR 3.17; p = 0.03) and AS (OR 3.49; p = 0.06).</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In addition to clinical assessment and echocardiographic evaluation, the measurement of plasma NT-proBNP levels may serve as a valuable additional indicator of the severity of heart valve disease in individual patients.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Behnes</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>First Department of Medicine, Institute of Clinical Chemistry, Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lang</LastName>
            <ForeName>Siegfried</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Breithardt</LastName>
            <ForeName>Ole-A</ForeName>
            <Initials>OA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kaden</LastName>
            <ForeName>Jens J</ForeName>
            <Initials>JJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Haghi</LastName>
            <ForeName>Dariusch</ForeName>
            <Initials>D</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ahmad-Nejad</LastName>
            <ForeName>Parviz</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Elmas</LastName>
            <ForeName>Elif</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wolpert</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Borggrefe</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Neumaier</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Brueckmann</LastName>
            <ForeName>Martina</ForeName>
            <Initials>M</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>J Heart Valve Dis</MedlineTA>
    <NlmUniqueID>9312096</NlmUniqueID>
    <ISSNLinking>0966-8519</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>114471-18-0</RegistryNumber>
        <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018618" MajorTopicYN="N">Echocardiography, Doppler, Color</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017548" MajorTopicYN="N">Echocardiography, Transesophageal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004489" MajorTopicYN="N">Edema, Cardiac</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006349" MajorTopicYN="N">Heart Valve Diseases</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>11</Month>
        <Day>5</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2009</Year>
        <Month>1</Month>
        <Day>24</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>11</Month>
        <Day>5</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18980090</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18840367</PMID>
<DateCompleted>
    <Year>2009</Year>
    <Month>01</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0149-2918</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>30</Volume>
            <Issue>9</Issue>
            <PubDate>
                <Year>2008</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>Clinical therapeutics</Title>
        <ISOAbbreviation>Clin Ther</ISOAbbreviation>
    </Journal>
    <ArticleTitle>An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1618-28</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2008.09.008</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A combination of antihypertensive agents of different drug classes in a fixed-dose combination (FDC) may offer advantages in terms of efficacy, tolerability, and treatment compliance. Combination of a calcium channel blocker with an angiotensin-converting enzyme inhibitor may act synergistically to reduce blood pressure (BP).</AbstractText>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to compare the efficacy and tolerability of an amlodipine/ramipril FDC with those of amlodipine monotherapy.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">This 18-week, prospective, randomized, double-blind study was conducted at 8 centers across Brazil. Patients with stage 1 or 2 essential hypertension were enrolled. After a 2-week placebo run-in phase, patients received amlodipine/ramipril 2.5/2.5 mg or amlodipine 2.5 mg, after which the doses were titrated, based on BP, to 5/5 then 10/10 mg (amlodipine/ramipril) and 5 then 10 mg (amlodipine). The primary end point was BP measured in the intent-to-treat (ITT) population. Hematology and serum biochemistry were assessed at baseline and study end. Tolerability was assessed using patient interview, laboratory analysis, and physical examination, including measurement of ankle circumference to assess peripheral edema.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 222 patients completed the study (age range, 40-79 years; FDC group, 117 patients [mean dose, 7.60/7.60 mg]; monotherapy, 105 patients [mean dose, 7.97 mg]). The mean (SD) changes in systolic BP (SBP) and diastolic BP (DBP), as measured using 24-hour ambulatory blood pressure monitoring (ABPM) and in the physician's office, were significantly greater with combination therapy than monotherapy, with the exception of office DBP (ABPM, -20.76 [1.25] vs -15.80 [1.18] mm Hg and -11.71 [0.78] vs -8.61 [0.74] mm Hg, respectively [both, P = 0.004]; office, -27.51 [1.40] vs -22.84 [1.33] mm Hg [P = 0.012] and -16.41 [0.79] vs -14.64 [0.75] mm Hg [P = NS], respectively). In the ITT analysis, the mean changes in ambulatory, but not office-based, BP were statistically significant (ABPM: SBP, -20.21 [1.14] vs -15.31 [1.12] mm Hg and DBP, -11.61 [0.72] vs -8.42 [0.70] mm Hg, respectively [both, P = 0.002]; office: SBP, -26.60 [1.34] vs -22.97 [1.30] mm Hg and DBP, -16.48 [0.78] vs -14.48 [0.75] mm Hg [both, P = NS]). Twenty-nine patients (22.1%) treated with combination therapy and 41 patients (30.6%) treated with monotherapy experienced &gt; or =1 adverse event considered possibly related to study drug. The combination-therapy group had lower prevalence of edema (7.6% vs 18.7%; P = 0.011) and a similar prevalence of dry cough (3.8% vs 0.8%; P = NS). No clinically significant changes in laboratory values were found in either group.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this population of patients with essential hypertension, the amlodipine/ramipril FDC was associated with significantly reduced ambulatory and office-measured BP compared with amlodipine monotherapy, with the exception of office DBP. Both treatments were well tolerated.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Miranda</LastName>
            <ForeName>Roberto Dischinger</ForeName>
            <Initials>RD</Initials>
            <AffiliationInfo>
                <Affiliation>Federal University of Săo Paulo, Săo Paulo, Brazil. roberto.miranda@uol.com.br</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mion</LastName>
            <ForeName>Décio</ForeName>
            <Initials>D</Initials>
            <Suffix>Jr</Suffix>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rocha</LastName>
            <ForeName>Joăo Carlos</ForeName>
            <Initials>JC</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kohlmann</LastName>
            <ForeName>Oswaldo</ForeName>
            <Initials>O</Initials>
            <Suffix>Jr</Suffix>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gomes</LastName>
            <ForeName>Marco Antonio Mota</ForeName>
            <Initials>MA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Saraiva</LastName>
            <ForeName>José Francisco Kerr</ForeName>
            <Initials>JF</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Amodeo</LastName>
            <ForeName>Celso</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Filho</LastName>
            <ForeName>Bráulio Luna</ForeName>
            <Initials>BL</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016448">Multicenter Study</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Clin Ther</MedlineTA>
    <NlmUniqueID>7706726</NlmUniqueID>
    <ISSNLinking>0149-2918</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>1J444QC288</RegistryNumber>
        <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>L35JN3I7SJ</RegistryNumber>
        <NameOfSubstance UI="D017257">Ramipril</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="accepted">
        <Year>2008</Year>
        <Month>08</Month>
        <Day>06</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>10</Month>
        <Day>9</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2009</Year>
        <Month>1</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>10</Month>
        <Day>9</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18840367</ArticleId>
    <ArticleId IdType="pii">S0149-2918(08)00301-9</ArticleId>
    <ArticleId IdType="doi">10.1016/j.clinthera.2008.09.008</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18693046</PMID>
<DateCompleted>
    <Year>2009</Year>
    <Month>01</Month>
    <Day>23</Day>
</DateCompleted>
<DateRevised>
    <Year>2012</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1535-7732</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>10</Issue>
            <PubDate>
                <Year>2008</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of vascular and interventional radiology : JVIR</Title>
        <ISOAbbreviation>J Vasc Interv Radiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Pilot study of cryoplasty with use of PolarCath peripheral balloon catheter system for dialysis access.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1460-6</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvir.2008.06.010</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the safety and feasibility of cryoplasty as the initial balloon treatment for dialysis access venous stenoses.</AbstractText>
        <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Twenty patients with grafts (n = 18) or arteriovenous fistulas (n = 2) were enrolled in an institutional review board-approved prospective study. Patients with high venous dialysis pressures (n = 7), poor flow (n = 3), abnormal thrill (n = 3), nonmaturation (n = 2), poor clearance (n = 2), edema (n = 1), prolonged bleeding (n = 1), or recurrent clotting (n = 1) in the presence of stenoses &gt;/=50% were eligible. Mean stenosis measurement was 62.8% (range, 51%-82%). Mean lesion length was 2.57 cm (range, 0.4-5.7 cm). Device success required complete cryoplasty balloon expansion. Procedure success required anatomic success combined with a clinical or hemodynamic indicator of success. Primary circuit patency ended with any restenosis. Primary lesion patency ended with index lesion restenosis.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The device success rate was 53% (nine of 17). The anatomic success rate after cryoplasty was 35% (seven of 20). Eighty percent of lesions (16 of 20) were treated with conventional percutaneous transluminal angioplasty (PTA) balloons after cryoplasty. The procedure success rate after supplemental PTA was 80% (16 of 20). The primary circuit patency rates were 82% (14 of 17) at 3 months and 19% (three of 16) at 6 months. The primary lesion patency rates were 88% (15 of 17) at 3 months and 25% (four of 16) at 6 months. All patients reported pain during cryoplasty, and the 16 who underwent supplemental PTA described cryoplasty as more painful than PTA. Cryoplasty-related complications included one case of transient spasm.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of the PolarCath peripheral balloon catheter system as the initial balloon for dialysis access venous stenoses is safe but painful. Anatomic success rates after cryoplasty are low. Results of cryoplasty supplemented by PTA appear comparable to those of PTA alone.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Gray</LastName>
            <ForeName>Richard J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Radiology, Georgetown University School of Medicine, Washington Hospital Center, 110 Irving Street Northwest, Washington, DC 20010, USA. rgray@aacllc.com</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Varma</LastName>
            <ForeName>Jay D</ForeName>
            <Initials>JD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cho</LastName>
            <ForeName>Sung S</ForeName>
            <Initials>SS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Lisa C</ForeName>
            <Initials>LC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2008</Year>
        <Month>08</Month>
        <Day>09</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Vasc Interv Radiol</MedlineTA>
    <NlmUniqueID>9203369</NlmUniqueID>
    <ISSNLinking>1051-0443</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D002404" MajorTopicYN="N">Catheterization</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003452" MajorTopicYN="N">Cryosurgery</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003956" MajorTopicYN="N">Dialysis</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019544" MajorTopicYN="N">Equipment Failure Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014689" MajorTopicYN="N">Venous Insufficiency</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2007</Year>
        <Month>11</Month>
        <Day>06</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2008</Year>
        <Month>06</Month>
        <Day>12</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2008</Year>
        <Month>06</Month>
        <Day>16</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>8</Month>
        <Day>12</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2009</Year>
        <Month>1</Month>
        <Day>24</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>8</Month>
        <Day>12</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18693046</ArticleId>
    <ArticleId IdType="pii">S1051-0443(08)00589-7</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jvir.2008.06.010</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18609482</PMID>
<DateCompleted>
    <Year>2008</Year>
    <Month>09</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>09</Month>
    <Day>17</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1120-6721</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>4</Issue>
            <PubDate>
                <MedlineDate>2008 Jul-Aug</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>European journal of ophthalmology</Title>
        <ISOAbbreviation>Eur J Ophthalmol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection.</ArticleTitle>
    <Pagination>
        <MedlinePgn>601-8</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of this study was to assess macular function by multifocal electroretinography (mfERG) in eyes with diabetic macular edema (DME) after intravitreal triamcinolone acetonide (IVTA) injection.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Fifteen eyes of 15 patients with DME scheduled for 4 mg IVTA injection were prospectively recruited. The response to treatment was monitored functionally by visual acuity (VA) measurement and mfERG and anatomically by foveal thickness measured by optical coherence tomography (OCT). The first-order kernel P1 mfERG responses from 0 to 7 degrees (central) and 7 to 25 degrees (peripheral) were grouped and analyzed. Changes in functional parameters (VAs and the P1 mfERG response amplitudes and peak latencies) and morphometric parameters (OCT foveal thickness) in eyes with DME 1 and 3 months after IVTA injection were compared with baseline values by Student t test.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean baseline logMAR value for VAs of the patients before treatment was 0.49+/-0.26. After treatment, it was 0.27+/-0.23 at 1 month and 0.26+/-0.18 at 3 months, and differences from pretreatment values were significant (for each, p&lt;0.001). There were statistically significant decreases in the mean foveal thickness at 1 and 3 months after treatment compared with pretreatment values (for each, p&lt;0.001). There were also statistically significant increases in the mean P1 response amplitude for both central and peripheral groups at all examinations compared with pretreatment (for each, p&lt;0.001). The mean P1 peak latencies for both the central and peripheral groups were shortened, but not significantly.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As well as the reduction in DME and improvement in VA, IVTA injection improves macular function as assessed by mfERG in diabetic patients.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Karacorlu</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>The Istanbul Retina Institute Inc., Istanbul, Turkey. retina@pobox.com</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ozdemir</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Senturk</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Arf Karacorlu</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Uysal</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Eur J Ophthalmol</MedlineTA>
    <NlmUniqueID>9110772</NlmUniqueID>
    <ISSNLinking>1120-6721</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>F446C597KA</RegistryNumber>
        <NameOfSubstance UI="D014222">Triamcinolone Acetonide</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003930" MajorTopicYN="N">Diabetic Retinopathy</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004596" MajorTopicYN="Y">Electroretinography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008266" MajorTopicYN="N">Macula Lutea</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014222" MajorTopicYN="N">Triamcinolone Acetonide</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014822" MajorTopicYN="N">Vitreous Body</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>7</Month>
        <Day>9</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2008</Year>
        <Month>9</Month>
        <Day>3</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>7</Month>
        <Day>9</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18609482</ArticleId>
    <ArticleId IdType="doi">10.1177/112067210801800417</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18603317</PMID>
<DateCompleted>
    <Year>2009</Year>
    <Month>09</Month>
    <Day>01</Day>
</DateCompleted>
<DateRevised>
    <Year>2015</Year>
    <Month>11</Month>
    <Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1874-1754</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>135</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2009</Year>
                <Month>Jun</Month>
                <Day>26</Day>
            </PubDate>
        </JournalIssue>
        <Title>International journal of cardiology</Title>
        <ISOAbbreviation>Int J Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema.</ArticleTitle>
    <Pagination>
        <MedlinePgn>165-74</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2008.03.045</ELocationID>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study was to determine the diagnostic power of a newly available assay for amino-terminal pro-brain natriuretic peptide (NT-proBNP) to identify patients with acute heart failure. In addition, the influence of initial NT-proBNP measurements on economic consequences, diagnostic procedures and staff involvement was evaluated.</AbstractText>
        <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">401 patients presenting with acute dyspnea or peripheral edema in the emergency department were enrolled. NT-proBNP was measured after initial clinical evaluation. Clinical routine care and diagnostic assessment were blinded to NT-proBNP results. Two cardiologists independently validated the period of hospitalization, clinical examinations and medical therapies of each patient considering NT-proBNP results. The median NT-proBNP level among patients with acute congestive heart failure (CHF) (n=122) was 3497 pg/ml as compared to 320 pg/ml in patients without (n=279) (p&lt;0.0001). An NT-proBNP cutoff level &lt;300 pg/ml was optimal to rule out acute CHF (negative predictive value 96%; sensitivity 96%). NT-proBNP &gt;or=300 pg/ml could strongly predict acute CHF when compared to patients' history or physical examination (odds ratio 9.5; p&lt;0.0001) and diagnostic technical findings (odds ratio 14.7; p&lt;0.05). In patients with NT-proBNP&lt;300 pg/ml, 14% of the period of hospitalization could be saved, corresponding to savings of US $481 per patient. In addition, 9% of the number and time of staff involvement of clinical examinations and therapies could be saved, 10% of the costs of clinical examinations. Chest X-rays were saved in 34%, echocardiography in 9%.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Measurement of NT-proBNP leads to multiple saving amounts and optimizes diagnostic pathways and resource allocation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Behnes</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Brueckmann</LastName>
            <ForeName>Martina</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ahmad-Nejad</LastName>
            <ForeName>Parviz</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lang</LastName>
            <ForeName>Siegfried</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wolpert</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Elmas</LastName>
            <ForeName>Elif</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kaelsch</LastName>
            <ForeName>Thorsten</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gruettner</LastName>
            <ForeName>Joachim</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Weiss</LastName>
            <ForeName>Christel</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Borggrefe</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Neumaier</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2008</Year>
        <Month>07</Month>
        <Day>07</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>Netherlands</Country>
    <MedlineTA>Int J Cardiol</MedlineTA>
    <NlmUniqueID>8200291</NlmUniqueID>
    <ISSNLinking>0167-5273</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>114471-18-0</RegistryNumber>
        <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002624" MajorTopicYN="N">Chemistry, Clinical</DescriptorName>
        <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017046" MajorTopicYN="N">Cost Savings</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004632" MajorTopicYN="N">Emergency Medical Services</DescriptorName>
        <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017721" MajorTopicYN="N">Hospital Costs</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2008</Year>
        <Month>01</Month>
        <Day>12</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2008</Year>
        <Month>03</Month>
        <Day>06</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>7</Month>
        <Day>8</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2009</Year>
        <Month>9</Month>
        <Day>2</Day>
        <Hour>6</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>7</Month>
        <Day>8</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18603317</ArticleId>
    <ArticleId IdType="pii">S0167-5273(08)00510-X</ArticleId>
    <ArticleId IdType="doi">10.1016/j.ijcard.2008.03.045</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18552607</PMID>
<DateCompleted>
    <Year>2008</Year>
    <Month>07</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2017</Year>
    <Month>11</Month>
    <Day>16</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1057-0829</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>4</Issue>
            <PubDate>
                <MedlineDate>2008 Jun-Jul</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Journal of glaucoma</Title>
        <ISOAbbreviation>J Glaucoma</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection.</ArticleTitle>
    <Pagination>
        <MedlinePgn>253-6</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1097/IJG.0b013e31815c3a07</ELocationID>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To find out the relationship between steroid-induced intraocular pressure (IOP) rise and the plasma levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-2 (TIMP-2) in diabetic patients who underwent intravitreal triamcinolone acetonide (IVTA) injection for the treatment of diabetic macular edema.</AbstractText>
        <AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">A total of 34 patients with diabetic macular edema who were treated with IVTA and 17 healthy subjects who served as control group for plasma MMP and TIMP levels were participated. Before IVTA treatment, patients and control subjects underwent complete ophthalmologic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, IOP measurement with Goldmann applanation tonometry, and indirect ophthalmoscopy; and peripheral blood samples were collected from each study participants. Plasma levels of MMP-9, TIMP-2, and HbA1c levels were measured. Patients were seen 1, 6, 12, and 24 weeks after treatment and then every 6 months for up to 1 year for probable IOP rise. Patients were divided into 2 groups as having nonproliferative or proliferative diabetic retinopathy. These 2 groups were further classified according to their IOP levels as normal or elevated IOP (&gt;21 mm Hg).</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of diabetic group of patients (n=34) and healthy control subjects (n=17) were 57.6+/-10.2 years (range: 22 to 70 y) and 53.1+/-10.3 years (range: 29 to 68 y), respectively. Seventeen (50%) diabetic patients had developed elevated IOP after a mean 2.2 months after IVTA injection. MMP-9 and TIMP-2 levels were found to be significantly higher in the diabetic groups with and without elevated IOP when compared with control group (P&lt;0.001). MMP-9/TIMP-2 did not change significantly among the groups. Logistic regression analysis showed that only higher plasma TIMP-2 levels increase the risk of IOP elevation after IVTA injection in proliferative diabetic retinopathy (odds ratio=1.06, P&lt;0.05). No significant relationship was found between IOP rise and HbA1c levels.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The high levels of TIMP in diabetic patients might have a role on steroid-induced IOP rise. The key pathogenetic events that up-regulate TIMP levels should be investigated in steroid IOP rise in diabetics.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Yildirim</LastName>
            <ForeName>Nilgun</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Eskisehir Osmangazi University Hospital, Eskisehir, Turkey. nyyildirim@yahoo.com</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sahin</LastName>
            <ForeName>Afsun</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Erol</LastName>
            <ForeName>Nazmiye</ForeName>
            <Initials>N</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kara</LastName>
            <ForeName>Selcuk</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Uslu</LastName>
            <ForeName>Sema</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Topbas</LastName>
            <ForeName>Seyhan</ForeName>
            <Initials>S</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Glaucoma</MedlineTA>
    <NlmUniqueID>9300903</NlmUniqueID>
    <ISSNLinking>1057-0829</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>127497-59-0</RegistryNumber>
        <NameOfSubstance UI="D019716">Tissue Inhibitor of Metalloproteinase-2</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 3.4.24.35</RegistryNumber>
        <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>F446C597KA</RegistryNumber>
        <NameOfSubstance UI="D014222">Triamcinolone Acetonide</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003930" MajorTopicYN="N">Diabetic Retinopathy</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007429" MajorTopicYN="N">Intraocular Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009798" MajorTopicYN="N">Ocular Hypertension</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019716" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-2</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014065" MajorTopicYN="N">Tonometry, Ocular</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014222" MajorTopicYN="N">Triamcinolone Acetonide</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014822" MajorTopicYN="N">Vitreous Body</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>6</Month>
        <Day>17</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2008</Year>
        <Month>7</Month>
        <Day>25</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>6</Month>
        <Day>17</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18552607</ArticleId>
    <ArticleId IdType="doi">10.1097/IJG.0b013e31815c3a07</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18379256</PMID>
<DateCompleted>
    <Year>2008</Year>
    <Month>04</Month>
    <Day>28</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>12</Month>
    <Day>09</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1530-0293</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2008</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>Critical care medicine</Title>
        <ISOAbbreviation>Crit Care Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Assessment of vascular permeability in an ovine model of acute lung injury and pneumonia-induced Pseudomonas aeruginosa sepsis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1284-9</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e318169ef74</ELocationID>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the time changes and mechanism of pulmonary and peripheral vascular permeability in sheep with acute lung injury and sepsis.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, controlled, randomized trial.</AbstractText>
        <AbstractText Label="SETTING" NlmCategory="METHODS">University research laboratory.</AbstractText>
        <AbstractText Label="SUBJECTS" NlmCategory="METHODS">A total of 21 chronically instrumented, adult female sheep.</AbstractText>
        <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Sheep were instrumented with lung and prefemoral lymph fistulas and allocated to either an uninjured control group (n = 5) or sepsis group (n = 5). The sheep in the sepsis group received cotton smoke inhalation injury followed by instillation of Pseudomonas aeruginosa into the lungs. All sheep were mechanically ventilated and fluid resuscitated for the entire duration of the 24-hr experiment. Additional sheep (n = 11) received injury and were killed at different time points for the measurement of vascular endothelial growth factor in lung tissue.</AbstractText>
        <AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">The injury induced a hypotensive-hyperdynamic circulation; increases in pulmonary capillary pressure, net fluid balance, lung and prefemoral lymph flow and protein content, lung water content, abdominal and thoracic fluid and protein content, neutrophil accumulation in the lung, and vascular endothelial growth factor expression in lung tissue; and decreases in PaO2/FiO2 ratio, plasma protein concentration, plasma oncotic pressure, and myocardial contractility.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lung edema formation in this model was the result of marked increases in both pulmonary microvascular permeability and pressure. Pulmonary vascular hyperpermeability peaked 12 hrs postinjury and was related to vascular endothelial growth factor overexpression. Early myocardial failure was a potential contributor to the constant increase in pulmonary capillary pressure. The sepsis-induced increase in peripheral microvascular permeability was associated with significant accumulation of fluid and protein in the third space.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Lange</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology, Investigational Intensive Care Unit, The University of Texas Medical Branch and Shriners Burns Hospital for Children, Galveston, TX, USA. lanm@gmx.de</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hamahata</LastName>
            <ForeName>Atsumori</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Enkhbaatar</LastName>
            <ForeName>Perenlei</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Esechie</LastName>
            <ForeName>Aimalohi</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Connelly</LastName>
            <ForeName>Rhykka</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nakano</LastName>
            <ForeName>Yoshimitsu</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jonkam</LastName>
            <ForeName>Collette</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cox</LastName>
            <ForeName>Robert A</ForeName>
            <Initials>RA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Traber</LastName>
            <ForeName>Lillian D</ForeName>
            <Initials>LD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Herndon</LastName>
            <ForeName>David N</ForeName>
            <Initials>DN</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Traber</LastName>
            <ForeName>Daniel L</ForeName>
            <Initials>DL</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>GM060688</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>GM066312</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Crit Care Med</MedlineTA>
    <NlmUniqueID>0355501</NlmUniqueID>
    <ISSNLinking>0090-3493</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012756" MajorTopicYN="N">Sheep</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2008</Year>
        <Month>4</Month>
        <Day>2</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2008</Year>
        <Month>4</Month>
        <Day>29</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2008</Year>
        <Month>4</Month>
        <Day>2</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18379256</ArticleId>
    <ArticleId IdType="doi">10.1097/CCM.0b013e318169ef74</ArticleId>
    <ArticleId IdType="pii">00003246-200804000-00034</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18035937</PMID>
<DateCompleted>
    <Year>2008</Year>
    <Month>03</Month>
    <Day>03</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1539-6851</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2007</Year>
            </PubDate>
        </JournalIssue>
        <Title>Lymphatic research and biology</Title>
        <ISOAbbreviation>Lymphat Res Biol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Clinical assessment of human lymph flow using removal rate constants of interstitial macromolecules: a critical review of lymphoscintigraphy.</ArticleTitle>
    <Pagination>
        <MedlinePgn>183-202</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Edema is a common clinical problem, and the daily avoidance of edema depends critically on the lymphatic system, which clears leaked plasma proteins and fluid from the interstitial compartment. There is often confusion as to the difference between chronic edema and lymphedema. Lymphedema is by definition primarily a disease of impaired lymphatic drainage and lymph flow, and progress in lymphedema research, currently an increasingly active field, requires a clinically viable method for the quantitative assessment of lymph drainage rate in patients. Measurement of the rate of clearance of a new protein marker, radiolabelled human immunoglobulin, from skin, subcutis, and muscle provides a way of measuring human lymph flow quantitatively and is the only viable clinical method currently available. Considerable strides have been made over the last 5-10 years in evaluating the method and its pitfalls, including potential complications such as vascular clearance, peripheral lymphovenous communications and label dissociation. The review assesses critically, for the first time, the evidence relating to the method: its pitfalls; human lymph flow in various healthy and oedematous tissues; and how this is altered in hyperfiltration edemas, inflammation, vasoconstriction and various primary and secondary human lymphedemas.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Modi</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Cardiac &amp; Vascular Sciences (Dermatology), St. George's Hospital Medical School, University of London, United Kingdom.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Stanton</LastName>
            <ForeName>A W B</ForeName>
            <Initials>AW</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mortimer</LastName>
            <ForeName>P S</ForeName>
            <Initials>PS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Levick</LastName>
            <ForeName>J R</ForeName>
            <Initials>JR</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Lymphat Res Biol</MedlineTA>
    <NlmUniqueID>101163587</NlmUniqueID>
    <ISSNLinking>1539-6851</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008196" MajorTopicYN="N">Lymph</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D061305" MajorTopicYN="Y">Lymphoscintigraphy</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>90</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2007</Year>
        <Month>11</Month>
        <Day>27</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2008</Year>
        <Month>3</Month>
        <Day>4</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2007</Year>
        <Month>11</Month>
        <Day>27</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">18035937</ArticleId>
    <ArticleId IdType="doi">10.1089/lrb.2007.5306</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17969895</PMID>
<DateCompleted>
    <Year>2008</Year>
    <Month>12</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>10</Month>
    <Day>18</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1003-5370</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>27</Volume>
            <Issue>9</Issue>
            <PubDate>
                <Year>2007</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine</Title>
        <ISOAbbreviation>Zhongguo Zhong Xi Yi Jie He Za Zhi</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Protective effect of Noningkang Granule on brain in intracerebral hemorrhagic rats].</ArticleTitle>
    <Pagination>
        <MedlinePgn>814-8</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the protective effect and mechanism of Naoningkang Granule (NG), a Chinese medicinal preparation formulated for clearing heat and detoxication, on brain tissue in intracerebral hemorrhagic (ICH) rats.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Rats were randomly divided into 5 groups: the sham operated group, the model group and the high-, medium- and low-dose NG groups. Collagenase VII was injected into caudate nucleus to induce rat model of ICH, corresponding dosage of NG was started to give to the 3 NG groups by gastrogavage 2 h after modeling, and saline of equal volume was given to the other 2 groups instead. The brain tissue of rats was taken in batches at the 3rd and 7th day for pathomorphological observation using HE stain, and detection of thrombin receptor-1 (PAR-1) expression and nerve cell apoptosis in the peripheral tissue of hemorrhagic brain with immunohistochemistry and TUNEL assay, as well as for measurement of water content in brain tissue by wet-to-dry weight method.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">PAR-1 expression elevated in the model rats. As compared with the model group, the pathomorphological changes significantly improved, PAR-1 expression decreased, apoptotic cells re-duced and brain edema alleviated in the 3 NG groups.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overexpression of PAR-1 in the brain tissue might mediate the nerve cell apoptosis and brain edema in ICH rats. The mechanism of NG in protecting hemor-rhagic brain tissue might be related with its actions in inhibiting the post-cerebral high PAR-1 expression to re-duce cell apoptosis and relieve brain edema.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Qing-Bo</ForeName>
            <Initials>QB</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Neurology, The Second Affiliated Hospital of Shandong University, Jinan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lu-Yang</ForeName>
            <Initials>LY</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
        </Author>
    </AuthorList>
    <Language>chi</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>China</Country>
    <MedlineTA>Zhongguo Zhong Xi Yi Jie He Za Zhi</MedlineTA>
    <NlmUniqueID>9211576</NlmUniqueID>
    <ISSNLinking>1003-5370</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D044463">Receptor, PAR-1</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C533632">naoningkang</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName>
        <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D044463" MajorTopicYN="N">Receptor, PAR-1</DescriptorName>
        <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2007</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2008</Year>
        <Month>12</Month>
        <Day>17</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2007</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">17969895</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17664993</PMID>
<DateCompleted>
    <Year>2008</Year>
    <Month>03</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>06</Month>
    <Day>06</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Electronic">1678-4170</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>88</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2007</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Arquivos brasileiros de cardiologia</Title>
        <ISOAbbreviation>Arq Bras Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Medial hypertrophy in patients with pulmonary embolism: anatomopathological study.</ArticleTitle>
    <Pagination>
        <MedlinePgn>660-6</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the arterial response of cases of acute and chronic embolism, seeking to associate ischemic pulmonary remodeling with progression to chronicity.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective analysis of 61 necropsies of patients who died in the Instituto do Coração (31 cases of pulmonary embolism and 30 cases of acute myocardial infarction). Slides of pulmonary tissue were obtained from all cases and analyzed qualitative and quantitatively (medial thickness measurement).</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Qualitative analysis enabled the differentiation between cases of embolism and the control group, thus characterizing the two groups and defining the adequate choice of the control group. The alterations predominated in patients with embolism (alveolar inflammation and edema, infarction, vasoconstriction, concentric intimal proliferation, presence of thrombus). Quantitative analysis demonstrated higher percent medial thickness in the cases of embolism than in the control group; among the cases of embolism, no differences in intra (acute--19.74 and chronic--20.04) and pre-acinar (acute--18.85 and chronic--18.68) arteries were observed.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The lack of difference among the groups with embolism and the higher values of percent medial thickness in the peripheral arteries allow the conclusion that the vascular response is more intense and starts in these arteries.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Arnoni</LastName>
            <ForeName>Renato Tambellini</ForeName>
            <Initials>RT</Initials>
            <AffiliationInfo>
                <Affiliation>Instituto do Coração, Hospital das Clínicas, FM, USP, São Paulo, SP, Brasil. rarnoni@uol.com.br</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jatene</LastName>
            <ForeName>Fábio Biscegli</ForeName>
            <Initials>FB</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bernardo</LastName>
            <ForeName>Wanderley Marques</ForeName>
            <Initials>WM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Aiello</LastName>
            <ForeName>Vera Demarchi</ForeName>
            <Initials>VD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jatene</LastName>
            <ForeName>Tanas</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Monteiro</LastName>
            <ForeName>Rosângela</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Demarchi</LastName>
            <ForeName>Lea Maria Macruz</ForeName>
            <Initials>LM</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <Language>por</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Brazil</Country>
    <MedlineTA>Arq Bras Cardiol</MedlineTA>
    <NlmUniqueID>0421031</NlmUniqueID>
    <ISSNLinking>0066-782X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006984" MajorTopicYN="N">Hypertrophy</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName>
        <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
        <QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017539" MajorTopicYN="N">Tunica Intima</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2006</Year>
        <Month>12</Month>
        <Day>03</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2007</Year>
        <Month>01</Month>
        <Day>09</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2007</Year>
        <Month>8</Month>
        <Day>1</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2008</Year>
        <Month>3</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2007</Year>
        <Month>8</Month>
        <Day>1</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">17664993</ArticleId>
    <ArticleId IdType="pii">S0066-782X2007000600006</ArticleId>
    <ArticleId IdType="doi">10.1590/s0066-782x2007000600006</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17373163</PMID>
<DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>13</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1545-9616</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2007</Year>
                <Month>Jan</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of drugs in dermatology : JDD</Title>
        <ISOAbbreviation>J Drugs Dermatol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Hair removal with the 3-msec alexandrite laser in patients with skin types IV-VI: efficacy, safety, and the role of topical corticosteroids in preventing side effects.</ArticleTitle>
    <Pagination>
        <MedlinePgn>60-6</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Laser hair removal targets melanin in the hair shaft. The abundance of melanin in the epidermis of patients with dark skin color has always been regarded as hazardous due to the increased incidence of side effects in this patient population.</AbstractText>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To establish the efficacy and safety of using the 3-msec alexandrite laser in patients with skin types IV to VI, and evaluate the role of topical corticosteroids in preventing side effects.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-seven patients with skin types IV to VI and brown or black hair were recruited and divided into 2 groups. Twenty-six patients were treated with the 18-mm spot size and 11 patients were treated with the 15-mm spot size. Hair shafts in the treatment and control areas were counted and clipped for measurement of the thickness at the base. The laser was used with fluences between 8 and 32 J/cm2. Two 16-cm2 areas were treated; one area was pretreated with a class I topical corticosteroid (TCS) cream (betamethasone dipropionate) 10 minutes prelaser and twice a day for 5 days postlaser. The dynamic cooling device (DCD) spray duration was set at 90 msec, and the delay was set at 20 msec. Pain was graded on a scale from I to 10. Patients were followed up on day 1 and day 7 and at 1, 3, and 6 months. Histological samples from the 2 treatment areas and control were obtained from 5 patients. At follow-up visits, side effects were graded on a scale from 1 to 3. Hair reduction was evaluated by performing hair counts. The thickness of hair was measured microscopically at the base. Average hair count reduction and hair thickness were recorded at the 3- and 6-month visits.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-one patients completed the study. The average hair count reduction at 6 months was 35.4%. The average hair thickness reduction was 31.2%. At one week hyperpigmentation was seen in 48.4% of the laser only treated area and in 45.2% of laser/TCS treated area. The effect of TCS was minimal and more prominent at 1 and 3 months. The incidence of hyperpigmentation was higher in the 15-mm group than the 18-mm group as a result of using higher fluence. Hypopigmentation was generally preceded by crust formation and lasted up to 3 months. Reducing spot size resulted in decreased peripheral crust formation. TCS appears to have a role in reducing the erythema and crusting. Histopathology of both groups at day one showed necrosis of the follicular infundibulum and the inner layer of the perifollicular epithelium. No vascular damage was seen.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The 3-msec alexandrite laser utilized in this study provides a safe and effective treatment achieving long-term reduction of unwanted, pigmented hair in skin types IV and V, but is less safe in skin type VI. Using a TCS helps in minimizing post-treatment erythema and edema; it also decreases the duration of hyperpigmentation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Aldraibi</LastName>
            <ForeName>Mohammed S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
                <Affiliation>King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Touma</LastName>
            <ForeName>Dany J</ForeName>
            <Initials>DJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Khachemoune</LastName>
            <ForeName>Amor</ForeName>
            <Initials>A</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Drugs Dermatol</MedlineTA>
    <NlmUniqueID>101160020</NlmUniqueID>
    <ISSNLinking>1545-9616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="C112654">alexandrite</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>OW5102UV6N</RegistryNumber>
        <NameOfSubstance UI="D001608">Beryllium</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001608" MajorTopicYN="N">Beryllium</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004817" MajorTopicYN="N">Epidermis</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004890" MajorTopicYN="N">Erythema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018859" MajorTopicYN="N">Hair Follicle</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006204" MajorTopicYN="N">Hair Removal</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017495" MajorTopicYN="N">Hyperpigmentation</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017496" MajorTopicYN="N">Hypopigmentation</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D028022" MajorTopicYN="N">Low-Level Light Therapy</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
        <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012880" MajorTopicYN="N">Skin Pigmentation</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012881" MajorTopicYN="N">Skin Temperature</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2007</Year>
        <Month>3</Month>
        <Day>22</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2007</Year>
        <Month>8</Month>
        <Day>19</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2007</Year>
        <Month>3</Month>
        <Day>22</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">17373163</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17154643</PMID>
<DateCompleted>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1174-5878</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2006</Year>
            </PubDate>
        </JournalIssue>
        <Title>Paediatric drugs</Title>
        <ISOAbbreviation>Paediatr Drugs</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A review of calcium channel antagonists in the treatment of pediatric hypertension.</ArticleTitle>
    <Pagination>
        <MedlinePgn>357-73</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>All children aged &gt; or = 3 years should have an annual blood pressure (BP) measurement taken during a routine physical examination. Physicians should become familiar with recommended pediatric normative BP tables. BP above the 95th percentile may require drug therapy. There are several categories of antihypertensives available to the clinician. Calcium channel antagonists (CCAs) are a class of drugs that exert their antihypertensive effect by inhibiting the influx of calcium ions across the cell membranes. This results in dilatation of peripheral arterioles. When given orally, CCAs are metabolised in the liver by cytochrome P450 (CYP) enzyme CYP3A4; hence, some CCAs will affect the half-life of drugs that share this enzyme system for their metabolism. CCAs can be safely used in children with renal insufficiency or failure and as a general rule there is no need to modify drug dosage in this population. CCAs are generally well tolerated; most adverse effects appear to be dose related. Headache, flushing, gastrointestinal upset, and edema of the lower extremities are the most common symptoms reported with the use of CCAs. Pediatric data regarding safety and efficacy of CCAs have mostly been obtained from retrospective analyses. Extended-release nifedipine and amlodipine are the two most commonly used oral CCAs in the management of pediatric hypertension. These drugs can be given once a day, although many children require twice-daily administration. Extended-release nifedipine has to be swallowed whole; hence, its use in younger children who cannot swallow pills is limited. Amlodipine can be made into a solution without compromising its long duration of action; therefore, it is the CCA of choice for very young children. Oral short-acting nifedipine and intravenous nicardipine are safe and effective CCAs for the management of hypertensive crisis in children. Short-acting nifedipine can cause unpredictable changes in BP; hence, it should be used cautiously and in low doses. Intravenous nicardipine has a rapid onset of action and a short half-life. Intravenous infusion of nicardipine can be titrated for effective control of BP. Intravenous nicardipine has been used safely in hospitalized children and newborns for the management of hypertensive crisis, and for controlled hypotension during surgery. CCAs are a class of antihypertensives that are safe and effective in pediatric patients. They have relatively few adverse effects and are well tolerated by children. This article reviews CCAs as antihypertensives in the management of pediatric hypertension.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Sahney</LastName>
            <ForeName>Shobha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Pediatric Nephrology, Loma Linda Children's Hospital, Loma Linda, California 92354, USA. ssahney@llu.edu</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Switzerland</Country>
    <MedlineTA>Paediatr Drugs</MedlineTA>
    <NlmUniqueID>100883685</NlmUniqueID>
    <ISSNLinking>1174-5878</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>CJ0O37KU29</RegistryNumber>
        <NameOfSubstance UI="D014700">Verapamil</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>CZ5312222S</RegistryNumber>
        <NameOfSubstance UI="D009529">Nicardipine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>I9ZF7L6G2L</RegistryNumber>
        <NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>N3RQ532IUT</RegistryNumber>
        <NameOfSubstance UI="D000638">Amiodarone</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>OL961R6O2C</RegistryNumber>
        <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>YO1UK1S598</RegistryNumber>
        <NameOfSubstance UI="D017275">Isradipine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000638" MajorTopicYN="N">Amiodarone</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
        <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017275" MajorTopicYN="N">Isradipine</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009529" MajorTopicYN="N">Nicardipine</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009543" MajorTopicYN="N">Nifedipine</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>116</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>12</Month>
        <Day>13</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2007</Year>
        <Month>3</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>12</Month>
        <Day>13</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">17154643</ArticleId>
    <ArticleId IdType="pii">864</ArticleId>
    <ArticleId IdType="doi">10.2165/00148581-200608060-00004</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>J Periodontol. 1997 Jul;68(7):645-50</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9249636</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Ther. 2001 Jan-Feb;8(1):3-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11304651</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JAMA. 1995 Aug 23-30;274(8):620-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7637142</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1995 Sep;50(3):560-86</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8521773</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1998 Apr;55(4):509-17</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9561341</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Dis Child. 1983 Dec;137(12):1162-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6637932</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 1988;14(5):519-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3221006</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 1991 Feb;99(2):393-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1989801</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1987 Jan;79(1):1-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3797155</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Nephrol Dial Transplant. 1995 Oct;10 Suppl 9:39-45</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8643207</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1996 Oct;98(4 Pt 1):649-58</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8885941</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Pharmacol. 1989 Jun;29(6):481-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2666449</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Hypertens Rep. 2002 Jun;4(3):191-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12003700</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Cardiol. 1987 Jan 23;59(2):66A-71A</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3544786</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Transplant. 1999 Nov;3(4):288-92</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10562973</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 1998 Jun;53(6):1559-73</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9607186</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Intern Med. 1997 Sep 1;127(5):337-45</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9273824</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Pharmacol. 1988;12 Suppl 7:S60-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2467131</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1991 Mar;41(3):478-505</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1711448</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 1999 May;55(5):1849-60</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10231447</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 2001 Jul;139(1):7-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11445783</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1986 Jun;77(6):862-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3714379</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 2000 Oct;13(10):1061-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11041159</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Pharmacother. 1997 Jun;31(6):704-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9184708</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Mayo Clin Proc. 1998 Dec;73(12):1196-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9868421</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 1990 Oct;117(4):664-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2170612</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Acta Anaesthesiol Scand. 1993 Jan;37(1):26-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8424289</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1988 Jul;82(1):16-23</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3288957</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Clin Pharmacol. 1996;50(1-2):147-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8739826</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Emerg Care. 2001 Dec;17(6):435-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11753188</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1990 Jul;40(1):31-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2143980</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1990 May;39(5):757-806</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2191851</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Kidney Dis. 2000 May;35(5):E20</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10793049</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Hypertension. 1997 Feb;29(2):634-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9040450</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Intern Med. 1997 Nov 24;157(21):2413-46</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9385294</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Cardiol. 1985 Mar 1;55(6):652-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3976506</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 1998 Jan;12(1):40-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9502566</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1971 Feb 25;284(8):401-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5540477</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1996 Jun 20;334(25):1649-54</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8628362</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 1988 May;112(5):811-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3361396</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br Med J (Clin Res Ed). 1981 Oct 10;283(6297):948</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6793184</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1983 May;71(5):748-55</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6340050</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Gen Intern Med. 2002 Dec;17(12):937-45</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12472930</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Transpl Int. 1996;9(2):115-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8639252</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Hum Hypertens. 2001 Jun;15(6):387-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11439313</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 2002 Jan;17(1):35-40</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11793132</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1992 Sep 3;327(10):669-77</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1386652</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 2003 Jan;18(1):1-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12520323</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Pharmacol. 1987;10 Suppl 7:S154-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2485054</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 2000 Dec;15(3-4):302-16</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11149130</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anaesthesia. 1997 Dec;52(12):1236</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9485990</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hosp Pharm. 1994 Jan 1;51(1):59-68</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8135260</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 1999 May;13(4):366</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10454793</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 2001 Jul;139(1):38-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11445792</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Soc Nephrol. 1998 Nov;9(11):2096-101</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9808096</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 1999 May;13(4):304-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10454779</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1989 Aug 31;321(9):580-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2668763</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 2001 Jul;139(1):34-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11445791</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 1998 Apr;12(3):259</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9630050</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 1997 Dec;11(6):786-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9438668</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Ann Intern Med. 1988 Feb;108(2):305-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3341662</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Paediatr Anaesth. 1995;5(3):171-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7489437</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hosp Pharm. 1994 Oct 1;51(19):2409-11</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7847406</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 1987 Jul;32(1):78-83</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3041097</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Nephrol. 2003 Jul-Aug;23(4):229-44</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12840599</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 1992 Dec;20(12):1637-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1458938</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JAMA. 1996 Oct 23-30;276(16):1328-31</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8861992</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 1989 Jan;2(1):57-64</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2643970</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Blood Press. 1996 Jul;5(4):206-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8809370</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1985 Jun;75(6):1091-100</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3889818</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Dev Med Child Neurol. 1990 Jul;32(7):567-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2391009</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Pediatr. 1998 Aug;157(8):618-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9727842</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 1986 May;65(5):507-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3083718</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1995 Apr;49(4):618-49</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7789292</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 1988 Aug;113(2):403-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3294363</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Contrib Nephrol. 1990;83:160-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1966072</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 1994 Oct;8(5):603-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7819013</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Exp Hypertens A. 1986;8(4-5):871-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3530561</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr Orthop. 1996 May-Jun;16(3):370-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8728640</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1988 Dec 8;319(23):1517-25</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3054561</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Pediatr. 1988 May;112(5):805-10</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3283314</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Curr Hypertens Rep. 1999 Oct;1(5):436-45</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10981103</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1992 Sep 3;327(10 ):685-91</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1463530</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 2000 Oct;14(12):1083-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11045391</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Kidney Int. 1992 Oct;42(4):1020-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1453578</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Dis Child. 1995 Aug;73(2):154-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7574861</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 2000 Jul;26(7):956-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10990112</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Dis Child. 1988 Aug;63(8):975-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3270332</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drugs. 1991 Dec;42(6):945-61</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1724641</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Clin Pediatr (Phila). 1998 Jan;37(1):31-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9475697</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatrics. 1990 Jul;86(1):91-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2359687</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S7-11</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11347860</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Am Pharm Assoc (Wash). 1999 May-Jun;39(3):375-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10363465</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Nephrol. 2002 Sep;17(9):748-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12215829</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>JAMA. 2003 May 21;289(19):2560-72</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12748199</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Drug Saf. 1996 Aug;15(2):91-106</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8884161</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Dis Child Fetal Neonatal Ed. 1997 Mar;76(2):F126-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9135293</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pharmacotherapy. 1998 Jan-Feb;18(1):84-112</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9469685</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pediatr Rev. 1993 May;14(5):169-79</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8493186</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Eur J Pediatr. 1993 Sep;152(9):712-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8223797</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>South Med J. 2000 Mar;93(3):287-93</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10728516</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Hypertens. 1995 Dec;8(12 Pt 2):106s-110s</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8845092</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17085859</PMID>
<DateCompleted>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>27</Day>
</DateCompleted>
<DateRevised>
    <Year>2020</Year>
    <Month>01</Month>
    <Day>06</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1734-1140</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>58</Volume>
            <Issue>5</Issue>
            <PubDate>
                <MedlineDate>2006 Sep-Oct</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Pharmacological reports : PR</Title>
        <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Effect of intraarticular tramadol administration in the rat model of knee joint inflammation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>672-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Local administration of exogenous opioids may cause effective analgesia without adverse symptoms from the central nervous system. Experiments show that peripheral antinociceptive effect of opioids is observed especially in inflammatory pain. The aim of the research was to estimate the effect of tramadol on nociceptive process at the level of peripheral nervous system, after its local administration in the model of knee joint inflammation. Tramadol was administered intraarticulary into the rat knee joint, before the inflammation as a preemptive analgesia and, for comparison, after the intraarticular injection of carrageenan. The research determined the influence of tramadol injection on pain threshold for thermal stimuli, development of inflammatory processes using the measurement of joint edema and motor function following the induction of knee joint inflammation in the rat. Functional assessment of knee joint with inflammation, in terms of rats' mobility and body position as well as joint loading and mobility were studied. The results of the experiments show that local administration of tramadol induces antinociceptive effect. The effect of tramadol, which elicits also a decrease in inflammatory edema, appears not only after its administration after carrageenan when inflammation was already present, but also in the case of its injection prior to carrageenan in the scheme of preemptive analgesia. The results of the described research show that not only morphine but also another opioid, tramadol, widely used in clinical practice, inhibits nociception, edema and functional impairment of the paw after its local application directly to the inflamed knee joint.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Garlicki</LastName>
            <ForeName>Jarosław</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Anesthesiology and Intensive Care, Jagiellonian University, Collegium Medicum, Kopernika 17, PL 31-501 Kraków, Poland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Dorazil-Dudzik</LastName>
            <ForeName>Magdalena</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wordliczek</LastName>
            <ForeName>Jerzy</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Przewłocka</LastName>
            <ForeName>Barbara</ForeName>
            <Initials>B</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Switzerland</Country>
    <MedlineTA>Pharmacol Rep</MedlineTA>
    <NlmUniqueID>101234999</NlmUniqueID>
    <ISSNLinking>1734-1140</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D009294">Narcotics</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>39J1LGJ30J</RegistryNumber>
        <NameOfSubstance UI="D014147">Tramadol</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007270" MajorTopicYN="N">Injections, Intra-Articular</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007719" MajorTopicYN="N">Knee Joint</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009294" MajorTopicYN="N">Narcotics</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014147" MajorTopicYN="N">Tramadol</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2006</Year>
        <Month>05</Month>
        <Day>29</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2006</Year>
        <Month>08</Month>
        <Day>21</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>11</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2007</Year>
        <Month>3</Month>
        <Day>28</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>11</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">17085859</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17033275</PMID>
<DateCompleted>
    <Year>2006</Year>
    <Month>11</Month>
    <Day>29</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>11</Month>
    <Day>10</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1527-5299</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>5</Issue>
            <PubDate>
                <MedlineDate>2006 Sep-Oct</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Congestive heart failure (Greenwich, Conn.)</Title>
        <ISOAbbreviation>Congest Heart Fail</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Increase in the QRS duration after amelioration of peripheral edema and after hemodialysis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>265-70</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Association among weights, amplitude of QRS complexes, and QRS duration in patients with peripheral edema has been described. This study explored whether increase in QRS duration occurs with amelioration of peripheral edema or after hemodialysis. Sums of the amplitudes of the 12 electrocardiographic leads and corresponding QRS duration were measured in 12 patients with peripheral edema before and after loss of weight, in 28 patients with a critical illness but without change in their weight ("controls"), and in 1 patient before and after hemodialysis. QRS duration increased from 90.1+/-25.0 milliseconds to 101.7+/-25.8 milliseconds (P=.001) in patients with peripheral edema, was unchanged in the controls, and increased from 87.8+/-5.9 milliseconds before to 92.7+/-6.7 milliseconds after hemodialysis (P=.007). It is proposed that these increases in QRS duration are only apparent (not electrophysiologically real), representing an extracardiac phenomenon mediated by alterations in the composite impedance of the passive body volume conductor, resulting in measurement of augmented QRS complexes after fluid removal. The clinical implications for patients with congestive heart failure are discussed.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Madias</LastName>
            <ForeName>John E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
                <Affiliation>Mount Sinai School of Medicine of New York University, New York, NY, USA. madiasj@nychhc.org</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Congest Heart Fail</MedlineTA>
    <NlmUniqueID>9714174</NlmUniqueID>
    <ISSNLinking>1527-5299</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004562" MajorTopicYN="Y">Electrocardiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>10</Month>
        <Day>13</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2006</Year>
        <Month>12</Month>
        <Day>9</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>10</Month>
        <Day>13</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">17033275</ArticleId>
    <ArticleId IdType="doi">10.1111/j.1527-5299.2006.05386.x</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16920147</PMID>
<DateCompleted>
    <Year>2006</Year>
    <Month>10</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2009</Year>
    <Month>11</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1532-8430</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2006</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of electrocardiology</Title>
        <ISOAbbreviation>J Electrocardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Reversible attenuation of voltage of QRS complexes and P waves and shortening of QRS duration and QTc interval consequent to large perioperative intravenous fluid infusions.</ArticleTitle>
    <Pagination>
        <MedlinePgn>415-8</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>A 39-year-old woman with a gangrenous pyelonephritis and septic shock underwent a nephrectomy, in preparation for which, she received large preoperative fluid resuscitation. Quantitative evaluation of her serial standard electrocardiograms (ECGs) revealed reversible attenuation of voltage in association with peripheral edema (PERE), with the latter being eventually completely abolished. The transient low-voltage ECG (LVECG) (attenuated amplitudes of QRS complexes) was associated with parallel transient attenuation of the amplitude of P waves and shortening of the QRS duration and QTc, whereas the P-wave duration increased. Awareness of these ECG changes with PERE of varying pathophysiologic mechanisms is useful, ensuring avoidance of improper procedural and laboratory testing and correct measurement of wave amplitudes and ECG time intervals for proper ECG diagnosis. In addition, these ECG associations can be used as indices of the presence and course of PERE postoperatively, as well as in a large variety of medical settings.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Madias</LastName>
            <ForeName>John E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Cardiology, Mount Sinai School of Medicine of the New York University, New York, NY 10029, USA. madiasj@nychhc.org</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2006</Year>
        <Month>08</Month>
        <Day>21</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Electrocardiol</MedlineTA>
    <NlmUniqueID>0153605</NlmUniqueID>
    <ISSNLinking>0022-0736</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008133" MajorTopicYN="N">Long QT Syndrome</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009392" MajorTopicYN="N">Nephrectomy</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019990" MajorTopicYN="N">Perioperative Care</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2005</Year>
        <Month>06</Month>
        <Day>07</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>8</Month>
        <Day>22</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2006</Year>
        <Month>10</Month>
        <Day>25</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>8</Month>
        <Day>22</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">16920147</ArticleId>
    <ArticleId IdType="pii">S0022-0736(05)00245-1</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jelectrocard.2005.08.015</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16883123</PMID>
<DateCompleted>
    <Year>2006</Year>
    <Month>09</Month>
    <Day>29</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1058-2916</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>52</Volume>
            <Issue>4</Issue>
            <PubDate>
                <MedlineDate>2006 Jul-Aug</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>ASAIO journal (American Society for Artificial Internal Organs : 1992)</Title>
        <ISOAbbreviation>ASAIO J</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Extravascular lung water and peripheral volume status in hemodialysis patients with and without a history of heart failure.</ArticleTitle>
    <Pagination>
        <MedlinePgn>423-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Determining volume status in hemodialysis patients with a history of congestive heart failure (CHF) is difficult. Extravascular lung water (EVLW) may be derived from blood ultrasound velocity changes following injections of 0.9% and 5% saline. Bioimpedance spectroscopy can measure total body water (TBW) and its intracellular fluid (ICF) and extracellular fluid (ECF) compartments. We studied 29 clinically euvolemic hemodialysis patients, 12 of whom had a history of CHF. The ECF and ICF were measured before dialysis, and EVLW was measured during dialysis. Values of EVLW were similar between patients without CHF and those with CHF (3.55 ml/kg +/- 0.94 SD versus 3.88 ml/kg +/- 0.82 SD, respectively; p = NS). The ECF/ICF ratio was higher among patients with a history of CHF (1.27 +/- 0.29) than among those without such a history (1.04 +/- 0.04; p &lt; 0.05), indicating that ECF volume overload was present in both groups, but was higher in those with a CHF history. There was a positive correlation between EVLW and ECF/ICF ratios (r = 0.54, p &lt; 0.01). Measurements of EVLW were higher in two pulmonary edema patients ((7.95 ml/kg and 5.95 ml/kg; p &lt; 0.05). The results of this study suggest that 1) hemodialysis patients with a history of CHF have more ECF volume overloaded than those without such a history; 2) the degree of ECF expansion is associated with increasing EVLW volume, even in patients without pulmonary edema; and 3) ECF volume expansion eventually exceeds limits and pulmonary edema occurs. These developing technologies of volume measurement may be of value in this challenging clinical area.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>Geena</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Nephrology, London Health Sciences Centre, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>MacRae</LastName>
            <ForeName>Jennifer M</ForeName>
            <Initials>JM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Heidenheim</LastName>
            <ForeName>A Paul</ForeName>
            <Initials>AP</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lindsay</LastName>
            <ForeName>Robert M</ForeName>
            <Initials>RM</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>ASAIO J</MedlineTA>
    <NlmUniqueID>9204109</NlmUniqueID>
    <ISSNLinking>1058-2916</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001810" MajorTopicYN="Y">Blood Volume</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017097" MajorTopicYN="N">Electric Impedance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015633" MajorTopicYN="N">Extravascular Lung Water</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007424" MajorTopicYN="N">Intracellular Fluid</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName>
        <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>8</Month>
        <Day>3</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2006</Year>
        <Month>9</Month>
        <Day>30</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>8</Month>
        <Day>3</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">16883123</ArticleId>
    <ArticleId IdType="doi">10.1097/01.mat.0000221751.98144.03</ArticleId>
    <ArticleId IdType="pii">00002480-200607000-00012</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16860390</PMID>
<DateCompleted>
    <Year>2006</Year>
    <Month>09</Month>
    <Day>14</Day>
</DateCompleted>
<DateRevised>
    <Year>2006</Year>
    <Month>09</Month>
    <Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
    <Journal>
        <ISSN IssnType="Electronic">1549-4713</ISSN>
        <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>9</Issue>
            <PubDate>
                <Year>2006</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>Ophthalmology</Title>
        <ISOAbbreviation>Ophthalmology</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Ocular features of west nile virus infection in North America: a study of 14 eyes.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1539-46</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To present a case series of ocular findings of West Nile virus infection (WNVI) in North America.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective, noncomparative, observational case series.</AbstractText>
        <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">All patients were referred to the authors for WNVI with ocular involvement between the years 2002 and 2005.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Chart review was performed on all participants. All participants underwent complete ophthalmic evaluation during each examination, including best-corrected Snellen visual acuity measurement, tonometry, slit-lamp biomicroscopy of the anterior and posterior segments, and dilated fundus examination with indirect ophthalmoscopy. Fundus photography and fluorescein angiography were also performed on all eyes. Relevant ocular findings associated with WNVI were recorded and tabulated.</AbstractText>
        <AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The authors studied the characteristics, frequency, and locations of ocular lesions found in participants' eyes.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 14 eyes (7 patients) with ocular West Nile virus lesions from 2002 to 2005. Average patient age was 58.4 years (range, 32-85 years). Ocular findings in descending order of frequency included multifocal chorioretinal target lesions in 12 eyes (85.7%), retinal hemorrhages in 7 eyes (50.0%), vitritis in 6 eyes (42.9%), chorioretinal linear streaks in 4 eyes (28.6%), perivascular sheathing and vasculitis in 4 eyes (28.6%), narrowed retinal vessels in 4 eyes (28.6%), disc edema in 4 eyes (28.6%), optic atrophy in 2 eyes (14.3%), vascular occlusion in 2 eyes (14.3%), and VIth nerve palsy in 1 eye (7.1%). Peripheral fundus lesions were found in all 14 eyes (100%), whereas posterior fundus lesions were found in 8 eyes (57.1%). Five patients (71.4%) were diabetic. Diabetic retinopathy was present in 7 eyes (70%).</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Multifocal choroiditis is the most common ocular manifestation associated with WNVI, with a typically benign clinical course. Less frequent ocular lesions, including optic neuritis and occlusive vasculitis, frequently induce persistent and likely permanent visual deficit. Diabetic patients and those older than 50 years of age are more vulnerable to the more severe features of WNVI, including more serious ocular lesions.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Clement K</ForeName>
            <Initials>CK</Initials>
            <AffiliationInfo>
                <Affiliation>Southern California Desert Retina Consultants, Palm Springs, California, USA. cchan@desertretina.com</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Limstrom</LastName>
            <ForeName>Scott A</ForeName>
            <Initials>SA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tarasewicz</LastName>
            <ForeName>Dariusz G</ForeName>
            <Initials>DG</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Steven G</ForeName>
            <Initials>SG</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <ArticleDate DateType="Electronic">
        <Year>2006</Year>
        <Month>07</Month>
        <Day>21</Day>
    </ArticleDate>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Ophthalmology</MedlineTA>
    <NlmUniqueID>7802443</NlmUniqueID>
    <ISSNLinking>0161-6420</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002825" MajorTopicYN="N">Chorioretinitis</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015828" MajorTopicYN="N">Eye Infections, Viral</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009887" MajorTopicYN="N">Ophthalmoscopy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014065" MajorTopicYN="N">Tonometry, Ocular</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014901" MajorTopicYN="N">West Nile Fever</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014902" MajorTopicYN="N">West Nile virus</DescriptorName>
        <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="received">
        <Year>2005</Year>
        <Month>10</Month>
        <Day>13</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="revised">
        <Year>2006</Year>
        <Month>04</Month>
        <Day>17</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="accepted">
        <Year>2006</Year>
        <Month>04</Month>
        <Day>17</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>7</Month>
        <Day>25</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2006</Year>
        <Month>9</Month>
        <Day>15</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>7</Month>
        <Day>25</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">16860390</ArticleId>
    <ArticleId IdType="pii">S0161-6420(06)00569-0</ArticleId>
    <ArticleId IdType="doi">10.1016/j.ophtha.2006.04.021</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16750465</PMID>
<DateCompleted>
    <Year>2006</Year>
    <Month>06</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>03</Month>
    <Day>12</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0149-2918</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>28</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2006</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>Clinical therapeutics</Title>
        <ISOAbbreviation>Clin Ther</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.</ArticleTitle>
    <Pagination>
        <MedlinePgn>537-51</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to compare the efficacy and tolerability of amlodipine orotate with those of amlodipine besylate in Korean patients with mild to moderate hypertension.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, randomized, double-blind, placebo-controlled, parallel-group study was designed as a noninferiority study. To be included in the study, previously untreated patients had to have a sitting diastolic blood pressure (SiDBP) of 90 to 109 mm Hg. Previously treated patients had to discontinue their current annhypertensive medications and have a baseline SiDBP between 90 and 109 mm Hg after a 2-week washout period. Patients who met the inclusion criteria were randomly assigned to receive 5 mg amlodipine orotate or 5 mg amlodipine besylate for 8 weeks. The medication dose was doubled (10 mg QD for either amlodipine orotate or amlodipine besylate) 4 weeks after enrollment if SiDBP was &gt;or=90 mm Hg. The primary efficacy analysis was noninferiority of the difference in mean trough SiDBP changes from baseline for amlodipin eorotate as compared with amlodipine besylate after 8 weeks of treatment. For the secondary efficacy analysis, 2 other measures were analyzed after 8 weeks of treatment. The SiDBP response rate was defined as an SiDBP measurement&lt;90 mm Hg at the last clinical follow-up visit or an absolute reduction of &gt;or=10 mm Hg in SiDBP from baseline until the last clinical follow-up visit. In addition, noninferiority of the difference in mean trough sitting systolic blood pressure (SiSBP) changes from baseline was analyzed for amlodipine orotate as compared with amlodipine besylate. The drug compliance rate was estimated by pillcount.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Eligible patients (n=109; 43 women and 66 men) were randomly assigned to receive amlodipine orotate (n=53) or amlodipine besylate (n=56). No significant differences were found in sex, age, weight, or current smoking between the groups (all, P=NS). The proportion of patients with previous antihypertensive medications was not different between the groups (47.2% [25/53] in the amlodipine orotate group and 50.0% [28/56] in the amlodipine besylate group; P=NS). No significant differences were found in baseline SiDBP (mean [SD], 100 [6] mm Hg [range, 90-109 mm Hg] in the amlodipine orotate group and 100 [6] mm Hg [range, 90-108 mm Hg] in the amlodipine besylate group; P=NS) or in baseline SiSBP (mean [SD], 149 [14] mm Hg [range, 125-179 mm Hg] in the amlodipine orotate group and 146 [10] mm Hg [range, 123-167 mm Hg] in the amlodipine besylate group; p=NS). The mean (SD) changes in SiDBP were -15.6 (6.3) mm Hg for the amlodipine orotate group and -14.5 (5.5) mm Hg for the amlodipine besylate groups was 1.1 (5.9) mm Hg (95% CI, -0.87 to infinity), and because the lower boundary of the 95% CI was greater than -5 mm Hg, amlodipine orotate was considered noninferior to amlodipine besylate. The response rate was 48 of 51 (94.1%) in the amlodipine orotate group compared with 50 (92.6%) of 54 in the amlodipine besylate group after 8 weeks of treatment (P=NS). The mean (SD) compliance rates were 97.6% (3.6%) in the amlodipine orotate group and 96.5% (4.3%) in the amlodipine besylate group (P=NS). The incidence of drug-related adverse events (AEs) was similar between the groups (1/53 [1.9%]) in the amlodipine orotate group vs 4/55 [7.3%] in the amlodipine besylate group; P=NS). The most common drug-related AE overall was peripheral edema (2/55 [3.6%]), and the most common of all the AEs was upper respiratory tract infection (4/55 [7.3%]) in the amlodipine besylate group. The most common drug-related AE was headache (1/53 [1.9%]) in the amlodipine orotate group and peripheral edema (2/55 [3.6%]) in the amlodipine besylate group. No severe AEs were found in either group.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The reduction in SiDBP after 8 weeks of amlodipine orotate treatment was noninferior to that of amlodipine besylate in these Korean patients with mild to moderate hypertension. The SiDBP response rate and the reduction in SISBP after 8 weeks of amlodipine orotate treatment were not significantly different from those of amlodipine besylate treatment. Both agents were wel tolerated.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>Soon Jun</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Cardiology, Korea University Anam Hospital, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ahn</LastName>
            <ForeName>Tae-Hoon</ForeName>
            <Initials>TH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Baek</LastName>
            <ForeName>Sang-Hong</ForeName>
            <Initials>SH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cho</LastName>
            <ForeName>Wook-Hyun</ForeName>
            <Initials>WH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jeon</LastName>
            <ForeName>Hui-Kyung</ForeName>
            <Initials>HK</Initials>
        </Author>
        <Author ValidYN="N">
            <LastName>Jeon</LastName>
            <ForeName>Hyee-Kyoung</ForeName>
            <Initials>HK</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kwan</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="N">
            <LastName>Kyun</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yoon</LastName>
            <ForeName>Myeong Ho</ForeName>
            <Initials>MH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kwan Jeh</ForeName>
            <Initials>KJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lim</LastName>
            <ForeName>Do-Sun</ForeName>
            <Initials>DS</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016448">Multicenter Study</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Clin Ther</MedlineTA>
    <NlmUniqueID>7706726</NlmUniqueID>
    <ISSNLinking>0149-2918</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>1J444QC288</RegistryNumber>
        <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
    <CommentsCorrections RefType="ErratumIn">
        <RefSource>Clin Ther. 2006 Aug;28(8):1245</RefSource>
        <Note>Jeon, Hyee-Kyoung [corrected to Jeon, Hui-Kyung]; Kyun, Jun [corrected to Kwan, Jun]</Note>
    </CommentsCorrections>
    <CommentsCorrections RefType="ErratumIn">
        <RefSource>Clin Ther. 2006 Aug;28(8):1245</RefSource>
        <PMID Version="1">29526193</PMID>
    </CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007723" MajorTopicYN="N" Type="Geographic">Korea</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="accepted">
        <Year>2006</Year>
        <Month>02</Month>
        <Day>17</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2006</Year>
        <Month>6</Month>
        <Day>6</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2006</Year>
        <Month>6</Month>
        <Day>23</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2006</Year>
        <Month>6</Month>
        <Day>6</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">16750465</ArticleId>
    <ArticleId IdType="pii">S0149-2918(06)00096-8</ArticleId>
    <ArticleId IdType="doi">10.1016/j.clinthera.2006.04.008</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16352960</PMID>
<DateCompleted>
    <Year>2006</Year>
    <Month>01</Month>
    <Day>11</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0090-3493</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>33</Volume>
            <Issue>12</Issue>
            <PubDate>
                <Year>2005</Year>
                <Month>Dec</Month>
            </PubDate>
        </JournalIssue>
        <Title>Critical care medicine</Title>
        <ISOAbbreviation>Crit Care Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Reliability of point-of-care testing for glucose measurement in critically ill adults.</ArticleTitle>
    <Pagination>
        <MedlinePgn>2778-85</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Glycemic control is increasingly being recognized as a priority in the treatment of critically ill patients. Titration and monitoring of insulin infusions involve frequent blood glucose measurement to achieve target glucose ranges and prevent adverse events related to hypoglycemia. Therefore, it is imperative that bedside glucose testing methods be safe and accurate.</AbstractText>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the accuracy and clinical impact of three common methods of bedside point-of-care testing for glucose measurements in critically ill patients receiving insulin infusions.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective observational study.</AbstractText>
        <AbstractText Label="SETTING" NlmCategory="METHODS">A 21-bed mixed medical/surgical intensive care unit of a tertiary care teaching hospital.</AbstractText>
        <AbstractText Label="PATIENTS" NlmCategory="METHODS">Thirty consecutive critically ill patients who were vasopressor-dependent (n = 10), had significant peripheral edema (n = 10), or were admitted following major surgery (n = 10).</AbstractText>
        <AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Findings from three different methods of glucose measurement were compared with central laboratory measurements: (1) glucose meter analysis of capillary blood (fingerstick); (2) glucose meter analysis of arterial blood; and (3) blood gas/chemistry analysis of arterial blood. Patients were enrolled for a maximum of 3 days and had a maximum of nine sets of measurements determined during this time.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical agreement with the central laboratory was significantly better with arterial blood analysis (69.9% and 76.5% for glucose meter and blood gas/chemistry analysis, respectively) than with capillary blood analysis (56.8%; p = .039 and .001, respectively). During hypoglycemia, clinical agreement was only 26.3% with capillary blood analysis and 55.6% and 64.9% for glucose meter and blood gas/chemistry analysis of arterial blood (p = .010 and &lt;.001, respectively). Glucose meter analysis of both arterial and capillary blood tended to provide higher glucose values, whereas blood gas/chemistry analysis of arterial blood tended to yield lower glucose values.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The magnitude of the differences in the glucose values offered by the four different methods of glucose measurement led to frequent clinical disagreements regarding insulin dose titration in the context of an insulin infusion protocol for aggressive glucose control.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kanji</LastName>
            <ForeName>Salmaan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Pharmacy, The Ottawa Hospital, Ottawa, Canada.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Buffie</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hutton</LastName>
            <ForeName>Brian</ForeName>
            <Initials>B</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bunting</LastName>
            <ForeName>Peter S</ForeName>
            <Initials>PS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Avinder</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>McDonald</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fergusson</LastName>
            <ForeName>Dean</ForeName>
            <Initials>D</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>McIntyre</LastName>
            <ForeName>Lauralyn A</ForeName>
            <Initials>LA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hebert</LastName>
            <ForeName>Paul C</ForeName>
            <Initials>PC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Crit Care Med</MedlineTA>
    <NlmUniqueID>0355501</NlmUniqueID>
    <ISSNLinking>0090-3493</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
    <CommentsCorrections RefType="CommentIn">
        <RefSource>Crit Care Med. 2005 Dec;33(12):2849-51</RefSource>
        <PMID Version="1">16352973</PMID>
    </CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001774" MajorTopicYN="N">Blood Chemical Analysis</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2005</Year>
        <Month>12</Month>
        <Day>15</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2006</Year>
        <Month>1</Month>
        <Day>13</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2005</Year>
        <Month>12</Month>
        <Day>15</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">16352960</ArticleId>
    <ArticleId IdType="pii">00003246-200512000-00010</ArticleId>
    <ArticleId IdType="doi">10.1097/01.ccm.0000189939.10881.60</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">15660804</PMID>
<DateCompleted>
    <Year>2005</Year>
    <Month>05</Month>
    <Day>05</Day>
</DateCompleted>
<DateRevised>
    <Year>2005</Year>
    <Month>01</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0147-8389</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>28</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>2005</Year>
                <Month>Jan</Month>
            </PubDate>
        </JournalIssue>
        <Title>Pacing and clinical electrophysiology : PACE</Title>
        <ISOAbbreviation>Pacing Clin Electrophysiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>QTc interval in patients with changing edematous states: implications on interpreting repeat QTc interval measurements in patients with anasarca of varying etiology and those undergoing hemodialysis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>54-61</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Associations have been described among weight, amplitude of QRS complexes, and QRS duration (QRSd) in patients with anasarca (AN), and changes in the amplitude of the QRS complexes, QRSd, and QTc after hemodialysis (HD) and in patients with heart failure with associated peripheral edema congestive heart failure. The objective of this study was to evaluate the hypothesis that changes in QTc in patients with AN and after HD are at least partially apparent, due to changing edematous states, and not totally due to altered electrophysiology. QTc was measured in patients with AN on admission, at peak weight (N = 28), and at their subsequent lowest weight (N = 12), in 28 control patients without change in weight during hospitalization, and in one patient before and after 26 HD sessions. In the patients with AN, the QTc was 451 +/- 36 ms on admission and dropped to 423 +/- 46 ms at peak weight (P = 0.005). QTc was 421 +/- 44 ms at peak weight and raised to 434 +/- 30 at subsequent lowest weight (P = 0.32). In the controls, QTc on admission and at discharge were 435 +/- 34 and 428 +/- 23 ms, correspondingly (P = 0.18). QTc increased from 472 +/- 18 ms before to 489 +/- 36 ms after HD (P = 0.017). Alterations in QTc in AN, or HD suggest that the changes in the QTc may be partially only apparent, and due to the electrocardiogram machine-based measurement of the attenuated/augmented QRST complexes resulting from fluid shifts.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Madias</LastName>
            <ForeName>John E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
                <Affiliation>Mount Sinai School of Medicine, New York University, New York, New York, USA. madiasj@nychhc.org</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Pacing Clin Electrophysiol</MedlineTA>
    <NlmUniqueID>7803944</NlmUniqueID>
    <ISSNLinking>0147-8389</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004562" MajorTopicYN="Y">Electrocardiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2005</Year>
        <Month>1</Month>
        <Day>22</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2005</Year>
        <Month>5</Month>
        <Day>6</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2005</Year>
        <Month>1</Month>
        <Day>22</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">15660804</ArticleId>
    <ArticleId IdType="pii">PACE9384</ArticleId>
    <ArticleId IdType="doi">10.1111/j.1540-8159.2005.09384.x</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">15460152</PMID>
<DateCompleted>
    <Year>2005</Year>
    <Month>04</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>17</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0025-682X</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>64</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>2004</Year>
            </PubDate>
        </JournalIssue>
        <Title>Medecine tropicale : revue du Corps de sante colonial</Title>
        <ISOAbbreviation>Med Trop (Mars)</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Abstract envenomation by the African puff adder (Bitis arietans): value of intracompartmental pressure measurement].</ArticleTitle>
    <Pagination>
        <MedlinePgn>187-91</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The purpose of this report is to describe a case of severe snake bite with envenomation by an African puff adder (Bitis arietans). Presenting symptoms warranted administration of antivenon upon admission. The patient's general condition improved. However bite-related trauma caused extensive phlyctenuar edema of the lower extremity with a high risk of compartimental syndrome due to hardening and compression. Due to the high risk for postoperative infection at our facility, aponevrotomy to relief pressure was not undertaken immediately. Instead management consisted in close surveillance with repeated measurement of peripheral pulses by Doppler ultrasound and of intracompartimental pressure. The outcome was favorable without need for aponevrotomy. This case demonstrates the value of intracompartimental pressure measurement in cases involving this type of envenomation in function of available technical facilities.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Le Dantec</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>Département d'anesthésie réanimation, Hôpital Principal de Dakar, BP 3006 Dakar Sénégal. ledantec@sentoo.sn</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hervé</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Niang</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Chippaux</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bellefleur</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Boulesteix</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Diatta</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
        </Author>
    </AuthorList>
    <Language>fre</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Morsure par vipère Bitis arietans au Sénégal, intérêt de la mesure de pression intracompartimentale.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>France</Country>
    <MedlineTA>Med Trop (Mars)</MedlineTA>
    <NlmUniqueID>8710146</NlmUniqueID>
    <ISSNLinking>0025-682X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003161" MajorTopicYN="N">Compartment Syndromes</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011312" MajorTopicYN="N">Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012675" MajorTopicYN="N" Type="Geographic">Senegal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012909" MajorTopicYN="N">Snake Bites</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017819" MajorTopicYN="Y">Viperidae</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2004</Year>
        <Month>10</Month>
        <Day>6</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2005</Year>
        <Month>4</Month>
        <Day>7</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2004</Year>
        <Month>10</Month>
        <Day>6</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">15460152</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">14992086</PMID>
<DateCompleted>
    <Year>2004</Year>
    <Month>03</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>11</Month>
    <Day>08</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0003-2417</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>52</Volume>
            <Issue>11</Issue>
            <PubDate>
                <Year>2003</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>Der Anaesthesist</Title>
        <ISOAbbreviation>Anaesthesist</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Assessment of volume responsiveness in mechanically ventilated patients].</ArticleTitle>
    <Pagination>
        <MedlinePgn>1005-7, 1010-3</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Monitoring and management of intravascular volume status is of crucial importance in critically ill patients. Hypovolemia, induced by hemorrhage or pathologic fluid shifts in the presence of systemic inflammation, is frequently the cause for hemodynamic instability and hypotension. This deficit of central blood volume leads to a reduction in biventricular cardiac preload. With respect to the Frank-Starling mechanism, this causes an alteration in left ventricular stroke volume. If this reduction in stroke volume cannot be compensated by an increase in heart rate, this finally results in a decline of cardiac output. In this clinical situation fluid loading is the treatment of choice. However, insufficient peripheral vascular resistance and thus reduced cardiac afterload as well as impaired myocardial contractility also have to be taken in account to be causative for hypotension. Potential hazards of fluid loading specifically in the latter situation include pulmonary edema, worsening of pulmonary gas exchange and myocardial failure. Thus, prediction of fluid responsiveness, i.e. the prediction of the hemodynamic response to fluid loading is of utmost importance in critically ill patients. Several conventional parameters of systemic hemodynamic monitoring such as the cardiac filling pressures CVP and PAOP, the estimation of the left ventricular end-diastolic area (LVEDA) by echocardiography and measurement of central blood volumes as the right-ventricular end-diastolic volume (RVEDV) or the global end-diastolic volume (GEDV) by thermodilution are frequently used for preload monitoring. Further, functional preload parameters such as the left ventricular stroke volume variation (SW), describing the specific interactions of the heart and the lungs under mechanical ventilation, have been recently proposed to be useful for predicting fluid responsiveness. Thus, it is the aim of the present article to analyze these different concepts of hemodynamic monitoring regarding their usefulness and clinical applicability to predict fluid responsiveness at the bedside.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Reuter</LastName>
            <ForeName>D A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
                <Affiliation>Klinik für Anästhesiologie, Klinikum der Universität München, Grosshadern-Innenstadt.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Goetz</LastName>
            <ForeName>A E</ForeName>
            <Initials>AE</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Peter</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Einschätzung der Volumenreagibilität beim beatmeten Patienten.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Anaesthesist</MedlineTA>
    <NlmUniqueID>0370525</NlmUniqueID>
    <ISSNLinking>0003-2417</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020896" MajorTopicYN="N">Hypovolemia</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008991" MajorTopicYN="Y">Monitoring, Physiologic</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016278" MajorTopicYN="N">Ventricular Function, Right</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>38</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2004</Year>
        <Month>3</Month>
        <Day>3</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2004</Year>
        <Month>3</Month>
        <Day>18</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2004</Year>
        <Month>3</Month>
        <Day>3</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">14992086</ArticleId>
    <ArticleId IdType="doi">10.1007/s00101-003-0600-1</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Intensive Care Med. 1998 Jul;24(7):651-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9722033</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 1990 Dec;98(6):1450-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2245688</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Br J Anaesth. 2002 Jan;88(1):124-6</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11881866</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 1987 Nov;67(5):630-4</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3499831</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Trauma. 1981 Aug;21(8):619-26</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7265333</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiothorac Vasc Anesth. 2001 Oct;15(5):584-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11687999</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 1994 Aug;81(2):376-87</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8053588</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 2001 Jan;27(1):201-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11280635</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 1992;18(3):142-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1644961</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Cardiothorac Vasc Anesth. 2002 Apr;16(2):191-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11957169</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 1987 Oct;67(4):498-502</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3310740</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 2002 Apr;28(4):392-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11967591</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 1994 Jan;78(1):46-53</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8267179</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 1998 Dec;89(6):1313-21</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9856704</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 1998 Aug;89(2):350-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9710392</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesthesiology. 1994 Jul;81(1):76-86</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8042813</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 2003 May;96(5):1254-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12707116</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am J Respir Crit Care Med. 2000 Jul;162(1):134-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10903232</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Surgery. 1981 Jul;90(1):61-76</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7245052</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>N Engl J Med. 1977 Apr 28;296(17):978-82</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">321961</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Clin Anesth. 2002 Jun;14(4):296-301</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12088815</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 2002 Oct;95(4):835-43, table of contents</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12351254</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 2002 Jun;121(6):2000-8</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12065368</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 2001 Mar;119(3):867-73</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11243970</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Circulation. 1983 Aug;68(2):266-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6861305</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>J Trauma. 1994 Dec;37(6):950-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7996610</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 2000 Feb;90(2):351-5</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10648320</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anaesthesist. 2000 Sep;49(9):788-808</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11076268</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Am Heart J. 1988 Jul;116(1 Pt 1):103-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3394612</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Chest. 1998 Apr;113(4):1048-54</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9554646</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Intensive Care Med. 2000 Feb;26(2):180-7</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10784306</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Arch Surg. 1992 Jul;127(7):817-21; discussion 821-2</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1524482</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 2003 May;31(5):1399-404</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12771609</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Anesth Analg. 2001 Apr;92(4):984-9</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11273937</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Crit Care Med. 1999 Nov;27(11):2407-12</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10579256</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">14642690</PMID>
<DateCompleted>
    <Year>2004</Year>
    <Month>01</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>04</Month>
    <Day>09</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0735-1097</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>42</Volume>
            <Issue>10</Issue>
            <PubDate>
                <Year>2003</Year>
                <Month>Nov</Month>
                <Day>19</Day>
            </PubDate>
        </JournalIssue>
        <Title>Journal of the American College of Cardiology</Title>
        <ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1793-800</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to determine the effect of amino-terminal pro-brain natriuretic peptide (N-BNP) on the diagnostic accuracy of heart failure (HF) in primary care.</AbstractText>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The accurate diagnosis of patients with suspected HF presenting in primary care is difficult. Amino-terminal pro-brain natriuretic peptide is present in high levels in cardiac dysfunction and may improve the diagnostic accuracy of HF in primary care.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">The Natriuretic Peptides in the Community Study was a prospective, randomized controlled trial of the effect of N-BNP on the accuracy of HF diagnosis. Patients presenting to their general practitioner (GP) with symptoms of dyspnea and/or peripheral edema were included. The GPs formulated an initial diagnosis based on clinical assessment. All patients underwent a full cardiologic assessment that included echocardiography and N-BNP. Each patient was randomized to the BNP group (GP received the N-BNP result) or the control group (GP did not receive the N-BNP result). Patients were then reviewed by their GP, and their diagnosis was reviewed. The primary end point was the accuracy of the GPs' diagnoses compared with the panel standard.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 305 patients were included; mean age was 72 years, 65% were female. Seventy-seven patients met the panel criteria for HF. The diagnostic accuracy improved 21% in the BNP group and 8% in the control group (p = 0.002). The main impact of N-BNP measurement on diagnostic accuracy was the GPs' correctly ruling out HF. The number needed to diagnose by N-BNP measurement was seven patients.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates that N-BNP measurement significantly improves the diagnostic accuracy of HF by GPs over and above customary clinical review.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Wright</LastName>
            <ForeName>Susan P</ForeName>
            <Initials>SP</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medicine, University of Auckland, Auckland, New Zealand.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Doughty</LastName>
            <ForeName>Robert N</ForeName>
            <Initials>RN</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pearl</LastName>
            <ForeName>Ann</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gamble</LastName>
            <ForeName>Greg D</ForeName>
            <Initials>GD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Whalley</LastName>
            <ForeName>Gillian A</ForeName>
            <Initials>GA</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Walsh</LastName>
            <ForeName>Helen J</ForeName>
            <Initials>HJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gordon</LastName>
            <ForeName>Gary</ForeName>
            <Initials>G</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bagg</LastName>
            <ForeName>Warwick</ForeName>
            <Initials>W</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Oxenham</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Yandle</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Richards</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sharpe</LastName>
            <ForeName>Norman</ForeName>
            <Initials>N</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Am Coll Cardiol</MedlineTA>
    <NlmUniqueID>8301365</NlmUniqueID>
    <ISSNLinking>0735-1097</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>114471-18-0</RegistryNumber>
        <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2003</Year>
        <Month>12</Month>
        <Day>4</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2004</Year>
        <Month>1</Month>
        <Day>24</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2003</Year>
        <Month>12</Month>
        <Day>4</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">14642690</ArticleId>
    <ArticleId IdType="pii">S0735109703011793</ArticleId>
    <ArticleId IdType="doi">10.1016/j.jacc.2003.05.011</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">12905669</PMID>
<DateCompleted>
    <Year>2004</Year>
    <Month>06</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>30</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1000-503X</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>24</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>2002</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae</Title>
        <ISOAbbreviation>Zhongguo Yi Xue Ke Xue Yuan Xue Bao</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Measurement of epidermal growth factor receptor concentration in the pre- and postoperative serum in patients with meningiomas].</ArticleTitle>
    <Pagination>
        <MedlinePgn>427-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate effect of the serum concentration of epidermal growth factor receptor (EGFR) in the pre- and postoperative peripheral blood in patients with meningiomas.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Using ELISA, the EGFR concentration were measured in the pre- and postoperative serum in 53 patients with meningiomas. In this study, the patients were divided into preoperative group, postoperative group (including 42 total resection, 11 subtotal resection), and 28 healthy control.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 53 patients with meningiomas, concentration of preoperative serum EGFR was (352.93 +/- 66.18) fmol/ml, to show higher than control group (159.11 +/- 40.50) fmol/ml (P &lt; 0.0001); Concentration of postoperative serum EGFR was (220.74 +/- 70.63) fmol/ml, to show lower than preoperative group (P &lt; 0.001). Including in 42 patients with meningomas by total resection, serum EGFRs of the 38 patients were decreased (191.20 +/- 32.13) fmol/ml, the 4 patients with peritumoral edema were decreased (248.75 +/- 10.31) fmol/ml, to show lower than preoperative group (P &lt; 0.001); the 11 patients with subtotal resection were decreased (322.14 +/- 89.53) fmol/ml, not to show different than preoperative group (P &lt; 0.05).</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In 92.16% patients with meningiomas, the more poison of the tumor is resected, the less the serum EGFR concentration is detected postoperatively, while the total resection of mangionmas resulted in a lowest level of EGFR. These results support the concept that human meningiomas may be autocrine EGFRs. The measurement of serum EGFR can be useful to patients with meningiomas for follow-up after surgery.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Yan-guo</ForeName>
            <Initials>YG</Initials>
            <AffiliationInfo>
                <Affiliation>Laboratory of Neurosurgery, PUMC Hospital, CAMS, PUMC, Beijing 100730, China. kongyg@yeah.net</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Chang-bao</ForeName>
            <Initials>CB</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Zu-yuan</ForeName>
            <Initials>ZY</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ren-zhi</ForeName>
            <Initials>RZ</Initials>
        </Author>
    </AuthorList>
    <Language>chi</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>China</Country>
    <MedlineTA>Zhongguo Yi Xue Ke Xue Yuan Xue Bao</MedlineTA>
    <NlmUniqueID>8006230</NlmUniqueID>
    <ISSNLinking>1000-503X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 2.7.10.1</RegistryNumber>
        <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008577" MajorTopicYN="N">Meningeal Neoplasms</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008579" MajorTopicYN="N">Meningioma</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2003</Year>
        <Month>8</Month>
        <Day>9</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2004</Year>
        <Month>6</Month>
        <Day>25</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2003</Year>
        <Month>8</Month>
        <Day>9</Day>
        <Hour>5</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">12905669</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">12396880</PMID>
<DateCompleted>
    <Year>2003</Year>
    <Month>01</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1527-0297</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>3</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2002</Year>
                <Season>Fall</Season>
            </PubDate>
        </JournalIssue>
        <Title>High altitude medicine &amp; biology</Title>
        <ISOAbbreviation>High Alt Med Biol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Characteristics of the ventilatory response in subjects susceptible to high altitude pulmonary edema during acute and prolonged hypoxia.</ArticleTitle>
    <Pagination>
        <MedlinePgn>267-76</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The present study compares the changes in ventilation in response to sustained hypobaric hypoxia and acute normobaric hypoxia between subjects susceptible to high altitude pulmonary edema (HAPE-S) and control subjects (C-S). Seven HAPE-S and five C-S were exposed to simulated high altitude of 4000 m for 23 h in a hypobaric chamber. Resting minute ventilation (V(E)), tidal volume (V(T)), and respiratory frequency (f(R)), as well as the end-tidal partial pressures of oxygen (P(ET(O2))) and carbon dioxide (P(ET(CO2))) were measured in all subjects sitting in a standardized position. Six measurement periods were recorded: ZH1 at 450 m at Zurich level, HA1 on attaining 3600 m altitude, HA2 after 20 min at 4000 m, HA3 after 21 h and HA4 after 23 h at 4000 m altitude, and ZH2 immediately after recompression to Zurich level. At ZH1 and HA3, the measurements were first done in lying, then in sitting, and afterwards in standing. Peripheral arterial oxygen saturation (Sa(O2)) was continuously recorded. All respiratory parameters were also measured during exercise lasting 30 min, the work load being 50% of maximal oxygen consumption (V(O2max)) at Zurich level and 26% of the Zurich V(O2max) at 4000 m. V(E), P(ET(O2)) and P(ET(CO2)) did not significantly differ between HAPE-S and C-S at rest and during exercise periods at Zurich level and at high altitude. However, Sa(O2) was significantly lower in HAPE-S than in C-S at rest and during exercise at 4000 m. Breathing through the mouthpiece during ventilation measurements increased significantly the Sa(O2) in HAPE-S in posture tests at HA3. This effect was most pronounced in the supine posture, in which HAPE-S had the lowest Sa(O2) values. These data provide evidence that (1) gas exchange might be impaired on the level of ventilation-perfusion mismatch or due to diffusion limitation in HAPE-S during the first 23 h of exposure to a simulated altitude of 4000 m, and (2) contrary to C-S, the Sa(O2) in HAPE-S is significantly affected by body position and by mouthpiece breathing.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Schirlo</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
                <Affiliation>Institute of Physiology, University of Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Pavlicek</LastName>
            <ForeName>Vojta</ForeName>
            <Initials>V</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Jacomet</LastName>
            <ForeName>Alfred</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gibbs</LastName>
            <ForeName>J Simon R</ForeName>
            <Initials>JS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Koller</LastName>
            <ForeName>Erwin</ForeName>
            <Initials>E</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Oelz</LastName>
            <ForeName>Oswald</ForeName>
            <Initials>O</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Seebauer</LastName>
            <ForeName>Magdalena</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kohl</LastName>
            <ForeName>Jana</ForeName>
            <Initials>J</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>High Alt Med Biol</MedlineTA>
    <NlmUniqueID>100901183</NlmUniqueID>
    <ISSNLinking>1527-0297</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000531" MajorTopicYN="N">Altitude</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000532" MajorTopicYN="N">Altitude Sickness</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001784" MajorTopicYN="N">Blood Gas Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011659" MajorTopicYN="N">Pulmonary Gas Exchange</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2002</Year>
        <Month>10</Month>
        <Day>25</Day>
        <Hour>4</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2003</Year>
        <Month>1</Month>
        <Day>17</Day>
        <Hour>4</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2002</Year>
        <Month>10</Month>
        <Day>25</Day>
        <Hour>4</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">12396880</ArticleId>
    <ArticleId IdType="doi">10.1089/152702902320604241</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11863308</PMID>
<DateCompleted>
    <Year>2002</Year>
    <Month>03</Month>
    <Day>21</Day>
</DateCompleted>
<DateRevised>
    <Year>2017</Year>
    <Month>02</Month>
    <Day>14</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0003-3197</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>53</Volume>
            <Issue>1</Issue>
            <PubDate>
                <MedlineDate>2002 Jan-Feb</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Angiology</Title>
        <ISOAbbreviation>Angiology</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A new technique for the quantification of peripheral edema with application in both unilateral and bilateral cases.</ArticleTitle>
    <Pagination>
        <MedlinePgn>41-7</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Current noninvasive techniques for the routine and frequent quantification of peripheral lymphedema in patients are total limb volume measurement (by water immersion or by circumferential measurements) and bioelectrical impedance analysis (BIA). However both of these techniques require standardizing the measurement using a contralateral measurement from the unaffected limb. Hence these techniques are essentially restricted to unilateral lymphedema. This paper describes the results from a preliminary study to investigate an alternative approach to the analysis of the data from multiple frequency BIA to produce an index of lymphedema without the need for normalization to another body segment. Twenty patients receiving surgical treatment for breast cancer were monitored prior to surgery and again after diagnosis with unilateral lymphedema. The data recorded were total limb volume, by circumferential measurements; and BIA measurements of both limbs. From these measurements total limb volumes and extracellular fluid volumes were calculated and expressed as ratios of the affected limb to that of the unaffected limb. An index of the ratio of the extracellular fluid volume to the intracellular fluid volume was determined. This ECW/ICW index was calculated for both the affected and unaffected limbs at both measurement times. Results confirmed that the established techniques of total limb volume and extracellular fluid volume normalized to the unaffected contralateral limb were accurate in the detection of lymphedema (p &lt; 10(-6)). Comparison of the ECW/ICW index from the affected limb after diagnosis with that from the pre-surgery measurement revealed a significant (p &lt; 10(-6)) and considerable (75%) increase. The results of this pilot study suggest that by using multiple frequency bioelectrical impedance analysis, an index of the ECW/ICW ratio can be obtained and this index appears to have an equal, or better, sensitivity than the other techniques in detecting lymphedema. More importantly, this index does not require normalization to another body segment and can be used to detect all types of peripheral edema including both unilateral and bilateral lymphedema.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Cornish</LastName>
            <ForeName>Bruce H</ForeName>
            <Initials>BH</Initials>
            <AffiliationInfo>
                <Affiliation>Centre for Medical and Health Physics, Queensland University of Technology, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ward</LastName>
            <ForeName>Leigh C</ForeName>
            <Initials>LC</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hirst</LastName>
            <ForeName>Cherrell</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bunce</LastName>
            <ForeName>Ian H</ForeName>
            <Initials>IH</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Angiology</MedlineTA>
    <NlmUniqueID>0203706</NlmUniqueID>
    <ISSNLinking>0003-3197</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017097" MajorTopicYN="Y">Electric Impedance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005121" MajorTopicYN="N">Extremities</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007424" MajorTopicYN="N">Intracellular Fluid</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008432" MajorTopicYN="Y">Mathematical Computing</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2002</Year>
        <Month>2</Month>
        <Day>28</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2002</Year>
        <Month>3</Month>
        <Day>22</Day>
        <Hour>10</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2002</Year>
        <Month>2</Month>
        <Day>28</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">11863308</ArticleId>
    <ArticleId IdType="doi">10.1177/000331970205300106</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11581330</PMID>
<DateCompleted>
    <Year>2001</Year>
    <Month>12</Month>
    <Day>07</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>02</Month>
    <Day>16</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0022-0949</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>204</Volume>
            <Issue>Pt 18</Issue>
            <PubDate>
                <Year>2001</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>The Journal of experimental biology</Title>
        <ISOAbbreviation>J Exp Biol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Frontiers of hypoxia research: acute mountain sickness.</ArticleTitle>
    <Pagination>
        <MedlinePgn>3161-70</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Traditionally, scientists and clinicians have explored peripheral physiological responses to acute hypoxia to explain the pathophysiological processes that lead to acute mountain sickness (AMS) and high-altitude cerebral edema (HACE). After more than 100 years of investigation, little is yet known about the fundamental causes of the headache and nausea that are the main symptoms of AMS. Thus, we review the evidence supporting a change in focus to the role of the central nervous system in AMS. Our justification is (i) that the symptoms of AMS and HACE are largely neurological, (ii) that HACE is considered to be the end-stage of severe AMS and was recently identified as a vasogenic edema, opening the door for a role for blood-brain barrier permeability in AMS, (iii) that new, non-invasive techniques make measurement of brain water levels and cerebral blood volume possible and (iv) that the available experimental evidence and theoretical arguments support a significant role for brain swelling in the pathophysiology of AMS. We believe that an examination of the responses of the central nervous system to acute hypoxia will reveal important new pathophysiological processes that may help explain AMS and HACE.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Roach</LastName>
            <ForeName>R C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
                <Affiliation>New Mexico Resonance, Box 343, Montezuma, NM 87731, USA. rroach@hypoxia.ney</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hackett</LastName>
            <ForeName>P H</ForeName>
            <Initials>PH</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>J Exp Biol</MedlineTA>
    <NlmUniqueID>0243705</NlmUniqueID>
    <ISSNLinking>0022-0949</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000532" MajorTopicYN="Y">Altitude Sickness</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000860" MajorTopicYN="Y">Hypoxia</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007427" MajorTopicYN="N">Intracranial Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>105</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2001</Year>
        <Month>10</Month>
        <Day>3</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2002</Year>
        <Month>1</Month>
        <Day>5</Day>
        <Hour>10</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2001</Year>
        <Month>10</Month>
        <Day>3</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">11581330</ArticleId>
    <ArticleId IdType="doi">10.1242/jeb.204.18.3161</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11456015</PMID>
<DateCompleted>
    <Year>2001</Year>
    <Month>12</Month>
    <Day>04</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>09</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1120-6721</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>2</Issue>
            <PubDate>
                <MedlineDate>2001 Apr-Jun</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>European journal of ophthalmology</Title>
        <ISOAbbreviation>Eur J Ophthalmol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A quantitative in vivo study of retinal thickness before and after laser treatment for macular edema due to retinal vein occlusion.</ArticleTitle>
    <Pagination>
        <MedlinePgn>145-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate quantitatively the effect of grid laser photocoagulation in macular edema due to central and branch retinal vein occlusion, using the retinal thickness analyzer.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">Five patients with cystoid and non-cystoid macular edema were studied before and after argon grid laser treatment. All were examined clinically, with fluorescein angiography, and measurement of retinal thickness. Macular thickness was correlated to visual acuity measured on the ETDRS chart.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Laser-slit images obtained with the retinal thickness analyzer in patients with macular edema disclosed discrete intraretinal changes after photocoagulation. Biomicroscopy and fluorescein angiography were insensitive to these small changes in the retinal thickness. No patient had any change in visual acuity after three months, but the retinal thickness was greater at this interval. The retinal thickening may be explained by a postoperative inflammatory response or by altered retinal blood flow or, in two of the eyes, by the effect of combined peripheral photocoagulation.</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The retinal thickness analyzer offers a refined tool for the diagnosis of subclinical changes of macular edema in retinal vein occlusion and is therefore also useful for assessing the effects of treatment.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>De Geronimo</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
                <Affiliation>University Eye Clinic of Créteil, France.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Glacet-Bernard</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Coscas</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Soubrane</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Eur J Ophthalmol</MedlineTA>
    <NlmUniqueID>9110772</NlmUniqueID>
    <ISSNLinking>1120-6721</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002199" MajorTopicYN="N">Capillary Permeability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003941" MajorTopicYN="N">Diagnostic Techniques, Ophthalmological</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017075" MajorTopicYN="Y">Laser Coagulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012170" MajorTopicYN="N">Retinal Vein Occlusion</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2001</Year>
        <Month>7</Month>
        <Day>18</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2002</Year>
        <Month>1</Month>
        <Day>5</Day>
        <Hour>10</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2001</Year>
        <Month>7</Month>
        <Day>18</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">11456015</ArticleId>
    <ArticleId IdType="doi">10.1177/112067210101100207</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11446063</PMID>
<DateCompleted>
    <Year>2001</Year>
    <Month>09</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2006</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0044-409X</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>126</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>2001</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zentralblatt fur Chirurgie</Title>
        <ISOAbbreviation>Zentralbl Chir</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Effectiveness of locoregional rt-PA lysis in acute leg and arm vein thrombosis].</ArticleTitle>
    <Pagination>
        <MedlinePgn>438-40</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>39 patients suffering from a thrombosis of the peripheral venous system were treated with a loco-regional lysis, using rt-PA. Two cycles of 40 mg rt-PA a day were applicated by means of a special drainage-management, using perforans veins. During lytic therapy, 20,000 to 30,000 IE of unfractionized heparin were additionally administered. Laboratory work including aPTT and fibrinogen measurement was performed every 8 hours. Additionally a phlebography was performed after 24 hours. Patients received an anticoagulative therapy using sintrom or marcumar the following 3 months. We obtained a successful thrombolysis without any major complications in 90%. Minor complications included 3 peripheral pulmonary embolisms. Duplex sonographic and plethysmographic follow up was performed in 25 patients one year after operation. In two patients with ankle edema insufficient valves at the popliteal vein were found with both diagnostic modalities. 23 patients showed no signs of insufficient valves neither clinically nor at duplex sonography and plethysmography. The locoregional lysis appears to be an effective method for the treatment of acute peripheral vein thrombosis.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Perkmann</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
                <Affiliation>Klinische Abteilung für Gefässchirurgie, Universitätsklinik für Chirurgie, Innsbruck. Reinhold.Perkmann@uibk.ac.at</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Neuhauser</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bodner</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tauscher</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fraedrich</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Wirksamkeit der loko-regionalen rt-PA-Lyse bei Bein- bzw. Armvenenthrombose.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Zentralbl Chir</MedlineTA>
    <NlmUniqueID>0413645</NlmUniqueID>
    <ISSNLinking>0044-409X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>EC 3.4.21.68</RegistryNumber>
        <NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002406" MajorTopicYN="N">Catheterization, Peripheral</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002408" MajorTopicYN="Y">Catheters, Indwelling</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010959" MajorTopicYN="N">Tissue Plasminogen Activator</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2001</Year>
        <Month>7</Month>
        <Day>12</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2001</Year>
        <Month>9</Month>
        <Day>8</Day>
        <Hour>10</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2001</Year>
        <Month>7</Month>
        <Day>12</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">11446063</ArticleId>
    <ArticleId IdType="doi">10.1055/s-2001-15036</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11312198</PMID>
<DateCompleted>
    <Year>2001</Year>
    <Month>07</Month>
    <Day>05</Day>
</DateCompleted>
<DateRevised>
    <Year>2015</Year>
    <Month>11</Month>
    <Day>19</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0361-803X</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>176</Volume>
            <Issue>5</Issue>
            <PubDate>
                <Year>2001</Year>
                <Month>May</Month>
            </PubDate>
        </JournalIssue>
        <Title>AJR. American journal of roentgenology</Title>
        <ISOAbbreviation>AJR Am J Roentgenol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Three-dimensional contrast-enhanced MR angiography of endovascular covered stents in patients with peripheral arterial occlusive disease.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1299-303</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Three-dimensional contrast-enhanced MR angiography was performed to study MR characteristics of Hemobahn devices.</AbstractText>
        <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Changes in endoluminal signal intensities and the precision of the endoluminal diameter measurement were investigated in phantom studies for different concentrations of gadopentetate dimeglumine. Before and after the Hemobahn devices had been implanted, 10 patients with peripheral arterial occlusive disease were examined on MR imaging and three-dimensional contrast-enhanced MR angiography.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Phantom experiments using three-dimensional MR angiography showed stent-related signal void as a dark ring in the axial image orientation, providing a precise delineation of the stent--vessel border (mean endoluminal diameter, 8.2 mm; SD, 0.6 mm). Changes in endoluminal signal intensity were evaluated quantitatively. Stent-related artifacts did not compromise diagnostic imaging quality. All Hemobahn devices were found to be patent without migration of an implanted graft. In one patient, an extensive perigraft reaction (edema and contrast-enhanced perivascular tissue) was postinterventionally detected on MR imaging and corresponded to clinically evident postimplantation symptoms.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Three-dimensional contrast-enhanced MR angiography is a suitable tool to follow up the implantation of Hemobahn devices and to detect intra- and extraluminal abnormalities.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Juergens</LastName>
            <ForeName>K U</ForeName>
            <Initials>KU</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Clinical Radiology, University of Muenster, Albert-Schweitzer-Str. 33, D-48129 Muenster, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tombach</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Reimer</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vestring</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Heindel</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>AJR Am J Roentgenol</MedlineTA>
    <NlmUniqueID>7708173</NlmUniqueID>
    <ISSNLinking>0361-803X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>K2I13DR72L</RegistryNumber>
        <NameOfSubstance UI="D019786">Gadolinium DTPA</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
    <CommentsCorrections RefType="CommentIn">
        <RefSource>AJR Am J Roentgenol. 2001 Dec;177(6):1483-4</RefSource>
        <PMID Version="1">11717113</PMID>
    </CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001157" MajorTopicYN="N">Arterial Occlusive Diseases</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019786" MajorTopicYN="N">Gadolinium DTPA</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018810" MajorTopicYN="N">Magnetic Resonance Angiography</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019047" MajorTopicYN="N">Phantoms, Imaging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015607" MajorTopicYN="Y">Stents</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2001</Year>
        <Month>4</Month>
        <Day>20</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2001</Year>
        <Month>7</Month>
        <Day>6</Day>
        <Hour>10</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2001</Year>
        <Month>4</Month>
        <Day>20</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">11312198</ArticleId>
    <ArticleId IdType="doi">10.2214/ajr.176.5.1761299</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11275381</PMID>
<DateCompleted>
    <Year>2001</Year>
    <Month>06</Month>
    <Day>28</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0304-3959</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>91</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>2001</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>Pain</Title>
        <ISOAbbreviation>Pain</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Facilitated neurogenic inflammation in complex regional pain syndrome.</ArticleTitle>
    <Pagination>
        <MedlinePgn>251-257</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0304-3959(00)00445-0</ELocationID>
    <Abstract>
        <AbstractText>Complex regional pain syndrome (CRPS) is characterized by a variety of clinical features including spontaneous pain and hyperalgesia. Increased neuropeptide release from peripheral nociceptors has been suggested as a possible pathophysiologic mechanism triggering the combination of trophic changes, edema, vasodilatation and pain. In order to verify the increased neuropeptide release in CRPS, electrically induced neurogenic vasodilatation and protein extravasation were evaluated in patients and controls. We performed a prospective study on 10 patients with acute and untreated CRPS and 10 matched healthy controls. Neurogenic inflammation was elicited by strong transcutaneous electrical stimulation via intradermal microdialysis capillaries which simultaneously enabled measurement of protein extravasation. Laser-Doppler scanning was used to assess axon reflex vasodilatation. Axon reflex vasodilatation was significantly increased in CRPS patients (438 +/- 68% of baseline vs. 306 +/- 52%; P &lt; 0.05) and transcutaneous electrical stimulation provoked protein extravasation only in the patients (before, 0.28 +/- 0.03 mg/ml; during stimulation, 0.34 +/- 0.04 mg/ml), whereas protein concentration steadily declined during stimulation in the healthy controls (before, 0.23 +/- 0.04 mg/ml; during stimulation, 0.18 +/- 0.04; P &lt; 0.001). The time course of electrically induced protein extravasation in the patients resembled the one observed following application of exogenous substance P (SP). We conclude that neurogenic inflammation is facilitated in CRPS. Our results suggest an increased releasability of neuropeptides in CRPS.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Neurologische Klinik, Friedrich Alexander Universität Erlangen-Nürnberg, Universitätsstrasse 17, D-91054 Erlangen, Germany Institut für Physiologie und experimentelle Pathophysiologie, Friedrich Alexander Universität Erlangen-Nürnberg, Universitätsstrasse 17, D-91054 Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Birklein</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Neundörfer</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Schmelz</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Pain</MedlineTA>
    <NlmUniqueID>7508686</NlmUniqueID>
    <ISSNLinking>0304-3959</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020918" MajorTopicYN="N">Complex Regional Pain Syndromes</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017078" MajorTopicYN="N">Laser-Doppler Flowmetry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009443" MajorTopicYN="N">Neuritis</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009619" MajorTopicYN="N">Nociceptors</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
        <QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2001</Year>
        <Month>3</Month>
        <Day>29</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2001</Year>
        <Month>6</Month>
        <Day>29</Day>
        <Hour>10</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2001</Year>
        <Month>3</Month>
        <Day>29</Day>
        <Hour>10</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">11275381</ArticleId>
    <ArticleId IdType="pii">00006396-200104000-00008</ArticleId>
    <ArticleId IdType="doi">10.1016/S0304-3959(00)00445-0</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Title>References</Title>
    <Reference>
        <Citation>Anderson C, Andersson T, Wardell K. Changes in skin circulation after insertion of a microdialysis probe visualized by laser Doppler perfusion imaging. J Invest Dermatol. 1994;102:807-811.</Citation>
    </Reference>
    <Reference>
        <Citation>Baron R, Maier C. Reflex sympathetic dystrophy: skin blood flow, sympathetic vasoconstrictor reflexes and pain before and after surgical sympathectomy. Pain. 1996;67:317-326.</Citation>
    </Reference>
    <Reference>
        <Citation>Birklein F, Sittl R, Spitzer A, Claus D, Neundörfer B, Handwerker HO. Sudomotor function in sympathetic reflex dystrophy. Pain. 1997;69:49-54.</Citation>
    </Reference>
    <Reference>
        <Citation>Birklein F, Claus D, Riedl B, Neundörfer B, Handwerker HO. Effects of cutaneous histamine application in patients with sympathetic reflex dystrophy. Muscle Nerve. 1997;20:1389-1395.</Citation>
    </Reference>
    <Reference>
        <Citation>Birklein F, Riedl B, Sieweke N, Weber M, Neundorfer B. Neurological findings in complex regional pain syndromes: analysis of 145 cases. Acta Neurol Scand. 2000;101:262-269.</Citation>
    </Reference>
    <Reference>
        <Citation>Birklein F, Weber M, Neundorfer B. Increased skin lactate in complex regional pain syndrome: evidence for tissue hypoxia? Neurology. 2000;55:1213-1215.</Citation>
    </Reference>
    <Reference>
        <Citation>Blair SJ, Chinthagada M, Hoppenstehdt D, Kijowski R, Fareed J. Role of neuropeptides in pathogenesis of reflex sympathetic dystrophy. Acta Orthop Belg. 1998;64:448-451.</Citation>
    </Reference>
    <Reference>
        <Citation>Blumberg H, Wallin BG. Direct evidence of neurally mediated vasodilatation in hairy skin of the human foot. J Physiol (Lond.). 1987;382:105-121.</Citation>
    </Reference>
    <Reference>
        <Citation>Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.</Citation>
    </Reference>
    <Reference>
        <Citation>Cline M, Ochoa JL, Torebjörk E. Chronic hyperalgesia and skin warming caused by sensitized C nociceptors. Brain. 1989;112:621-647.</Citation>
    </Reference>
    <Reference>
        <Citation>Drummond PD, Finch PM, Gibbins I. Innervation of hyperalgesic skin in patients with Complex Regional Pain Syndrome. Clin J Pain. 1996;12:222-231.</Citation>
    </Reference>
    <Reference>
        <Citation>Hargreaves KM, Swift JQ, Roszkowski MT, Bowles W, Garry MG, Jackson DL. Pharmacology of peripheral neuropeptide and inflammatory mediator release. Oral Surg Oral Med Oral Pathol. 1994;78:503-510.</Citation>
    </Reference>
    <Reference>
        <Citation>Helme RD, McKernan S. Neurogenic flare responses following topical application of capsaicin in humans. Ann Neurol. 1985;18:505-509.</Citation>
    </Reference>
    <Reference>
        <Citation>Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol. 1998;30:5-11.</Citation>
    </Reference>
    <Reference>
        <Citation>Hsieh ST, Lin WM. Modulation of keratinocyte proliferation by skin innervation. J Invest Dermatol. 1999;113:579-586.</Citation>
    </Reference>
    <Reference>
        <Citation>Hua XY, Chen P, Marsala M, Yaksh TL. Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids. Neuroscience. 1999;89:525-534.</Citation>
    </Reference>
    <Reference>
        <Citation>Hukkanen M, Konttinen YT, Santavirta S, Paavolainen P, Gu XH, Terenghi G, Polak JM. Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling. Neuroscience. 1993;54:969-979.</Citation>
    </Reference>
    <Reference>
        <Citation>Kemler MA, van de Vússe AC, van den Berg-Loonen EM, Barendse GA, van Kleef M, Weber WE. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology. 1999;53:1350-1351.</Citation>
    </Reference>
    <Reference>
        <Citation>Kurvers HA, Jacobs MJ, Beuk RJ, van den Wildenberg FA, Kitslaar PJ, Slaaf DW, Reneman RS. Reflex sympathetic dystrophy: evolution of microcirculatory disturbances in time. Pain. 1995;60:333-340.</Citation>
    </Reference>
    <Reference>
        <Citation>Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature. 1986;323:158-160.</Citation>
    </Reference>
    <Reference>
        <Citation>Lundblad L, Lundberg JM, Anggard A, Zetterstrom O. Capsaicin-sensitive nerves and the cutaneous allergy reaction in man: possible involvement of sensory neuropeptides in the flare reaction. Allergy. 1987;42:20-25.</Citation>
    </Reference>
    <Reference>
        <Citation>Magerl W, Szolcsanyi J, Westerman RA, Handwerker HO. Laser Doppler measurements of skin vasodilation elicited by percutaneous electrical stimulation of nociceptors in humans. Neurosci Lett. 1987;82:349-354.</Citation>
    </Reference>
    <Reference>
        <Citation>McLachlan EM, Jang W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature. 1993;363:543-546.</Citation>
    </Reference>
    <Reference>
        <Citation>Mori T, Ogata T, Okumura H, Shibata T, Nakamura Y, Kataoka K. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochem Biophys Res Commun. 1999;262:418-422.</Citation>
    </Reference>
    <Reference>
        <Citation>Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, Finke MP, Li J, Lappi DA, Simone DA, Mantyh PW. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science. 1999;286:1558-1561.</Citation>
    </Reference>
    <Reference>
        <Citation>Ochoa JL. Truths, errors, and lies around ‘reflex sympathetic dystrophy’ and ‘complex regional pain syndrome’. J Neurol. 1999;246:875-879.</Citation>
    </Reference>
    <Reference>
        <Citation>Ochoa JL, Yarnitsky D, Marchettini P, Cline M. Interaction between sympathetic vasoconstrictor outflow and C nociceptor-induced antidromic vasodilatation. Pain. 1993;54:191-196.</Citation>
    </Reference>
    <Reference>
        <Citation>Oyen WJ, Arntz IE, Claessens RM, Van der Meer JW, Corstens FH, Goris RJ. Reflex sympathetic dystrophy of the hand: an excessive inflammatory response? Pain. 1993;55:151-157.</Citation>
    </Reference>
    <Reference>
        <Citation>Parkhouse N, Crowe R, McGrouther DA, Burnstock G. Painful hypertrophic scarring and neuropeptides. Lancet. 1992;340:1410.</Citation>
    </Reference>
    <Reference>
        <Citation>Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med. 1988;318:1306-1309.</Citation>
    </Reference>
    <Reference>
        <Citation>Petersen LJ, Winge K, Brodin E, Skov PS. No release of histamine and substance P in capsaicin-induced neurogenic inflammation in intact human skin in vivo: a microdialysis study. Clin Exp Allergy. 1997;27:957-965.</Citation>
    </Reference>
    <Reference>
        <Citation>Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I. Ligands and mechanisms of cellular activation. Neuropeptides. 1997;31:537-563.</Citation>
    </Reference>
    <Reference>
        <Citation>Ramamurthy S, Hoffman J. Intravenous regional guanethidine in the treatment of reflex sympathetic dystrophy/causalgia: a randomized, double-blind study. Anesth Analg. 1995;81:718-723.</Citation>
    </Reference>
    <Reference>
        <Citation>Ravin N. New hair growth over fracture sites. N Engl J Med. 1990;323:350.</Citation>
    </Reference>
    <Reference>
        <Citation>Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science. 1991;251:1608-1610.</Citation>
    </Reference>
    <Reference>
        <Citation>Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neurosci Lett. 1997;230:117-120.</Citation>
    </Reference>
    <Reference>
        <Citation>Schmelz M, Michael K, Weidner C, Schmidt R, Torebjork HE, Handwerker HO. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport. 2000;11:645-648.</Citation>
    </Reference>
    <Reference>
        <Citation>Schwartzman RJ, McLellan TL. Reflex sympathetic dystrophy. Arch Neurol. 1987;44:555-561.</Citation>
    </Reference>
    <Reference>
        <Citation>Sieweke N, Birklein F, Riedl B, Neundörfer B, Handwerker HO. Patterns of hyperalgesia in complex regional pain syndrome. Pain. 1999;80:171-177.</Citation>
    </Reference>
    <Reference>
        <Citation>Stanton-Hicks M, Jänig W, Hassenbusch S, Haddox JD, Boas RA, Wilson PR. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995;63:127-133.</Citation>
    </Reference>
    <Reference>
        <Citation>Steen KH, Reeh PW. Actions of cholinergic agonists and antagonists on sensory nerve endings in rat skin in vitro. J Neurophysiol. 1993;70:397-405.</Citation>
    </Reference>
    <Reference>
        <Citation>Steen KH, Reeh PW, Anton F, Handwerker HO. Protons selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin in vitro. J Neurosci. 1992;12:86-95.</Citation>
    </Reference>
    <Reference>
        <Citation>Sudeck P. Über die akute (reflektorische) Knochenatrophie nach Entzündungen und Verletzungen in den Extremitäten und ihre klinischen Erscheinungen. Fortschr Röntgenstr. 1901;5:227-293.</Citation>
    </Reference>
    <Reference>
        <Citation>Tanaka T, Danno K, Ikai K, Imamura S. Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol. 1988;90:399-401.</Citation>
    </Reference>
    <Reference>
        <Citation>Torebjörk E, Wahren LK, Wallin G, Hallin R, Koltzenburg M. Noradrenaline-evoked pain in neuralgia. Pain. 1995;63:11-20.</Citation>
    </Reference>
    <Reference>
        <Citation>van der Laan L, Kapitein PJ, Oyen WJ, Verhofstad AA, Hendriks T, Goris RJ. A novel animal model to evaluate oxygen derived free radical damage in soft tissue. Free Radic Res. 1997;26:363-372.</Citation>
    </Reference>
    <Reference>
        <Citation>van der Laan L, Kapitein P, Verhofstad A, Hendriks T, Goris RJ. Clinical signs and symptoms of acute reflex sympathetic dystrophy in one hindlimb of the rat, induced by infusion of a free-radical donor. Acta Orthop Belg. 1998;64:210-217.</Citation>
    </Reference>
    <Reference>
        <Citation>Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993;342:1012-1016.</Citation>
    </Reference>
    <Reference>
        <Citation>Wardell K, Naver HK, Nilsson GE, Wallin BG. The cutaneous vascular axon reflex in humans characterized by laser Doppler perfusion imaging. J Physiol (Lond.). 1993;460:185-199.</Citation>
    </Reference>
    <Reference>
        <Citation>Wasner G, Heckmann K, Maier C, Baron R. Vascular abnormalities in acute reflex sympathetic dystrophy (CRPS I): complete inhibition of sympathetic nerve activity with recovery. Arch Neurol. 1999;56:613-620.</Citation>
    </Reference>
    <Reference>
        <Citation>Weidner C, Schmelz M, Hansson B, Handwerker HO, Torebjörk HE. Functional attributes discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. J Neurosci. 1999;19:10184-10190.</Citation>
    </Reference>
    <Reference>
        <Citation>Westerman RA, Pano I, Rabavilas A, Hahn A, Nunn A, Roberts RG, Burry H. Reflex sympathetic dystrophy: altered axon-reflexes and autonomic responses. Clin Exp Neurol. 1992;29:210-233.</Citation>
    </Reference>
    <Reference>
        <Citation>Xu XJ, Dalsgaard CJ, Maggi CA, Wiesenfeld-Hallin Z. NK-1, but not NK-2, tachykinin receptors mediate plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw: demonstrated with the NK-1 antagonist CP-96,345 and the NK-2 antagonist Men 10207. Neurosci Lett. 1992;139:249-252.</Citation>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">10847492</PMID>
<DateCompleted>
    <Year>2000</Year>
    <Month>09</Month>
    <Day>27</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>16</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1082-3069</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>31</Volume>
            <Issue>3</Issue>
            <PubDate>
                <MedlineDate>2000 May-Jun</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Ophthalmic surgery and lasers</Title>
        <ISOAbbreviation>Ophthalmic Surg Lasers</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Optical coherence tomography for retinal thickness measurement in diabetic patients without clinically significant macular edema.</ArticleTitle>
    <Pagination>
        <MedlinePgn>182-6</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the potential of optical coherence tomography (OCT) as a screening method for retinal thickness measurements in diabetic patients.</AbstractText>
        <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We used a previously described pattern of six 5 mm OCT scans through the center of fixation in 45 diabetic patients without clinically significant macular edema: 22 patients (group 1) had no diabetic retinopathy (ETDRS classification); 18 (group 2) had nonproliferative retinopathy; 5 patients with peripheral neovascularization did not enter statistical analysis; 25 normal healthy subjects were used as a control group. Retinal thickness was measured at five locations in each scan: in the fovea, at the foveal rim, and outside the macula. Measurements were identified in nonaligned images and taken from raw data A-scans. Locations were grouped into hemispheres, quadrants and rings, and mean values tested for statistically significant differences using Mann-Whitney U-Wilcoxon rank sum W test.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Differences in retinal thickness were found to be significant in the macula (controls vs group 2 P = 0.0266), at the foveal rim (controls vs group 1 and 2: P = 0.0386 and P = 0.0193), in the nasal and superior hemisphere (controls vs group 2: P = 0.0251 and P = 0.0187), and in the superior nasal quadrant (controls vs group 1 and group 1 vs group 2: P = 0.0022 and P = 0.0462).</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Significant differences of retinal thickness between patients with diabetic retinopathy and normals can be detected by OCT even in the absence of clinically significant macular edema. Significant differences between diabetic patients with and without retinopathy are most likely to be found in the superior nasal quadrant.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Schaudig</LastName>
            <ForeName>U H</ForeName>
            <Initials>UH</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Ophthalmology, Augenklinik und Poliklinik, Universitats-Krankenhaus Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Glaefke</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Scholz</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Richard</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Ophthalmic Surg Lasers</MedlineTA>
    <NlmUniqueID>9517132</NlmUniqueID>
    <ISSNLinking>1082-3069</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003930" MajorTopicYN="N">Diabetic Retinopathy</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003941" MajorTopicYN="Y">Diagnostic Techniques, Ophthalmological</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007368" MajorTopicYN="N">Interferometry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014054" MajorTopicYN="N">Tomography</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>2000</Year>
        <Month>6</Month>
        <Day>10</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>2000</Year>
        <Month>9</Month>
        <Day>30</Day>
        <Hour>11</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>2000</Year>
        <Month>6</Month>
        <Day>10</Day>
        <Hour>9</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">10847492</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">10420515</PMID>
<DateCompleted>
    <Year>1999</Year>
    <Month>09</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0948-2393</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>203</Volume>
            <Issue>2</Issue>
            <PubDate>
                <MedlineDate>1999 Mar-Apr</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Zeitschrift fur Geburtshilfe und Neonatologie</Title>
        <ISOAbbreviation>Z Geburtshilfe Neonatol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Fiberoptic measurement of arterial oxygen saturation in premature and term neonates].</ArticleTitle>
    <Pagination>
        <MedlinePgn>77-80</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Non-invasive oxygen monitoring with pulse oximetry or transcutaneous monitoring has gained widespread use in neonatology. Different factors like arterial hypotension, peripheral vasoconstriction and edema adversely affect the accuracy of both methods. To ensure reliable monitoring of oxygen saturation in critically ill patients we measured oxygen saturation with a fiberoptic catheter via umbilical artery.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">In ventilated premature infants (FiO2 &gt; 0.4) a 4F-fiberoptic catheter (Oximetrix)-3, Abbott) was inserted to the descending aorta (Th 6-8). Simultaneously pulse oximetry (SaPO2) was performed with the Ohmeda Biox 3700. To compare the reliability of both methods, blood was analysed for arterial partial oxygen pressure (PaO2), fetal hemoglobin (HbF) and arterial oxygen saturation (SaO2) by complete co-oximetry (Radiometer Copenhagen OSM3) as reference.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 10 premature infants (median gestational age 30.5 weeks; median birth weight 1360 g) oxygen saturation was measured with the fiberoptic catheter (SaFO2) over a total period of 935 hours. In all, 137 blood samples were analysed for arterial saturation (SaO2) by co-oximetry. The mean difference between the SaO2 and SaFO2 was -1.89% (+/- 1.53); the mean difference between SaO2 and the values obtained by pulse oximetry (SaPO2) was -3.09% (+/- 2.33). The SaFO2 results correlated closely with the co-oximetry values (r = 0.97; p &lt; 0.0001).</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In critically ill patients, if non-invasive oxygen monitoring fails, a fiberoptic catheter offers the possibility of continuous and reliable measurement of oxygen saturation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Merz</LastName>
            <ForeName>U</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
                <Affiliation>Kinderklinik, Neonatologische Intensivmedizin, Universitätsklinikum der RWTH Aachen.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Peschgens</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hörnchen</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D016430">Clinical Trial</PublicationType>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Fiberoptische Messung der arteriellen Sauerstoffsättigung bei Früh- und Neugeborenen.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Z Geburtshilfe Neonatol</MedlineTA>
    <NlmUniqueID>9508901</NlmUniqueID>
    <ISSNLinking>0948-2393</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>S88TT14065</RegistryNumber>
        <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001785" MajorTopicYN="N">Blood Gas Monitoring, Transcutaneous</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002406" MajorTopicYN="N">Catheterization, Peripheral</DescriptorName>
        <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019719" MajorTopicYN="N">Diagnostic Equipment</DescriptorName>
        <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005336" MajorTopicYN="N">Fiber Optic Technology</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007232" MajorTopicYN="N">Infant, Newborn, Diseases</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007234" MajorTopicYN="N">Infant, Premature</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015931" MajorTopicYN="N">Intensive Care, Neonatal</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014469" MajorTopicYN="N">Umbilical Arteries</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1999</Year>
        <Month>7</Month>
        <Day>27</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1999</Year>
        <Month>7</Month>
        <Day>27</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1999</Year>
        <Month>7</Month>
        <Day>27</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">10420515</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">10052063</PMID>
<DateCompleted>
    <Year>1999</Year>
    <Month>05</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>10</Month>
    <Day>18</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0891-6640</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
                <MedlineDate>1999 Jan-Feb</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Journal of veterinary internal medicine</Title>
        <ISOAbbreviation>J Vet Intern Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Increased splenic capacity in response to transdermal application of nitroglycerine in the dog.</ArticleTitle>
    <Pagination>
        <MedlinePgn>44-6</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>This study was conducted to determine if application of transdermal 2% nitroglycerine ointment (TDNG) to dogs anesthetized with alpha chloralose would produce splenic dilatation by relaxation of venous smooth muscle. Sonomicrometer crystals were applied to the spleen in each of 15 dogs, and a pressure-measuring catheter was inserted into a splenic vein. The sonomicrometer crystals permitted measurement of splenic dimension, which is known to correlate with splenic volume. Ten dogs were given 2.5 cm TDNG/10 kg, and 5 dogs (vehicle controls) were given only petrolatum, both applied to the inner surface of the auricular pinna. Splenic dimension in all dogs receiving TDNG increased significantly (P &lt; .05) by 7.0 +/- 4.8%, whereas splenic dimension in dogs receiving petrolatum did not increase. Splenic venous pressures did not change significantly in either group. Spleens began to dilate 482 +/- 652 seconds after application of TDNG and achieved maximal dilatation at 861 +/- 632 seconds. Splenic dilatation occurred in the absence of elevation of splenic venous pressure, indicating that the dilatation probably resulted from relaxation of splenic smooth muscle. TDNG was absorbed transdermally and produced splenic dilatation in health dogs anesthetized with alpha chloralose. If the spleen is a sentinel for peripheral veins, then TDNG may increase venous capacity, retaining blood from the lungs and thereby functioning to reduce pulmonary congestion and edema in dogs with left-sided heart failure.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Parameswaran</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Veterinary Biosciences, Ohio State University, Columbus, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hamlin</LastName>
            <ForeName>R L</ForeName>
            <Initials>RL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nakayama</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>S S</ForeName>
            <Initials>SS</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Vet Intern Med</MedlineTA>
    <NlmUniqueID>8708660</NlmUniqueID>
    <ISSNLinking>0891-6640</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>238BZ29MUE</RegistryNumber>
        <NameOfSubstance UI="D002698">Chloralose</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>G59M7S0WS3</RegistryNumber>
        <NameOfSubstance UI="D005996">Nitroglycerin</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002698" MajorTopicYN="N">Chloralose</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005996" MajorTopicYN="N">Nitroglycerin</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013162" MajorTopicYN="N">Splenic Vein</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014690" MajorTopicYN="N">Venous Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1999</Year>
        <Month>3</Month>
        <Day>3</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1999</Year>
        <Month>3</Month>
        <Day>3</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1999</Year>
        <Month>3</Month>
        <Day>3</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">10052063</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">9854750</PMID>
<DateCompleted>
    <Year>1999</Year>
    <Month>02</Month>
    <Day>25</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0362-2436</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>23</Issue>
            <PubDate>
                <Year>1998</Year>
                <Month>Dec</Month>
                <Day>01</Day>
            </PubDate>
        </JournalIssue>
        <Title>Spine</Title>
        <ISOAbbreviation>Spine (Phila Pa 1976)</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Acute effects of nucleus pulposus on blood flow and endoneurial fluid pressure in rat dorsal root ganglia.</ArticleTitle>
    <Pagination>
        <MedlinePgn>2517-23</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">An experimental study to elucidate the initial factors in the pathogenesis of lumbar pain caused by disc herniation.</AbstractText>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effects of autologous nucleus pulposus on blood flow and endoneurial fluid pressure in dorsal root ganglia.</AbstractText>
        <AbstractText Label="SUMMARY OF BACKGROUND DATA" NlmCategory="BACKGROUND">Human sciatica is known to be associated with compression of lumbar nerve roots and dorsal root ganglia by herniated intervertebral discs. Recently, it has been shown that application of nucleus pulposus to nerve roots induces injury and pain-related behavior in experimental animals. In this study, the authors hypothesized that nucleus pulposus applied to a nerve root would cause increased intraneural edema and reduced blood flow in the corresponding dorsal root ganglia. Studies in peripheral nerves have shown that these initial pathophysiologic disturbances initiate complex events that exacerbate nerve injury and cause pain.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 29 adult female Sprague-Dawley rats weighing 200 to 250 g had their left L5 nerve roots and associated dorsal root ganglia exposed. Autologous nucleus pulposus was harvested from the tail and applied to the L5 nerve root just proximally to the dorsal root ganglia (nucleus pulposus group). For control, the same volume of muscle was harvested from the surgical area in the back and applied similarly to the neural tissue (control group). Blood flow was continuously monitored using a laser Doppler flow probe for 3 hours (n = 10) or 4 hours (n = 8) in animals with indwelling cannulas for measurement of systemic arterial pressure. Endoneurial fluid pressures were recorded with a servonull micropipette system using glass micropipettes with tip diameters of 4 microns. Endoneurial fluid pressure in the dorsal root ganglia was measured before and 3 hours after application of nucleus pulposus (n = 7) or muscle (n = 4). After measurement of blood flow and endoneurial fluid pressure, the nerve root and dorsal root ganglia were processed for histology and evaluated by light microscope.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Blood flow in the nucleus pulposus group was reduced by 10% to 20% from the initial value after 3 to 4 hours. This reduction was statistically significant compared with that of the control group (P &lt; 0.01). Endoneurial fluid pressure was initially 2.6 +/- 1.2 cm H2O in the nucleus pulposus group, and 2.1 +/- 0.6 cm H2O in the control group. Three hours after application, endoneurial fluid pressure was 7.5 +/- 4.6 in the nucleus pulposus group (P &gt; 0.05), and 2.0 +/- 0.8 in the control group (P &gt; 0.05). Edema was the principal pathologic finding seen consistently in the nerve roots and in many of the associated dorsal root ganglia from animals treated with nucleus pulposus.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Application of nucleus pulposus to nerve root increased endoneurial fluid pressure and decreased blood flow in the dorsal root ganglia. This study's acute observations in the dorsal root ganglia may thus help to explain why disc herniations without compression of neural tissue are sometimes painful because similar pathologic findings are observed after only nucleus pulposus application to the nerve root. The authors further suggest that exposure of nerve roots to nucleus pulposus may establish a "compartment syndrome" in the dorsal root ganglia.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Yabuki</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
                <Affiliation>Department Orthopaedic Surgery, Fukushima Medical College, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kikuchi</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Olmarker</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Myers</LastName>
            <ForeName>R R</ForeName>
            <Initials>RR</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>NS 18715-14</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Spine (Phila Pa 1976)</MedlineTA>
    <NlmUniqueID>7610646</NlmUniqueID>
    <ISSNLinking>0362-2436</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006874" MajorTopicYN="N">Hydrostatic Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007405" MajorTopicYN="N">Intervertebral Disc Displacement</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017078" MajorTopicYN="N">Laser-Doppler Flowmetry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008159" MajorTopicYN="N">Lumbar Vertebrae</DescriptorName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1998</Year>
        <Month>12</Month>
        <Day>17</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1998</Year>
        <Month>12</Month>
        <Day>17</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1998</Year>
        <Month>12</Month>
        <Day>17</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">9854750</ArticleId>
    <ArticleId IdType="doi">10.1097/00007632-199812010-00006</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">9767542</PMID>
<DateCompleted>
    <Year>1998</Year>
    <Month>12</Month>
    <Day>31</Day>
</DateCompleted>
<DateRevised>
    <Year>2009</Year>
    <Month>09</Month>
    <Day>29</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0085-2538</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>54</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>1998</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>Kidney international</Title>
        <ISOAbbreviation>Kidney Int</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Peripheral microvascular parameters in the nephrotic syndrome.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1261-6</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Peripheral edema, in combination with severe proteinuria and low serum albumin levels, is pathognomonic of the nephrotic syndrome, yet the exact mechanism of its formation is unknown. Two of the most important of the factors in Starling's forces controlling fluid filtration across the capillary have hitherto not been studied in nephrotic subjects.</AbstractText>
        <AbstractText Label="METHODS" NlmCategory="METHODS">The hydrostatic capillary pressure at the finger nail-fold in actively nephrotic subjects and age and sex matched controls was studied, using direct puncture of the apex of the capillary under video microscopy, and a servonulling apparatus to give a direct measurement of capillary pressure. Capillary filtration capacity (CFC) at the calf was measured noninvasively by a modern derivative of the technique of mercury strain gauge plethysmography. Fifteen nephrotic subjects with a variety of underlying pathological lesions, and age matched controls were studied.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Contrary to the assumption of the "overflow" hypothesis of edema formation, there was no evidence of capillary hypertension. The capillary pressure showed no difference between nephrotic subjects and controls: median (range) of 17.6 (12.0 to 24.2) compared with 17.3 (9.0 to 21.6) mm Hg, P = NS. CFC was significantly higher in nephrotic subjects than controls [5.23 (3.28 to 8.52) x 10(-3) versus 3.55 (2.43 to 5.28) x 10(-3) ml/min/100 g/mm Hg, P &lt; 0.01].</AbstractText>
        <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An increase in CFC provides a potentially novel mechanism contributing at least in part to the formation of peripheral edema in the nephrotic syndrome.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Lewis</LastName>
            <ForeName>D M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
                <Affiliation>Royal Devon and Exeter Hospital, and Department of Vascular Medicine, University of Exeter, England, United Kingdom. David.Lewis@dial.pipex.com</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tooke</LastName>
            <ForeName>J E</ForeName>
            <Initials>JE</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Beaman</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Gamble</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shore</LastName>
            <ForeName>A C</ForeName>
            <Initials>AC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Kidney Int</MedlineTA>
    <NlmUniqueID>0323470</NlmUniqueID>
    <ISSNLinking>0085-2538</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009404" MajorTopicYN="N">Nephrotic Syndrome</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1998</Year>
        <Month>10</Month>
        <Day>10</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1998</Year>
        <Month>10</Month>
        <Day>10</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1998</Year>
        <Month>10</Month>
        <Day>10</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">9767542</ArticleId>
    <ArticleId IdType="doi">10.1046/j.1523-1755.1998.00100.x</ArticleId>
    <ArticleId IdType="pii">S0085-2538(15)30748-1</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">9727878</PMID>
<DateCompleted>
    <Year>1999</Year>
    <Month>05</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">1065-7541</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>1998</Year>
            </PubDate>
        </JournalIssue>
        <Title>Radiation oncology investigations</Title>
        <ISOAbbreviation>Radiat Oncol Investig</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy.</ArticleTitle>
    <Pagination>
        <MedlinePgn>182-90</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Postoperative computed tomography (CT)-based dosimetric analysis of transperineal ultrasound-guided conformal prostate brachytherapy provides detailed information regarding the coverage and uniformity of the implant. However, there is no generally accepted standard for the optimal timing of the postoperative dosimetry. This report details dosimetric analysis and the effect of timing based upon CT and orthogonal film evaluation for ten unselected patients implanted with either iodine-125 (125I) or palladium-103 (103Pd). Within 2 hours after implantation, patients underwent a CT scan and the first of four sequential sets of orthogonal films. Subsequent orthogonal films were obtained on days 3, 14, and 28 postimplant. CT-based dosimetry revealed coverage of the prostate to the prescribed minimal peripheral dose (mPD) at 93.1 +/- 3.6% of the volume, the prostate volume receiving 150% of mPD was 38.2 +/- 8.7%, and the urethral and rectal doses were 114 +/- 12% and 78 +/- 19% of mPD, respectively. The implanted seeds seen on orthogonal films acted as markers for temporal changes in prostate dimensions, and the standard deviation of each dimension was used as input in an ellipsoidal volume calculation. Seed coordinates were self normalized to the center of gravity of each two-dimensional view and were measured relative to the linear regression line in the superior-inferior direction. The reproducibility of the anteroposterior (AP) film setup in terms of temporal variation in the angle of the regression line was markedly better than that of the lateral films, 1.8 degrees +/- 1.2 degrees vs. 4.3 degrees +/- 2.6 degrees, respectively. Dimensional contraction from day 0 to day 28 averaged 11.3% in the superior-inferior direction, 8.5% in the AP/PA (posteroanterior) direction, and 2.5% in the right-left lateral direction. This translated into a volume change of 20.9% (ranged 11.6-31.6%), which was determined by using the ellipsoid method. The half-life for edema resolution was 10.6 +/- 1.8 days (range 8.6-14.3 days). However, because of variability in the degree and extent of edema and its rate of resolution, we believe that it may be futile to define a single point in time as the most accurate indicator of the postoperative dose distribution. Rather, it may be preferable to accept universal standardization of timing and methodology for CT-based postoperative dosimetry, which would facilitate comparison of results between centers and maximize the information content of that single measurement. We conclude that day 0 represents the optimal time, because dosimetric evaluation at that time minimizes patient discomfort and inconvenience (a catheter is already in place), provides information about edema when it is near its maximum extent, and provides prompt closure of the learning loop and, as such, hopefully will result in improved implantation techniques and results.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Merrick</LastName>
            <ForeName>G S</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
                <Affiliation>Schiffler Oncology Center, Wheeling Hospital, Wheeling Medical Park, West Virginia 26003, USA. oncology@hgo.net</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Butler</LastName>
            <ForeName>W M</ForeName>
            <Initials>WM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Dorsey</LastName>
            <ForeName>A T</ForeName>
            <Initials>AT</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Walbert</LastName>
            <ForeName>H L</ForeName>
            <Initials>HL</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Radiat Oncol Investig</MedlineTA>
    <NlmUniqueID>9437448</NlmUniqueID>
    <ISSNLinking>1065-7541</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011868">Radioisotopes</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>5TWQ1V240M</RegistryNumber>
        <NameOfSubstance UI="D010165">Palladium</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001918" MajorTopicYN="N">Brachytherapy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004307" MajorTopicYN="N">Dose-Response Relationship, Radiation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010165" MajorTopicYN="N">Palladium</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011868" MajorTopicYN="N">Radioisotopes</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011880" MajorTopicYN="N">Radiotherapy Planning, Computer-Assisted</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D020266" MajorTopicYN="N">Radiotherapy, Conformal</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1998</Year>
        <Month>9</Month>
        <Day>4</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1998</Year>
        <Month>9</Month>
        <Day>4</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1998</Year>
        <Month>9</Month>
        <Day>4</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">9727878</ArticleId>
    <ArticleId IdType="doi">10.1002/(SICI)1520-6823(1998)6:4&lt;182::AID-ROI6&gt;3.0.CO;2-U</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">9630014</PMID>
<DateCompleted>
    <Year>1998</Year>
    <Month>09</Month>
    <Day>02</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>09</Month>
    <Day>05</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0340-5761</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>72</Volume>
            <Issue>5</Issue>
            <PubDate>
                <Year>1998</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>Archives of toxicology</Title>
        <ISOAbbreviation>Arch Toxicol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Assessment of early acute lung injury in rodents exposed to phosgene.</ArticleTitle>
    <Pagination>
        <MedlinePgn>283-8</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Phosgene is a highly reactive oxidant gas used in the chemical industry. Phosgene can cause life-threatening pulmonary edema by reacting with peripheral lung compartment tissue components. Clinical evidence of edema is not usually apparent until well after the initial exposure. This study was designed to investigate early signs of acute lung injury in rodents within 45-60 min after the start of exposure. Male mice, rats, or guinea pigs were exposed to 87 mg/m3 (22 ppm) phosgene or filtered room air for 20 min followed by room air washout for 5 min. This concentration-time exposure causes a doubling of lung wet weight within 5 h. After exposure, animals were immediately anesthetized i.p., with pentobarbital. Bronchoalveolar lavage (BAL) was performed and fluid analyzed for total glutathione (GSH), lipid peroxidation thiobarbituric acid reactive substances (TBARS), and protein concentration. Lungs were perfused with saline to remove blood, freeze-snapped in liquid N2, analyzed for tissue GSH, and TBARS. Lung edema was assessed gravimetrically by measuring tissue wet/dry (W/D) weight ratios and tissue wet weights (TWW). W/D and TWW were significantly higher in mice for phosgene vs air (P=0.001, P &lt; 0.0001, respectively), but not in rats or guinea pigs. Tissue TBARS was significantly higher in phosgene-exposed guinea pigs, P=0.027; however, BAL TBARS was higher in both rats and guinea pigs, P=0.013 and P=0.006, respectively. Tissue GSH was significantly lower in phosgene-exposed rats and guinea pigs but not mice, whereas BAL GSH was higher in rats, P &lt; 0.0001. There were significantly higher BAL protein levels in all phosgene-exposed species: mice, P &lt; 0.0001; rats, P &lt; 0.0001; and guinea pigs, P=0.002. Although there appears to be a species-specific biochemical effect of phosgene exposure for some biochemical indices, measurement of BAL protein in all three species is a better indicator of ensuing edema formation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Sciuto</LastName>
            <ForeName>A M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
                <Affiliation>Neurotoxicology Branch, Pharmacology Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5425, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Arch Toxicol</MedlineTA>
    <NlmUniqueID>0417615</NlmUniqueID>
    <ISSNLinking>0340-5761</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>117K140075</RegistryNumber>
        <NameOfSubstance UI="D010705">Phosgene</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>GAN16C9B8O</RegistryNumber>
        <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
        <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005069" MajorTopicYN="N">Evaluation Studies as Topic</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010705" MajorTopicYN="N">Phosgene</DescriptorName>
        <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017392" MajorTopicYN="N">Thiobarbituric Acid Reactive Substances</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1998</Year>
        <Month>6</Month>
        <Day>18</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1998</Year>
        <Month>6</Month>
        <Day>18</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1998</Year>
        <Month>6</Month>
        <Day>18</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">9630014</ArticleId>
    <ArticleId IdType="doi">10.1007/s002040050503</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">9336510</PMID>
<DateCompleted>
    <Year>1997</Year>
    <Month>11</Month>
    <Day>24</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>07</Month>
    <Day>04</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0004-0010</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>132</Volume>
            <Issue>10</Issue>
            <PubDate>
                <Year>1997</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>Archives of surgery (Chicago, Ill. : 1960)</Title>
        <ISOAbbreviation>Arch Surg</ISOAbbreviation>
    </Journal>
    <ArticleTitle>High-volume vs standard fluid therapy in a septic pig model. Impact on pulmonary function.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1111-5</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare pulmonary function and peripheral organ blood flow in septic pigs receiving high-volume fluid resuscitation or standard-volume fluid resuscitation with similar goals in oxygen delivery.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective study comparing 2 groups of septic pigs.</AbstractText>
        <AbstractText Label="SETTING" NlmCategory="METHODS">A university animal research laboratory.</AbstractText>
        <AbstractText Label="SUBJECTS" NlmCategory="METHODS">Eleven septic pigs.</AbstractText>
        <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Basal oxygen delivery was increased from 450 to 550 mL/min to at least 600 mL/min by the sixth hour and maintained for 24 hours. From a baseline pulmonary artery occlusion pressure (PAOP) measurement of approximately 6 mm Hg, the high-volume group (n = 5) was treated until a PAOP measurement of 12 mm Hg was reached and the standard-volume group (n = 6) was treated until a PAOP measurement of 8 mm Hg was reached. Blood transfusions and inotropic agents were added as necessary to reach the oxygen delivery goal.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">The high-volume group had a significantly greater positive fluid balance, greater weight gain, and a higher PAOP but similar intrapulmonary shunt and extravascular lung water as compared with the standard-volume group.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Resuscitation with large volumes of fluid in early sepsis with a physiological goal of a higher PAOP to augment oxygen delivery did not cause increased pulmonary edema and oxygenation deficit compared with maintenance of lower cardiac filling pressures.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Surgery, University of Hawaii, Honolulu, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hasaniya</LastName>
            <ForeName>N W</ForeName>
            <Initials>NW</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Takanishi</LastName>
            <ForeName>D M</ForeName>
            <Initials>DM</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Caldeira</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Caldeira</LastName>
            <ForeName>C C</ForeName>
            <Initials>CC</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Char</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Arch Surg</MedlineTA>
    <NlmUniqueID>9716528</NlmUniqueID>
    <ISSNLinking>0004-0010</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1997</Year>
        <Month>10</Month>
        <Day>23</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1997</Year>
        <Month>10</Month>
        <Day>23</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1997</Year>
        <Month>10</Month>
        <Day>23</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">9336510</ArticleId>
    <ArticleId IdType="doi">10.1001/archsurg.1997.01430340065010</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8706493</PMID>
<DateCompleted>
    <Year>1996</Year>
    <Month>09</Month>
    <Day>10</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>07</Month>
    <Day>06</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0090-3493</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>24</Volume>
            <Issue>8</Issue>
            <PubDate>
                <Year>1996</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Critical care medicine</Title>
        <ISOAbbreviation>Crit Care Med</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Effects of E-selectin and P-selectin blockade on neutrophil sequestration in tissues and neutrophil oxidative burst in burned rats.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1366-72</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Neutrophil deposition in tissues (leukosequestration) after shock may produce local tissue injury from proteases and high-energy oxygen species released from sequestered neutrophils. The initial step in the binding of neutrophils to capillary endothelium is the interaction of adhesion molecule (selectin) receptors between neutrophils and endothelial cells. We quantified leukosequestration in the tissues of burned rats using two methods of analysis: a) measurement of lung myeloperoxidase; and b) measurement of radiolabeled neutrophils and erythrocytes deposited in multiple tissues. We then determined the ability of a selectin receptor blocking agent to affect neutrophil deposition in tissues after burn injury.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, controlled, laboratory study.</AbstractText>
        <AbstractText Label="SETTING" NlmCategory="METHODS">University research laboratory.</AbstractText>
        <AbstractText Label="SUBJECTS" NlmCategory="METHODS">Male Wistar rats (200 to 300 g).</AbstractText>
        <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">After tracheostomy and venous cannulation, rats received 17% total body surface area full-thickness contact burns and were resuscitated with saline (20 mL i.p.). Experimental animals received 2 mg/kg body weight i.v. administration of a P- and E-selectin blocking monoclonal antibody, CY-1747, immediately after burn. Lung tissue neutrophils were estimated by measuring myeloperoxidase in lung tissue. Neutrophil retention in lung, liver, spleen, gut, skin, muscle, kidney, and brain tissues was determined by removing (preburn) and differentially radiolabeling neutrophils (111In) and erythrocytes (51Cr), reinfusing cells 4.5 hrs after burn, and measuring tissue radioactivity 30 mins later. Edema was estimated by measuring extravasated 125 I-labeled albumin in the various tissues. Peripheral blood neutrophils were analyzed for intracellular hydrogen peroxide content, utilizing a fluorescent dye that reacts with hydrogen peroxide, coupled with analysis of cell fluorescence by flow cytometry.</AbstractText>
        <AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Myeloperoxidase concentration was increased in lungs 5 hrs after burn (p &lt; .05), indicating neutrophil deposition. Radioisotope studies demonstrated significant (p &lt; .05) leukosequestration into the lung, gut, kidney, skin, and brain tissues at 5 hrs after burn. Flow cytometry showed increased intracellular hydrogen peroxide content in peripheral blood neutrophils 5 hrs after burn. Tissue edema, manifested by radiolabeled albumin retention, was not seen in any tissues. Postburn neutrophil deposition in lungs and liver was blocked (p &lt; .05) by administration of CY-1747 after burn, but maximal neutrophil hydrogen peroxide content was unaffected.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Burn injury in rats results in accumulation of neutrophils in multiple tissues. Neutrophil deposition in the lungs and liver is blocked by administration of the E/P-selectin blocking antibody, CY-1747. Since sequestration of metabolically active neutrophils may induce tissue injury, therapies that block postburn leukosequestration may improve clinical outcomes by limiting remote tissue injury.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Hansbrough</LastName>
            <ForeName>J F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Surgery, University of California, San Diego Medical Center, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wikström</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Braide</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tenenhaus</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rennekampff</LastName>
            <ForeName>O H</ForeName>
            <Initials>OH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kiessig</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Zapata-Sirvent</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bjursten</LastName>
            <ForeName>L M</ForeName>
            <Initials>LM</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Crit Care Med</MedlineTA>
    <NlmUniqueID>0355501</NlmUniqueID>
    <ISSNLinking>0090-3493</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D019040">E-Selectin</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.11.1.7</RegistryNumber>
        <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001998" MajorTopicYN="N">Bronchopulmonary Sequestration</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019040" MajorTopicYN="N">E-Selectin</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019007" MajorTopicYN="N">P-Selectin</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009195" MajorTopicYN="N">Peroxidase</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016897" MajorTopicYN="N">Respiratory Burst</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1996</Year>
        <Month>8</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1996</Year>
        <Month>8</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1996</Year>
        <Month>8</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">8706493</ArticleId>
    <ArticleId IdType="doi">10.1097/00003246-199608000-00016</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8865505</PMID>
<DateCompleted>
    <Year>1997</Year>
    <Month>06</Month>
    <Day>11</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>05</Month>
    <Day>12</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0161-8105</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>19</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>1996</Year>
                <Month>Jul</Month>
            </PubDate>
        </JournalIssue>
        <Title>Sleep</Title>
        <ISOAbbreviation>Sleep</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Sleep-related breathing disorders in patients with multiple system atrophy and vocal fold palsy.</ArticleTitle>
    <Pagination>
        <MedlinePgn>479-84</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>We performed sleep studies in eight patients with multiple system atrophy (MSA) and three patients with peripheral bilateral vocal fold palsy (PBVFP) and investigated stenosis of the upper airway tract during sleep in MSA patients with vocal fold palsy. Among the eight MSA patients in this study, five had definite glottic snoring and two others were suspected of having glottic snoring. Of the PBVFP patients, two had glottic snoring. Three of 11 patients died, and two of the three deaths occurred during sleep. Glottic snoring indicated a high degree of negative esophageal pressure. High negative esophageal pressure demonstrates severe narrowing of the upper airway tract. Therefore, glottic snoring should be considered a risk factor for sudden death in sleep. Repeated laryngoscopic examination is useful in evaluating the progressive process of vocal fold palsy while awake, but this examination performed only while awake is not enough to evaluate narrowing of the upper airway during sleep. Sleep studies that include the measurement of esophageal pressure can be very useful in evaluating the severity of narrowing in the upper airway tract. It is suspected that sudden nocturnal death in MSA patients is caused not only by abnormal respiration resulting from impairment of the respiratory center, but also by glottic obstruction caused by sputum or by edema of the vocal folds. We recommend treatment of respiratory disorders when loud laryngeal snoring occurs in patients with MSA, even if they do not complain of dyspnea while awake.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Sadaoka</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Otolaryngology, Osaka Medical College, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kakitsuba</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fujiwara</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kanai</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Sleep</MedlineTA>
    <NlmUniqueID>7809084</NlmUniqueID>
    <ISSNLinking>0161-8105</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009849" MajorTopicYN="N">Olivopontocerebellar Atrophies</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012119" MajorTopicYN="N">Respiration</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012791" MajorTopicYN="N">Shy-Drager Syndrome</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014826" MajorTopicYN="N">Vocal Cord Paralysis</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1996</Year>
        <Month>7</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1996</Year>
        <Month>7</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1996</Year>
        <Month>7</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">8865505</ArticleId>
    <ArticleId IdType="doi">10.1093/sleep/19.6.479</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8769936</PMID>
<DateCompleted>
    <Year>1996</Year>
    <Month>12</Month>
    <Day>30</Day>
</DateCompleted>
<DateRevised>
    <Year>2022</Year>
    <Month>03</Month>
    <Day>17</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0022-4804</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>61</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>1996</Year>
                <Month>Feb</Month>
                <Day>15</Day>
            </PubDate>
        </JournalIssue>
        <Title>The Journal of surgical research</Title>
        <ISOAbbreviation>J Surg Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Neutrophil activation and tissue neutrophil sequestration in a rat model of thermal injury.</ArticleTitle>
    <Pagination>
        <MedlinePgn>17-22</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Neutrophil (PMN) deposition in tissues (leukosequestration) after shock may produce local tissue injury from proteases and oxygen intermediaries which are released from sequestered PMNs. We quantified leukosequestration in tissues in burned rats using two methods of analysis: 1), measurement of lung myeloperoxidase (MPO); 2), measurement of radiolabeled PMNs and erythrocytes deposited in multiple tissues. After tracheostomy and venous cannulation, rats received 17% TBSA full-thickness contact burns and were resuscitated with 20 cc intraperitoneal saline. Lung PMNs were estimated by measuring MPO in lung tissue. PMN influx into lung, liver, spleen, gut, skin, muscle, kidney, and brain was determined by removing (preburn) and differentially radiolabeling PMNs (111In) and erythrocytes (51Cr), reinfusing cells 4.5 hr postburn, and measuring tissue radioactivity 5 hr postburn. Tissue edema was measured by determining extravasation of 125I-labeled albumin in tissues. Peripheral blood PMNs were analyzed for intracellular H2O2 content utilizing a fluorescent dye which reacts with H2O2 coupled with analysis of cell fluorescence by flow cytometry. MPO was elevated in lungs 8 hr postburn (P &lt; 0.05). PMN influx into lung tissues was confirmed by histologic examination. Radioisotope studies demonstrated significant (P &lt; 0.05) leukosequestration into lung, gut, kidney, skin, and brain tissues at 5 hr postburn. Respiratory burst activity of peripheral blood PMNs was increased 5 hr postburn (P &lt; 0.05). Flow cytometric analysis indicated that peripheral blood PMNs were capable of producing markedly increased H2O2 levels 5 hr postburn. Tissue edema, manifested by radiolabeled albumin influx, was not seen in any tissues. Since others have shown that sequestration of metabolically active PMNs may induce remote tissue injury, therapies which block postburn leukosequestration may be able to improve clinical outcomes by limiting remote tissue injury.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Hansbrough</LastName>
            <ForeName>J F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Surgery, University of California, San Diego Medical Center 92103, USA.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Wikström</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Braide</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tenenhaus</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rennekampff</LastName>
            <ForeName>O H</ForeName>
            <Initials>OH</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kiessig</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Bjursten</LastName>
            <ForeName>L M</ForeName>
            <Initials>LM</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>J Surg Res</MedlineTA>
    <NlmUniqueID>0376340</NlmUniqueID>
    <ISSNLinking>0022-4804</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName>
        <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018375" MajorTopicYN="Y">Neutrophil Activation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016897" MajorTopicYN="N">Respiratory Burst</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1996</Year>
        <Month>2</Month>
        <Day>15</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1996</Year>
        <Month>2</Month>
        <Day>15</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1996</Year>
        <Month>2</Month>
        <Day>15</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">8769936</ArticleId>
    <ArticleId IdType="pii">S0022-4804(96)90074-8</ArticleId>
    <ArticleId IdType="doi">10.1006/jsre.1996.0074</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">7967780</PMID>
<DateCompleted>
    <Year>1994</Year>
    <Month>12</Month>
    <Day>27</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>05</Month>
    <Day>16</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0025-6196</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>69</Volume>
            <Issue>12</Issue>
            <PubDate>
                <Year>1994</Year>
                <Month>Dec</Month>
            </PubDate>
        </JournalIssue>
        <Title>Mayo Clinic proceedings</Title>
        <ISOAbbreviation>Mayo Clin Proc</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Noninvasive diagnosis of renovascular disease.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1172-81</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present the epidemiologic and clinical features of renovascular disease and discuss various diagnostic approaches.</AbstractText>
        <AbstractText Label="DESIGN" NlmCategory="METHODS">We describe the findings in patients with fibromuscular dysplasia or atherosclerotic disease of the renal arteries and review pertinent studies from the literature.</AbstractText>
        <AbstractText Label="RESULTS" NlmCategory="RESULTS">Renovascular disease is an important cause of resistant hypertension and progressive renal insufficiency, particularly in the elderly population. Improved blood pressure control and renal function after revascularization have generated intense interest in identifying those patients likely to benefit from this intervention. Fibromuscular dysplasia and atherosclerotic renal artery stenosis account for most cases of renovascular disease. Both entities produce resistant hypertension; the latter is the more common cause of progressive renal insufficiency--occasionally leading to end-stage renal disease. Angiotensin-converting enzyme inhibitor-related renal dysfunction, otherwise unexplained renal insufficiency, and recurrent pulmonary edema are increasingly recognized clinical manifestations of renovascular disease. Traditional screening tests such as intravenous pyelography, intravenous digital subtraction angiography, radionuclide scintirenography, and measurement of the peripheral venous plasma renin activity have limited accuracy for diagnosing renal artery stenosis and do not accurately predict the blood pressure response to revascularization. In comparison, recently developed noninvasive tests such as captopril renography, renal artery duplex sonography, and magnetic resonance angiography seem to be more accurate and, in the case of captopril renography, may be more predictive of the blood pressure response to revascularization.</AbstractText>
        <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Future directions in the area of renovascular disease should include a direct comparison among these new noninvasive diagnostic techniques, with a particular focus on the identification of those patients most likely to benefit from revascularization in terms of both blood pressure control and improved renal function.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Canzanello</LastName>
            <ForeName>V J</ForeName>
            <Initials>VJ</Initials>
            <AffiliationInfo>
                <Affiliation>Division of Hypertension, Mayo Clinic Rochester, MN 55905.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Textor</LastName>
            <ForeName>S C</ForeName>
            <Initials>SC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Mayo Clin Proc</MedlineTA>
    <NlmUniqueID>0405543</NlmUniqueID>
    <ISSNLinking>0025-6196</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006977" MajorTopicYN="N">Hypertension, Renal</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012078" MajorTopicYN="N">Renal Artery Obstruction</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>99</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1994</Year>
        <Month>12</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1994</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1994</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">7967780</ArticleId>
    <ArticleId IdType="pii">S0025-6196(12)65771-1</ArticleId>
    <ArticleId IdType="doi">10.1016/s0025-6196(12)65771-1</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8310976</PMID>
<DateCompleted>
    <Year>1994</Year>
    <Month>03</Month>
    <Day>15</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>06</Month>
    <Day>22</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0002-9149</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>73</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>1994</Year>
                <Month>Jan</Month>
                <Day>27</Day>
            </PubDate>
        </JournalIssue>
        <Title>The American journal of cardiology</Title>
        <ISOAbbreviation>Am J Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment.</ArticleTitle>
    <Pagination>
        <MedlinePgn>44A-49A</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Hemodynamic studies at rest as well as during exercise are useful for profiling the hemodynamic derangements in essential hypertension and for evaluating the changes produced by antihypertensive therapy. Modern, lightweight, 24-hour ambulatory blood pressure monitoring devices can provide useful information in understanding circadian variation of blood pressure, and also in evaluating blood pressure control over 24 hours. We have studied in &gt; 400 patients the hemodynamic profiles of most of the commonly used antihypertensive agents. Results from our study of amlodipine, a novel calcium antagonist, are presented as an example. Nineteen patients with mild-to-moderate essential hypertension underwent invasive hemodynamic studies while at rest, supine, and sitting, and during 50, 100, and 150 W bicycle exercise in the sitting position. Systolic, diastolic, and mean arterial blood pressure decreased 16% (p &lt; 0.01) at rest and during exercise, and total peripheral resistance was reduced 18%. Blood pressure during the daytime and during sleep was reduced approximately 16%. The reductions in systolic and diastolic pressures were similar. There were no significant changes in heart rate or cardiac output. Amlodipine was well tolerated. Two patients developed ankle edema, which disappeared when the dose was reduced, and in 1 patient the drug was withdrawn because of nondrug-related side effects.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Lund-Johansen</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>Medical Department, University of Bergen School of Medicine, Haukeland Hospital, Norway.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Omvik</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>White</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Am J Cardiol</MedlineTA>
    <NlmUniqueID>0207277</NlmUniqueID>
    <ISSNLinking>0002-9149</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>1J444QC288</RegistryNumber>
        <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015924" MajorTopicYN="Y">Blood Pressure Monitors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1994</Year>
        <Month>1</Month>
        <Day>27</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1994</Year>
        <Month>1</Month>
        <Day>27</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1994</Year>
        <Month>1</Month>
        <Day>27</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">8310976</ArticleId>
    <ArticleId IdType="pii">0002-9149(94)90274-7</ArticleId>
    <ArticleId IdType="doi">10.1016/0002-9149(94)90274-7</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">7693360</PMID>
<DateCompleted>
    <Year>1993</Year>
    <Month>12</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>07</Month>
    <Day>06</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0009-7330</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>73</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>1993</Year>
                <Month>Dec</Month>
            </PubDate>
        </JournalIssue>
        <Title>Circulation research</Title>
        <ISOAbbreviation>Circ Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Depressed beta-adrenergic receptor- and endothelium-mediated vasodilation in conscious dogs with heart failure.</ArticleTitle>
    <Pagination>
        <MedlinePgn>1013-23</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Peripheral vasodilator responsiveness was examined in pacing-induced heart failure (HF) in 11 conscious dogs chronically instrumented for measurement of systemic (total peripheral resistance [TPR]) and local (iliac blood flow) vascular resistance. Dose responses to isoproterenol (ISO), acetylcholine (ACh), and nitroglycerin (NTG) were examined in the same dogs before pacing (control) and after 4 to 7 weeks of rapid ventricular pacing, which induced congestive HF, characterized by increased left ventricular end-diastolic pressure (6.7 +/- 0.4 [control] versus 28 +/- 1.5 [HF] mm Hg) and decreased cardiac output (-30 +/- 5%) and left ventricular dP/dt (-53 +/- 3%), as well as ascites and peripheral edema. In the control state, TPR fell by 57 +/- 2% in response to ISO (100 ng/kg), by 61 +/- 3% in response to ACh (3 micrograms/kg), and by 55 +/- 2% in response to NTG (10 micrograms/kg). In HF, smaller decreases (P &lt; .05) in TPR were observed with the same doses of ISO (-50 +/- 2%) and ACh (-49 +/- 2%) but not with NTG (-58 +/- 3%). Depressed responses to systemic ISO and ACh, but not NTG, were observed in HF in the presence of ganglionic blockade and also after local administration of smaller doses of the drugs in the absence of ganglionic blockade, but where systemic effects were not elicited. Inhibition of nitric oxide synthase increased TPR to a greater degree before HF (+154 +/- 28% [control]) than after (+80 +/- 22% [HF]) and eliminated the depressed responses to ACh but not to ISO. beta-Adrenergic receptor density, as determined by 125I-cyanopindolol binding in membrane preparations from mesenteric vessels was significantly decreased after HF (130 +/- 3 [control] versus 100 +/- 8 [HF] fmol/mg, P &lt; .05) without any change in affinity. Thus, peripheral vascular beta-adrenergic receptor downregulation occurs in HF, independent of altered endothelium-mediated peripheral vasodilation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Kiuchi</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medicine, Harvard Medical School, Boston, Mass.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Shannon</LastName>
            <ForeName>R P</ForeName>
            <Initials>RP</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vatner</LastName>
            <ForeName>D E</ForeName>
            <Initials>DE</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Morgan</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Vatner</LastName>
            <ForeName>S F</ForeName>
            <Initials>SF</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>HL-33107</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL-37404</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>HL-38070</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Circ Res</MedlineTA>
    <NlmUniqueID>0047103</NlmUniqueID>
    <ISSNLinking>0009-7330</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D005730">Ganglionic Blockers</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.14.13.39</RegistryNumber>
        <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>EC 1.4.-</RegistryNumber>
        <NameOfSubstance UI="D000594">Amino Acid Oxidoreductases</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>G59M7S0WS3</RegistryNumber>
        <NameOfSubstance UI="D005996">Nitroglycerin</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>L628TT009W</RegistryNumber>
        <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>N9YNS0M02X</RegistryNumber>
        <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000594" MajorTopicYN="N">Amino Acid Oxidoreductases</DescriptorName>
        <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002303" MajorTopicYN="N">Cardiac Output, Low</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005730" MajorTopicYN="N">Ganglionic Blockers</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007083" MajorTopicYN="N">Iliac Artery</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007545" MajorTopicYN="N">Isoproterenol</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D019001" MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005996" MajorTopicYN="N">Nitroglycerin</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011943" MajorTopicYN="N">Receptors, Adrenergic, beta</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013152" MajorTopicYN="N">Splanchnic Circulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1993</Year>
        <Month>12</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1993</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1993</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">7693360</ArticleId>
    <ArticleId IdType="doi">10.1161/01.res.73.6.1013</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8249588</PMID>
<DateCompleted>
    <Year>1994</Year>
    <Month>01</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>08</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0001-639X</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>71</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>1993</Year>
                <Month>Aug</Month>
            </PubDate>
        </JournalIssue>
        <Title>Acta ophthalmologica</Title>
        <ISOAbbreviation>Acta Ophthalmol (Copenh)</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Topographical corneal edema. An update.</ArticleTitle>
    <Pagination>
        <MedlinePgn>539-43</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Measurement of the topographical corneal edema response has been previously restricted by the use of optical pachometry and small sample sizes. This study uses ultrasound pachometry to measure changes in the corneal thickness of 23 subjects at 9 locations during 2 hours' wear of a thick soft contact lens. The data are analysed using both averaged and individual location data. The averaged location analysis supports the current paradigm that less edema occurs in the peripheral cornea than in the central cornea during contact lens wear. However, the individual location analysis reveals a more complex corneal edema response in which the greatest amount of edema following 2 hours' contact lens wear occurred in the central and mid-peripheral temporal cornea, in comparison with the peripheral nasal and peripheral inferior cornea which showed the least edema. The edema measured in the peripheral temporal and peripheral superior cornea following 2 hours' contact lens wear was not significantly different from that measured in the central cornea. The edema measured in the central cornea following 2 hours' contact lens wear was not significantly different from that found at any mid-peripheral location. This study demonstrates that the corneal edema response associated with 2 hours' wear of a thick soft contact lens is a complex dynamic topographical process and cannot be simply modelled using averaged data from small samples.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Herse</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Optometry, University of Auckland, New Zealand.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Akakura</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ooi</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Denmark</Country>
    <MedlineTA>Acta Ophthalmol (Copenh)</MedlineTA>
    <NlmUniqueID>0370347</NlmUniqueID>
    <ISSNLinking>0001-639X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003263" MajorTopicYN="N">Contact Lenses, Hydrophilic</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003315" MajorTopicYN="N">Cornea</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015715" MajorTopicYN="N">Corneal Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1993</Year>
        <Month>8</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1993</Year>
        <Month>8</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1993</Year>
        <Month>8</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">8249588</ArticleId>
    <ArticleId IdType="doi">10.1111/j.1755-3768.1993.tb04632.x</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8098306</PMID>
<DateCompleted>
    <Year>1993</Year>
    <Month>06</Month>
    <Day>17</Day>
</DateCompleted>
<DateRevised>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0046-5968</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>1993</Year>
                <Month>Feb</Month>
            </PubDate>
        </JournalIssue>
        <Title>Giornale italiano di cardiologia</Title>
        <ISOAbbreviation>G Ital Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Neurohormonal assessment in heart failure: from the sophisticated laboratory to practical indications].</ArticleTitle>
    <Pagination>
        <MedlinePgn>193-204</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Heart failure is a syndrome characterized by the activation of neurohumoral mechanisms (sympathoadrenergic, renin-angiotensin, vasopressin) which cause peripheral vasoconstriction, sodium retention and myocardial hypertrophy. In acute myocardial disfunction these systems can play a critical role in patient survival, however, they can directly worsen myocardial function and patient prognosis on a long-term basis. Other neurohumoral systems activated in heart failure (atrial natriuretic factor, prostaglandins, dopamine) tend to counterbalance the vasoconstrictive, sodium retentive mechanisms. Though their secretion is increased in heart failure, it is however not sufficient, and peripheral vasoconstriction and sodium retention prevail. Moreover the role of local factors, such as tissue renin-angiotensin system, EDRF and endothelin secretion has been recently pointed out. Neurohumoral activation is directly related to the severity of the clinical and hemodynamic impairment and prognosis of the patient with heart failure. A thorough evaluation of the neurohumoral mechanisms is therefore of paramount importance for the assessment of patients with heart failure. Neurohumoral activation can be roughly assessed using some simple laboratory measurements: plasma sodium concentration, for example, is inversely related to the degree of activation of many neurohormones such as norepinephrine, angiotensin II, vasopressin and atrial natriuretic factor. The method most commonly used to assess neurohumoral activity relies on the direct measurement of the plasma concentrations. It must be noted, however, that plasma levels are critically dependent on many factors besides hormone secretion and metabolism. For example, 3-4 days on a low sodium diet or standing for at least 2 hours can increase plasma renin activity in a normal subject from 1.5 to 5-10 pg/ml/hr. Plasma concentrations of neurohormones are related to the factors controlling their secretion: for example, "normal" values of plasma renin activity in presence of fluid retention and edema are to be judged as excessively elevated. Autonomic nervous system activity can also be assessed studying reflexes in which this system is involved (orthostasis, cold pressor test, phenylephrine test...). Another method consists in the study of the spontaneous variability of some parameters controlled by this system, such as heart rate and blood pressure. The most reliable method is based on the power spectral analysis of heart rate variability. With this last method, a low frequency component depending mainly on sympathetic activity and an high frequency component depending on vagal activity can be identified in heart rate variability. Thus, complex phenomena such as sympatho-vagal balance can be easily studied through simple noninvasive tools.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Dei Cas</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
                <Affiliation>Cattedra di Cardiologia, Università degli Studi di Brescia.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Metra</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Visioli</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
        </Author>
    </AuthorList>
    <Language>ita</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>La valutazione neuro-ormonale nell'insufficienza cardiaca: dal laboratorio sofisticato alle indicazioni pratiche.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Italy</Country>
    <MedlineTA>G Ital Cardiol</MedlineTA>
    <NlmUniqueID>1270331</NlmUniqueID>
    <ISSNLinking>0046-5968</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>11000-17-2</RegistryNumber>
        <NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>85637-73-6</RegistryNumber>
        <NameOfSubstance UI="D009320">Atrial Natriuretic Factor</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000311" MajorTopicYN="N">Adrenal Glands</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009320" MajorTopicYN="N">Atrial Natriuretic Factor</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007010" MajorTopicYN="N">Hyponatremia</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013564" MajorTopicYN="N">Sympathetic Nervous System</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014667" MajorTopicYN="N">Vasopressins</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
</MeshHeadingList>
<NumberOfReferences>82</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1993</Year>
        <Month>2</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1993</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1993</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">8098306</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">1736435</PMID>
<DateCompleted>
    <Year>1992</Year>
    <Month>03</Month>
    <Day>11</Day>
</DateCompleted>
<DateRevised>
    <Year>2006</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0041-5782</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>154</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>1992</Year>
                <Month>Jan</Month>
                <Day>06</Day>
            </PubDate>
        </JournalIssue>
        <Title>Ugeskrift for laeger</Title>
        <ISOAbbreviation>Ugeskr Laeger</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Tendency to edema as the initial symptom of hyperthyroidism].</ArticleTitle>
    <Pagination>
        <MedlinePgn>90-1</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Peripheral oedema which is not of cardiac origin may be an early clinical sign of hyperthyroidism. Measurement of the thyroid parameters is recommended in patients with sudden onset of oedema of the lower limbs and tachycardia without any immediate cause.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Toft</LastName>
            <ForeName>J C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
                <Affiliation>Speciallaegeklinik, Helsingørsgade, Hillerød.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Larsen</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
        </Author>
    </AuthorList>
    <Language>dan</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Odemtendens som debutsymptom ved hypertyreose.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Denmark</Country>
    <MedlineTA>Ugeskr Laeger</MedlineTA>
    <NlmUniqueID>0141730</NlmUniqueID>
    <ISSNLinking>0041-5782</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006980" MajorTopicYN="N">Hyperthyroidism</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1992</Year>
        <Month>1</Month>
        <Day>6</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1992</Year>
        <Month>1</Month>
        <Day>6</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1992</Year>
        <Month>1</Month>
        <Day>6</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">1736435</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">1665298</PMID>
<DateCompleted>
    <Year>1992</Year>
    <Month>03</Month>
    <Day>31</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>08</Month>
    <Day>24</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0065-4299</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>34</Volume>
            <Issue>1-2</Issue>
            <PubDate>
                <Year>1991</Year>
                <Month>Sep</Month>
            </PubDate>
        </JournalIssue>
        <Title>Agents and actions</Title>
        <ISOAbbreviation>Agents Actions</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Neurogenic and tissue-mediated components of formalin-induced edema: evidence for supraspinal regulation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>264-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Injection of formalin into a hind paw of rats produces localized inflammation and pain. The nociceptive effect of formalin, recorded as flinching/shaking of the injected paw, is biphasic. The present study shows that formalin-induced inflammation and edema (assessed by measurement of paw volume up to 24 h post-injection) is also biphasic, an early neurogenic component being followed by a later tissue-mediated response. Rapid initiation of edema is closely related to early phase nociception and is dependent on activity in primary afferent neurons and axon reflexes, but not on transmission of the noxious stimulus and the perception of pain itself. The major site responsible for down-regulating the inflammatory response, particularly in the later stages when tissue-mediated components are most heavily involved, appears to be located supraspinally. Down-regulation occurs principally by means of descending neuronal pathways but may also involve a secondary humoral component. The perhaps surprising dependence on neuronal mechanisms which this study demonstrates promotes spinal and peripheral sites as potential therapeutic targets in certain inflammatory conditions.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Wheeler-Aceto</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Cowan</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>03945</GrantID>
            <Agency>PHS HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>07237</GrantID>
            <Agency>PHS HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Switzerland</Country>
    <MedlineTA>Agents Actions</MedlineTA>
    <NlmUniqueID>0213341</NlmUniqueID>
    <ISSNLinking>0065-4299</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>1HG84L3525</RegistryNumber>
        <NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>S07O44R1ZM</RegistryNumber>
        <NameOfSubstance UI="D002211">Capsaicin</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002211" MajorTopicYN="N">Capsaicin</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003714" MajorTopicYN="N">Denervation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005528" MajorTopicYN="N">Foot</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009407" MajorTopicYN="N">Nerve Block</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009420" MajorTopicYN="N">Nervous System</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009475" MajorTopicYN="N">Neurons, Afferent</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1991</Year>
        <Month>9</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1991</Year>
        <Month>9</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1991</Year>
        <Month>9</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">1665298</ArticleId>
    <ArticleId IdType="doi">10.1007/BF01993299</ArticleId>
</ArticleIdList>
<ReferenceList>
    <Reference>
        <Citation>Br J Pharmacol Chemother. 1967 Sep;31(1):138-51</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6055248</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pain. 1977 Dec;4(2):161-74</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">564014</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Gen Pharmacol. 1988;19(1):1-43</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3278943</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Science. 1979 Oct 26;206(4417):481-3</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">228392</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Brain Res. 1984 Mar 12;295(1):77-84</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6713178</ArticleId>
        </ArticleIdList>
    </Reference>
    <Reference>
        <Citation>Pain. 1990 Feb;40(2):229-38</Citation>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2308768</ArticleId>
        </ArticleIdList>
    </Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">3245261</PMID>
<DateCompleted>
    <Year>1989</Year>
    <Month>06</Month>
    <Day>06</Day>
</DateCompleted>
<DateRevised>
    <Year>2008</Year>
    <Month>02</Month>
    <Day>26</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0343-8554</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>1988</Year>
                <Month>Dec</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zeitschrift fur Lymphologie. Journal of lymphology</Title>
        <ISOAbbreviation>Z Lymphol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Secondary leg edema--experimental study].</ArticleTitle>
    <Pagination>
        <MedlinePgn>48-53</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Peripheral lymphedema can be induced experimentally by obliteration or destruction of the veins and/or lymphatics, extirpation of the lymph nodes and occlusion of lymphatics, circular incision of the soft tissues, experimentally induced thrombophlebitis and by simultaneous traumatization of the veins and lymphatics. Our own animal experiments were designed to provoke leg edema after ligation of the femoral vein and/or accompanying lymphatics below the inguinal ligament. In 23 animals, only one ligature of the femoral vein was applied, below the inguinal ligament and in 12 animals all accompanying lymphatics were ligated in addition. In all animals, the leg circumferences were measured in three precisely fixed positions before the experiments and daily for 22 days during the experiment. The greatest increase in circumference was found in the lower leg irrespective of the time of measurement. The peak increase of circumference was between the third and sixth day after the operation. Permanent lymph edema has not developed in any of the animals. At the latest after three weeks, the leg circumference has normalized. Additional ligation of the lymphatics merely led to a nonsignificant increase in circumference and to displacement of the maximum point by two to three days. Immediately after the operation, phlebographic and lymphographic control investigations were carried out in all animals.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Gregl</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Abteilung Mammographie und Lymphographie, Zentrums Radiologie der Universität Göttingen.</Affiliation>
            </AffiliationInfo>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Sekundäres Beinödem--experimentelle Untersuchungen.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Z Lymphol</MedlineTA>
    <NlmUniqueID>7805527</NlmUniqueID>
    <ISSNLinking>0343-8554</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006614" MajorTopicYN="N">Hindlimb</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008026" MajorTopicYN="N">Ligation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008196" MajorTopicYN="N">Lymph</DescriptorName>
        <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008208" MajorTopicYN="N">Lymphatic System</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008220" MajorTopicYN="N">Lymphography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014680" MajorTopicYN="N">Veins</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014689" MajorTopicYN="N">Venous Insufficiency</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1988</Year>
        <Month>12</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1988</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1988</Year>
        <Month>12</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">3245261</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">3281528</PMID>
<DateCompleted>
    <Year>1988</Year>
    <Month>04</Month>
    <Day>22</Day>
</DateCompleted>
<DateRevised>
    <Year>2012</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0003-0805</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>137</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>1988</Year>
                <Month>Apr</Month>
            </PubDate>
        </JournalIssue>
        <Title>The American review of respiratory disease</Title>
        <ISOAbbreviation>Am Rev Respir Dis</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Pulmonary edema after Escherichia coli peritonitis correlates with thiobarbituric-acid-reactive materials in bronchoalveolar lavage fluid.</ArticleTitle>
    <Pagination>
        <MedlinePgn>783-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>We developed a new model of acute lung injury caused by live Escherichia coli peritonitis in guinea pigs. Arterial blood gas determinations, arterial blood pressure, and white blood cell counts were monitored serially for 12 h after the injection of either 2 x 10(9) E. coli J96 or saline. Lung water, albumin concentration in bronchoalveolar lavage fluid (BALF) and in lung tissue, WBC counts in BALF, and thiobarbituric-acid-reactive materials (TBARM) in plasma, lung tissue, and BALF were examined. Increased TBARM might be associated with pulmonary injury and are produced either by the generation of lipoperoxides secondary to oxygen-free radicals or as metabolic byproducts of prostanoid metabolism. Lung tissue sections were studied by light microscopy. E. coli peritonitis, as compared with control animals, caused significant peripheral neutropenia, histopathologic evidence of lung inflammation, acidosis, and hypotension. The wet-to-dry lung ratio was increased in the peritonitis group when compared with that in the control group (p less than 0.01). Pulmonary edema in the peritonitis group was associated with significantly increased albumin concentrations in BALF and lung tissue. We report the new finding of increased TBARM concentrations in BALF after E. coli peritonitis (p less than 0.01 and p less than 0.05, respectively). In contrast, plasma TBARM concentrations were unchanged. The levels of TBARM in the BALF correlated significantly with both lung water (p less than 0.01) and lung tissue albumin concentration (p less than 0.01). The measurement of elevated TBARM in BALF may allow acute lung injury to be detected. We conclude that this model may be useful for further studies of acute lung injury caused by E. coli peritonitis.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ishizaka</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Medicine, Stanford University Medical Center, California 94305-5236.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Stephens</LastName>
            <ForeName>K E</ForeName>
            <Initials>KE</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Tazelaar</LastName>
            <ForeName>H D</ForeName>
            <Initials>HD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hall</LastName>
            <ForeName>E W</ForeName>
            <Initials>EW</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>O'Hanley</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Raffin</LastName>
            <ForeName>T A</ForeName>
            <Initials>TA</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Am Rev Respir Dis</MedlineTA>
    <NlmUniqueID>0370523</NlmUniqueID>
    <ISSNLinking>0003-0805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D013858">Thiobarbiturates</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>M1YZW5SS7C</RegistryNumber>
        <NameOfSubstance UI="C029684">thiobarbituric acid</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001834" MajorTopicYN="N">Body Water</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004927" MajorTopicYN="Y">Escherichia coli Infections</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009994" MajorTopicYN="N">Osmolar Concentration</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
        <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013858" MajorTopicYN="N">Thiobarbiturates</DescriptorName>
        <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1988</Year>
        <Month>4</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1988</Year>
        <Month>4</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1988</Year>
        <Month>4</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">3281528</ArticleId>
    <ArticleId IdType="doi">10.1164/ajrccm/137.4.783</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">2964798</PMID>
<DateCompleted>
    <Year>1988</Year>
    <Month>04</Month>
    <Day>18</Day>
</DateCompleted>
<DateRevised>
    <Year>2017</Year>
    <Month>02</Month>
    <Day>14</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0003-3197</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>39</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>1988</Year>
                <Month>Feb</Month>
            </PubDate>
        </JournalIssue>
        <Title>Angiology</Title>
        <ISOAbbreviation>Angiology</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Clinical experiences using pneumatic massage therapy for edematous limbs over the last 10 years.</ArticleTitle>
    <Pagination>
        <MedlinePgn>154-63</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText Label="UNLABELLED">A pneumatic massage apparatus has been developed for the treatment of peripheral lymphedema. The stagnant lymph and venous blood are displaced toward the heart by this pneumatic massage. It has been applied to more than 650 patients with edematous limbs in the authors' Hadomer clinic over the last ten years. Satisfactory results were obtained, including decrease in swelling, pain, and induration. The authors' clinical experiences and statistical analysis of the patients are reported here.</AbstractText>
        <AbstractText Label="STATISTICAL ANALYSIS" NlmCategory="METHODS">9 primary (4 males and 5 females) and 646 secondary (28 males and 618 females) patients with lymphatic edema of extremities have been treated. The majority of the patients had postmastectomy edema of the upper extremity.</AbstractText>
        <AbstractText Label="CLINICAL STUDIES" NlmCategory="METHODS">The circumference of the edematous limb was measured before and after pneumatic massage treatment of forty to sixty minutes, daily or every second day. (Formula: see text). The rate of swelling was calculated by the formula described above. Twenty-six cases, treated with pneumatic massage for more than fifteen months, have been investigated. A decrease in the rate of swelling was observed in 14 cases (54%), there was no change in 7 (27%), and an increase was seen in 5 (19%). Electric impedance plethysmographic analysis of peripheral lymph volume and blood flow indicated that pneumatic massage was effective in the treatment of edema of the limbs, and its effectiveness was confirmed also by core temperature measurement of the hand during pneumatic massage. The decreased circumference of the edematous limb was kept constant for a long period of time by daily repeated pneumatic massage and ordinary conservative treatments. In conclusion, most lymphedema is of a secondary type. Pneumatic massage was effective in the treatment of peripheral lymph edema, and the improvement was maintained by repeated daily pneumatic massage and ordinary conservative treatment. Therefore, before it becomes worse, lymphedema of the limb should be treated by use of conservative treatments, including pneumatic massage continued as a long-term schedule.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Yamazaki</LastName>
            <ForeName>Z</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Surgery, University of Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Idezuki</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Nemoto</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Togawa</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D002363">Case Reports</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Angiology</MedlineTA>
    <NlmUniqueID>0203706</NlmUniqueID>
    <ISSNLinking>0003-3197</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008405" MajorTopicYN="N">Massage</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>
        <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010992" MajorTopicYN="N">Plethysmography, Impedance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012212" MajorTopicYN="N">Rheology</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013736" MajorTopicYN="N">Testicular Neoplasms</DescriptorName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1988</Year>
        <Month>2</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1988</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1988</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">2964798</ArticleId>
    <ArticleId IdType="doi">10.1177/000331978803900205</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">3340421</PMID>
<DateCompleted>
    <Year>1988</Year>
    <Month>03</Month>
    <Day>14</Day>
</DateCompleted>
<DateRevised>
    <Year>2021</Year>
    <Month>01</Month>
    <Day>12</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0304-3959</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>32</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>1988</Year>
                <Month>Jan</Month>
            </PubDate>
        </JournalIssue>
        <Title>Pain</Title>
        <ISOAbbreviation>Pain</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Pain measurement in reflex sympathetic dystrophy syndrome.</ArticleTitle>
    <Pagination>
        <MedlinePgn>27-34</MedlinePgn>
    </Pagination>
    <ELocationID EIdType="doi" ValidYN="Y">10.1016/0304-3959(88)90020-6</ELocationID>
    <Abstract>
        <AbstractText>The reflex sympathetic dystrophy syndrome (RSDS) consists of a triad of pain, edema and sympathetic dysfunction of an extremity following trauma, peripheral nerve injury or central nervous system disorder. Reflex sympathetic dystrophy syndrome is a difficult and costly pain syndrome to treat. One of the difficulties in evaluating treatment efficacy is the objectification and quantification of patient findings. The purpose of this investigation was to develop a simple, reproducible and systematic evaluation of pain and neurologic impairment in RSDS. The protocol evaluation included the following measures of pain and impairment: (1) objectification of distal joint pain by palpation (0-4 scale); (2) volumetric measurement by water displacement of the distal limb; (3) skin temperature measurement; (4) active range of motion assessment of the affected limb (AROM); (5) McGill Pain Questionnaire (MPQ); and (6) visual analogue pain scale (VAS). Seventeen subjects with definite or probable RSDS were evaluated. The mean age of patients was 35.6 years +/- 8.0 years (+/- 2 S.E.M.), and the mean duration of symptoms was 11.8 +/- 4.8 months. There were an equal number of subjects with upper and lower extremity involvement. The VAS had significant correlations with limb volume, AROM-lower extremity and joint pain indices (P less than 0.0005). The MPQ subscales had robust correlation with the joint pain indices alone (P less than 0.0001). Skin temperature was not predictive of changes in joint pain score, AROM, limb volume or subjective pain measures. However, there was internal consistency between volumetric and AROM measures and joint pain indices. This protocol is recommended for use in therapeutic trials for the treatment of the RSDS.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Davidoff</LastName>
            <ForeName>Gary</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
                <Affiliation>Department of Physical Medicine and Rehabilitation, University of Michigan Medical Center, Ann Arbor, MI 48109-0042 U.S.A.</Affiliation>
            </AffiliationInfo>
        </Author>
        <Author ValidYN="Y">
            <LastName>Morey</LastName>
            <ForeName>Kathy</ForeName>
            <Initials>K</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Amann</LastName>
            <ForeName>Mary</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Stamps</LastName>
            <ForeName>Janice</ForeName>
            <Initials>J</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>NS01120-01</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Pain</MedlineTA>
    <NlmUniqueID>7508686</NlmUniqueID>
    <ISSNLinking>0304-3959</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012019" MajorTopicYN="N">Reflex Sympathetic Dystrophy</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1988</Year>
        <Month>1</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1988</Year>
        <Month>1</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1988</Year>
        <Month>1</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">3340421</ArticleId>
    <ArticleId IdType="pii">00006396-198801000-00005</ArticleId>
    <ArticleId IdType="doi">10.1016/0304-3959(88)90020-6</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">3492731</PMID>
<DateCompleted>
    <Year>1987</Year>
    <Month>03</Month>
    <Day>04</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>09</Month>
    <Day>19</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0033-8303</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>35</Volume>
            <Issue>10</Issue>
            <PubDate>
                <Year>1986</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>Radioisotopes</Title>
        <ISOAbbreviation>Radioisotopes</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Regional cerebral blood flow measurement in brain tumors].</ArticleTitle>
    <Pagination>
        <MedlinePgn>528-34</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The regional cerebral blood flow (CBF) was determined on seventeen patients with brain tumors. Ring type single photon emission CT (SPECT) was used following intravenous injection of 133Xe. Case materials included eleven meningiomas and six malignant gliomas. Evaluation was performed with emphasis on the following points; Correlation of the flow data within tumors to the angiographic tumor stains, Influence of tumors on the cerebral blood flow of the normal brain tissue, Correlation between degree of peripheral edema and the flow data of the affected hemispheres. There was significant correlation between flow data within tumors and angiographic tumor stains in meningiomas. Influence of tumors on cerebral blood flow of the normal tissue was greater in meningiomas than in gliomas. There was negative correlation between the degree of peripheral edema and the flow data of the affected hemisphere. It has been concluded that the measurement of CBF in brain tumors is a valuable method in evaluation of brain tumors.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Izunaga</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hirota</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Fuwa</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Kodama</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Matsukado</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
        </Author>
    </AuthorList>
    <Language>jpn</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Japan</Country>
    <MedlineTA>Radioisotopes</MedlineTA>
    <NlmUniqueID>20010290R</NlmUniqueID>
    <ISSNLinking>0033-8303</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014980">Xenon Radioisotopes</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008577" MajorTopicYN="N">Meningeal Neoplasms</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008579" MajorTopicYN="N">Meningioma</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014980" MajorTopicYN="N">Xenon Radioisotopes</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1986</Year>
        <Month>10</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1986</Year>
        <Month>10</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1986</Year>
        <Month>10</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">3492731</ArticleId>
    <ArticleId IdType="doi">10.3769/radioisotopes.35.10_528</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">3908591</PMID>
<DateCompleted>
    <Year>1986</Year>
    <Month>02</Month>
    <Day>05</Day>
</DateCompleted>
<DateRevised>
    <Year>2011</Year>
    <Month>07</Month>
    <Day>29</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0300-9165</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>37</Volume>
            <Issue>11</Issue>
            <PubDate>
                <Year>1985</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>Nihon Sanka Fujinka Gakkai zasshi</Title>
        <ISOAbbreviation>Nihon Sanka Fujinka Gakkai Zasshi</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Measurement of blood flow in maternal pelvic artery and umbilical cord artery with the ultrasonic pulsed Doppler flow method].</ArticleTitle>
    <Pagination>
        <MedlinePgn>2335-43</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The maternal pelvic artery was detected with the B-mode, and volume of flow through it measured with the pulsed ultrasound Doppler device in the supine and left recumbent positions. The blood flow state and vascular resistance of the maternal pelvic artery and of the umbilical cord artery were investigated in gestosis and normal pregnancy. The volume of blood flow through the right maternal pelvic artery showed a tendency to increase after the posture was changed to the left recumbent position. The peak frequency (Fp) showed a tendency to increase in gestosis, particularly in the edema group. The spectral width (SWp)/Fp value showed a tendency to be lower in the edema group than in normal subjects, and showed a higher value in hypertension accompanied by proteinuria than in normal subjects. As an indication of peripheral vascular resistance, the pulsatility index (PI) in the maternal pelvic artery was determined, and resistance index (RI) in the umbilical cord artery was also determined. The PI showed a tendency to increase more in gestosis than in normal subjects, particularly in hypertension accompanied by proteinuria. The RI was higher in maternal hypertension accompanied by proteinuria than in normal pregnancy. The hematocrit and fibrinogen vales were slightly higher, though insignificantly, in gestosis than in normal subjects.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ishihara</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
        </Author>
    </AuthorList>
    <Language>jpn</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>Japan</Country>
    <MedlineTA>Nihon Sanka Fujinka Gakkai Zasshi</MedlineTA>
    <NlmUniqueID>7505749</NlmUniqueID>
    <ISSNLinking>0300-9165</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001783" MajorTopicYN="Y">Blood Flow Velocity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001811" MajorTopicYN="N">Blood Volume Determination</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005312" MajorTopicYN="Y">Fetal Blood</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007083" MajorTopicYN="Y">Iliac Artery</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1985</Year>
        <Month>11</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1985</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1985</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">3908591</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">6095731</PMID>
<DateCompleted>
    <Year>1985</Year>
    <Month>01</Month>
    <Day>18</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0364-5134</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>16</Volume>
            <Issue>5</Issue>
            <PubDate>
                <Year>1984</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>Annals of neurology</Title>
        <ISOAbbreviation>Ann Neurol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Galactose neuropathy: impact of chronic endoneurial edema on nerve blood flow.</ArticleTitle>
    <Pagination>
        <MedlinePgn>587-94</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Peripheral neuropathy induced by galactose feeding results in endoneurial edema with increased tissue pressure and ultimate demyelination of nerve fibers. To assess the role of ischemia in the pathogenesis of this neuropathy, nerve blood flow was measured 6 months after the start of galactose ingestion, between the onset of edema and nerve fiber changes. Measurement was carried out by a noninvasive technique involving the use of [14C]iodoantipyrine as a radioactive tracer of tissue perfusion. A significant decline in nerve blood flow was found, which correlated positively with increased nerve water content as quantified by a microgravimetric technique. We sought to establish the pathogenic role of nerve edema in the development of schwannopathy and demyelination by morphological examination. It was found that Schwann cells appeared normal in areas of the peripheral nervous system in which edema does not occur, such as spinal ganglia and roots, whereas in regions in which there was edema, massive glycogen accumulation in Schwann cells and demyelination occurred. These findings suggest that edema, rather than hyperactivity in the sorbitol pathway, is responsible for the pathological changes in galactosemic neuropathy and that ischemia resulting from edema and increased endoneurial fluid pressure is the mechanism responsible for fiber injury.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Myers</LastName>
            <ForeName>R R</ForeName>
            <Initials>RR</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Powell</LastName>
            <ForeName>H C</ForeName>
            <Initials>HC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>NS 14162</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Ann Neurol</MedlineTA>
    <NlmUniqueID>7707449</NlmUniqueID>
    <ISSNLinking>0364-5134</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>X2RN3Q8DNE</RegistryNumber>
        <NameOfSubstance UI="D005690">Galactose</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005690" MajorTopicYN="Y">Galactose</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011312" MajorTopicYN="N">Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1984</Year>
        <Month>11</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1984</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1984</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">6095731</ArticleId>
    <ArticleId IdType="doi">10.1002/ana.410160510</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">6338293</PMID>
<DateCompleted>
    <Year>1983</Year>
    <Month>04</Month>
    <Day>21</Day>
</DateCompleted>
<DateRevised>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>14</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0023-6837</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>48</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>1983</Year>
                <Month>Mar</Month>
            </PubDate>
        </JournalIssue>
        <Title>Laboratory investigation; a journal of technical methods and pathology</Title>
        <ISOAbbreviation>Lab Invest</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Early changes in experimental allergic neuritis.</ArticleTitle>
    <Pagination>
        <MedlinePgn>332-8</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Edema and increased endoneurial fluid pressure (EFP) accompany the inflammatory process in experimental allergic neuritis. EFP was measured at regular intervals 6 to 21 days after intradermal inoculation of Lewis rats with an emulsion of peripheral nerve in complete Freund's adjuvant. Control rats received similar injections of an emulsion containing all other ingredients, except peripheral nerve. Altered vascular permeability was illustrated by leakage of horseradish peroxidase into rat sciatic nerve endoneurial space as early as 10 days after inoculation. A difference in EFP between controls and test animals became apparent after 11 days, and highest values were obtained 12 to 16 days postinoculation. Nerves were excised for histologic examination after EFP measurement. Severe endoneurial edema was present after 12 days and was associated with appreciable inflammatory cell infiltration. Inflammatory cells were clustered around small vessels and also were numerous in the subperineurial space which was expanded by edema. Degranulation of mast cells was also noted in association with edema and inflammation. Immunoperoxidase staining revealed immunoglobulin in the subperineurial and perivascular spaces 10 to 12 days postinoculation, but not in sections 6 to 9 days (postinoculation). These findings suggest suggest that altered vascular permeability is the earliest morphologic change in experimental allergic neuritis, followed by accumulation of antibody-containing edema fluid, penetration of the endoneurium by inflammatory cells, and increased EFP.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Powell</LastName>
            <ForeName>H C</ForeName>
            <Initials>HC</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Braheny</LastName>
            <ForeName>S L</ForeName>
            <Initials>SL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Myers</LastName>
            <ForeName>R R</ForeName>
            <Initials>RR</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Rodriguez</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lampert</LastName>
            <ForeName>P W</ForeName>
            <Initials>PW</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>NS 07078</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>NS 09053</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>NS 14162</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Lab Invest</MedlineTA>
    <NlmUniqueID>0376617</NlmUniqueID>
    <ISSNLinking>0023-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName>
        <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName>
        <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009444" MajorTopicYN="N">Neuritis, Autoimmune, Experimental</DescriptorName>
        <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
        <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011917" MajorTopicYN="N">Rats, Inbred Lew</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName>
        <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1983</Year>
        <Month>3</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1983</Year>
        <Month>3</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1983</Year>
        <Month>3</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">6338293</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">6283035</PMID>
<DateCompleted>
    <Year>1982</Year>
    <Month>08</Month>
    <Day>26</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>05</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0022-3069</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>41</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>1982</Year>
                <Month>Jul</Month>
            </PubDate>
        </JournalIssue>
        <Title>Journal of neuropathology and experimental neurology</Title>
        <ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Reduced nerve blood flow in hexachlorophene neuropathy: relationship to elevated endoneurial fluid pressure.</ArticleTitle>
    <Pagination>
        <MedlinePgn>391-9</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>To test the hypothesis that increased endoneurial fluid pressure (EFP) causes a reduction in nerve blood flow (NBF) in the vasa nervorum, we adapted a noninvasive method for measurement of nerve blood flow which was originally developed for measurement of local cerebral blood flow. This technique measures tissue distribution to the radioisotope, 14C-iodoantipyrine, and was used to compare NBF in sciatic nerves of rats with increased EFP induced by feeding them hexachlorophene (HCP), a neurotoxin which causes edema exclusively to the nervous system and confined to the myelin sheath. Elevation of interstitial fluid pressure in peripheral nerves from control values of 2.0 +/- 1.0 cm H2O to over approximately 6 cm H2O was associated with a statistically significant reduction in nerve blood flow from 14.8 +/- 5.9 to 7.8 +/- 2.5 ml/100 g of tissue/minute (min). These results support the hypothesis that increased endoneurial fluid pressure exacerbates the neuropathy by diminishing local blood flow.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Myers</LastName>
            <ForeName>R R</ForeName>
            <Initials>RR</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Mizisin</LastName>
            <ForeName>A P</ForeName>
            <Initials>AP</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Powell</LastName>
            <ForeName>H C</ForeName>
            <Initials>HC</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Lampert</LastName>
            <ForeName>P W</ForeName>
            <Initials>PW</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
        <Grant>
            <GrantID>NS 09053</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
        <Grant>
            <GrantID>NS 14162</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
        </Grant>
    </GrantList>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>J Neuropathol Exp Neurol</MedlineTA>
    <NlmUniqueID>2985192R</NlmUniqueID>
    <ISSNLinking>0022-3069</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>IWW5FV6NK2</RegistryNumber>
        <NameOfSubstance UI="D006582">Hexachlorophene</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006582" MajorTopicYN="N">Hexachlorophene</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName>
        <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014650" MajorTopicYN="N">Vasa Nervorum</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1982</Year>
        <Month>7</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1982</Year>
        <Month>7</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1982</Year>
        <Month>7</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">6283035</ArticleId>
    <ArticleId IdType="doi">10.1097/00005072-198207000-00002</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">7136177</PMID>
<DateCompleted>
    <Year>1982</Year>
    <Month>12</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>23</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0343-8554</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
                <Year>1982</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Zeitschrift fur Lymphologie. Journal of lymphology</Title>
        <ISOAbbreviation>Z Lymphol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Value of phlebography in the diagnosis of edema of the leg].</ArticleTitle>
    <Pagination>
        <MedlinePgn>41-50</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>In the diagnosis of leg edema, important phlebographic procedures are explained in terms of their technique and the information they provide. Ascending phlebography is the most important procedure for diagnosis of phlebothromboses, post-thrombotic syndromes, occlusions of the deep veins of other genesis, perforans insufficiency as well as vessel malformations. Additional administrations of selective contrast medium, intraoperative techniques as well as transosseous contrast medium administration are mentioned as rare supplementary methods. Peripheral open measurement of venous pressure constitutes an important additional documentation of vein function. The limits of the information provided are explained with reference to the normal phlebogram as well as to findings of venous reflux disturbances in the region of the deep veins, especially in acute thrombosis and occlusion of deep veins.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Schuster</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Stellenwert der Phlebographie in der Odemdiagnostik des Beines.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Z Lymphol</MedlineTA>
    <NlmUniqueID>7805527</NlmUniqueID>
    <ISSNLinking>0343-8554</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010690" MajorTopicYN="Y">Phlebography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014690" MajorTopicYN="N">Venous Pressure</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1982</Year>
        <Month>6</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1982</Year>
        <Month>6</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1982</Year>
        <Month>6</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">7136177</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">482368</PMID>
<DateCompleted>
    <Year>1979</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateCompleted>
<DateRevised>
    <Year>2006</Year>
    <Month>11</Month>
    <Day>15</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0031-8280</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>32</Volume>
            <Issue>2</Issue>
            <PubDate>
                <MedlineDate>1979 Apr-Jun</MedlineDate>
            </PubDate>
        </JournalIssue>
        <Title>Phlebologie</Title>
        <ISOAbbreviation>Phlebologie</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[Proof of the effectiveness of compression by nuclear medicine, plethysmography and venous pressure measurement].</ArticleTitle>
    <Pagination>
        <MedlinePgn>179-88</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>1) In a lying down position a) immediately and under rapid compression, one observes a reduction in muscle flow as well as a reduction of the perfusion of the foot and of the systolic pressure of the big toe. After disinfiltration of the leg by compression, the muscular flow more than doubles (clearance with Xenon 133). b) a reduction in the venous blood volume of the limb by about 1/3. c) an increase in the venous circulation speed by about 1.5 times (tracer in a vein of the back of the foot). The degree of change is depending from the pressure of the compressive bandage (in a lying down position, between 20 mmHg and a maximum of 40 mmHg). 2) while walking a) shortening of the pathological refluxes in the veins of the lower limbs (directional Doppler). b) improvement of the pump output (increase inthe volume of blood pumped upwards), and a variable influence of the peripheral venous pressure (simultaneous methods of plethysmography of the foot and the venous pressure). c) reduction of edema, improvement of the disturbed lymphatic flow (plethysmography, lymphotropic tracers with radioactive marking).</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Partsch</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
        </Author>
    </AuthorList>
    <Language>fre</Language>
    <PublicationTypeList>
        <PublicationType UI="D003160">Comparative Study</PublicationType>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Preuves de l'efficacité de la compression par des méthodes de médecine nucléaire la pléthysmographie et la mesure de pression veineuse.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>France</Country>
    <MedlineTA>Phlebologie</MedlineTA>
    <NlmUniqueID>0376212</NlmUniqueID>
    <ISSNLinking>0031-8280</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D014980">Xenon Radioisotopes</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>7440-26-8</RegistryNumber>
        <NameOfSubstance UI="D013667">Technetium</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D001158" MajorTopicYN="N">Arteries</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001458" MajorTopicYN="Y">Bandages</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001776" MajorTopicYN="N">Blood Circulation Time</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName>
        <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010991" MajorTopicYN="N">Plethysmography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName>
        <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D013667" MajorTopicYN="N">Technetium</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014690" MajorTopicYN="N">Venous Pressure</DescriptorName>
        <QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014980" MajorTopicYN="N">Xenon Radioisotopes</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1979</Year>
        <Month>4</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1979</Year>
        <Month>4</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1979</Year>
        <Month>4</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">482368</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">311455</PMID>
<DateCompleted>
    <Year>1979</Year>
    <Month>05</Month>
    <Day>16</Day>
</DateCompleted>
<DateRevised>
    <Year>2004</Year>
    <Month>11</Month>
    <Day>17</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0022-023X</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>2</Issue>
            <PubDate>
                <Year>1979</Year>
                <Month>Feb</Month>
            </PubDate>
        </JournalIssue>
        <Title>Ophthalmic surgery</Title>
        <ISOAbbreviation>Ophthalmic Surg</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The management of patients with intraocular lenses. Guidelines for those who do not perform this operation.</ArticleTitle>
    <Pagination>
        <MedlinePgn>56-64</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The management of patients with intraocular lenses can be done quite well by any knowledgeable ophthalmologist. Every examination must include the measurement of intraocular pressure and a thorough slit-lamp examination, specifically noting: Corneal edema, local or diffuse; Increasing corneal guttata; Touch of lens or iris suture to the cornea; Aqueous ray or cells, KP, LP (lens precipitates); Lens displacement; Iris suture problems; Pupil margin erosion; Secondary cataract; Vitreous face: loss or thickening; Retrolenticular membrane formation; Vitreous cells. Ophthalmoscopy should include examination of the peripheral retina for detachment, but visual fields should be done whenever detachment is suspected. Contact lens--slit-lamp examination of the macula for cystoid edema should be supplemented by Flourescein angioscopy when needed. Lens removal should be done only after careful consideration. The damage induced by such surgery must be weighed against the problems of leaving the lens in place. Consultation is mandatory. When in doubt, refer.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Drews</LastName>
            <ForeName>R C</ForeName>
            <Initials>RC</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Ophthalmic Surg</MedlineTA>
    <NlmUniqueID>0241035</NlmUniqueID>
    <ISSNLinking>0022-023X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005128" MajorTopicYN="N">Eye Diseases</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007429" MajorTopicYN="N">Intraocular Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007906" MajorTopicYN="N">Lens Subluxation</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007910" MajorTopicYN="N">Lenses, Intraocular</DescriptorName>
        <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009885" MajorTopicYN="N">Ophthalmology</DescriptorName>
        <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009887" MajorTopicYN="N">Ophthalmoscopy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
        <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D012163" MajorTopicYN="N">Retinal Detachment</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1979</Year>
        <Month>2</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1979</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1979</Year>
        <Month>2</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">311455</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">532237</PMID>
<DateCompleted>
    <Year>1980</Year>
    <Month>04</Month>
    <Day>23</Day>
</DateCompleted>
<DateRevised>
    <Year>2009</Year>
    <Month>11</Month>
    <Day>11</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0323-5580</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>3</Issue>
            <PubDate>
                <Year>1979</Year>
            </PubDate>
        </JournalIssue>
        <Title>Zeitschrift fur experimentelle Chirurgie</Title>
        <ISOAbbreviation>Z Exp Chir</ISOAbbreviation>
    </Journal>
    <ArticleTitle>[The functional behavior of peripheral circulation in cryogenic surgery].</ArticleTitle>
    <Pagination>
        <MedlinePgn>171-80</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The reactive behaviour of little vessels of the circulatory periphery against the effect of extremely deep temperatures was examined in a sense of a microflow measurement by means of the intravital microcinematography. The results obtained by mathematical analysis of the single figure demonstrate that the vessels of microcirculation are remarkably resistant against rapid withdrawal of heat. In this way the quickly recovered blood-flow in the periphery of circulation can reduce detrimentally the time of tissue thawing treated by cryosurgery. Both the shortening of the thawing phase after cryosurgery conditioned by hemodynamics and the development of a cold edema can be met by experimentally confirmed adrenergic influence of the vasoconstriction under local anesthesia.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Ernst</LastName>
            <ForeName>F D</ForeName>
            <Initials>FD</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Knoch</LastName>
            <ForeName>H G</ForeName>
            <Initials>HG</Initials>
        </Author>
    </AuthorList>
    <Language>ger</Language>
    <PublicationTypeList>
        <PublicationType UI="D004740">English Abstract</PublicationType>
        <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
    <VernacularTitle>Das funktionelle Verhalten der terminalen Strombahn bei der Kryochirurgie.</VernacularTitle>
</Article>
<MedlineJournalInfo>
    <Country>Germany</Country>
    <MedlineTA>Z Exp Chir</MedlineTA>
    <NlmUniqueID>0154510</NlmUniqueID>
    <ISSNLinking>0323-5580</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002610" MajorTopicYN="N">Cheek</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003452" MajorTopicYN="Y">Cryosurgery</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007421" MajorTopicYN="N">Intestine, Small</DescriptorName>
        <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008833" MajorTopicYN="Y">Microcirculation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1979</Year>
        <Month>1</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1979</Year>
        <Month>1</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1979</Year>
        <Month>1</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">532237</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">707295</PMID>
<DateCompleted>
    <Year>1978</Year>
    <Month>12</Month>
    <Day>27</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>06</Month>
    <Day>22</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0002-9149</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>42</Volume>
            <Issue>5</Issue>
            <PubDate>
                <Year>1978</Year>
                <Month>Nov</Month>
            </PubDate>
        </JournalIssue>
        <Title>The American journal of cardiology</Title>
        <ISOAbbreviation>Am J Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Effect of afterload reduction on plasma volume during acute heart failure.</ArticleTitle>
    <Pagination>
        <MedlinePgn>823-7</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Previous investigations in our unit indicated that acute cardiogenic pulmonary edema is associated not only with an increase in left ventricular end-diastolic pressure and pulmonary arterial wedge pressure but also with a relative increase in colloid osmotic (oncotic) pressure and peripheral hemoglobin concentration. This combination of changes suggested that acute congestive heart failure with pulmonary edema, unlike chronic congestive heart failure, is associated with a contraction of intravascular blood volume. In this study, plasma volume changes were measured before and during the treatment of acute cardiogenic pulmonary edema in 14 patients with arteriosclerotic heart disease. The plasma volume measurement in all 14 patients before the initiation of treatment was either normal or decreased. After treatment with the alpha adrenergic blocking agent phentolamine, the plasma volume increased rather than decreased when measured 4 and 12 hours after the initiation of treatment. During this time colloid osmotic pressure and peripheral hemoglobin concentration progressively decreased. These findings suggest that acute cardiogenic pulmonary edema is associated with the extravasation of large quantities of plasma water from the intravascular compartment into the interstitial compartment and contraction of the intravascular plasma volume. The treatment of acute cardiogenic pulmonary edema is associated with the return of hypo-oncotic fluid from the interstitial compartment back into the intravascular compartment with expansion of plasma volume and reduction of colloid osmotic pressure and hemoglobin concentration.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Henning</LastName>
            <ForeName>R J</ForeName>
            <Initials>RJ</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Weil</LastName>
            <ForeName>M H</ForeName>
            <Initials>MH</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Am J Cardiol</MedlineTA>
    <NlmUniqueID>0207277</NlmUniqueID>
    <ISSNLinking>0002-9149</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>7LXU5N7ZO5</RegistryNumber>
        <NameOfSubstance UI="D005665">Furosemide</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>Z468598HBV</RegistryNumber>
        <NameOfSubstance UI="D010646">Phentolamine</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D003971" MajorTopicYN="N">Diastole</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005665" MajorTopicYN="N">Furosemide</DescriptorName>
        <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006400" MajorTopicYN="N">Hematocrit</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007263" MajorTopicYN="N">Infusions, Parenteral</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010646" MajorTopicYN="N">Phentolamine</DescriptorName>
        <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D010953" MajorTopicYN="Y">Plasma Volume</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011652" MajorTopicYN="N">Pulmonary Circulation</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
        <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName>
        <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1978</Year>
        <Month>11</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1978</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1978</Year>
        <Month>11</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">707295</ArticleId>
    <ArticleId IdType="pii">0002-9149(78)90103-0</ArticleId>
    <ArticleId IdType="doi">10.1016/0002-9149(78)90103-0</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">865920</PMID>
<DateCompleted>
    <Year>1977</Year>
    <Month>07</Month>
    <Day>23</Day>
</DateCompleted>
<DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0031-3998</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>6</Issue>
            <PubDate>
                <Year>1977</Year>
                <Month>Jun</Month>
            </PubDate>
        </JournalIssue>
        <Title>Pediatric research</Title>
        <ISOAbbreviation>Pediatr Res</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Magnesium deficiency anemia in the rat fetus.</ArticleTitle>
    <Pagination>
        <MedlinePgn>758-64</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>Magnesium-deficient fetuses exhibited malformations (44%), anemia, and edema. Maternal plasma magnesium levels at day 21 of pregnancy reflected the level of dietary magnesium (2.43 +/- 0.09 mg Mg/100 ml, control; 0.74 +/- 0.02 mg Mg/100 ml, deficient). Plasma magnesium levels of deficient fetuses showed similar decreases although all fetal magnesium values at term were hihger than maternal values from the same group (3.29 +/- 0.22 mg Mg/100 ml, control; 1.78 +/- 0.07 mg Mg/100 ml, deficient). Magnesium deficiency did not appear to affect the maternal blood parameters. However, when fetal blood was examined, all of the parameters measured were altered in magnesum-deficient fetuses (Table 2). No abnormalities in hemoglobin bands or plasma proteins were seen between any groups by electrophoresis. Measurement of total protein contents showed no differences between maternal blood protein contents, but total plasma protein from magnesium-deficient fetuses was significantly lower than controls (2.00 +/- 0.14 versus 2.62 +/- 0.13 g/100 ml), thus establishing a factor in fetal edema production. Morphologic data showed that in magnesium-deficient fetuses, fetal erythropoiesis was significantly greater in liver, adrenal glands, and spleen than in controls and that maturation was normoblastic. Stained and unstained peripheral blood smears of magnesium-deficient fetuses showed and obvious macrocytosis and at least 50% of the red cells stained abnormally, exhibiting pale areas. Erythrocytic morphology seen in fetal magnesium deficiency is consistent with inadequate filling of the cell by hemoglobin as suggested by Cohlan et al. (5), a probable cause of membrane collapse. The inadequate filling of magnesium-deficient red blood cells (RBC) with hemoglobin might be explained by a reduction in hemoglobin synthesis which is consistent with the reduced mean corpuscular hemoglobin (MCH) and MCH concentration (MCHC) of the deficient fetal red cells. The role of magnesium in protein synthesis is also compatible with a reduction in hemoglobin synthesis, yet may not completely explain the abnormalities and resultant shortened lifespan of the red cells.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Cosens</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Diamond</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Theriault</LastName>
            <ForeName>L L</ForeName>
            <Initials>LL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Hurley</LastName>
            <ForeName>L S</ForeName>
            <Initials>LS</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Pediatr Res</MedlineTA>
    <NlmUniqueID>0100714</NlmUniqueID>
    <ISSNLinking>0031-3998</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
    <Chemical>
        <RegistryNumber>0</RegistryNumber>
        <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
        <RegistryNumber>I38ZP9992A</RegistryNumber>
        <NameOfSubstance UI="D008274">Magnesium</NameOfSubstance>
    </Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004906" MajorTopicYN="N">Erythrocyte Count</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D004913" MajorTopicYN="N">Erythrocytes, Abnormal</DescriptorName>
        <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005313" MajorTopicYN="N">Fetal Death</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005315" MajorTopicYN="N">Fetal Diseases</DescriptorName>
        <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006400" MajorTopicYN="N">Hematocrit</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
        <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008274" MajorTopicYN="N">Magnesium</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008275" MajorTopicYN="N">Magnesium Deficiency</DescriptorName>
        <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1977</Year>
        <Month>6</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1977</Year>
        <Month>6</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1977</Year>
        <Month>6</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">865920</ArticleId>
    <ArticleId IdType="doi">10.1203/00006450-197706000-00013</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">970327</PMID>
<DateCompleted>
    <Year>1976</Year>
    <Month>12</Month>
    <Day>01</Day>
</DateCompleted>
<DateRevised>
    <Year>2019</Year>
    <Month>06</Month>
    <Day>22</Day>
</DateRevised>
<Article PubModel="Print">
    <Journal>
        <ISSN IssnType="Print">0002-9149</ISSN>
        <JournalIssue CitedMedium="Print">
            <Volume>38</Volume>
            <Issue>4</Issue>
            <PubDate>
                <Year>1976</Year>
                <Month>Oct</Month>
            </PubDate>
        </JournalIssue>
        <Title>The American journal of cardiology</Title>
        <ISOAbbreviation>Am J Cardiol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Serial measurements of left ventricular ejection fraction by radionuclide angiography early and late after myocardial infarction.</ArticleTitle>
    <Pagination>
        <MedlinePgn>407-15</MedlinePgn>
    </Pagination>
    <Abstract>
        <AbstractText>The left ventricular ejection fraction was determined serially with radioisotope angiography in 63 patients with acute myocardial infarction. After the peripheral injection of a bolus of technetium-99m, precordial radioactivity was recorded with a gamma scintillation camera and the ejection fraction calculated from the high frequency left ventricular time-activity curve. Since this technique requires no assumptions with respect to left ventricular geometry, it is particularly useful in patients with segmental left ventricular dysfunction. Serial measurements during the first 5 days after hospital admission were made in 50 patients, 30 of whom were studied during the subsequent 2 to 39 months (mean 19.9 months). Late follow-up serial studies were also performed in an additional 13 patients who had only one measurement of the left ventricular ejection fraction during the early postinfarction period. Early after infarction, the left ventricular ejection fraction was normal (more than 0.52) in only 15 of the 63 patients, and averaged 0.52 +/- 0.05 (standard deviation) in the 27 patients with an uncomplicated infarct. The ejection fraction was reduced in 24 patients with mild to moderate left ventricular failure (0.40 +/- 0.05, P less than 0.0001) and in the 12 patients with overt pulmonary edema (0.33 +/- 0.07, P less than 0.0001). In 35 patients the ejection fraction correlated with the mean pulmonary arterial wedge pressure (r = 0.72). In 15 patients with normal left ventricular wall motion by heart motion videotracking, the ejection fraction was significantly higher (0.53 +/- 0.08) than in the 26 patients with regional left ventricular dysfunction (0.41 +/- 0.10, P less than 0.0001). During the early postinfarction period, the left ventricular ejection fraction improved in 55 percent of patients and remained unchanged or decreased in 45 percent. A further increase in the ejection fraction was noted in 61 percent of patients during the late follow-up period. Patients with an initially low or decreasing ejection fraction had a significantly greater incidence of early mortality and left ventricular dysfunction (P less than 0.02) than those whose ejection fraction was normal or improved to normal early after infarction. These data indicate that the ejection fraction is a sensitive indicator of left ventricular function after acute myocardial infarction and that serial measurements are helpful in predicting early mortality and morbidity.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
        <Author ValidYN="Y">
            <LastName>Schelbert</LastName>
            <ForeName>H R</ForeName>
            <Initials>HR</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Henning</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Ashburn</LastName>
            <ForeName>W L</ForeName>
            <Initials>WL</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Verba</LastName>
            <ForeName>J W</ForeName>
            <Initials>JW</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>Karliner</LastName>
            <ForeName>J S</ForeName>
            <Initials>JS</Initials>
        </Author>
        <Author ValidYN="Y">
            <LastName>O'Rourke</LastName>
            <ForeName>R A</ForeName>
            <Initials>RA</Initials>
        </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
        <PublicationType UI="D016428">Journal Article</PublicationType>
        <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
    </PublicationTypeList>
</Article>
<MedlineJournalInfo>
    <Country>United States</Country>
    <MedlineTA>Am J Cardiol</MedlineTA>
    <NlmUniqueID>0207277</NlmUniqueID>
    <ISSNLinking>0002-9149</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
    <MeshHeading>
        <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D000790" MajorTopicYN="N">Angiocardiography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002140" MajorTopicYN="N">California</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D002302" MajorTopicYN="Y">Cardiac Output</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
        <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
        <DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName>
    </MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
    <PubMedPubDate PubStatus="pubmed">
        <Year>1976</Year>
        <Month>10</Month>
        <Day>1</Day>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
        <Year>1976</Year>
        <Month>10</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>1</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
        <Year>1976</Year>
        <Month>10</Month>
        <Day>1</Day>
        <Hour>0</Hour>
        <Minute>0</Minute>
    </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
    <ArticleId IdType="pubmed">970327</ArticleId>
    <ArticleId IdType="pii">0002-9149(76)90455-0</ArticleId>
    <ArticleId IdType="doi">10.1016/0002-9149(76)90455-0</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
</PubmedArticleSet>